| 1 |
Poster Presentation |
Capturing the spatial landscape of tumor and immune cell lineages in the microenvironment of human cancer tissues |
Reggie Prioli, Ph.D.; Lisa Arvidson, B.S.; Sam Jensen, Ph.D.; Michael Smith, Ph.D.; Katie O. White, MBE; Richard A. Heil-Chapdelaine, Ph.D.; Melinda L. Angus-Hill, Ph.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
B cell;MDSC;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 2 |
Poster Presentation |
Characterization of the tumor microenvironment in pancreatic ductal adenocarcinoma using multiplexed imaging |
Michael Smith, Ph.D., Katie White, Richard Heil-Chapdelaine, Melinda L. Angus-Hill, Ph.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Metabolism;Solid tumors;T cell;Tumor microenvironment;Tumor stroma |
| 3 |
Poster Presentation |
Adaptive immune receptor repertoire profiling for biomarker discovery |
Alex Chenchik, PhD; Mikhail Makhanov; Dongfang Hu; Tianbing Liu; Lester Kobzik, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Autoimmunity;B cell;Biomarkers;Immune monitoring;Inflammation;RNA;Solid tumors;T cell;Tumor antigens |
| 4 |
Poster Presentation |
Potentiation of the immune checkpoint blockade response by tumor acidosis and hypoxia modulation is predictable using molecular imaging |
Renee Chin, MS; Xiaofei Liang, PhD; Tianzhe Li; Jorge de la Cerda; F. William Schuler; Mark D. Pagel, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Checkpoint blockade;Immune monitoring;Metabolism;Tumor microenvironment |
| 5 |
Poster Presentation |
Development of a Vaccine to Intercept Oral Cancer |
Traci L. Hilton, PhD; Andrew J. Gunderson, PhD; Mark Schmidt; Christopher C. Paustian, PhD; Sam Bookhardt, BA; Glenna B. McDonnell, MS; Tarsem L. Moudgil, MS; Hong-Ming Hu, PhD; Bryan R. Bell, MD, DDS, FACS; Bernard A. Fox, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Carcinogenesis;Neoantigens;Solid tumors;Tumor antigens;Vaccine |
| 6 |
Poster Presentation |
Use of real-world (RW) data to assess the ability of circulating cell-free tumor DNA (ctDNA) molecular response to assess therapeutic outcomes in patients with non-small cell lung cancer (NSCLC) |
Caroline Weipert, MS; Leylah Drusbosky; Leslie A. Bucheit, MS CGC; Kyle Chang; Shaun Forbes; Sean Gordon |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;Targeted therapy |
| 7 |
Poster Presentation |
Anti-PD1 treatment response prediction and monitoring in non-small cell lung cancer patients using plasma cell-free DNA hydroxymethylation |
Gulfem D. Guler, PhD; Yuhong Ning; David Haan; Michael Kesling; Ceyda Coruh; Giuliana Mognol; Tierney Phillips; Kyle Hazen; Wayne Volkmuth; Samuel Levy |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Epigenetics |
| 8 |
Poster Presentation |
Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody |
Noriko Iwamoto, PhD; Yoshinobu Koguchi, MD, PhD; Kotoko Yokoyama; Akinobu Hamada, PhD; Atsushi Yonezawa, PhD; Brian D. Piening, PhD; Eric Tran, PhD; Bernard A. Fox, PhD; William L. Redmond, Ph.D.; Takashi Shimada, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Immune monitoring |
| 9 |
Poster Presentation |
A pan-cancer multi-omic immune single-cell atlas for cancer immunotherapy: focus on CD4+ T cells |
Roberta Zappasodi, PhD; Lydia Mok; Andrea Orlando; Julian Lehrer; Joshua M. Stuart; Nils-Petter Rudqvist, PhD; Benjamin G. Vincent, MD; Anne Monette, PhD; Yasin Senbabaoglu, PhD; Kellie N. Smith; Paul G. Thomas, PhD; Nicholas P. Tschernia, MD; Vesteinn Thorsson; Vanessa D. Jonsson |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs) |
| 10 |
Poster Presentation |
Automated detection of RNA, DNA, and Protein Targets in Tissues on the ONCORE ProX |
Julio S. Masabanda, PhD, MS; Jason Ramos, PhD, MS |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;RNA;Tumor microenvironment |
| 11 |
Poster Presentation |
Tertiary lymphoid structures in melanomas harbor increased proportions of stem-like effector T-cells compared to tumor-infiltrating lymphocytes |
Ileana S. Mauldin, PhD; Priya Kaytal; Nicole L. Edmonds; Craig L. Slingluff, Jr., MD |
Biomarkers, Immune Monitoring and Novel Technologies |
B cell;Biomarkers;Checkpoint blockade;Immune contexture;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 12 |
Poster Presentation |
Evaluating the contribution of extracellular matrix invasion for killing of tumor cells by natural killer cells |
Jyothi T. Mony, Ph.D; Yama Abassi, PhD; Brandon Lamarche, Ph.D |
Biomarkers, Immune Monitoring and Novel Technologies |
NK/NKT cell;Solid tumors;Tumor microenvironment |
| 13 |
Poster Presentation |
Real-world Tissue-based circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay predicts outcome in lung cancer patients who had curative treatments |
Youjin Oh, MD; Liam Il-Young Chung; Soowon Lee; Timothy Hong; Leesul Kim; Sung Mi Yoon; Joo Hee Park; Trie Arni Djunadi; Young Kwang Chae, MD, MPH, MBA |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Clinical study;Epidemiology |
| 14 |
Poster Presentation |
Exploring real-world concordance of tumor mutation burden (TMB) from blood and tissue in patients with solid tumors |
Youjin Oh, MD; Jewel Park; Liam Il-Young Chung; Soowon Lee; Timothy Hong; Young Kwang Chae, MD, MPH, MBA |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Clinical study;Epidemiology |
| 15 |
Poster Presentation |
Integration of multiple immune-associated biomarkers facilitates classification of solid tumors by primary immune escape mode and prediction of patient outcomes |
R.J. Seager, PhD; Maria-Fernanda Senosain, PhD; Erik Van Roey; Shuang Gao; Mary K. Nesline; Jeffrey M. Conroy; Sarabjot Pabla, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Checkpoint blockade;Gene expression;Inflammation;RNA;Solid tumors;Tumor evasion;Tumor microenvironment |
| 16 |
Poster Presentation |
Multi-dimensional analysis of CD19-CAR T cells at single cell resolution on the Berkeley Lights platform enable unique insights into relationships between cytotoxicity kinetics and cytokine secretion |
Joseph M. Valdez, Ph.D.; Guido Stadler, Ph.D.; Milton Quintanilla; Pei-Yu (Kate) Lin, Ph.D.; Aribet De Jesus, Ph.D.; Deric M. Griffin, Ph.D.; Sapna Tandon, M.D.; Yiyang Xu, Ph.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;Antigen presenting cells;Biomarkers;CAR T cells;Carcinogenesis;Immune monitoring;Leukemia/Lymphoma;Solid tumors;T cell;Tumor antigens |
| 17 |
Poster Presentation |
Isolation and expansion of circulating tumor-reactive lymphocytes for adoptive cell therapy |
Shana Kelley; Zongjie Wang, Ph.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;T cell;T cell lineages;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 18 |
Poster Presentation |
Identification and characterization of circular RNAs as novel putative biomarkers to predict the survival benefit among metastatic melanoma patients treated with anti-PD-1 monotherapy |
Jian-Guo Zhou, MD; Udo S. Gaipl; Hu Ma; Haitao Wang |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers |
| 19 |
Poster Presentation |
Peripheral lymphocytes and lactate dehydrogenase correlate with improved response and survival in head and neck cancer treated with immune checkpoint inhibitors |
Cassie Pan, MD; Qian Vicky Wu; Jenna Voutsinas; Jeffrey J. Houlton; Brittany Barber; Zain Rizvi; Emily Marchiano; Neal Futran; George E. Laramore; Jay J. Liao; Upendra Parvathaneni; Renato G. Martins |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Granulocyte;Immune toxicity;Inflammation;Monocyte/Macrophage;Myeloid cells;Solid tumors |
| 20 |
Poster Presentation |
Development of VISTA-centric tumor immunophenotyping as a novel approach for identification of potential biomarkers for anti-VISTA therapy |
Andrey Ugolkov, MD, PhD; Rosanna Hok; Reinhard von Roemeling, MD; Alexander Martin, MD; Robert Martell, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 21 |
Poster Presentation |
IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy - a real life study |
Domenico Mallardo, PhD; Maria Antonietta Isgrò; Vito Vanella, MD; Marilena Tuffanelli; Lucia Festino, MD; Maria Grazia Vitale, MD; Grazia D'Angelo; Francesca Sparano; Mario Mallardo; Eleonora Cioli; Benedetta Alfano; Claudia Trojaniello; Alfredo Budillon; Ester Simeone, MD; Corrado Caracò; Ernesta Cavalcanti; Paolo A. Ascierto, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Cytokine;Immune monitoring;Inflammation;Tumor evasion |
| 22 |
Poster Presentation |
Activity of the Tumor-intrinsic NLRP3 Inflammasome Pathway Predicts for Response to Checkpoint Inhibitor Immunotherapy in Melanoma Patients |
Tarek Haykal, MD; Nagendra Yarla, PhD; Nicholas C. DeVito, MD; Georgia Beasley, MD, MHSc; April Salama, MD; Brent Hanks, MD, PhD; Balamayooran B.T. Theivanthiran, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Solid tumors |
| 23 |
Poster Presentation |
Clues from the Matrix - peripheral collagen fragments originating from activity of lymphoid cells, myeloid cells, and fibroblasts may have biomarker potential for cancer immunotherapy |
Jeppe Thorlacius-Ussing; Nicholas N.W. Willumsen, PhD; Neel I. Nissen, PhD; Christina Jensen; Morten Karsdal, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune monitoring;Post-translational modifications;Solid tumors;Tumor microenvironment;Tumor stroma |
| 24 |
Poster Presentation |
Proteomic analysis of breast cancer based on immune subtypes |
Yeonjin Jeon, MD; Hee Jin Lee |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Chemotherapy;Immune suppression;Proteomics;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 25 |
Poster Presentation |
Potential predictive biomarkers for BXCL701 in Acute Myeloid Leukemia (AML) |
Veena R. Agarwal, Ph.D.; Shubhendu Trivedi, Ph.D.; Dimple Bhatia, Ph.D.; Zeenia Jagga, Ph.D.; Moses Donkor, Ph.D.; Vincent O'Neill, M.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Gene expression;Leukemia/Lymphoma |
| 26 |
Poster Presentation |
Tumor infiltrating CD8/CD103/TIM-3 expressing lymphocytes in Epithelial Ovarian Cancer co-express CXCL13 and associate with improved survival |
Vrouyr Bilemjian, MSc; Edwin Bremer |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Tumor infiltrating lymphocytes (TILs) |
| 27 |
Poster Presentation |
Tumor agnostic CD8 Immune-phenotype related gene signature defines clinical outcome across early and late phase clinical trials |
Andreas Roller, PhD; Iakov I. Davydov, PhD; Martha Serrano-Serrano, PhD; Astrid Heller, PhD; Nicolas Staedler, PhD; Claudia Ferreira, PhD; Gabriele Dietmann; Irina Klaman; Konstanty Korski, MD; Petra Schwalie, PhD; Michael A. Cannarile, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Clinical trial;Gene expression;Immune contexture;Immune monitoring;Immunoscore;Systems biology;T cell;Tumor microenvironment |
| 28 |
Poster Presentation |
Identification and Functional Validation of Neoantigens-Specific T-Cell Receptors in Lynch Syndrome |
Fahriye Duzagac, PhD; Krishna Sinha, PhD; Ana M. Bolivar, MS; Nan Deng, PhD; Laura Reyes Uribe, MD; Alexandre Reuben, PhD; Eduardo Vilar-Sanchez, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antigen presenting cells;Biomarkers;Immune monitoring;Neoantigens;T cell;Vaccine |
| 29 |
Poster Presentation |
Lung-MAP Composite Signature for Immune Checkpoint Inhibitor (ICI) Efficacy in Advanced Squamous Cell Lung Cancer (SCC) |
David R. Gandara, MD; Xing Hua, PhD; Khaled Tolba; David Fabrizio; Lee Albacker, Ph.D; Ryan Brennick, PhD; Meagan Montesion, Ph.D.; Geoff Oxnard; Stacey Adam; Fred Hirsch; Karen Kelly; Roy Herbst, MD, PhD; Michael LeBlanc; Mary Redman, Ph.D; Michael Wu; David Kozono, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immunoscore |
| 30 |
Poster Presentation |
Single cell multiomic profiling of the antigen-specific immune response using antigen specific dCODE Dextramer (RiO) reagents and BD AbSeq Reagents on the BD Rhapsody™ Single-Cell Analysis System |
Kivin Jacobsen; Dilek Inekci, Ph.D; Liselotte Brix, Ph.D CSO |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;Antigen presenting cells;B cell;Biomarkers;Immune monitoring;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 31 |
Poster Presentation |
Cellular Composition of Malignant Pleural Effusions Show a Similar Landscape to that of their Primary Tumor Sites: A Pilot Study |
Caddie D. Laberiano-Fernández, MD; Qiong Gan, MD; Auriole Tamegnon, Technician; Sinchita Roy Chowdhuri, MD,PhD; Edwin Parra, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Immune monitoring;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 32 |
Poster Presentation |
Real-world prevalence of deficient mismatch repair across 5 solid tumor types in China |
Xiaohua Shi, PhD; Xiang-Hong Yang; Jing-Ping Yun; Xiang-Shan Fan; Ying-Yong Hou; Zhe Wang; Peng Li; Jie-Yu Chen; Juan Yu; Longyun Chen; Yan Wang; Rubentiran Ramar; Michael Wong; Zhiyong Liang |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Solid tumors |
| 33 |
Poster Presentation |
Role of plasma T-cell-derived circulating DNA level in anti-PD(L)1 immunotherapy in advanced stage non-small cell lung cancer |
Nuthchaya Mejun; Nophol Leelayuwatanakul, MD; Pongsakorn Ouwongprayoon, MD; Chanida Vinayanuwattikun, MD, PhD; Nattiya Hirankarn, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Solid tumors;T cell |
| 34 |
Poster Presentation |
Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy |
Vincent Pozorski; Yeonhee Park; Dahlia H. Tesfamichael; Yusuf R. Mohamoud; Vincent T. Ma, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune monitoring;Immune toxicity |
| 35 |
Poster Presentation |
Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody |
Malin Lindstedt, PhD; Peter Ellmark, PhD; Aastha Sobti, Doctoral Candidate, MClinDent Oral Surgery; Karin Enell Smith, PhD, MS; Yago Pico de Coaña, PhD; Sumeet V. Ambarkhane, MBBS, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;B cell;Dendritic cell;Gene expression;Myeloid cells;T cell |
| 36 |
Poster Presentation |
Analysis of T-cell receptor sequences identifies signatures associated with neoantigen exposure in peripheral blood of Lynch Syndrome patients |
Ana M. Bolivar, MS; Eduardo Vilar-Sanchez, MD, PhD; Krishna Sinha, PhD; Laura Reyes Uribe, MD; Nan Deng, PhD; Fahriye Duzagac, PhD; Alexandre Reuben, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Immune monitoring;Neoantigens;Solid tumors;T cell |
| 37 |
Poster Presentation |
Signal amplification strategies for in situ detection of low-expressed markers in multiplex immunofluorescence |
Pino Bordignon, PhD; Paula Juricic, PhD; Victor de Gautard, M.Sc.; Alexandre Kehren, M.Sc.; Saska Brajkovic, PhD; Diego G. Dupouy, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Checkpoint blockade;Immune contexture;Proteomics;Solid tumors;T cell;Tumor microenvironment;Tumor stroma |
| 38 |
Poster Presentation |
Fully automated spatial multi-omics analysis to map the tumor microenvironment with single-cell resolution |
Pino Bordignon, PhD; Alice Comberlato, PhD; Saska Brajkovic, PhD; Diego G. Dupouy, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Cytokine;Gene expression;Proteomics;RNA;Solid tumors;T cell;Tumor microenvironment;Tumor stroma |
| 39 |
Poster Presentation |
Interrogating Elite Responder humoral responses to identify novel targets and therapeutic antibodies for the treatment of cancer |
Ramya Chandrasekaran, M.S. Ph.D.; Darbie Whitman, BS; Ray Fox; Tom Graddis; Kamal D. Puri, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;B cell;Biomarkers;Checkpoint blockade;Myeloid cells;Solid tumors |
| 40 |
Poster Presentation |
NGS-based immunology panel: applications in preclinical immuno-oncology research |
Jia Xue, PhD; Xiaobo Chen, PhD; Xiaoyu An, PhD; Jingjing Wang, Ph.D; Henry Li, Ph.D; Sheng Guo, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Gene expression;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 41 |
Poster Presentation |
External reproducibility of PD-L1 IHC 22C3 pharmDx for cervical cancer at CPS >= 1 and CPS >= 10 |
Greg A. Cherryholmes, PhD; Alexander Posch, B.S.; Siena Tabuena-Frolli, B.A.; Jesse Vasquez, M.S.; Tiffany Evans, M.S.; Chris La Placa, M.S.; Kristopher Kersch, M.D.; Angeliki Apostolaki, Ph.D; Jonathan Juco, M.D., Ph.D.; Karina Kulangara, Ph.D |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Checkpoint blockade;Solid tumors;Targeted therapy |
| 42 |
Poster Presentation |
Modulation of fibrosis and angiogenesis in post-ischaemic extracellular matrix |
Paolo Contessotto, PhD; Doriana Orbanic; Mark Da Costa; Chunsheng Jin; Peter Owens; Niclas Karlsson; José Carlos Rodríguez-Cabello; Peter Dockery; Michelle Kilcoyne; Abhay Pandit |
Biomarkers, Immune Monitoring and Novel Technologies |
Angiogenesis;Inflammation;Post-translational modifications;Proteomics |
| 43 |
Poster Presentation |
Tumor mutational burden corrected for human leukocyte antigen somatic defects predicts response to checkpoint blockade in advanced non-small cell lung cancer |
Yinjie Gao, MS; Ramit Bharanikumar, MS; Aly Khan; Michelle M. Stein |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Neoantigens;Tumor microenvironment |
| 44 |
Poster Presentation |
Immune signatures of severe immune-related adverse events detected by mass cytometry immune profiling in blood in patients with advanced melanoma treated with immunotherapy |
Connor P. Healy, PhD; Magdalena Kovacsovics, MD; Natalia Sigal, PhD; Li-Chun Cheng, PhD; Shane Evans, PhD; John Marsiglio, MD; Berit Gibson; Yoko DeRose, PhD; Annaleah Larson; Carlos O. Medina, PhD; Jolien Sweere, PhD; Ramji Srinivasan; Matthew Spitzer, PhD; John Hyngstrom, MD; Siwen Hu-Lieskovan, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Autoimmunity;Bioinformatics;Biomarkers;Checkpoint blockade;Immune monitoring;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;Systems biology;T cell |
| 45 |
Poster Presentation |
Prevalent binding motif in C57BL6 mice cured of B78 melanoma via immunotherapy |
Anna Hoefges, MS; Nicholas G. Mathers; Sean J. Mcilwain, PhD; Richard S. Pinapati, PhD; Bradley Garcia, II, PhD; Jigar Patel, PhD; Amy K. Erbe, PhD; Irene M. Ong, PhD; Paul M. Sondel, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Neoantigens;Proteomics;Solid tumors;Tumor antigens |
| 46 |
Poster Presentation |
Genetic Analysis of tumor cells derived from the stress of immune response for understanding of immunotherapy |
Tomoyuki Ishiguro, MD; Daisuke Takayanagi; Toshiaki Tsurui; Risako Suzuki; Nana Iriguchi; Yuya Hirasawa, MD; Ryotaro Ohkuma, MD; Hirotsugu Ariizumi, MD. PhD; Yutaro Kubota; Kazuyuki Hamada, MD, PhD; Atsushi Horiike; Satoshi Wada, MD, PhD; Kiyoshi Yoshimura, PhD, MD; Kazuyoshi Takeda; Takuya Tsunoda, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Gene expression;Neoantigens;Tumor antigens;Tumor evasion |
| 47 |
Poster Presentation |
Multispectral imaging to detect immune phenotypes associated with the tumor microenvironment in a multi-tissue study: A full automated 7-color mIF immuno-oncology workflow |
Navi Mehra, PhD; Bhavika Patel, PhD; Stephanie Allen; Noah Ramirez; Najiba Mammadova, PhD; Agnes Haggerty, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Clinical study;Immune monitoring;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 48 |
Poster Presentation |
Whole-slide multispectral imaging reveals the immune subtypes of melanoma associated with the tumor microenvironment: An automated 7-color mIF assay |
Navi Mehra, PhD; Bhavika Patel, PhD; Stephanie Allen; Noah Ramirez; Najiba Mammadova, PhD; Agnes Haggerty, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Immune contexture;Immune monitoring;Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 49 |
Poster Presentation |
Immuno-Oncology Imaging Mass Cytometry Study of the Structural and Cellular Composition of the Tumor Microenvironment in Human Cancers |
Thomas D. Pfister, PhD; Christina Loh, PhD; Sam Lim; Qanber Raza, PhD; Shaida Ouladan, PhD; Nick Zabinyakov |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune monitoring;Myeloid cells;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 50 |
Oral Presentation |
Merkel cell polyomavirus-specific CD8 T cells in blood, but not in tumors, correlate with immunotherapy response in Merkel cell carcinoma |
Thomas Pulliam; Saumya H. Jani; Lichen Jing; Jiajia Zhang, MD, MPH; Rima Kulikauskas; Candice Church, Ph.D.; Charlie Garnett-Benson, PhD; Kelly G. Paulson, MD, PhD; Kellie N. Smith; Andrew M. Pardoll, MD, PhD; David M. Koelle, MD; Suzanne L. Topalian, MD; Paul T. Nghiem, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Immune monitoring;Immunoscore;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 51 |
Poster Presentation |
A combination of antigen presentation and T-cell recognition features improves neoantigen immunogenicity predictions |
Neeraja Ravi, PhD; Rachel M. Pyke, PhD; Steven Dea, MS; Prateek Tandon; Richard O. Chen, MD; Sean M. Boyle, PhD, MS |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;Neoantigens;T cell;Tumor antigens |
| 52 |
Poster Presentation |
Digital pathology training effectiveness for the evaluation of PD-L1 expression in multiple tumor indications |
Jennifer D. Robinson, HT(ASCP)CM, BA; Edward A. Manna, CT(ASCP), BS; Charlotte M. Roach, BS; Ryan J. Marczak, BS; Arkendra De, PhD, BS; Joshua Littrell, BA; Micki Adams, BS |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor evasion |
| 53 |
Poster Presentation |
Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab |
Eric D. Routh, PhD; Benjamin G. Vincent, MD; Mark G. Woodcock, MD; Jonathan S. Serody, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;B cell;Bioinformatics;Checkpoint blockade;Immune monitoring;Neoantigens;Solid tumors;Tumor antigens |
| 54 |
Poster Presentation |
Prognostic value of T cell immunoscore estimated from transcriptomic data in patients with advanced malignancies treated with immune checkpoint inhibitors |
Ahmad A. Tarhini, MD, PhD, MS; Payman Ghasemi Saghand, PhD; Aik Choon Tan, PhD; James Chen; Aakrosh Ratan; Martin McCarter, MD; John Carpton, PhD; Howard Colman, MD; Alexandra Ikeguchi, MD; Igor Puzanov, MD, MSCI, FACP; Susanne M. Arnold, MD; Michelle L. Churchman, PhD; Patrick Hwu; Jose Conejo-Garcia, MD, PhD; William (Bill) S. Dalton, PhD, MD; George J. Weiner, MD; Issam M. El Naqa, Ph.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Gene expression;Immunoscore;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 55 |
Poster Presentation |
Identification of the O-glycan epitope targeted by an anti-human carcinoma monoclonal antibody (mAb) NEO-201 |
Massimo Fantini, PhD; Anjum Zaki; Sharon A. Mavroukakis; Christina M. Annunziata, MD, PhD; Kwong Y. Tsang, PhD; Philip M. Arlen, M.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Immune monitoring;Neoantigens;Post-translational modifications;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 56 |
Poster Presentation |
High pretreatment DHEA level is associated with shorter overall survival in newly diagnosed metastatic non-small cell lung cancer patients receiving immune checkpoint inhibitors |
Yumeng Zhang, MD; Lancia Darville, PhD; Stephanie Hogue; Julie E. Hallanger Johnson; Youngchul Kim, PhD; Jhanelle E. Gray, MD; Lary A. Robinson, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune suppression;Solid tumors |
| 57 |
Oral Presentation |
CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy |
Emily Cohen, BSc; Daphne W. Wang; Elizabeth L. Engle, MSc; Benjamin F. Green, BSc; Justina X. Caushi, PhD; Jiajia Zhang, MD, MPH; Joel C. Sunshine, MD, PhD; Sonali Uttam, MSc; Michael Fotheringham, BSc; Alexa Fiorante, BSc; Nicole Espinosa, BSc; Bhakti Pandey, BSc; Teodora Popa, MD; Aleksandra Ogurtsova; Sigfredo Soto-Diaz; Jose Loyola; Jeffrey S. Roskes, PhD; Margaret Eminizer, PhD; Dmitry Medvedev, MSc; Jamie E. Chaft, MD; Julie R. Brahmer, MD, MSc; Joshua E. Reuss, MD; Patrick Forde, MBBCh; Alexander S. Szalay, PhD; Andrew M. Pardoll, MD, PhD; Kellie N. Smith; Janis M. Taube, MD; Tricia R. Cottrell, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune contexture;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 58 |
Poster Presentation |
Examining Elevated TMB and Clinical Benefit of 1L Immune Checkpoint Inhibitor in Advanced NSCLC |
David P. Carbone, MD, PhD; Jacob Sands, MD; Gerald Li; Alexa B. Schrock; Ryon P. Graf; Liangliang Zhang; Karthikeyan Murugesan; Jeffrey S. Ross; Khaled Tolba; Geoffrey R. Oxnard; Richard S. Huang, MD; David R. Spigel, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Chemotherapy;Solid tumors |
| 59 |
Poster Presentation |
DetermaIO (IO score) is associated with efficacy of ICI monotherapy in advanced NSCLC patients: a retrospective BC Cancer study |
David L. Saltman, MD PhD; Nicole S. Croteau; Heather M. Lockyer; Rob S. Seitz, PhD; Frank B. McMahon; Jeremy Spille; Andrea Dickey; Jordan R. Jennings; Matthew G. Varga, PhD; Kimberly McGregor, MD; Tyler J. Nielsen, MS; David R. Hout, PhD; Brock L. Schweitzer, PhD; Douglas T. Ross, MD, PhD; David R. Gandara, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Clinical study;Gene expression;RNA;Solid tumors;Tumor microenvironment;Tumor stroma |
| 60 |
Poster Presentation |
Enablement of single-cell spatial insight addressing T-cell and CAF involvement in pancreatic invasive ductal adenocarcinoma using AI-based deep learning image analysis |
Andrew Quong, PhD; Smriti Kala, PhD; Nina Lane; Michelle MacPherson; Gourab Chatterjee; Devan Fleury; Kirsteen H. Maclean, Ph.D; Dan Winkowski, PhD; Fabian Schneider; Jeppe S. Thagaard; James R. Mansfield, MSc |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune contexture;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 61 |
Poster Presentation |
Combination of novel biomarkers of collagen fiber and immune architecture are associated with clinically relevant outcomes in gynecological cancers treated with immunotherapy |
Arpit Aggarwal, Pursuing PhD in Biomedical Engineering; Sepideh Azarianpour-Esfahani; Haojia Li; Pingfu Fu; Mojgan Mokhtari; Stefanie Avril; Haider Mahdi; Anant Madabhushi |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Chemotherapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 62 |
Poster Presentation |
Resistance to frameshift neoantigen-specific T cell surveillance in microsatellite unstable cancers |
Matthew Brown, MS, BA; Leandra Velazquez, BA; Mona Saleh, MD; Alexandros Polydorides, MD, PhD; Aimee Lucas, MD, MS; Cansu Cimen Bozkus, PhD; Robert Samstein, MD, PhD; Nina Bhardwaj, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune suppression;Neoantigens;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 63 |
Poster Presentation |
EpiScan: A synthetic biology platform for targeted immunopeptidomics |
Peter M. Bruno, PhD; Richard Timms; Nouran S. Abdelfattah; Yumei Leng; Felipe Lelis; Duane R. Wesemann; Xu G. Yu; Stephen J. Elledge |
Biomarkers, Immune Monitoring and Novel Technologies |
Antigen presenting cells;Bioinformatics;Biomarkers;COVID and Immunotherapy;Neoantigens;Systems biology;T cell;Tumor antigens |
| 64 |
Poster Presentation |
Spatial whole transcriptome profiling of the tumor microenvironment in archived and freshly-mounted FFPE tissues |
Jun Chiang, Dr, PhD; Augusto Tentori; Hardeep Singh; Anuj Patel; Han Lu; Alex Hermes |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Carcinogenesis;Gene expression;Immune monitoring;Tumor microenvironment |
| 66 |
Poster Presentation |
Surface nanotopography and cell shape modulate tumor cell susceptibility to NK cell cytotoxicity |
Jeehun Park, PhD; Junsang Doh; Yongbum Cho |
Biomarkers, Immune Monitoring and Novel Technologies |
NK/NKT cell;Solid tumors;Tumor evasion;Tumor microenvironment |
| 67 |
Poster Presentation |
Germline mutations in DNA damage response and repair genes are associated with increased clinical benefit from immune checkpoint inhibitors |
Michael J. Dennis, MD; Sophia Bylsma; Lisa Madlensky, PhD; Sandip P. Patel, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Clinical study;Immune toxicity;Solid tumors |
| 69 |
Poster Presentation |
A high content screening platform for testing immunotherapies in patient-derived organoids |
Gera Goverse, Dr.; Saskia de Man; Tomas Veenendaal; Nataliia Beztsinna; Daniel Okkes; Ashgard Weterings; Kuan Yan; Leo Price |
Biomarkers, Immune Monitoring and Novel Technologies |
Immune monitoring;Immune suppression;Monocyte/Macrophage;Myeloid cells;Systems biology;T cell;Tumor microenvironment |
| 70 |
Poster Presentation |
Whole genome CRISPR-Cas9 screens in a cancer cell line panel co-cultured with antigen-specific cytotoxic CD8 T cells are a powerful engine for immuno-oncology drug target discovery |
Serge Gueroussov; Chengyin Min; Alan Huang, PhD; Samuel Meier; Jessica Finkler; Lei Ji; Ashley Choi; Tenzing Khendu; Disha Subramanya; Shangtao Liu, BS; Binzhang Shen; Teng Teng; Xuewen Pan, PhD; Yi Yu, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;Systems biology;T cell |
| 71 |
Poster Presentation |
High scoring precision demonstrated in multiple tumor indications stained with PD-L1 IHC 22C3 pharmDx used in conjunction with Combined Positive Score |
Julia Hand, B.S.; Francisco J. Ponce, BS; Stephanie Hund, B.S.; Lindsay Peltz, M.S.; Micki Adams, BS; Deanna Moquin, B.S.; Megan Kalpakoff, B.A.; Siena Tabuena-Frolli, B.A.; Jay Milo, M.A.S; Angeliki Apostolaki, Ph.D; Karina Kulangara, Ph.D |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Solid tumors;Targeted therapy |
| 72 |
Poster Presentation |
Intravital multiphoton autofluorescence imaging is sensitive to changes in CD8 T cell and tumor cell metabolism during immunotherapy in a murine melanoma model |
Alexa R. Heaton, PhD; Anna Hoefges, MS; Peter R. Rehani, BS; Nathaniel J. Burkard; Arika S. Feils, BS; Dan V. Spiegelman, BS; Noah W. Tsarovsky, BS; Alina Hampton; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, Ph.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Checkpoint blockade;Immune contexture;Metabolism;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 73 |
Poster Presentation |
Delta-radiomics predicts response and overall survival in advanced non-small cell lung cancer patients treated with durvalumab |
Mohammadhadi Khorrami, PhD; Vidya Sankar Viswanathan, M.B.B.S.; Amit Gupta, M.D.; Qin Li, PhD; Ashok Gupta; Ikbel Achour, PhD; Brian Fitzgerald; Vamsidhar Velcheti, MD FACP; Anant Madabhushi |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Solid tumors;Tumor microenvironment |
| 74 |
Poster Presentation |
DeepTCRMatch: An effective way of computing T cells antigen specificity |
Seungtae Park, BA; Sungsik Kim, Ph.D.; Hee Joon Jeon; Na Ri Yoon; Bo Ryeong Lee; Sung-Min Kim, PhD; Woong-Yang Park, MD, PhD; Hyung Ju Hwang |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Bioinformatics;Biomarkers;Neoantigens;Proteomics;Systems biology;T cell;T cell lineages;Targeted therapy;Vaccine |
| 75 |
Poster Presentation |
Methods to improve co-expression efficacy of genes modulating promoter and linker |
Suji Kim; Jong Moo Hong; Kwanghee Kim; Hee Jin Lee; Gyungyub Gong |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;Gene expression;T cell |
| 76 |
Poster Presentation |
Discovery of blood pharmacodynamic biomarkers for ATR inhibitors |
Ya Kong; Lulu Jiang; Bin Jiang; Hui Yuwen; Jay Mei; Bo Shan; Bing Hou, Ph.D |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Chemokine;Cytokine;Gene expression;RNA;Targeted therapy |
| 77 |
Poster Presentation |
An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity |
Scott Kopetz, PhD; Maria Pia Morelli; Julian R. Molina, MD, PhD; Diane M. Simeone, MD; J. Randolph Hecht, MD; Kedar Kirtane; Mitesh J. Borad, MD; Theodore H. Welling; Edward B. Garon; Armen Mardiros; Xueyin Wang; Eric W. Ng, MD; Tyler Danek; Shannon Gallagher; Ariane Lozac'hmeur; Karl Beutner; John S. Welch; David G. Maloney, MD, PhD; William Y. Go; Sandip P. Patel, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;CAR T cells;Gene expression;Genetic polymorphism;Solid tumors;T cell;Tumor antigens;Tumor evasion |
| 78 |
Poster Presentation |
Mapping the tissue composition with hyperplex immunofluorescence on delicate samples |
Joanna Kowal, PhD; Diego G. Dupouy, PhD; Jonathan Mignot, MSc; Benjamin Pelz, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Immune contexture;Solid tumors;Tumor microenvironment;Tumor stroma |
| 79 |
Poster Presentation |
High-dimensional Spatial Phenotyping of Cutaneous Squamous Cell Carcinoma from Immune-competent and Immunocompromised Patients |
Arutha Kulasinghe; Niyati Jhaveri; Dmytro Klymyshyn; Bassem Ben Cheikh; Rahul Ladwa; Howard Liu; Caroline Cooper; Gabrielle Belz; Sandro Porceddu; Oliver Braubach |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune contexture;Metabolism;Proteomics;Tumor microenvironment |
| 80 |
Poster Presentation |
Tumor-specific alternative splicing generates immunogenic spatially-conserved HLA-binding neoantigens detected through integrative transcriptomic and proteomic analyses |
Darwin Kwok, MS; Takahide Nejo, MD, PhD; Chibo Hong, MD, PhD; Aidan Du; Maggie Colton; James Woo; Joseph Costello, PhD; Hideho Okada, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Antigen presenting cells;Bioinformatics;Epigenetics;Neoantigens;Proteomics;T cell;Targeted therapy;Tumor antigens;Vaccine |
| 81 |
Poster Presentation |
T Cell stimulation Assay and Immunoassays comparison for Soluble Cytokines Profiling in Drug Discovery |
Celine Lefranc; Nicole Meritet; Karine Berthelot; Odile Flamand; Jeremy Baudhuin; Jack Pollard, PhD; Luc Canard; Angelique Biancotto, ph.D |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Chemokine;Costimulation;Immune monitoring;T cell |
| 82 |
Poster Presentation |
Differential expression and function of toll-like receptor 3 within tumor immune microenvironment of clear cell renal cell carcinoma |
Mingjia Li, MD; Patrick Stevens, MS; Maciej Pietrzak, PhD; Jinesh Gheeya, MD, PhD; Amir Mortazavi, MD; Ming Yin, MD; Steven Clinton, MD, PhD; Daniel Spakowicz, PhD; Anil Parwani, MD, PhD; Zihai Li, MD, PhD; Yuanquan Yang, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Solid tumors;TLR;Tumor microenvironment |
| 83 |
Poster Presentation |
Immunotherapy eluting intratumoral nanoseed achieves local and systemic tumor control of pancreatic cancer |
Hsuan-Chen Liu, PhD; Daniel Davila Gonzalez; Robin Vander Pol; Dixita I. Viswanath; Shani Saunders; Corrine Ying Xuan Chua, PhD; Alessandro Grattoni, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Immune contexture;Immune monitoring;Immune toxicity;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 84 |
Poster Presentation |
Systemic levels of the soluble co-inhibitory and co-stimulatory immune checkpoint molecules in basal cell carcinoma |
Nonkululeko Z. Malinga, MBChB; Bernardo L. Rapoport, MD, MMed; Siwele Shalete, MBChB; Helen Steel, PhD; Luyanda Kwofie; Pieter Meyer, PhD; Ronald Anderson, PhD; Mahlatse Kgokolo, PhD; Teresa T. Smit, MPharm |
Biomarkers, Immune Monitoring and Novel Technologies |
Coinhibition;Costimulation;Immune suppression;TLR;Tumor microenvironment;Tumor stroma |
| 85 |
Poster Presentation |
Mapping the tumor microenvironment with sequential immunofluorescence, an automated image analysis pipeline, and spatial metrics |
Joanna Kowal, PhD; Diego G. Dupouy, PhD; Pedro Machado Almeida, PhD; James Mansfield; Benjamin Pelz, PhD; Fabian Schneider; David Mason, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Immune contexture;Immune monitoring;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment;Tumor stroma |
| 86 |
Poster Presentation |
HPV16 E1 and E2 elicit a robust cytotoxic immune response in virally driven Oropharyngeal Squamous Cell Carcinoma |
Christine M. McInnis; Shilpa Bhatia; Brinda Vijaykumar; Qiaomu Tian; Yanbo Sun; Del Leistritz-Edwards; Charles Quinn; Sean Donnelly; Ravindra Uppaluri, MD PhD; Ann Marie Egloff; Daniel C. Pregibon; Lakshmi Srinivasan; Anthony Coyle, PhD; Glenn J. Hanna, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 87 |
Poster Presentation |
Deep phenotyping and spatial immune contexture through a combined multiplex immunofluorescence approach |
Harry Nunns, PhD; Arezoo Hanifi; Erinn A. Parnell; Nam Tran; Sara Pollan; Qingyan Au, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune contexture;Proteomics;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 88 |
Poster Presentation |
Genetic association between vitiligo genetic susceptibility and response to immune-checkpoint inhibitor therapy in advanced melanoma patients. |
Wouter Ouwerkerk, PhD; Saskia Chielie; Marcel W. Bekkenk; Remco van Doorn; Christian U. Blank; John B.A. Haanen; Karlijn de Joode; Ron HJ. Mathijssen; Astrid AM. van der Veldt; Ellen Kapiteijn; Karijn Suijkerbuijk; Kalijn Bol; Geke A.P. Hospers; Tomas Kirchhoff; Rosalie M. Luiten |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade |
| 89 |
Poster Presentation |
Multiplexed Ion Beam Imaging (MIBI) uncovers adaptive immune responses associated with clinical outcomes in oral cavity squamous cell carcinoma treated with neoadjuvant PD-1 inhibitor |
Raghav Padmanabhan; Hannah M. Knochelmann, MD, PhD; Monirath Hav, MD, PhD; Mate L. Nagy, PhD; Peng Si, PhD; Sweta Bajaj, M.S.; Gregory B. Lesinski, Ph.D.; David Neskey, MD; Chrystal M. Paulos, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Checkpoint blockade;Immune monitoring;Tumor microenvironment |
| 90 |
Poster Presentation |
Circulating altruistic stem cells as a marker of immunosuppression in oral cancer |
Lekhika Ms. Pathak, MSc.; Seema Bhuyan, MSc; Bidisha Pal, MS; Partha J. Saikia, MSc; Sukanya Gayan, MSc; Shirsajit Mitra, Btech; Tutumoni Baishya, MSc; Ramana V. Chilakamarti, PhD; Bikul Das, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Chemotherapy;Immune monitoring;Immune suppression;Inflammation;Stem cell/cancer-initiating cell;Tumor microenvironment;Tumor stroma |
| 91 |
Poster Presentation |
Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors. |
Federica Pecci, MD; Luca Cantini; Valeria Cognigni, MD; Fabiana Perrone, MD; Veronica Agostinelli, MD; Giulia Mazzaschi; Elda Favari; Michele Maffezzoli; Alessio Cortellini, MD, PhD; Francesca Rossi; Rebecca Chiariotti; Francesco Venanzi; Giulia Mentrasti; Giuseppe Lo Russo; Giulia Galli; Claudia Proto; Monica Ganzinelli; Francesca Tronconi; Francesca Morgese; Carla Campolucci; Marco Moretti; Arianna Vignini; Melissa Bersanelli, MD, PhD; Sebastiano Buti; Rossana Berardi |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Metabolism;Solid tumors |
| 92 |
Poster Presentation |
Novel RNA-Seq Platform Enables Repurposing of Approved Drugs in Rare Cancers, Improving Outcomes |
Gitte Pedersen, MSc |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;RNA;Solid tumors;Tumor microenvironment;Vaccine |
| 93 |
Poster Presentation |
PCR assay to identify Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element in CAR-T and TCR-T cells for fresh and formalin-fixed samples |
Shalini Pullarkat, Bachelor's of Science (In Progress); Jocelyn H. Wright; David W. Woolston; Erik L. Kimble; Bo M. Lee; Alexandre V. Hirayama; Aude G. Chapuis, PhD; Denise Buenrostro; Graeme Black; Marie Bleakley, MD; Brandon W. Seaton; Jennifer Specht; Cameron J. Turtle, MBBS, PhD; Cecilia C.S. Yeung, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;Biomarkers;CAR T cells;Targeted therapy |
| 94 |
Poster Presentation |
CyTOF and serum proteomics show distinct differences in immune responses between Mycosis Fungoides and Sezary Syndrome to mono- and combination anti-PD-1 immunotherapy |
Nirasha Ramchurren, PhD; Rachael Parks; Laura Islas; Steven P. Fling, PhD; Michael Khodadoust, MD PhD; Evan W. Newell, PhD; David R. Glass |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Immune monitoring;Proteomics;T cell;Tumor microenvironment |
| 95 |
Poster Presentation |
Characterization of human breast cancer tissue with the Xenium In Situ platform reveals a novel marker for invasiveness |
Robert Y. Henley, PhD; Nicole Rapicavoli; Amanda Janesick; Robert Shelansky; Albert Kim; Janine Hensel; Francesca Meschi; Navid Farahani; Vijay Kumar; Xiaoyan Qian; Sarah Taylor, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Gene expression;RNA;Tumor microenvironment |
| 96 |
Poster Presentation |
Metastatic breast cancer is associated with increased levels of soluble inhibitory immune checkpoint proteins and decreased levels of soluble stimulatory immune checkpoint proteins |
Bernardo L. Rapoport, MD, MMed; Helen Steel, PhD; Carol Benn, MD; Liezl Heyman, BScHons(Med.Imun); Teresa T. Smit, MPharm; Ronald Anderson, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Coinhibition;Costimulation;Solid tumors;TLR;Tumor microenvironment;Tumor stroma |
| 97 |
Poster Presentation |
Effect of administration of neoadjuvant chemotherapy to newly diagnosed early breast cancer patients on the depressed plasma levels of soluble co-stimulatory and co-inhibitory immune checkpoint molecules |
Bernardo L. Rapoport, MD, MMed; Helen Steel, PhD; Carol Benn, MD; Simon Nayler, MD; Teresa T. Smit, MPharm; Liezl Heyman, BScHons(Med.Imun); Annette Theron, PhD; Nomsa Hlatshwayo; Luyanda Kwofie; Pieter Meyer, PhD; Ronald Anderson, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Coinhibition;Costimulation;Immune monitoring;Solid tumors;Tumor microenvironment;Tumor stroma |
| 98 |
Poster Presentation |
Imaging Mass Cytometry Identifies Immuno-Oncology-Based Pathophysiological Features of the Mouse Tumor Tissue Microenvironment |
Thomas D. Pfister, PhD; Christina Loh, PhD; Michael Cohen, PhD; Sam Lim; Qanber Raza, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Bioinformatics;Immune monitoring;Leukemia/Lymphoma;Metabolism;Myeloid cells;Proteomics;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 99 |
Poster Presentation |
Spatial Insights into Tumor Immune Evasion Illuminated with the CosMx™ Spatial Molecular Imager Platform |
Jason W. Reeves, PhD; Patrick Danaher; Shanshan He, MD, PhD; Sean Kim; Michael Patrick; Julian Preciado; Justin Jenkins; Rachel Liu; Sarah Murphy; Christine Kang, PhD; Byron Hartman; Vik Devgan, PhD; Youngmi Kim, PhD; Michael Rhodes, PhD; Joseph M. Beechem, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Gene expression;Immune contexture;Solid tumors;Systems biology;Tumor microenvironment;Tumor stroma |
| 100 |
Poster Presentation |
Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy |
Guilhem Richard, PhD; Gary Steinberg; Nicole Ruggiero; William Martin, BA MD; Anne S. de Groot, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;Immune tolerance;Neoantigens;Regulatory T cell (Treg cell);T cell;Tumor antigens;Tumor evasion |
| 101 |
Poster Presentation |
DetermaIO (IO score) is associated with efficacy of ICI monotherapy in advanced NSCLC patients with ECOG 2 |
David L. Saltman, MD PhD; Rob S. Seitz; Tyler J. Nielsen, MS; Matthew G. Varga, PhD; Nicole S. Croteau; Heather M. Lockyer; David R. Hout, PhD; Brock L. Schweitzer, PhD; Douglas T. Ross, MD, PhD; Amit Jain, MD; Gregory Vidal, MD PhD; David R. Gandara, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Clinical study;Gene expression;RNA;Solid tumors;Tumor microenvironment;Tumor stroma |
| 102 |
Poster Presentation |
Exploring the spatial heterogeneity of immune cells in nasopharyngeal tumours |
Aastha Sobti, Doctoral Candidate, MClinDent Oral Surgery; Christina Sakellariou, PhD; Johan S. Nilsson, MD, PhD; David Askmyr, MD; Lennart Greiff, MD, PhD; Malin Lindstedt, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antigen presenting cells;Bioinformatics;Biomarkers;Dendritic cell;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 103 |
Poster Presentation |
Spatial protein analysis of the tumor microenvironment and biomarkers in Hodgkin's Lymphoma |
Alexander M. Xu, PhD; Tomohiro Aoki; Aixiang Jiang; Alicia Gamboa; Anthony Colombo; Christian Stiedl; Akil A. Merchant, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Leukemia/Lymphoma;Systems biology;Tumor microenvironment |
| 104 |
Poster Presentation |
Comprehensive Single-Cell Immune Profiling of Lymphoid and Peripheral Tissues of Aged Mice Using High-Parameter Flow Cytometry by CyTOF Technology. |
Wenxi Xu, Ph.D.; Stephen Li, Ph.D.; Alexandre Bouzekri; Thomas D. Pfister, PhD; Christina Loh, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;B cell;Dendritic cell;Immune contexture;Immune monitoring;Immunoscore;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;T cell |
| 105 |
Poster Presentation |
Prevalence of Claudin18.2 and PD-L1 Expression in Chinese Gastric/Gastroesophageal Junction Adenocarcinoma |
Linlin Mao, PhD; Wei Yi, PhD; Xu-Alan Lin, PhD; Ying Gu, PhD; Zhenzhong Xia, MD; Chuan Qi, MD; Michael Shi, MD; Steven Yu, PhD; Xueming Qian, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Solid tumors;Targeted therapy |
| 106 |
Poster Presentation |
Development of RO assay for anti-PD-1 mAb and anti-PD-1×CD47 BsAb utilizing hPD-1/hCD47 dual humanized mice, at preclinical setting to facilitate clinical validation |
Xiaoyu An, PhD; Mingfa Zang; Ke Hang, Ph.D; Xianfei He, Ph.D; Ruilin Sun; Jian Fei; Henry Li, Ph.D; Haijuan Yu |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Bispecifics;Solid tumors |
| 107 |
Poster Presentation |
Tumor specific MHC-I expression determines the local immune microenvironment in breast cancer |
Xiaopeng Sun, BS; Brandie C. Taylor, MS; Paula I. Gonzalez Ericsson; Violeta Sanchez, MS; Justin M. Balko, PhD, PharmD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune monitoring;NK/NKT cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 108 |
Poster Presentation |
Prediction of cancer immunotherapy response using ultrasound imaging of tumor stiffness and perfusion |
Chrysovalantis Voutouri, PhD; Triantafyllos Stylianopoulos; Fotios Mpekris; Myrofora Panagi; Christina Michael; John D. Martin |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Solid tumors;Tumor microenvironment |
| 109 |
Oral Presentation |
Quantitative spatial assessment of the tumor-immune microenvironment in the metastatic melanoma lymph node |
Rachel L. Maus, PhD; Raymond M. Moore; Alexey A. Leontovich, PhD; Zachary Fogarty; Ruifeng Guo, MD, PhD; Chathu Dona; Burak Tekin, MD; Jill Schimke; Betty Dicke; Benjamin Chen, MD,PhD; Svetomir N. Markovic, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Immune contexture;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 110 |
Poster Presentation |
Characterization of HPV-specific T-cells in Blood and Tissue in Ugandan Women Living with HIV with Cervical Low Grade Squamous Intraepithelial Lesions |
Amy S. Codd, PhD; Scott V. Adams; Cecilia C.S. Yeung, MD; Lauri D. Aicher; Corey Casper; Lisa M. Frenkel; Thomas S. Uldrick, MD; Evan W. Newell, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Carcinogenesis;Immune monitoring;Neoantigens;T cell;Tumor antigens;Tumor microenvironment |
| 111 |
Poster Presentation |
Integrating multidimensional mass cytometry and multiplex immunohistochemistry to infer spatial relationships between human glioblastoma infiltrating immune cells that correlate with patient outcome. |
Todd Bartkowiak, Ph.D.; Asa A. Brockman; Sierra M. Lima; Madeline J. Hayes; Caroline E. Roe; Justine Sinnaeve; Akshitkumar M. Mistry, M.D.; Nalin Leelatian, M.D., Ph.D; Bret C. Mobley, M.D.; Lola B. Chambless, MD; Reid C. Thompson, MD; Kyle D. Weaver, M.D.; Rebecca A. Ihrie, Ph.D.; Jonathan M. Irish, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Immune contexture;Immune suppression;Monocyte/Macrophage;Myeloid cells;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 112 |
Poster Presentation |
Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors |
Khalil Choucair, MD, MSc; Caroline A. Nebhan, MD, PhD; Alessio Cortellini, MD, PhD; Stijn Hentzen, MD; Yinghong Wang, MD, PhD; April Salama, MD; Andrew Elliott, PhD; Matthew J. Oberley, MD., PhD; Phillip Walker, PhD; Raza H. Bokhari; Raffaele Giusti; Marco Filetti; Paolo A. Ascierto, MD; Vito Vannella; Domenico Galetta; Annamaria Catino; Pamela Pizzutilo; Carlo Genova, MD, MD; Melissa Bersanelli, MD, PhD; Sebastiano Buti, MD; Azhaar Saeed; Wafik S. El-Deiry; Himisha Beltran, MD; Chadi Nabhan, MD; Douglas B. Johnson, M.D.; Claudia A.M. Fulgenzi; David J. Pinato, MD, MRes, PhD; Maluki Radford; Stephen V. Liu, MD; Chul Kim, MD; Rafeh Naqash; Anwaar Saeed, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Clinical study;Gene expression;Inflammation;Monocyte/Macrophage;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 113 |
Poster Presentation |
Uncovering the Dark Immunopeptidome of Head and Neck Squamous Cell Carcinoma (HNSCC): Relevance for Universal Cancer Vaccines, Immunological Monitoring and TIL therapy |
Noriko Iwamoto, PhD; Takashi Shimada, PhD; Tarsem L. Moudgil, MS; Ryan Meng; Tanisha L. Christie; Alexa K. Dowell; Rom Leidner, MD; Bryan R. Bell, MD, DDS, FACS; William L. Redmond, Ph.D.; Eric Tran, PhD; Hong-Ming Hu, PhD; Traci L. Hilton, PhD; Brian D. Piening, PhD; Yoshinobu Koguchi, MD, PhD; Bernard A. Fox, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune monitoring;Neoantigens;Proteomics;Surfaceome;T cell;Tumor antigens;Vaccine |
| 114 |
Poster Presentation |
Characterization of suppressive myeloid cells in solid tumors to refine disease selection in a Phase 1 study of the multi-Siglec inhibitor AL009 |
Julie Y. Huang, PhD; Sam C. Nalle, PhD; Helen Lam; Arnon Rosenthal, PhD; Daniel J. Maslyar, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Clinical trial;MDSC;Myeloid cells |
| 115 |
Poster Presentation |
Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structures |
Bryan Iorgulescu; Sophia Liu; Shuqiang Li; Mehdi Borji; Irving Barrera-Lopez; Vignesh Shanmugam; Haoxiang Lyu; Julia Morriss; Zoe Garcia; Evan Murray; David Reardon, MD; Charles Yoon; David A. Braun; Ken J. Livak, PhD; Catherine J. Wu, MD; Fei Chen |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Gene expression;Monocyte/Macrophage;T cell lineages;Tumor microenvironment |
| 116 |
Poster Presentation |
Deep High-plex Spatial Phenotyping of Glioblastoma multiforme Provides New Insights into the Immune Landscape and Tumor Heterogeneity |
Dmytro Klymyshyn; Niyati Jhaveri; Yasmin Kassim; Bassem Ben Cheikh; Oliver Braubach; Keith L. Black; Tao Sun |
Biomarkers, Immune Monitoring and Novel Technologies |
Immune contexture;Proteomics;Solid tumors;Tumor microenvironment |
| 117 |
Poster Presentation |
High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response |
Arutha Kulasinghe; Habib Sadeghirad; Ning Liu; James Monkman; Chin Wee Tan; Caroline Cooper; Sarah E. Church, PhD; Fabian Schneider; Jeppe Thaagard; James Mansfield; Kenneth J. O'Byrne, MD; Melissa Davis; Brett G.M. Hughes, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Proteomics;Solid tumors;Tumor microenvironment;Tumor stroma |
| 118 |
Poster Presentation |
Delineation of spatial tissue signatures of immunotherapy response groups in non-small cell lung cancer (NSCLC) |
Arutha Kulasinghe; James Monkman; Honesty Kim; Aaron Mayer, PhD; Ahmed Mehdi; Marie Cumberbatch; Milan Bhagat; Fabian Schneider; Jeppe Thaagard; James Mansfield; Rahul Ladwa; Scott N. Mueller; Mark Adams; Kenneth J. O'Byrne, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune contexture;Solid tumors;Tumor microenvironment |
| 119 |
Poster Presentation |
Sensitive prediction of immunotherapy response by integrating immune infiltration and neoantigen presentation score in late-stage melanoma |
Bailiang Li, MD; Charles W. Abbott, PhD; Lee D. McDaniel, Jr., MD, MSE; Rachel M. Pyke, PhD; Fabio Navarro, Ph.D.; Hima Anbunathan; Michael Synder; Sekwon Jang, MD; Sean M. Boyle, PhD, MS; Richard O. Chen, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Gene expression;Neoantigens;Tumor infiltrating lymphocytes (TILs) |
| 120 |
Poster Presentation |
Decoding Immunotherapy Responses with High-dimensional and High-throughput Spatial Phenotyping of Non-small cell Lung Cancer (NSCLC) |
Ning Ma; Aditya Pratapa; James Monkman; Ken O'Byrne; Oliver Braubach; Arutha Kulasinghe |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune contexture;Proteomics;Solid tumors;Tumor microenvironment |
| 121 |
Poster Presentation |
Tetraspanin molecule CD9 as a novel marker of tumor-reactive T cells |
Yoshihiro Miyahara, MD, PhD; Makiko Yamane, MS; Tae Hayashi, MS; Yuji Toiyama, MD, PhD; Kazushi Hiranuka, PhD; Hiroyuki Kishi, PhD; Hiroshi Shiku, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;Gene expression;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 122 |
Poster Presentation |
The Next Generation of Immunotherapy Response Signatures Revealed by Biophysical Simulations |
Gregory Norris; John R. Pfeiffer; Joseph R. Peterson, PhD; Nicole Liadis; Matthew Biancalana; Dorys A. Lopez-Ramos, PhD; Anuja K. Antony, MD; Daniel J. Cook |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Solid tumors;Tumor evasion |
| 123 |
Oral Presentation |
Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy |
Cristina Puig Saus; Barbara Sennino; Songming Peng; Zheng Pan, PhD; Benjamin Yuen; Bhamini Purandare; Kyle Jacoby; Olivier Dalmas; Duo An; Boi Quach; Clifford L. Wang; Huiming Xia; Sameeha Jilani; Diana Nguyen; Kevin Shao; Claire McHugh; John E. Greer; Phillip Peabody; Saparya Nayak; Jonaathan Hoover; Sara Said; Susan Foy, PhD; Andrew Conroy; Michael Yi; Christine Shieh; William Lu; Katharine A. Heeringa; Yan Ma; Shahab Chizari; Melissa Pilling; Marc Ting; Ramya Tunuguntla; Salemiz Sandoval; Robert Moot; Theresa Hunter; Sidi Zhao; Justin Saco; Ivan Perez-Garcilaso; Agustin Vega-Crespo; Ignacio Baselga; Gabriel Abril-Rodriguez, MS; Grace Cherry; Deborah J. Wong, M.D., Ph.D.; Jasreet Hundal; Bartosz Chmielowski, MD, PhD; Daniel E. Speiser, MD; Michael T. Bethune; Xiaoyan Bao; Alena Gros, PhD; Obi Griffith; Malachi Griffith, Ph.D.; James R. Heath, PhD; Alex Franzusoff; Stefanie J. Mandl, PhD; Antoni Ribas, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;Biomarkers;Checkpoint blockade;Neoantigens;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 124 |
Poster Presentation |
Identification of tumor antigens from multiple genomics sources using LENS (Landscape of Effective Neoantigens Software) |
Benjamin G. Vincent, MD; Steven Vensko; Kelly S. Olsen; Dante Bortone; Christof C. Smith, PhD; Shengjie Chai, PhD; Alexander Rubinsteyn |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Immune monitoring;Tumor antigens |
| 125 |
Poster Presentation |
Characterization and label-free isolation of phenotypically defined Human immune cells using Ghost Cytometry, a novel AI powered flow cytometry technology |
Keisuke Wagatsuma; Hiroko Nomaru; Kazuki Teranishi; Satoru Akai; Yuri An; Kaoru Komoriya; Yoko Kawamura; Asako Tsubouchi; Andy Wu; Sadao Ota |
Biomarkers, Immune Monitoring and Novel Technologies |
Immune monitoring;T cell;Tumor microenvironment |
| 126 |
Poster Presentation |
Prognostic gene signature reflecting CD8+ T cell enrichment in early-stage triple-negative breast cancer |
Chang M. Kim, PhD; Yun Suk Yu; Jin Young Park; Kyong Hwa Park |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Gene expression;RNA;T cell;Tumor microenvironment |
| 127 |
Poster Presentation |
Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance to immunotherapy in melanoma patients. |
Thazin N. Aung, PhD; Jonathan Warrell, PhD; Sandra Martinez-Morilla, PhD; Niki Gavrielatou, MD; Ioannis A. Vathiotis, MD; Nay N.N. Chan, PhD; Harriet Kluger, MD; David L. Rimm, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;RNA;Solid tumors;Systems biology;Tumor microenvironment;Tumor stroma |
| 128 |
Poster Presentation |
Multiomic spatial interrogation of tumor-infiltrated immune cells using the RNAscope™ Co-detection assay with vivid dyes |
Anushka Dikshit, PhD; Sayantani Basak; Emerald Doolittle, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Chemokine;Cytokine;Immune contexture;Inflammation;RNA;T cell;Tumor infiltrating lymphocytes (TILs) |
| 129 |
Poster Presentation |
Platform to conditionally induce lung tumors in genetically engineered mouse models using Cre mRNA containing nanoparticles |
Vidit Bhandarkar, BS; Elen Torres-Mejia; Namita Nabar; Tamara Dacoba; Paula T. Hammond; Stefani Spranger, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Myeloid cells;RNA;Solid tumors |
| 130 |
Poster Presentation |
Precise spatial multiplexing for immune cell profiling of the tumor microenvironment with ChipCytometry |
Thomas Campbell; Nancy Stanslowski; Jennifer Brooks |
Biomarkers, Immune Monitoring and Novel Technologies |
Immune monitoring;Proteomics;Tumor microenvironment |
| 131 |
Poster Presentation |
Quantitative spatial profiling of the tumor microenvironment in NSCLC tissue microarray cores using a 6-plex multiplex imaging technology and AI-powered phenotyping analysis |
Nicole Couper; Bethany Remeniuk; Karen McClymont; Bei Hopkins, MS; Natalie Monteiro; Lorcan Sherry, PhD; Darren Locke |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune contexture;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 132 |
Poster Presentation |
Racial differences in TMB measures between paired tumor/normal and tumor-only sequencing across endometrial, bladder, and non-small cell lung cancers |
Francisco M. De La Vega, Ph.D.; Yannick Pouliot; Chad Reichard; Rotem Ben-Shachar; Brooke Rhead; Kenneth Carson; Matheww Cooney; Kristiyana Kaneva; Justin Guinney; Afshin Dowlati |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Solid tumors |
| 133 |
Oral Presentation |
Spatially defined gene signatures uncover the association of extracellular matrix genes with immunotherapy resistance in head and neck squamous cell carcinoma |
Niki Gavrielatou, MD; Jonathan Warrell, PhD; Thazin N. Aung, PhD; Ioannis A. Vathiotis, MD; Panagiota Economopoulou, MD, PhD; Barbara A. Burtness, MD; Amanda Psyrri, MD, PhD; David L. Rimm, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;Immune contexture;Immune suppression;Solid tumors;Tumor microenvironment;Tumor stroma |
| 134 |
Poster Presentation |
B and Myeloid Cell Populations Dominate in the Metastasis Compared to Primary Tumors of Patients with Pancreatic Cancer |
Emily Greene, MS; Deon B. Doxie, PhD; Maria Diab; Bassel El-Rayes; Shishir K. Maithel, MD; Juan Sarmiento; Olatunji B. Alese, MD; Jayden Kim; Cameron J. Herting, PhD; Kavita M. Dhodapkar; Madhav V. Dhodapkar; Haydn Kissick, PhD; Chrystal M. Paulos, PhD; Gregory B. Lesinski, Ph.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
B cell;Immune monitoring;Myeloid cells;Solid tumors;T cell;Tumor microenvironment |
| 135 |
Poster Presentation |
Identification of super-exhausted T cells: a novel population predictive of response to immunotherapy |
Alban Bessede, PhD; Florent Peyraud, MD; Jean Philippe Guegan, PhD; Christophe Rey, PhD; Sylvestre Le Moulec, MD, PhD; Fabrice Barlesi, MD, PhD; Sophie Cousin, MD, PhD; Guilhem Roubaud, MD; Mathilde Cabart, MD; Maxime Brunet, MD; Ezogelin Gruyters, PhD; Ariel Savina, PhD; Berengère Dadone-Montaudon, MD, PhD; Aurélien Marabelle, MD, PhD; Jean Charles Soria, MD, PhD; Yohann Loriot, MD, PhD; Jean-Yves Scoazec, MD, PhD; François Le Loarer, MD, PhD; Antoine Italiano, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Coinhibition;Immune contexture;Immunoscore;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 136 |
Poster Presentation |
A plasma proteomic based predictive biomarker for response to immunotherapy in NSCLC |
Michal Harel, PhD; Coren Lahav, MSc; Ido Wolf, MD. PhD; Ella Tepper, MD; Maya Gottfried, MD; Raya Leibowitz, MD. PhD; Mahmoud Abu-Amna, MD; Abed Agbarya, MD; Rivka Katzenelson, MD; Michal Lotem, MD. PhD; Mor Moskovitz, MD; Alona Zer, MD; Ina Koch, PhD; Niels Reinmuth, MD. PhD; Adam P. Dicker, MD, PhD; David R. Gandara, MD; David P. Carbone, MD, PhD; Petros Christopoulos, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;Clinical study;Proteomics;Solid tumors;Systems biology |
| 137 |
Poster Presentation |
FcγRIIa-specific DARPins as a novel tool toward specific gene delivery into HIV reservoir cells |
Arezoo Jamali, PhD; Vanessa Riechert, MSc.; Samuel Theuerkauf, MSc.; Sascha Hein, Dr.; Philipp Adams, PhD; Elena Herreracarrillo, PhD; Ben Berkhout, Prof.PhD; Klaus Cichutek, PhD; Jessica Hartmann, PhD; Christian J. Buchholz, Prof, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Targeted therapy |
| 138 |
Poster Presentation |
Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy |
Astrid Z. Johansen; Sif I. Novitski; Jessica X. Hjaltelin, Assistant Professor; Susann Theile; Mogens K. Boisen, MD, PhD; Søren Brunak, Professor, Head of Research; Daniel H. Madsen, Associate Professor; Dorte L. Nielsen, Professor; Inna M. Chen, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Inflammation;Radiotherapy;Solid tumors |
| 139 |
Poster Presentation |
Identification of distinct tissue phenotypes in lung and colorectal cancers by Imaging Mass Cytometry is consistent across serial sections |
Smriti Kala, PhD; Rasmus Lyngby, PhD; Rasmus Sorensen; Andrew Quong, PhD; Sam Lim; Clinton Hupple; Nina Lane; Jeppe S. Thagaard; Johan Dore-Hansen; James R. Mansfield, MSc; Fabian Schneider; Michelle MacPherson |
Biomarkers, Immune Monitoring and Novel Technologies |
Immune contexture;Immune monitoring;Myeloid cells;Proteomics;Solid tumors;Systems biology;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 140 |
Poster Presentation |
Assessment of differences in tumor mutational burden identified on liquid biopsy in 16,870 patients newly diagnosed with metastatic cancer |
Eugene Kwon; Daniel S. Childs; Bradley J. Stish; Stephen Boorjian; Matthew Tollefson; Cameron Britton; Ahmed Mahmoud; Ahmed Mohamed; Angela Thompson; Reagan Barnett; Leylah Drusbosky; Leslie A. Bucheit, MS CGC |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Solid tumors |
| 141 |
Poster Presentation |
Indoleamine 2,3 dioxygenase expression predicts response to Immune Checkpoint Blockers in advanced Non-Small Cell Lung Cancer |
Alban Bessede, PhD; Sylvestre Le Moulec, MD, PhD; Jean Philippe Guegan, PhD; Isabelle Soubeyran, MD, PhD; Florent Peyraud, MD; Christophe Rey, PhD; Antoine Italiano, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune monitoring;Immune suppression;Immune tolerance;Metabolism;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 142 |
Poster Presentation |
Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histoculture platform |
Satish Sankaran, PhD; Oliyarasi M; Rajashekar M.; Ritu Malhotra; Kowshik Jaganathan; Gowri Shankar K; Vasanth K.; Manjula B.V.; MS Ganesh; Amritha Prabha; Prakash BV; C. Jaya Prakash; Arjun Chakraborty; Syamkumar V.; Biswajit Das; Aditi Satish; Nandini P. Basak |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Cytokine;Immune contexture;Immune monitoring;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 143 |
Poster Presentation |
A comprehensive workflow for highplex imaging, tissue segmentation, and multiplex cellular phenotyping for tumor microenvironment analysis |
Fabian Schneider; Rasmus Lyngby, PhD; Rasmus Sorensen; Andrew Quong, PhD; Smriti Kala, PhD; Sam Lim; Clinton Hupple; Nina Lane; Michelle MacPherson; Jeppe S. Thagaard; Johan Dore-Hansen; James R. Mansfield, MSc |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune contexture;Immune monitoring;Monocyte/Macrophage;Solid tumors;Systems biology;T cell;T cell lineages;Tumor microenvironment;Tumor stroma |
| 144 |
Poster Presentation |
CD3 humanized mouse models as validated tools to assess immune-related adverse events of T cell engagers |
Perrine Martin-Jeantet; Gaelle Martin, PhD; Angela Pappalardo; Florence Renart-Depontieu; Patricia Isnard-Petit; Yacine Cherifi; Fabiane Sônego, PhD, MS; Kader Thiam |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Bispecifics;Cytokine;Immune toxicity;T cell;Targeted therapy |
| 145 |
Poster Presentation |
Nadunolimab inhibits IL-1α/β-induced CXCR1/2 ligand expression and reduces serum levels of CXCL1 and CXCL5 in NSCLC and PDAC patients |
Camilla R. Millrud, PhD; Elin J. Gyllenbäck; Petter Skoog; Annika Sanfridson; David Liberg |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Chemokine;Chemotherapy;Clinical trial;Immune suppression;Myeloid cells;Solid tumors;Tumor microenvironment;Tumor stroma |
| 146 |
Poster Presentation |
Transcriptome augmentation provides accurate and sensitive quantification of genes associated with the tumor microenvironment |
Fabio Navarro, Ph.D.; Pamela Milani, PhD; Koichi Hashikawa, Ph.D.; Shruti Bhide, M.S.; Upasana Dutta, M.S.; Dave Delano; Charles W. Abbott, PhD; Robin Li, MS; Zeid Rusan; John S. West, MBA; John Lyle; Sean M. Boyle, PhD, MS; Richard O. Chen, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
B cell;Gene expression;Granulocyte;Immune contexture;T cell;Tumor infiltrating lymphocytes (TILs) |
| 147 |
Poster Presentation |
Comprehensive in situ immune phenotyping with the CosMxTM high plex protein assay |
Tien M. Phan-Everson, PhD; Jianji Chen, PhD; Zachary Lewis, PhD; Gary Geiss, PhD; Yan Liang, MD PhD; Emily Brown; Liuliu Pan, PhD; Stefan Phelan, MS; Charlie Glaser; Mithra Korukonda, PhD; Carl Brown, PhD; Dwayne Dunaway, PhD; Joseph Phan, PhD; Alyssa Rosenbloom, PhD; Brian Filanoski, PhD; Rhonda Meredith; Kan Chantranuvatana; Brian Birditt; Giang Ong, MS; Hye Son Yi; Erin Piazza, PhD; Jason W. Reeves, PhD; Subham Basu, PhD; Christine Kang, PhD; Vik Devgan, PhD; Edward Zhao, PhD; Michael Rhodes, PhD; Joseph M. Beechem, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;B cell;Biomarkers;Monocyte/Macrophage;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 148 |
Oral Presentation |
TAP2 deficiency mediates adaptive immune evasion and immunotherapy resistance in human non-small cell lung cancer |
Kishu Ranjan, Ph.D.; Imad Ud Deen, MD; Miguel López de Rodas, MD; Nicole Gianino, MS; Soldano Ferrone, MD, PhD; Kurt A. Schalper, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Chemokine;Cytokine;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor microenvironment |
| 149 |
Poster Presentation |
Complementary PhenoCode Signature Panels comprehensively map cell interactions and identify Spatial Phenotypic Signatures in the tumor microenvironment |
Bethany Remeniuk; Bei Hopkins, MS; Natalie Monteiro; Darren Locke |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Immune contexture;Immune suppression;Inflammation;Myeloid cells;Solid tumors;T cell;Tumor microenvironment;Tumor stroma |
| 150 |
Poster Presentation |
Circulatory plasma proteomic biomarkers predict response to immunotherapy in melanoma patients and reveal biological insights into the tumor microenvironment |
Arnav Mehta; Marijana Rucevic; Emmett Sprecher; Nir Hacohen; Genevieve Boland, MD PhD; Milan Parikh; Jiajia Chen; Dennie T. Frederick; Elliot Woods; Lynn Bi; David Lieb; Lina Hultin-Rosenberg; Jamey Guess; Ryan J. Park; Alexis Schneider; William Michaud; Benchun Miao; Gyulnara Kasumova; Michelle S. Kim; Xue Bai; Russell W. Jenkins; Samuel J. Klempner; Anna LK. Gonye; Keren Yizhak; Moshe Sade-Feldman; David Liu; Ryan J. Sullivan; Keith T. Flaherty |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Cytokine;Immune monitoring;Immune suppression;Monocyte/Macrophage;Myeloid cells;Proteomics;Solid tumors;Tumor microenvironment |
| 151 |
Poster Presentation |
Using Additional Morphology Markers in NanoString GeoMx Whole Transcriptome Atlas assay to assess NSCLC tumor subtype |
Jessica Runyon, MA; Christian Nievera, PhD; Vijay Baichwal, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Tumor microenvironment |
| 152 |
Poster Presentation |
The immune expression landscape of solid tumors with tertiary lymphoid structures |
Maria-Fernanda Senosain, PhD; R.J. J. Seager, Jr., Ph.D.; Erik Van Roey; Shuang Gao; Mary K. Nesline; Jeffrey Conroy, BS; Sarabjot Pabla, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 153 |
Poster Presentation |
Clinical implication of Exhaustive T-Cell Environment in Uveal Melanoma Patients |
Mithalesh K. Singh, Dr., PhD; Seema Kashyap, MD; Nikhil Kumar, M.Sc; Jayanti Jha, M.Sc; Neiwete Lomi, MD; Lata Singh, Ph.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Gene expression;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 154 |
Poster Presentation |
Generation of humanized mouse models for the preclinical evaluation of novel immune checkpoint inhibitors, immune cell engagers and cell therapies |
Maria Stecklum, PhD; Annika Wulf-Goldenberg, PhD; Bernadette Brzezicha; Christian Rupp, PhD; Wolfgang Walther, PhD; Jens Hoffmann |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Bispecifics;Checkpoint blockade;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 155 |
Poster Presentation |
MHC class I antigen presentation is associated with an inflamed SCLC tumor microenvironment characterized by a higher density of cytotoxic T-cells in closer proximity to tumor cells |
Markus Schick, PhD; Miljenka Vuko; Mingchao Xie, PhD; Monica Azqueta Gavaldon; Felix Segerer; Andreas Spitzmüller; Harald Hessel; Marco Testori; Johannes Zimmermann; Michael J. Surace, PhD; Mari Heininen-Brown; Jaime Rodriguez Canales; Shashank Saran; Helen K. Angell, PhD, BSc; Guenter Schmidt, PhD; Hadassah Sade, PhD; J. Carl Barrett, PhD; Giulia Fabbri |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune contexture;Immune monitoring;Solid tumors;Tumor microenvironment |
| 156 |
Poster Presentation |
Establishment of an Immune Cell Phenotyping Multiplexed Immunofluorescence Assay and Digital Image Analysis Workflow to Investigate the Tumor Microenvironment in Solid Tumors |
Dirk Zielinski; Suso Platero |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune monitoring;Tumor microenvironment |
| 157 |
Poster Presentation |
Interrogation of the Tumor Immune Microenvironment and ex vivo Profiling of PD-1 Blockade using the 3D-EXplore ex vivo Platform of Fresh Patient Tumor Tissue |
Brittney Ruedlinger, PhD; Jasmin D'Andrea, MS; Jared C. Ehrhart, PhD; Soner Altiok, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Checkpoint blockade;Immune suppression;MDSC;Myeloid cells;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 158 |
Poster Presentation |
A novel, highly accurate liquid biopsy-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer. |
Klaus Lindpaintner, MD, MPH; Apoorva Srinivasan, PhD; Alan Mitchell, PhD; Apurva Dixit, PhD; Gege Xu, PhD; Xin Cong, PhD; Daniel Serie, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Checkpoint blockade;Post-translational modifications;Targeted therapy |
| 159 |
Poster Presentation |
Xerna tumor microenvironment subtypes as a biomarker in lung cancer patients |
Mark Landers, B.S.; Patrick Eimerman, Ph.D; Steve Mastrian; Tracey White, Ph.D; Janine LoBello, D.O,. FCAP; Gargi Basu, Ph.D; Szabolcs Szelinger, PhD; Jessica Aldrich, Ph.D; Matthew Halbert; Jess Hoag; David Hall; Farjana Fattah, Ph.D; Daniel Pointing; Luka Ausec, Ph.D; Anze Gregorc; Seema Iyer; Mark Uhlik, Ph.D; Laura Benjamin, Ph.D; Rick Baehner, M.D. |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Gene expression;Immune suppression;RNA;Targeted therapy;Tumor microenvironment |
| 160 |
Poster Presentation |
Novel, high-plex, and flexible biomarker panels for rapid development of spatial signatures to improve stratification of response to combination therapies |
Rachel Schaefer; Jacob Circelli; Oscar Perez; Linying Liu; Michael McLane, II; Yi Zheng, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 161 |
Oral Presentation |
Single-cell spatial in situ transcriptomics unravels vulvar HSIL composition associated with complete response to therapeutic vaccination |
Ziena Abdulrahman, MD; Mariette I.E. van Poelgeest; Marij J.P. Welters; Sjoerd H. van der Burg |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Inflammation;Myeloid cells;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma;Vaccine |
| 162 |
Poster Presentation |
Detecting T-cell reinvigoration and persistence using patient derived ex vivo three-dimensional spheroid models |
Katy A. Lassahn, MS; Ashley K. Elrod; Tessa M. DesRochers, PhD; Kathryn M. Appleton, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 163 |
Poster Presentation |
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions |
Ziena Abdulrahman, MD; Natasja Hendriks; Arnold J. Kruse; Antonios Somarakis; Anna J.M. van de Sande; Heleen van Beekhuizen; Jurgen M.J. Piek; Noel F.C.C. de Miranda; Loes F.S. Kooreman; Brigitte F.M. Slangen; Sjoerd H. van der Burg; Peggy J. de Vos van Steenwijk; Edith M.G. van Esch |
Biomarkers, Immune Monitoring and Novel Technologies |
Antigen presenting cells;Bioinformatics;Biomarkers;Dendritic cell;Monocyte/Macrophage;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 164 |
Poster Presentation |
Evaluation of liquid biopsy-based plasma copy number burden, DNA methylation and Personalized minimal residual disease approach for monitoring molecular response to different drug regimens in metastatic colorectal cancer patient |
Zheng Feng, PhD, MD; Neil R. Smith, PhD; Giancarlo Bonora, PhD; Juergen Scheuenpflug; Pan Du |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Epigenetics;Solid tumors;Targeted therapy |
| 165 |
Poster Presentation |
PAHR: the pan-cancer AHR signature pipeline |
Peter K. Schulz-Knappe, MD, PhD; Christiane A. Opitz; Saskia Trump; Ahmed Sadik |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Clinical trial;Gene expression;Immune monitoring;Immune suppression;Proteomics;Regulatory T cell (Treg cell);T cell;Tumor microenvironment |
| 167 |
Poster Presentation |
Comprehensive profiling of cancer-associated fibroblasts in CD8+T cell-exclusive non-small cell lung cancer tumor microenvironments using the Nanostring GeoMX Digital Spatial Profiler |
Christina Cho, PhD; Gavitt Woodard, MD; Francesc Lopez-Giraldez, PhD; Ti Badri, MS, MS, MPH; Matthew D. Vesely, MD, PhD; Lieping Chen, MD, PhD, FAIO |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Gene expression;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 168 |
Poster Presentation |
Exploring features and parameters for neighborhood analysis in human cancer multiplexed immunofluorescence data |
Ian Dryg, PhD; Madison Turner; Ann-Elizabeth Le, MS; Anne E. Carlisle, PhD; Kathleen L. Pfaff, PhD; Jason L. Weirather, PhD; F. Stephen Hodi, Jr., MD; Scott J. Rodig, MD, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Biomarkers;Immune contexture;Proteomics;Solid tumors;Tumor microenvironment;Tumor stroma |
| 169 |
Poster Presentation |
Immunotherapeutic Potential of the Humanized Anti-MUC16 Antibody AR9.6 against PDAC |
Christabelle Rajesh; Satish Sagar; Cory L. Brooks; Michael A. Hollingsworth; Prakash Radhakrishnan |
Biomarkers, Immune Monitoring and Novel Technologies |
Antibody;Biomarkers;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 171 |
Poster Presentation |
Tumor microenvironment immune cell landscape varies among molecular subtypes in gastric cancer. |
Sanyog Dwivedi, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Immunoscore;MDSC;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 172 |
Poster Presentation |
Body mass index (BMI) and serum albumin level as a predictor of survival outcomes in advanced-stage melanoma patients treated with anti-PD1 therapy |
Yusuf R. Mohamoud; Yeonhee Park; Dahlia H. Tesfamichael; Vincent Pozorski; Vincent T. Ma, MD |
Biomarkers, Immune Monitoring and Novel Technologies |
Biomarkers;Checkpoint blockade;Clinical study |
| 173 |
Poster Presentation |
Sensitivity and concordance of CD274 expression by RNA sequencing (RNA-seq) in comparison with three PD-L1 immunohistochemistry methods in head and neck squamous cell carcinoma (HNSCC) |
Mary K. Nesline; Sarabjot Pabla, Ph.D.; Jeffrey Conroy, BS; Paul DePietro, PhD; Shengle Zhang; Roger Klein; Achyut Bhagelu, PhD; Rebecca Previs; Prasanth Reddy; Shakti Ramkissoon; Eric Severson |
Biomarkers, Immune Monitoring and Novel Technologies |
Gene expression;RNA;Solid tumors |
| 174 |
Poster Presentation |
Single cell FFPE and spatial transcriptomic profiling of an invasive ductal carcinoma enhances cellular and spatial insights |
Ryan Stott, PhD; Jawad Abousoud; Stephen Williams, PhD; Shamoni Maheshwari, PhD; Valeria Giangarra, PhD; Sarah Taylor, PhD; Andrew Kohlway, PhD |
Biomarkers, Immune Monitoring and Novel Technologies |
Bioinformatics;Gene expression;RNA;Solid tumors |
| 175 |
Poster Presentation |
CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma |
Paul D. Rennert, PhD; Lihe Su, PhD; Lan Wu, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell |
| 176 |
Poster Presentation |
Immune Activation by Antigen-specific T cells Elicited in Patients Receiving Standard Therapy for Pediatric Solid Tumors |
Jillian P. Smith, MD; Amy Hont, MD; Catherine Bollard, MD |
Cellular Therapies |
Adoptive immunotherapy;Pediatric tumors;Solid tumors;T cell |
| 177 |
Poster Presentation |
Preclinical characterization of CYT-100 iPSC derived NK cells alone and in combination with CYT-303 NK cell engager for hepatocellular carcinoma (HCC). |
Liang Lin; Andrea Chambers; Marshall Chao Ma; Hao-Ming Chang; David Zou; Preeti Ashok; Elisabetta Burchi; Armin Rath; Stanley Frankel; Jean Kadouche; Daniel Tepper; Nejmi Dilmac; Antonio Arulanandam; Wei Li |
Cellular Therapies |
Adoptive immunotherapy;Bispecifics;NK/NKT cell |
| 178 |
Poster Presentation |
Targeting ER-Mitochondrial dynamics to improve responses to immune checkpoint blockade |
Katherine L. Cook, PhD; Elizabeth R. Stirling, MS, PhD; Jessica D. Mackert, PhD; Mitra Kooshki, MS; Adam S. Wilson; Wei Zhang, PhD; Pierre L. Triozzi, MD; David R. Soto-Pantoja, PhD |
Cellular Therapies |
Checkpoint blockade;Immune suppression;Metabolism;Tumor evasion;Tumor microenvironment |
| 179 |
Poster Presentation |
T-cells derived from malignant pleural effusions (MPE) are readily expandable, polyfunctional and cytotoxic to autologous tumor |
Vera S. Donnenberg, PHD; Albert D. Donnenberg, MD; James D. Luketich, MD; Shannon Puhalla, MD; Yasa S. Mutlu, MD; David Bartlett, MD |
Cellular Therapies |
Adoptive immunotherapy;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 180 |
Poster Presentation |
The in-vitro measure of T cell avidity between tumor-effector pairs, not affinity, predicts optimal anti-tumor response in vivo |
Justin M. Moser, PhD; Yotam Bar-Ephraim, PhD; Jens Eberlein, PhD; Keith Bailey, PhD; Song-My Hoang, PhD; Andrea Candelli, PhD; Will Singleterry, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Bispecifics;Solid tumors;T cell |
| 181 |
Poster Presentation |
High throughput screening strategies in the development of logic gated cell therapies |
Rona Harari-Steinfeld, PhD; Laura Lim; Angela C. Boroughs; Sofia Kyriazopoulou Panagiotopoulou; Cate Sue; Jamie Thomas; Jon Chen; Aaron Cooper; Ryan Fong; Mary Chua; Ed Yashin; Christine Shieh; Sophie Xu; Nicholas Haining |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell |
| 182 |
Poster Presentation |
Discovery of TSC-203-A02: A PRAME-specific TCR-T cell therapy candidate for the treatment of solid tumors |
Mollie M. Jurewicz, PhD; Elizabeth M. Hall; Alexandra L. Luther; Kimberly M. Cirelli, PhD; Vivin Karthik; Kenneth L. Jahan; Tary Traore, PhD; Maytal Bowman; Victor Ospina; Sonal Jangalwe, PhD; Shubhangi Kamalia; Sadie Lee; Daniel C. Pollacksmith; Sida Liao, PhD; Amy Virbasius, PhD; Kristen Murray; Jillian L. Oliveira; Lisa Nip, PhD; Christina E. Lam; Livio Dukaj, PhD; Danielle Ramsdell; Jin He; Joel W. Sher, PhD; Ribhu Nayar, PhD; Qikai Xu, PhD; Yifan Wang, PhD; Antoine J. Boudot, PhD; Cagan Gurer, PhD; Gavin MacBeath, PhD |
Cellular Therapies |
Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 183 |
Poster Presentation |
Cancer-mutation-specific T cells: novel immunotherapy approach for low mutational burden patients |
Alfred E. Slanetz, Ph.D.; Walter Barry, Ph.D.; Benjamin Schwarz, M.D. Ph.D.; Farzonai Muzaffar; Ryan Campbell; Abenezer Abera |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Cytokine;Neoantigens;RNA;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor microenvironment |
| 184 |
Poster Presentation |
Discovery, cloning and functional validation of a neoantigen specific patient derived TCR on the Berkeley Lights platform, with implications in personalized cancer immunotherapy |
Joseph M. Valdez, Ph.D.; Guido Stadler, Ph.D.; Pei-Yu (Kate) Lin, Ph.D.; Milton Quintanilla; Tyler Helmann; Xiuli Zhang, M.D.; S. Peter Goedegebuure, Ph.D.; Malachi Griffith, Ph.D.; William E. Gillanders, MD; William A. Hoos, MBA, MS; Yiyang Xu, Ph.D. |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Cytokine;Dendritic cell;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Vaccine |
| 185 |
Poster Presentation |
Tuning the cell-cell distance via the non-signaling extracellular spacer domain of chimeric antigen receptors is critical for optimal activity |
Jason K. Yokoyama, BS; Lisa Song; Quinn Walker; Bijan A. Boldajipour, PhD; Howell Moffett; Brian Weitzner; Scott Boyken; Marc Lajoie |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;T cell |
| 186 |
Poster Presentation |
Tumor reactive, cytokine induced, engineered human natural killer cells demonstrate serial cytotoxicity against liquid and solid tumor cell targets |
Ting Lu; Christian Bustillos; Zhiyao Li; Jianying Zhang; Lei Zhang; Li Chen; Jianhua Yu; Michael A. Caligiuri, MD |
Cellular Therapies |
Adoptive immunotherapy;Cytokine;NK/NKT cell |
| 187 |
Poster Presentation |
A live tumor fragment platform suitable for assessing response to T-cell therapies |
Christopher D. Zahm, PhD; Laura Hrycyniak; Ellen Wargowski; Dinesh Joshi; Team Adstamongkonkul; Greg Ochs; Gabriella Stueber; Debra Bloom; Ryan Fischer; Christina Scribano; Christin Johnson; Anura Shrestha; Nathan Marhefke; Ariah Law; Jonathan Oliner |
Cellular Therapies |
Biomarkers;CAR T cells;Clinical trial;Cytokine;Immune monitoring;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 188 |
Poster Presentation |
Arginine pre-conditioning enhances T-cell potency and metabolic fitness |
Rashmi Pillai, PhD; Xiaoyu Zhang; Brandon Lamarche, Ph.D.; Yama Abassi, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Metabolism;T cell;Tumor microenvironment |
| 189 |
Poster Presentation |
CRISPR-mediated metabolic reprograming of adoptively transferred T cells to potentiate antitumor response |
Soraya Zorro Manrique, Ph.D.; Yunfei Wang, PHD; Ana L. Dominguez; Debra S. Armendariz; Patrick Hwu |
Cellular Therapies |
Adoptive immunotherapy;Immune suppression;Metabolism;Solid tumors;T cell;Tumor microenvironment |
| 190 |
Poster Presentation |
Novel Cellular Immunotherapy with anti-mesothelin CAR-killer lymphocytes against advanced Cholangiocarcinoma |
Annamaria Massa, PhD; Annamaria Massa; Valeria Leuci; Federica Galvagno; Chiara Donini; Francesca Vita; Ramona Rotolo; Alessia Proment; Letizia Vitali; Elisabetta Fenocchio; Elisa Vigna; Giuliana Cavalloni; Massimo Aglietta; Dario Sangiolo |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell lineages;Tumor antigens |
| 191 |
Poster Presentation |
Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Bladder Cancer to Enhance Efficacy of Adoptive Cell Therapy (ACT) |
Sarah Bazargan, PhD Candidate; Brittany Bunch, PhD; Jamie Blauvelt; Annick Landin; Johannes Ali; Dominique Abrahams; Amy Hall; Matthew Beatty, PhD; Michael Poch, MD; Shari Pilon-Thomas, PhD |
Cellular Therapies |
Adoptive immunotherapy;Chemotherapy;MDSC;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs) |
| 192 |
Poster Presentation |
Characterization of antibodies against BTN2A1 for Vδ2+ γδ T cell-based tumor immunotherapy |
Kok Fei Chan, PhD; Simone Ostrouska; Ranjeeta Prasad; Daria Kurtov; Andrew Hammet; Marc Rigau; Adam P. Uldrich; Andreas Behren |
Cellular Therapies |
Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 193 |
Poster Presentation |
CAR-T manufactured from frozen PBMC yield efficient function with delayed in vitro expansion |
Julieta Abraham-Miranda, Pharm, PhD; Meghan Menges; Reginald Atkins; Mike Mattie, PhD; Justyna Kanska; Joel Turner; Melanie J. Hidalgo-Vargas; Frederick L. Locke, MD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Cytokine;T cell |
| 194 |
Poster Presentation |
Pre-clinical development of CT-1119, a mesothelin targeting chimeric antigen receptor macrophage (CAR-M), for solid tumor immunotherapy |
Nicholas R. Anderson, PhD; Michael Klichinsky, PharmD, PhD; Kerri Ciccaglione; Stefano Pierini; Brinda Shah; Alison Worth, MSc; Rashid Gabbasov, PhD; Brett Menchel, MBT; Daniel Blumenthal, PhD; Sabrina DeLong, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD |
Cellular Therapies |
Antigen presenting cells;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy |
| 195 |
Poster Presentation |
Characterization of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity |
Laura L. Arthur, PhD; Mary E. Mathyer, PhD; Celeste J. Dufour, B.S.; Bryan Cruz, B.S.; Melissa Berrien-Elliot, PhD; Mark Foster, PhD; Nitin Mahajan, PhD; Alun Carter, PhD; Matthew L. Cooper; Ryan Sullivan, PhD |
Cellular Therapies |
Adoptive immunotherapy;NK/NKT cell |
| 196 |
Poster Presentation |
Expansion of tumor-infiltrating lymphocytes from colorectal cancer liver metastasis; characteristics and potential histologic marker of successful cell expansion |
Jina Baek, MD; Hyun Lee, MD; Gyungyub Gong; Chae-Lyul Lim; Hee Jin Lee |
Cellular Therapies |
Adoptive immunotherapy;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 197 |
Poster Presentation |
Preliminary safety and efficacy of autologous anti-MSLN T cell engager-loaded T cells (CAB-T) in patients with mesothelin-expressing advanced solid tumors |
Xuanwen Bao; Lulu Liu; Jialin Gu; Mei Li; Zhou Tong; Hangyu Zhang; Yalin Li; Xinjiang Gong; Peng Wang; Andy Tsun; Guoqiang Hu; Chuan-Chu Chou, PhD; Zhiyuan Li; Weijia Fang |
Cellular Therapies |
Adoptive immunotherapy;Bispecifics;CAR T cells;Clinical study;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 198 |
Poster Presentation |
Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of γδ T Cell Immunotherapy |
Marissa Herrman, PhD; Taylor Barca; Xue (Cher) Yang; Maryam Tabrizizad; Morgan Smith-Boeck; Louise Kiru; Jonathan T.S. Wong; Ramandeep Kaur; Smitha R.Y. Gundurao; Gauri Lamture, PhD; Aruna Azameera; Kevin P. Nishimoto, PhD; Arun Bhat; Blake T. Aftab, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;T cell |
| 199 |
Poster Presentation |
3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing |
Sander Basten, PhD; Nataliia Beztsinna; Fanny Grillet; Kuan Yan; Niels Meesters; Donny van der Meer; Emma Spanjaard; Willemijn Vader; Leo Price |
Cellular Therapies |
Biomarkers;Checkpoint blockade;Chemokine;Chemotherapy;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 200 |
Poster Presentation |
A Unique CRISPR-Based Nuclease with a Non-NGG PAM Efficiently Targets Multiple Exclusive Genomic Sites for Immuno-Oncology Based Therapy |
Rachel Diamant, M.Sc; Lior Lior Izhar; Ira Gotliv; Yonit Ben David; Sigal Cohen; Maya Noff; Nir Shahar; Rafi Emmanuel; Bar Ben Baruch |
Cellular Therapies |
CAR T cells;NK/NKT cell;T cell;Targeted therapy;Tumor microenvironment |
| 201 |
Poster Presentation |
Development of GUCY2C-TAC T cells for the treatment of colorectal cancer |
Tania Benatar, PhD; Ling Wang, MD; Thanyashanthi Nitya-Nootan, BSc; Heather L. MacGregor, PhD; Suzanna L. Prosser, PhD; Philbert Ip, PhD; Prabha Lal, PhD; Stacey X. Xu, PhD; Laura M. Shaver; Sadhak Sengupta, PhD; Christopher W. Helsen, PhD; Andreas G. Bader, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 202 |
Poster Presentation |
Single step knock-in of next generation inducible IL-12 armored CAR T constructs |
Alexander Benton, BA; Anze Smole, Ph.D.; Mathilde Poussin; Monika A. Eiva, BS; Daniel J. Powell, PhD |
Cellular Therapies |
CAR T cells;Cytokine;Immune toxicity;Solid tumors |
| 203 |
Poster Presentation |
Preclinical Discovery and Characterization of Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer |
Nitya S. Ramadoss, PhD; Aruna Azameera; Alexander G. Teague; Jonathan T.S. Wong; Atrish Bagchi; Tonya Capillo; Morgan Smith-Boeck; Michael Salum; Erika Meaddough; Elizabeth Speltz; Matthew Hoopes; Katherine Wang; Ramandeep Kaur; Smitha R.Y. Gundurao; Marissa Herrman, PhD; Yvan Chanthery; Blake T. Aftab, PhD; Kevin P. Nishimoto, PhD; Arun Bhat |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 204 |
Poster Presentation |
Combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity |
John Goulding, PhD; Bryan Hancock; Robert Blum; Wen-I Yeh, PhD; Chia-Wei Chang, PhD; Mochtar Pribadi, PhD; Yijia Pan, PhD; Hui-Yi Chu, PhD; Shohreh Sikaroodi, PhD; Thomas Dailey, BS; Miguel Meza; Lucas Ferrari de Andrade, PhD; Peter Szabo, MD, PhD; Sarah Cooley, MD, MS; Jeffrey Chou, MD, PhD; John D. Powderly, II, MD; Yu-Waye Chu, MD; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Kai W. Wucherpfennig, MD, PhD; Bob Valamehr, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antibody;NK/NKT cell;Solid tumors |
| 205 |
Oral Presentation |
Specific AMPK agonism during CART in vitro expansion enhances oxidative metabolism and improves in vivo leukemia clearance |
Erica Braverman, MD; Harrison Brown; Manda Ramsey; Craig Byersdorfer, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;Metabolism |
| 206 |
Poster Presentation |
Novel intermediate-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against human hepatocellular carcinoma |
Leidy D. Caraballo-Galva; Xiaotao Jiang; Mohamed S. Hussein; Huajun Zhang; Rui Mao; Pierce Brody; Yibing Peng; AIwu He; Mercy Kehinde-Ige; Ramses Sadek; Xiangguo Qiu; Huidong Shi; Yukai He |
Cellular Therapies |
Adoptive immunotherapy;Antibody;CAR T cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 207 |
Poster Presentation |
Claudin18.2-targeting CAB-T cells have superior safety over traditional CAR-T, while maintaining potent in vivo anti-tumor efficacy |
Jitian Chai; Weifeng Huang; Shaogang Peng; Zhenqing Zhang; Yao Yan; Chuan-Chu Chou, PhD; Andy Tsun; Zhiyuan Li |
Cellular Therapies |
Antibody;Bispecifics;Costimulation;Immune toxicity;Solid tumors;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 208 |
Poster Presentation |
T-SIGn vector-mediated antigen 'spray painting' and tumor microenvironment (TME) reprogramming to enable CAR-T cell targeting of solid tumors |
Maria Stella Sasso; Rachel Bergin; Manuela Zonca; Eva Vainiute; Tae Hyun Jang; Zahra Oubihi; Meg Snowden; Alice Muntzer; Carla Cerqueira; Rochelle Lear; Katy West; Brian R. Champion, PhD |
Cellular Therapies |
Bispecifics;CAR T cells;Gene expression;Solid tumors;T cell;Tumor microenvironment |
| 209 |
Poster Presentation |
Anti-ALPP CAR-T Cell Immunotherapy for Ovarian and Endometrial Cancer |
Si Li, PhD; Qi-Jing Li, PhD; Nicole Palmer; Johnny Guan; Zhenbo Su; Peter Alexander, PhD; Rui Chen, PhD; Lixia Zhao, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;T cell;Tumor antigens |
| 210 |
Poster Presentation |
Generation of hypoimmunogenic allogeneic CAR T cells by inactivation of transcriptional regulators of HLA Class I and II genes |
Hsinyuan Cheng, PhD; Michael Yi; Michael T. Bethune; Eric Gschweng; Melinda Au; Duy Nguyen; Kristen Zhang; Tanu Shenoy; Barbra J. Sasu, PhD; Thomas Van Blarcom; Cesar Sommer |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Gene expression;Immune tolerance;Leukemia/Lymphoma;NK/NKT cell;T cell |
| 211 |
Poster Presentation |
Chemical priming of natural killer cells for cancer immunotherapy |
Seung Hee Choi; Eun-Su Ko; Joo Dong Park, MS; Kyung-Soon Park |
Cellular Therapies |
Chemokine;Cytokine;Granulocyte;Immune contexture;Immune toxicity;Metabolism;NK/NKT cell;Proteomics;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 212 |
Oral Presentation |
Adoptively transferred Th17 cells cooperate with host B cells to mediate robust immunity to tumors |
Anna C. Cole, B.A.; Hannah M. Knochelmann, MD, PhD; Amalia M. Rivera-Reyes; Aubrey S. Smith, Ph.D.; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Jeremy M. Boss, Ph.D.; Gregory B. Lesinski, Ph.D.; Chrystal M. Paulos, PhD |
Cellular Therapies |
Adoptive immunotherapy;B cell;Solid tumors;T cell |
| 213 |
Poster Presentation |
Design, characterization and preclinical validation of a combinatorial CAR-based immunotherapy against colorectal cancer with HER2 amplification |
Marco Cortese, PhD; Erica Torchiaro, Post-doc; Simonetta M. Leto, Post-doc; Consalvo Petti, Post-doc; Alice D'Andrea, MS; Federica Invrea, Post-doc; Sabrina Arena, Associate Professor; Enzo Medico, MD PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;NK/NKT cell;Solid tumors |
| 214 |
Poster Presentation |
Investigating the Consequences of TIM-3 Expression on mTOR Activation and NK Cell Cytotoxicity against Glioblastoma |
Tram Dao, BS; Sandro Matosevic, PhD |
Cellular Therapies |
Adoptive immunotherapy;Metabolism;NK/NKT cell;Tumor infiltrating lymphocytes (TILs) |
| 215 |
Poster Presentation |
Targeting ovarian carcinoma with GDT002, a first-in-class γδTCR-based T cell therapy |
Esther Drent, PhD; Sabine Middendorp, PhD; Andrea Bisso, PhD; Sjoerd Baardman; Dagmar Verweij; Estefania Salcedo; Chris Coomans; Steven Braem; Sander van de Weg; Menno Meijer; Natalie Proost; Marieke van de Ven; Haakan Norell; Marleen van Loenen; Nia Emami; Sara Melief; Stefania Gobessi; Mark Throsby, PhD |
Cellular Therapies |
Adoptive immunotherapy;Solid tumors;T cell |
| 216 |
Poster Presentation |
Dual targeting of CAR-NK cells to PD-L1 and ErbB2 facilitates specific elimination of cancer cells of solid tumor origin and overcomes immune escape by antigen loss |
Jiri Eitler, PhD; Kristin Freudenberg; Paola Ortiz Montero; Wiebke Rackwitz; Winfried Wels, PhD; Torsten Tonn |
Cellular Therapies |
Checkpoint blockade;NK/NKT cell;Targeted therapy;Tumor evasion |
| 217 |
Poster Presentation |
Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth |
Piril Erler, PhD; Tomasz Kurcon; Jordan Skinner; Chantel Dixon; Steven Grudman; Ben Mumford; Shipra Das, PhD; Alexander Boyne, PhD; Alexandre Juillerat; Roman Galetto, PhD; Julien Valton, PhD; Hana Cho; Laurent Poirot, PhD; Beatriz Aranda-Orgilles, PhD |
Cellular Therapies |
CAR T cells;Solid tumors;Tumor microenvironment |
| 218 |
Oral Presentation |
Immunogenic landscape and therapeutic targeting of mutant NRAS 'public' neoantigens |
Iñaki Etxeberria, PhD; Lauren B. Banks, MD PhD; Smita S. Chandran, PhD; Arianna Correa; Bryan C. Novak; Jessica M. Fleischman; Alexander Drilon, MD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD; Christopher A. Klebanoff, MD |
Cellular Therapies |
Adoptive immunotherapy;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 219 |
Poster Presentation |
The Functional Activity of Gavo-cel TRuC-T Cells is not Impaired by Soluble Mesothelin |
Michael Lofgren, PhD; Robert Tighe, PhD; Robert Hofmeister, PhD; Jian Ding, PhD; Nate Bagge, BS; Alec Andrews, MS; Michelle Fleury, PhD; Courtney Anderson, PhD |
Cellular Therapies |
Clinical trial;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor microenvironment |
| 220 |
Poster Presentation |
Luciferase reporter cancer cell lines facilitate CAR-T development |
John G. Foulke, MS; Luping Chen, BS; Brian Della Fera, BS; Hyeyoun Chang, PhD; Kevin Tyo, PhD; Zhizhan Gu, MD, PhD; Fang Tian, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Immune monitoring;Leukemia/Lymphoma;Solid tumors;Targeted therapy;Tumor antigens |
| 221 |
Poster Presentation |
SENTI-401, an Allogeneic Logic-Gated and Multi-Armed CAR-NK Cell Therapy for the Treatment of CEA-Expressing Solid Tumors with Enhanced Selectivity and Efficacy |
Alba Gonzalez Junca, PhD; Nicholas Frankel, PhD; Maelig Morvan, PhD; Assen Roguev, PhD; Michelle Hung, PhD; Russell Gordley, PhD; Miguel R. Palermo; Tyler Santomaso; Pearley Chinta; Aldo Sotelo, MS; Marcus Gainer, MS; Derrick Lee; Tony Hua, PhD; Andrew Banicki; Mengxi Tian; Niran Almudhfar; Atahualpa Contreras; Chen-Ting Lee, PhD; Timothy K. Lu, PhD |
Cellular Therapies |
Adoptive immunotherapy;Cytokine;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment |
| 222 |
Poster Presentation |
Developing an Adoptive Cell Transfer Immunotherapy for Pediatric High-Grade Gliomas |
Stephen C. Frederico, M.S.; Chaim T. Sneiderman, B.S.; Ian F. Pollack, M.D.; Gary Kohanbash, Ph.D. |
Cellular Therapies |
Adoptive immunotherapy;Pediatric tumors;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 223 |
Poster Presentation |
anti-TnMuc1 CAR-T Cells that are Conditionally Armed with IL12 Eliminate Adenocarcinomas in Preclinical Models |
Albert Gacerez, PhD; Eytan Herzig, PhD; Tiger G. Ren, MD,PhD; Nicole Grant; Jay Danao; Daniel Roche, PhD; Daeun Nam, PhD; Krista McNally; Ben Wang; Melissa Fardy, PhD; Gus Zeiner, PhD |
Cellular Therapies |
CAR T cells;Cytokine;Gene expression;Immune toxicity;Metabolism;Post-translational modifications;RNA;Solid tumors;T cell;Tumor microenvironment |
| 224 |
Poster Presentation |
Generation of cell therapies for diverse applications using microfluidic Cell Squeeze manufacturing technology |
Jonathan Gilbert, PhD; Maisam Dadgar; Scott M. Loughhead, PhD; Ipsita Roymoulik; Devin Bridgen, PhD; Howard Bernstein, MD, PhD; Armon Sharei, PhD |
Cellular Therapies |
Antigen presenting cells;CAR T cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 225 |
Poster Presentation |
Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) immune checkpoint as a modulator of T-cell effector function |
Miguel Gomez Fontela, PhD; Sebastian Snedal; Daniel Abate-Daga, PhD |
Cellular Therapies |
CAR T cells;Checkpoint blockade;Cytokine;Immune suppression;Solid tumors;Systems biology;T cell;Targeted therapy |
| 227 |
Poster Presentation |
hunTR™: a hyperplex platform for the discovery of neoantigen-reactive T-cell receptors |
Guowei Gu, Ph.D Pharm.D; Julissa Simmons; Kristen Rimaila; Gaby Garland; Ugochi Ibekwe; Donghyun Joo; An Lu; Amanda Montoya; Pretty R. Mathew; Hao Zhao; Beatriz A. Santillan; Matthew R. Collinson-Pautz; Drew C. Deniger |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Bioinformatics;Gene expression;Neoantigens;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 228 |
Poster Presentation |
Multi-Arming and Regulator Dial gene circuits tackle key challenges in solid tumors |
Marcela Guzman Ayala, PhD; Michelle Hung, PhD; Deepika Kaveri, PhD; Rebecca Cottman, PhD; Elizabeth Leitner; Priscilla Wong; Ronni Ponek; Enping Hong, PhD; Manan Shah; Andrew Banicki; Lawrence Naitmazi; Kelly Lee, PhD; Wesley Gorman; Russell Gordley, PhD; Philip Lee, PhD; Timothy K. Lu, PhD |
Cellular Therapies |
Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy |
| 229 |
Poster Presentation |
A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer |
J. Randolph Hecht, MD; Mark L. Sandberg, PhD; Xueyin Wang; Aaron D. Martin, M.A.; Daniel Nampe; Grant Gabrelow; Chuck Z. Li; Michele Mcelvain; Wen-Hua Lee; Sanam Shafaattalab; Sara Martire; Fernando Fisher; Yuta Ando; Edwin Liu; David Ju; Jing-Ping Hsin; Alexandre Zampieri; Diane M. Simeone, MD; Scott Kopetz, PhD; Maria Pia Morelli; Mitesh J. Borad, MD; Theodore H. Welling; Sandip P. Patel, MD; Edward B. Garon; Kedar Kirtane; Frederick L. Locke, MD; John S. Welch; Eric W. Ng, MD; William Y. Go; Armen Mardiros; David G. Maloney, MD, PhD; Lu-Min Wong; Alexander Kamb, PhD; Han Xu, PhD; Julian R. Molina, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Gene expression;Genetic polymorphism;Solid tumors;T cell;Tumor antigens;Tumor evasion |
| 230 |
Poster Presentation |
TCR-like chimeric-antigen-receptor to recognize neoepitopes derived from driver mutations |
Yafei Hou, phD; David Hou, BA |
Cellular Therapies |
CAR T cells;Neoantigens;Solid tumors;T cell |
| 231 |
Poster Presentation |
Dysfunctional immune synapses restrain anti-DIPG activity of CAR T cells |
Jorge Ibanez, PhD; Haley Houke; Michaela Meehl; Jennifer Ocasio; Nikhil Hebbar; Paulina Velasquez; Suzanne Baker; Giedre Krenciute, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Immune suppression;Pediatric tumors;Solid tumors;T cell |
| 232 |
Poster Presentation |
Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-RTM genetic reprogramming technology |
Helle Jensen; Rachel Fukuda; Megan Murt; Xiao Wang; Lora Zhao; Sheila Lou; Purnima Sundar; Christopher Navas; Andrew Jimena; Amanda Sims; Travis Beckett; Shobha Potluri; Rowena Martinez; David Chian; Candace Sims; Quinn Walker; Abira Bandyopadhyay; Breanna Pamintuan; Bijan Boldajipour; Chang-Chih Wu; Martin Wohlfahrt; Byoung Ryu; Viola C. Lam; Rachel C. Lynn; Hajime Hiraragi; Johannes Breuning; Ashley Hamilton; Fotini Kouri; Jack Euesden; Sara Brett; Blythe Sather |
Cellular Therapies |
Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy |
| 233 |
Poster Presentation |
A real-world case of second chimeric antigen receptor t-cell therapy |
Jacinth Joseph, MD; Dennis Marjoncu, PharmD; Kori Holman, PharmD; Sara Leidy, PharmD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma |
| 234 |
Poster Presentation |
Bead-bound antibody-activation of T cells provides sub-optimal metabolic programming and tumour control compared to dendritic cell-activated T cells |
Meghan Kates, BSc; Gavin Yuen; Michael St. Paul, PhD; Alisha R. Elford; Pamela S. Ohashi, PhD; Sam Saibil, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Dendritic cell;Metabolism;T cell |
| 235 |
Poster Presentation |
CRISPR-mediated insertion of IL-12 into the PDCD1 locus improves the antitumor activity of TCR-T cells against solid tumors |
Segi Kim; Choi Park; Sunhwa Lee; Hyeongryeol Choi; Chan Hyuk Kim |
Cellular Therapies |
Adoptive immunotherapy;Cytokine;Solid tumors;T cell |
| 236 |
Poster Presentation |
Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the successful expansion factors for developing adoptive cell therapy |
Mofazzal Hossain, MBBS; Jong Hyeok Kim; Hyun Lee, MD; Chae-Lyul Lim; Gyungyub Gong; Hee Jin Lee |
Cellular Therapies |
Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs) |
| 237 |
Oral Presentation |
Neoantigen-specific expansion of tumor-infiltrating lymphocytes enables effective treatment of p53-mutant cancer in mice |
Peter Kim, PhD; Noam Levin; Nolan Vale; Steven A. Rosenberg, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Neoantigens;Solid tumors;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 238 |
Poster Presentation |
Exogenous GOT2 in CAR-T cells improves metabolic function and preserves early memory T cell subsets |
John W. Hinds, PhD; Sujatha Muralidharan, PhD; Ann M. Ranger, PhD; Jennifer A. Coccia; Thomas P. Giordano, III; Emily G. Kuiper, PhD; Pratirodh Koirala, PhD |
Cellular Therapies |
CAR T cells;Metabolism;Solid tumors;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 239 |
Poster Presentation |
Engineering of potency-enhanced TCR-edited T cells for shared neoantigen-targeted cancer immunotherapy |
Lianne Kok; Sander R. Eshuis, MSc; Paula Kroon, PhD; Vanessa Tubb, PhD; Xiangjun Kong, PhD; Carsten Linnemann; Gavin M. Bendle; Jeroen W.J. van Heijst, PhD |
Cellular Therapies |
T cell |
| 240 |
Poster Presentation |
Humanized CD30 chimeric antigen receptor T cells with a novel 4-1BB derived spacer have improved activity and safety against CD30-positive lymphomas |
Lindsay Kua, PhD; Chee Hoe Ng; Jin Wei Tan; Richard Ong; Cheah Chen Seh; Fiona Wong; Don Sim; Ivan David Horak; Lionel Low; Kar Wai Tan |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell |
| 241 |
Poster Presentation |
Development of a personalized neoantigen-specific TCR discovery platform |
Robbert M. Spaapen, PhD; Thomas Kuilman, PhD; Bo S. Schrikkema; Jules Gadiot; Raquel Gomez; Julia Walker; Laura Bies; Oscar Krijgsman; Yvonne B. Claassen; Milena Viyacheva; Demi Houg; Manuel Soarnil; Huiwen Ding; Bas Stringer; Gavin M. Bendle; Carsten Linnemann; Ton N. Schumacher, PhD |
Cellular Therapies |
Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 242 |
Poster Presentation |
Development of pooled screening platform for discovering the next generation Chimeric Antigen Receptors |
Taeyoon Kyung, PhD; Nicole Wong; Andreas Rolfs; Lucas Hartsough; Joshua Mace; Jai Raman; Adam Scheidegger; Adam Meyer; Siqi Zhao; Lauren Baugh; Keith Robison; Narendra Maheshri; Shawdee Eshghi |
Cellular Therapies |
CAR T cells;Costimulation;T cell |
| 243 |
Poster Presentation |
NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo |
Viola C. Lam, PhD; Jessica Barragan; Christina Cheung, MS; Jia Lu, PhD; David Chian; Rowena Martinez; Candace Sims; Purnima Sundar; Hajime Hiraragi; Shobha Potluri; Rachel C. Lynn, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy |
| 244 |
Oral Presentation |
AFNT-111, a safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation |
Hubert Lam, PhD; Xingyue He, PhD; Cheryl Black; Michele M. Hoffmann, PhD; Joshua Francis, PhD; James Parsons; Christian Roy; Jinsheng Liang; Hongjing Qu; Martin Campbell; Tomasz Sewastianik, PhD; Jessica Webb; Aude G. Chapuis, PhD; Thomas M. Schmitt, PhD; Philip D. Greenberg, MD; Damien Hallet; Markus P. Vallaster; Piotr Pierog; Gary Shapiro, PhD; Loic Vincent, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Clinical trial;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 245 |
Poster Presentation |
Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia |
Monica Raimo, PhD; Nina Lamers-Kok; Didem O'Zkazanc; Daniëlle Steenmans; Greis Shahini; Amanda van Vliet; Denise Panella; Arianna Micciché; Youri van Waardenburg; Anna-Maria Georgoudaki; Jan Spanholtz; Adil D. Duru |
Cellular Therapies |
Adoptive immunotherapy;B cell;Bioinformatics;Gene expression;Leukemia/Lymphoma;NK/NKT cell;Tumor antigens |
| 246 |
Poster Presentation |
Allogeneic 'off-the-shelf' γδ T cells modified with CD27-containing CAR for targeting CD70+ cancers |
Gauri Lamture, PhD; Alexander G. Teague; Morgan Smith-Boeck; Michael Salum; Ramandeep Kaur; Smitha R.Y. Gundurao; Pannaga Parthasarathy; Yvan Chanthery; Marissa Herrman, PhD; Blake T. Aftab, PhD; Arun Bhat; Kevin P. Nishimoto, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor antigens |
| 247 |
Poster Presentation |
Preclinical Discovery and Evaluation of Allogeneic 'Off-the-Shelf' γδ CAR T Cells Targeting B7-H6+ Tumors |
Gauri Lamture, PhD; Alexander G. Teague; Jonathan T.S. Wong; Morgan Smith-Boeck; Michael Salum; Erika Meaddough; Pannaga Parthasarathy; Atrish Bagchi; Matthew Hoopes; Elizabeth Speltz; Ramandeep Kaur; Smitha R.Y. Gundurao; Nitya S. Ramadoss, PhD; Marissa Herrman, PhD; Blake T. Aftab, PhD; Arun Bhat; Kevin P. Nishimoto, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 248 |
Poster Presentation |
Intrathecal Delivery of Dendritic Cell Vaccine Eradicates Tumor Growth and Protects Against Leptomeningeal Disease Re-inoculation in Immunocompetent HER2+ and Triple Negative Breast Cancer LMD Xenograft Models |
Vincent Law, MS; Krithika N. Kodumudi, PhD; Colin Snyder, MS; Brian Czerniecki, MD, PhD; Peter Forsyth |
Cellular Therapies |
Adoptive immunotherapy;Dendritic cell;Targeted therapy |
| 249 |
Poster Presentation |
Heterogeneity and changes of T-cell subset proportion during the expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer |
Hyun Lee, MD; Gyungyub Gong; Chae-Lyul Lim; Hee Jin Lee |
Cellular Therapies |
Adoptive immunotherapy;Biomarkers;T cell;Tumor infiltrating lymphocytes (TILs) |
| 250 |
Poster Presentation |
Chimeric antigen receptors containing CD30-derived costimulatory domain elicit augmented T cell effector functions and anti-tumor efficacy |
Hyun-Il Cho, Ph.D.; Chung-Hyo Kang; Sang-Eun Lee; In-Sil Song; Jung-Min Ha; Hyun-Jung Sohn; Tai-Gyu Kim |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Costimulation;Solid tumors |
| 251 |
Poster Presentation |
Application of Antibody-Cell Conjugation Technology in a Novel Off-the-shelf CD20-targeting Gamma Delta T Cell Therapy ACE1831 |
Hao-Kang Li, Ph.D; Tai-Sheng Wu; Yi-Chiu Kuo; Ching-Wen Hsiao; Hsiu-Ping Yang; Chia-Yun Lee; Pei-Ju Leng; Zih-Fei Cheng; Sen-Han Yang; Yang-Liang Lin; Shih-Chia Hsiao; Sai-Wen Tang |
Cellular Therapies |
Adoptive immunotherapy;Leukemia/Lymphoma;T cell |
| 252 |
Poster Presentation |
Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-RTM technology, a programmable synthetic cell-signaling platform |
Aileen Li, PhD; Jessica Briones; Jia Lu, PhD; Candace Sims; Quinn Walker; Rowena Martinez; Stefan Siebert; Lora Zhao; Emily Fu-Sum; Sheila Lou; Andrew Jimena; Elizabeth Pedrosa; Purnima Sundar; Hajime Hiraragi; Shobha Potluri; Bijan Boldajipour; Omar Ali; Alexander Cheung |
Cellular Therapies |
CAR T cells;Costimulation;Solid tumors;T cell |
| 253 |
Poster Presentation |
Fully human CD123 CAR T cells irradicate AML in pre-clinical models and exhibit a favorable safety profile |
Genqing Liang, PhD; Peirong Hu; Ngoc Tran; Hasan Mahmud; Pradyot Dash; Dina Schneider, Ph.D |
Cellular Therapies |
CAR T cells;Leukemia/Lymphoma;T cell;Targeted therapy |
| 254 |
Poster Presentation |
The CBL-B inhibitor, NX-0255, enhances human drug enhanced tumor infiltrating lymphocyte (DeTIL) expansion and T cell function in full-scale runs |
Xiaoyan Liang, PhD; Xianzhu Wu, PhD; Jeevitha Jeevan, MS; Samuel Butler; Pranav Murthy, MS; Arthur T. Sands, MD PhD; Michael T. Lotze, MD |
Cellular Therapies |
Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs) |
| 255 |
Poster Presentation |
ExPRESSTM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTILTM product |
Sharon Lin; Leila J. Williams, MS; Mitali Ghose, MS; Hugh Gannon, PhD; Conor Calnan; Angelina Pizzo; Pei-Lun Kao; Mallory Brady; Katri Sofjan; Anne Dodson, PhD; Sol Shenker, PhD; Michael Schlabach, PhD; Fiona Sharp, PhD; Frank Stegmeier, PhD; Micah J. Benson, PhD; Karrie K. Wong, PhD |
Cellular Therapies |
Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 256 |
Poster Presentation |
In Vivo expansion of endogenous antigen-specific CD8+ T cells using artificial T-cell stimulating microparticles |
Natalie K. Livingston, BS; John W. Hickey, PhD; Hajin Sim; Hai-Quan Mao, PhD; Jonathan P. Schneck, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Neoantigens;Solid tumors;T cell;Tumor antigens |
| 257 |
Poster Presentation |
An off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors |
Miguel Lopez-Lago; William Williams; Giuseppe del Priore; Sagarika Pachhal; Vikas Bhardwaj; Xiaoyi Zheng; Mingjin Chang; Charles Wiseman |
Cellular Therapies |
Antigen presenting cells;Solid tumors;T cell;Targeted therapy;Vaccine |
| 258 |
Poster Presentation |
Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance in solid tumors |
Yong Lu, Ph.D; Ningbo Zheng |
Cellular Therapies |
CAR T cells;T cell |
| 259 |
Poster Presentation |
iPSC-derived NK cells engineered with a novel TGFβ signal redirector receptor exhibit enhanced performance against solid tumors |
Eigen Peralta, PhD; Dan Lu; Hui-Yi Chu, PhD; Justin Rahman; Diana Galvan; Amit Mehta; Eric Sung; Jeffrey Chen; Masanao Tsuda; Elena Demeester; Earl Avramis; Alec Witty; Tom T. Lee, PhD; Bob Valamehr, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Costimulation;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 260 |
Poster Presentation |
Investigating cancer cell autonomous CAR T cell therapy resistance in DLBCL in vitro |
Fabiana Lueoend, PhD; Youngchul Song; Beverly Nguyen; Xiaoyan Li; Andreas Raue; Jennifer L. Brogdon; Glenn Dranoff; Matthew J. Niederst; Louise M. Treanor |
Cellular Therapies |
CAR T cells;Leukemia/Lymphoma;Tumor evasion |
| 261 |
Poster Presentation |
Evidence for durable anti-tumor responses by TAC-T cells in preclinical models of solid tumors |
Heather L. MacGregor, PhD; Duane Moogk, PhD; Stacey X. Xu, PhD; Joanne A. Hammill, PhD; Philbert Ip, PhD; Ling Wang, MD; Swati Shetty; Kyle MacDonald; Laura M. Shaver; Sailaja Pirati; Prabha Lal, PhD; Christopher W. Helsen, PhD; Jonathan L. Bramson, PhD; Sadhak Sengupta, PhD; Andreas G. Bader, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 262 |
Poster Presentation |
Multiple targeting of solid tumors with iPSC-derived gamma delta CAR T cells in combination with therapeutic antibodies |
Hillary J. Millar Quinn; Justin Bianchini; Liam Campion; Katherine Santostefano; Toshinobu Nishimura; Sydney Bucher; Buddha Gurung; Shelby Keating; Rebecca Genovese; Steven DeLuca; Bruno Bonanno; David Walker; Marilda Beqiri; Chris Dower; Kaitlin Idank; Tomas Aramburu; Michael Naso; Luis Borges; Mark Wallet, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antibody;CAR T cells;Solid tumors;T cell;T cell lineages |
| 263 |
Poster Presentation |
A2B694, an autologous logic-gated cell therapy targeting mesothelin |
Julian R. Molina, MD, PhD; Talar Tokatlian; Jason Wang; Shruti Sharma; Diane Manry; Martin S. Naradikian; Grace E. Asuelime; Breanna DiAndreth; Aaron Winters; Tisha San Miguel; Armen Mardiros; Sandip P. Patel, MD; Edward B. Garon; Diane M. Simeone, MD; Scott Kopetz, PhD; Maria Pia Morelli; Theodore H. Welling; Mitesh J. Borad, MD; Kedar Kirtane; Eric W. Ng, MD; John S. Welch; David G. Maloney, MD, PhD; William Y. Go; Alexander Kamb, PhD; Agi E. Hamburger, PhD; J. Randolph Hecht, MD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Gene expression;Genetic polymorphism;Solid tumors;T cell;Tumor antigens;Tumor evasion |
| 264 |
Poster Presentation |
Allogeneic natural killer cells engineered to express HER2-directed CAR, interleukin-15 and TGFß dominant negative receptor effectively control HER2+ tumors |
Finola Moore, PhD; Andres Alvarez; Alexia Barandiaran; Luke Barron; Eugene Choi; Krista Daniel; Charlotte Franco; Bashar Hamza; Jennifer Johnson; Annie Khamhoung; Marilyn Marques; Henry Moreno; Angela Nunez; Dominic Picarella; Jared Sewell; Alex Storer; Meghan Walsh, MS; Vipin Suri |
Cellular Therapies |
Adoptive immunotherapy;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment |
| 265 |
Poster Presentation |
Empowering iPSC-Derived iNK Cells with Multiple Gene Edits to Improve Persistence and Anti-Tumor Efficacy |
Buddha Gurung, PhD; Annalise Jethon; Maisha Harris; Shelby Keating; Spencer Moros; Rebecca Genovese; Steven DeLuca; Arden Edgerton; Nicholas Alexander; Chiamin Bullaughey, PhD; Barry Morse, PhD; Liam Campion; Mark Mendonca; Kaitlin Idank; Hillary J. Millar Quinn; Diana Chin; Jill Carton, PhD; Michael F. Naso, PhD; Mark Wallet, PhD; Luis G. Borges, PhD |
Cellular Therapies |
Adoptive immunotherapy;NK/NKT cell |
| 266 |
Poster Presentation |
STING activation improves T cell engaging immunotherapy of Acute Myeloid Leukemia |
Daniel Nixdorf, M.Sc.; Andreas Linder, Dr. med.; Niklas Kuhl; TengTeng Xu, M.Sc.; Roman Kischel, PhD; Veit Bücklein, Dr. med.; Thomas Carell, Prof. Dr.; Veit Hornung, Prof. Dr.; Marion Subklewe, Prof. Dr. med. |
Cellular Therapies |
Bispecifics;Immune adjuvant;Leukemia/Lymphoma;T cell;Targeted therapy;Tumor microenvironment |
| 267 |
Poster Presentation |
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy |
Irene Olivera, MSc; Elixabet Bolanos; Jose González-Gomariz; Sandra Hervas-Stubbs; Karina V. Mariño; Carlos Luri-Rey; Iñaki Etxeberria; Assunta Cirella; Josune Egea; Javier Glez-Vaz; Saray Garasa, BS; Maite Alvarez; Iñaki Eguren-Santamaria; Sonia Guedan; Miguel F. Sanmamed; Pedro Berraondo, PharmD; Gabriel A. Rabinovich, PhD; Alvaro Teijeira, PhD; Ignacio I.M. Melero, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Cytokine;Metabolism;RNA;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 268 |
Poster Presentation |
Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells |
Alessia Potenza, PhD; Chiara Bonini, MD; Chiara Balestrieri; Luca Albarello; Federica Pedica; Martina Spiga; Francesco Manfredi; Beatrice C. Cianciotti; Claudia De Lalla; Lorena Stasi; Elena Tassi; Silvia Bonfiglio; Giulia M. Scotti; Miriam Redegalli; Donatella Biancolini; Danilo Abbati; Fabio Simeoni; Dejan Lazarevic; Ugo Elmore; Guido Fiorentini; Giulia Di Lullo; Giulia Casorati; Paolo Dellabona; Claudio Doglioni; Giovanni Tonon; Riccardo Rosati; Luca Aldrighetti; Eliana Ruggiero, PhD |
Cellular Therapies |
Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 269 |
Poster Presentation |
Mitochondrial apoptosis mediates CAR T cell cytotoxicity |
Alexandra L. Pourzia, MD, PhD; Michael L. Olson, PhD; Stefanie R. Bailey, PhD; Aditi Aryal, BS; Jeremy Ryan, MS; Marcela V. Maus, MD, PhD; Anthony Letai, PhD MD |
Cellular Therapies |
CAR T cells;Leukemia/Lymphoma;Solid tumors;T cell;Tumor evasion |
| 270 |
Poster Presentation |
Developing placental CD34+-derived natural killer cells with high affinity and cleavage resistant CD16 (CYNK-101) in combination with Avelumab for enhanced therapy against PD-L1+ solid tumors |
Irene Raitman, PhD; Gavin Foley; Eric He; Hemlata Rana, MS; Niranjan Ghimire, PhD; Xuan Guo, PhD; Robert Hariri, MD PhD; Lin Kang, PhD |
Cellular Therapies |
Antibody;Checkpoint blockade;Solid tumors;Tumor antigens |
| 271 |
Poster Presentation |
B cell primed CD8 T cells generate similar phenotype, function and anti-tumor responses to DC primed CD8 T cells. |
Ichwaku Rastogi, MS; Douglas G. McNeel, MD, PhD |
Cellular Therapies |
Antigen presenting cells;B cell;Dendritic cell;Vaccine |
| 272 |
Poster Presentation |
Pre-clinical evaluation and first-in-dog clinical trials of intravenous infusion of PBMC-expanded adoptive NK cell therapy in dogs with cancer |
Aryana M. Razmara, MS; Lauren E. Farley, BS; Rayna M. Harris, PhD; Sean J. Judge, MD, MS; Marshall Lammers, BS; Cordelia M. Dunai, MS; William J. Murphy; Robert M. Rebhun, DVM PhD; Michael S. Kent, DVM; Robert J. Canter, MD |
Cellular Therapies |
Adoptive immunotherapy;Bioinformatics;NK/NKT cell;Radiotherapy;Solid tumors |
| 273 |
Poster Presentation |
GDA-501: Engineered NAM-NK cells with HER2-CAR expression demonstrate increased cytotoxicity against HER2-expressing solid tumors |
Julia Rifman |
Cellular Therapies |
NK/NKT cell;Solid tumors |
| 274 |
Poster Presentation |
LCK Knockout CAR-T Cells as a Novel Allogeneic Platform |
Previtha Dawn Sakthi Vale, B.Sc; Ling Wu, Ph.D.; Vivian Jia Yi Tan, B.Sc; Benson Chua; Liangzhe Wu; Jia Chi Tan; Clara Kai Ting Koh; June Ong; Nicholas Gascoigne |
Cellular Therapies |
Adoptive immunotherapy;Autoimmunity;CAR T cells;Immune tolerance;Leukemia/Lymphoma;Pediatric tumors;T cell;Targeted therapy |
| 275 |
Poster Presentation |
Manufacture of allogeneic, HLA-matched, TCR-edited T-cell therapy reactive against minor histocompatibility antigen 1 to treat Acute Myeloid Leukemia in combination with CD34 HSCT with the potential for high potency and durability |
Robert Keefe, PhD; Tim mayall; Egidio Cofano; Marlyn Anguelov; Constantinos Panousis; Paola Sette |
Cellular Therapies |
Adoptive immunotherapy;T cell |
| 276 |
Poster Presentation |
Engineering of synthetic chemokine receptors into iPSC-derived CAR-T cells to increase homing and enhance trafficking into solid tumors |
Soheila Shirinbak, PhD; Joy Grant; Angela Gentile; Bishwas Shrestha, PhD; Philip Chu; Amit Mehta; Yijia Pan, PhD; Bjoern Gaertner; Mochtar Pribadi, PhD; Joyee Yao; Matthew Denholtz; Alec Witty; Layton H. Smith, PhD; Tom T. Lee, PhD; Eigen Peralta, PhD; Martin Hosking, PhD; Bob Valamehr, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Chemokine;Chemotherapy;Immune suppression;Solid tumors;T cell;Tumor evasion;Tumor microenvironment |
| 277 |
Poster Presentation |
Development of a robust manufacturing process for AB-1015, an integrated circuit T cell (ICT) product, using targeted, CRISPR integration of transgenes by electroporation (CITE) editing |
Alice Chang; Sophia Phillips; Max Lee; Elizabeth Huang; Navneet Anand; Hayden Ko; Stella Tran; Lindsay Rios; Rory Dai; Anton Nguyen; Anu Vasudevan; Rona Harari Steinfeld; Dina Polyak; Jessica Fuhriman; Hongruo Yun; Jun Feng; Haixia Wang; Ben Tran; Jenessa Smith; Tim Sirichoke |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;Targeted therapy;Tumor microenvironment |
| 278 |
Poster Presentation |
Pharmacologically-controlled expression of membrane-bound IL-12 results in T-cell therapy with enhanced potency in preclinical solid tumor models |
Sean G. Smith, PhD; Benjamin Primack, MS; Theresa Ross; Patricia Timpug; Dexue Sun, MS; Dan Jun Li, MD; Scott Lajoie; Violet Young; Meghan Langley; Jeremy Tchaicha, PhD; Dhruv Sethi; Jan H. ter Meulen, MD, PhD; Michelle L. Ols, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 279 |
Poster Presentation |
Preclinical in vivo model development: Highlighting success and discussing xenograft advancements, a step closer to predicting patient outcomes |
Thomas Dailey, BS; Angela Gentile; Lexe Linderhof; Layton H. Smith, PhD; Bob Valamehr, PhD |
Cellular Therapies |
CAR T cells;Solid tumors |
| 280 |
Poster Presentation |
Rapid and simplified process for manufacturing multi-tumor-associated antigen specific T cells |
Anastasiya Smith, PhD; Tara Shahim; Jeanette Crisostomo, M.D.; Eric A. Smith, PhD; Jennifer Pickering; Anna Wilga-Savitski; Tsvetelina Hoang, PhD; Juan Vera, M.D. |
Cellular Therapies |
Leukemia/Lymphoma;T cell |
| 281 |
Poster Presentation |
The two sides of the coin: pro-inflammatory stimuli lead to upregulation of CD70 in AML, but also reduce NK-cell-based immunotherapy efficacy. |
Monika Sponheimer; Gerulf Hänel; Lisa Rohrbacher; Nora Philipp; Daniel Nixdorf; Anetta Marcinek; Christian Wichmann, Dr. med.; Andreas Humpe, Prof. Dr. med.; Shyra J. Gardai; Daniel Diolaiti; Veit Leonhardt Bücklein, Dr. med.; Marion Subklewe, Prof. Dr. med. |
Cellular Therapies |
Antibody;Biomarkers;Costimulation;Cytokine;Immune suppression;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 282 |
Poster Presentation |
Anti-folate receptor alpha (FRα) CoStimulatory Antigen Receptor (CoStAR) improves T-cell function across physiologically relevant ranges of FRα expression and T-cell receptor (TCR) affinities |
Martina Sykorova; Michelle Mojadidi; Leyuan Bao; Eric Gschweng; Milena Kalaitsidou; Gray Kueberuwa; Xingliang Zhou; Rubén Alvarez-Rodríguez; John S. Bridgeman |
Cellular Therapies |
Adoptive immunotherapy;Costimulation;Cytokine;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 283 |
Poster Presentation |
Genome-wide CRISPR screens of cytotoxic T cells identify a novel regulator that enhances T cell effector function |
Vivian Jia Yi Tan, B.Sc; Ling Wu, Ph.D.; Clara Kai Ting Koh; Yen Leong Chua; Liangzhe Wu; June Xu Hui Ong; Nicholas Gascoigne |
Cellular Therapies |
Adoptive immunotherapy;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 284 |
Poster Presentation |
Epstein Barr Virus Specific T cells (EBVSTs) expressing B7-H3 targeting chimeric antigen receptors (CAR) exhibit good pre-clinical activity and safety against B7-H3 positive solid tumors |
Kar Wai Tan, PhD; Kar Wai Tan; Lionel Low; Xin Yu Koh; Lindsay Kua, PhD; Jin Wei Tan; Siok Ping Yeo; Joanna Kristyn Lim; May Delos Santos; Fiona Wong; Chek Meng Poh; Ivan David Horak; Angeline Goh |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;T cell |
| 285 |
Poster Presentation |
Multiomic Analysis of TIL Suggests That CD4+ Polarization Represses TIL Expansion and CD8+ Activation and is Associated with Progression of Disease. |
Brian Thompson; David M. Woods, PhD; Ann M. Strange; Carol M. Amato, MS; Jonathan Hester-McCullough; Jeffrey S. Weber, MD, PhD; Amod A. Sarnaik, MD, FACS |
Cellular Therapies |
Adoptive immunotherapy;Biomarkers;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 286 |
Poster Presentation |
Systemic distribution of gamma-delta PSCA-CAR T cells in combination with zoledronate in a model of bone metastatic prostate cancer |
Leticia Tordesillas, PhD; Junior Cianne; Jeremy S. Frieling, PhD; Xiomar E. Bustos, MS; Conor C. Lynch, PhD; Daniel Abate-Daga, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell |
| 287 |
Poster Presentation |
Novel, boosted, fully human ROR1-targeting CAR T cells effectively eliminate hematologic and solid tumors, and resist tumor microenvironment |
Tri M. Tran; Bal Krishna Chand Thakuri; Saule Nurmukhambetova; Brittany Steimle; Ngoc Tran; Darong Wu, MS; Peirong Hu, PhD; Pradyot Dash; Dina Schneider, PhD |
Cellular Therapies |
CAR T cells;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor microenvironment |
| 288 |
Poster Presentation |
Targeting cold tumors using iPSC-derived CAR T Cells directed to the immune checkpoint molecule and tumor-associated antigen B7-H3 |
Jon Tuncel; Bahram Valamehr, PhD; Xu Yuan, PhD; Francisco Martinez, PhD; Nicholas Brookhouser; Philip Chu; Duygu Ozmadenci; Zachary Davis; Robert Blum; Bryan Hancock; Bjoern Gaertner; Nicholas Zorko; Shohreh Sikaroodi, PhD; Miguel Meza; Thomas Dailey, BS; Martin Felices; Frank Cichocki; Lauren Fong, PhD; Tom T. Lee, PhD; Raedun Clarke, PhD; John Goulding; Ryan Bjordahl, PhD; Jeffrey S. Miller, MD |
Cellular Therapies |
CAR T cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor microenvironment |
| 289 |
Poster Presentation |
Clinical expansion and persistence of CAR T-cells: An essential biomarker in need of standardization |
David Turicek; Victoria Giordani; Naomi Taylor, M.D., Ph.D.; Nirali N. Shah, MD |
Cellular Therapies |
Biomarkers;CAR T cells;Immune monitoring |
| 290 |
Poster Presentation |
A novel iPSC-derived CAR-invariant natural killer T (iNKT) cell therapy platform for hematologic malignancies and solid tumors |
Akane Urakami, PhD; Tomokuni Shigeura; Makoto Kondo; Mari Isomi; Yuko Kokubu, PhD; Ken-Ichi Suzuki, PhD; Haruhiko Koseki, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;NK/NKT cell;Targeted therapy;Tumor microenvironment |
| 291 |
Poster Presentation |
CAR T cells as a surgical adjuvant for unresectable adenocarcinoma |
Ugur Uslu, MD; Tong Da; Charles-Antoine Assenmacher; John Scholler; Regina M. Young; Julia Tchou; Carl June |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;Surgery;T cell |
| 292 |
Poster Presentation |
Discovery and development of t cell receptors for adoptive t cell therapy against solid tumors |
Juliana Velez Lujan, PhD; Hannah Fields; Kan Xing Wu; Natalie Epstein; Florence Chioh; Nicholas Tan; Daniel Carbajo; Neeraja Kulkarni; Lorenz Gerber; Yovita Purwanti; Alessandra Nardin, DVM; Michael Fehlings; Katja Fink; Dan Macleod |
Cellular Therapies |
Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 293 |
Poster Presentation |
The effects of negative isolation and aggregate strainers on expanded gamma/delta T cells and their cancer cell cytotoxicity |
Georg von Massow, MSc, BSc; Kenth Gustafsson; Jack Firth; Steve Oh; Alan Lam |
Cellular Therapies |
T cell;T cell lineages |
| 294 |
Poster Presentation |
Preclinical studies of TAC01-CLDN18.2, an autologous Claudin 18.2-directed TAC T cell therapy, in the treatment of gastric cancer |
Ling Wang, MD; Stacey X. Xu, PhD; Tania Benatar, PhD; Suzanna L. Prosser, PhD; Laura M. Shaver; Ritu R. Randhawa, MSc; Philbert Ip, PhD; Prabha Lal, PhD; Thanyashanthi Nitya-Nootan, BSc; Heather L. MacGregor, PhD; Sadhak Sengupta, PhD; Christopher W. Helsen, PhD; Andreas G. Bader, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 295 |
Poster Presentation |
Affinity Fine-Tuning Anti-CAIX CAR-T Cells Mitigate On-Target Off-Tumor Side Effects |
Yufei Wang, PhD; Alicia Buck; Michael Lynch; Gabriella Kastrunes; Jae-Won Cho; Marion Grimaud; David A. Braun; Cecile Razimbaud; Matthew Chang, MS; Atef Fayed; Audrey Apollon; Ze-Hua Li; Luann Zerefa; Brandon Piel; Elena Ivanova; Dennis Bonal; Kristen L. Jones, LATg; Quang-De Nguyen; Zhu Zhu; Kevin Wei; Rebecca Jennings; Miriam Ficial; Maura Aliezah Sticco-Ivins; Sabina Signoretti, MD; Catherine J. Wu, MD; Toni K. Choueiri, MD; Jon Wee; Cloud P. Paweletz, Ph.D.; Martin Hemberg; Aedin Culhane; David A. Barbie, MD; Gordon J. Freeman, PhD; Wayne Marasco, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors |
| 296 |
Poster Presentation |
Targeting B-cell malignancies with anti-ROR1 CAR T-cell therapy |
Jinsheng Weng, MD, PhD; Owhofasa O. Agbedia; Jingjing Cao; Xiaoyun Cheng; Shao Qing Kuang; Fuliang Chu; Sridevi Patchv; Yongfu Tang; Divyam Bansal; Jingwei Liu; Neeraj Saini; Sattva S. Neelapu, MD |
Cellular Therapies |
Adoptive immunotherapy;Antibody;Biomarkers;CAR T cells;Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy |
| 297 |
Poster Presentation |
Manufacture of KSQ-001, a CRISPR/Cas9-engineered TIL (eTIL) therapy, for the treatment of Head and Neck Squamous Cell Carcinoma |
Karrie K. Wong, PhD; Leila J. Williams, MS; Nick Constant; Mitali Ghose, MS; Sharon Lin; Frank Thompson; Conor Calnan; Fiona Sharp, PhD; Sean Donnelly; Charles Quinn; Glenn J. Hanna, MD; Frank Stegmeier, PhD; Micah J. Benson, PhD |
Cellular Therapies |
Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs) |
| 298 |
Poster Presentation |
Oncometabolites in the tumor microenvironment drive altered natural killer cell functional capacity |
Xinyu Wu, MSc; Sandro Matosevic, PhD |
Cellular Therapies |
NK/NKT cell |
| 299 |
Poster Presentation |
3D in vitro Tumor microenvironment models for screening CAR-T cell therapy efficacy. |
Bin Xue, PhD; Sophie C. Vermond, MSc; Ulrike Herbrand, PhD; David Harris; Gemma Moiset; Kolin C. Hribar, PhD; Julia Schuler, DVM PhD |
Cellular Therapies |
CAR T cells;Immune toxicity;Solid tumors;Tumor microenvironment |
| 300 |
Poster Presentation |
Tri-modal CAR+TCR+hnCD16+ iPSC-derived T cells co-targeting surface and intracellular/neoantigens demonstrate additive effect on overcoming tumor heterogeneity and cancer escape. |
Bi-Huei Yang, PhD; Soheila Shirinbak, PhD; Wen-I Yeh, PhD; Alma Gutierrez; Mochtar Pribadi, PhD; Bjoern Gaertner; Hui-Yi Chu, PhD; David Gonzalez; Angela Liao, MSc; Tom T. Lee, PhD; Eigen Peralta, PhD; Ryan Bjordahl, PhD; Martin Hosking, PhD; Chia-Wei Chang, PhD; Bob Valamehr, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy |
| 301 |
Poster Presentation |
Single-cell RNA study of transcriptional activities associated with anakinra prophylaxis and axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma |
Ning Yao, MS; Matthew J. Frigault; Marc Wehrli; Kathleen M.E. Gallagher; Charlotte Graham; Caron A. Jacobson, MD, MMSc; Rhine Shen; Simone Filosto, PhD; Justin Budka; Sao-Mai Nyugen-Mau; Jenny Nater; Mike Mattie, PhD; Gad Getz; Nicholas J. Haradhvala; Marcela V. Maus, MD, PhD |
Cellular Therapies |
Bioinformatics;CAR T cells;Chemokine;Clinical trial;Gene expression;Immune toxicity;Inflammation;Monocyte/Macrophage;Regulatory T cell (Treg cell);T cell |
| 302 |
Poster Presentation |
Allogenic adoptive NK cells and irradiation join force to control triple negative breast cancer stem cells |
Meesun Yoon, MD. PHD |
Cellular Therapies |
Adoptive immunotherapy;NK/NKT cell;Radiotherapy |
| 303 |
Poster Presentation |
Targeting Ewing sarcoma with anti-IL1RAP chimeric antigen receptor modified natural killer cells |
Wen Luo, PhD; Poul Sorensen, PhD; Mitchell S. Cairo; Hai Hoang; Yaya Chu, PhD; Janet Ayello, MS, MT(ASCP); Wei Li, PhD; Michael Lizardo, PhD; Renata Ribeiro; Melanie Rouleau; Dimiter S. Dimitrov, PhD; Dean A. Lee; Hai-Feng Zhang, PhD |
Cellular Therapies |
NK/NKT cell;Pediatric tumors;Solid tumors |
| 304 |
Poster Presentation |
Off-the-shelf iPSC-derived CAR-T cells containing seven functional edits overcome antigen heterogeneity, improve trafficking, and withstand immunosuppression associated with failed tumor treatment |
Martin Hosking, PhD; Soheila Shirinbak, PhD; Bishwas Shrestha, PhD; Joy Grant; Kyla Omilusik, PhD; Hannah Keegan; Demetrio Cardenas; Angela Gentile; Shilpi Chandra, PhD; Lorraine Loter; Lexe Linderhof; Nicholas Brookhouser, PhD; Stephanie Kennedy; Francisco Martinez, PhD; Loraine Campanati; Chris Ecker, PhD; Xu Yuan, PhD; Karina Palomares, PhD; Yi-Shin Lai, PhD; Lauren Fong, PhD; Yijia Pan, PhD; Shohreh Sikaroodi, PhD; Mark Jelcic, PhD; Philip Chu; Amit Mehta, PhD; Layton H. Smith, PhD; Eigen Peralta, PhD; Tom T. Lee, PhD; Ramzey Abujarour, PhD; Raedun Clarke, PhD; Bob Valamehr, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Chemokine;Immune suppression;Solid tumors;T cell;Tumor evasion;Tumor microenvironment |
| 305 |
Poster Presentation |
Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors |
Anthony K. Park, PhD; Saul J. Priceman, PhD; Leslie M.O. Chong; Yuman Fong; Isabel Monroy; Colin Cook; Monil Shah, PharmD |
Cellular Therapies |
Adoptive immunotherapy;Bispecifics;CAR T cells;Solid tumors |
| 306 |
Poster Presentation |
Evaluation of AB-101, an Allogeneic Cord Blood-derived Natural Killer (NK) Cell Therapy, as an ADCC Enhancer in Hematologic and Solid Tumors |
Paul Rogers, PhD; Bitna Yang; Hyojin Kim; Yusun Kim, PhD; Sunglim Cho, PhD; Bret Morin; Amanda Conerty; Lavakumar Karyampudi; Lisa Guerrettaz, PhD; Peter Flynn, PhD; Bokyung Min, PhD; Heather Raymon, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antibody;Leukemia/Lymphoma;NK/NKT cell;Solid tumors |
| 307 |
Poster Presentation |
IL12 genetically engineered myeloid cells effectively target the myeloid-enriched tumor and metastatic microenvironment in an immune-competent murine model of osteosarcoma |
Kristin M. Wessel, MD; Miranda Clements, PhD; Wei Ju, PhD; Sabina Kaczanowska, PhD; Rosandra N. Kaplan, MD |
Cellular Therapies |
Adoptive immunotherapy;Myeloid cells;Pediatric tumors;Solid tumors;Tumor microenvironment |
| 308 |
Poster Presentation |
Harnessing tumor localized IL-12 to enhance STEAP1 CAR T cell therapy for prostate cancer |
Vipul Bhatia, PhD; Nikhil V. Kamat, MD; Tiffany E. Pariva; Li-Ting Wu; Annabelle Tsao; Koichi Sasaki; Lauren T. Wiest; Ailin Zhang; Dmytro Rudoy; Lawrence D. True; Radhika A. Patel; Martine P. Roudier; Roman Gulati; Michael C. Haffner; Peter S. Nelson; Saul J. Priceman, PhD; Jun Ishihara; John K. Lee |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Immune adjuvant;Solid tumors;Surfaceome;T cell;Tumor antigens;Tumor microenvironment |
| 309 |
Poster Presentation |
Determining the histocompatibility barriers between Universal CAR T (UCART) cells and NK cells |
Kimberly M. Apodaca, BS; Chong Xu, PhD; Kelsey Stanton; Beatriz M. Carreno, PhD; Gerald P. Linette, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;NK/NKT cell;T cell |
| 310 |
Poster Presentation |
Engineering optimal CAR T cells to overcome pancreatic tumors with secreted antagonistic peptides |
Heather K. Lin, BS; Ruby M. Freeman, BS; Alysa N. Evans, BS; Tenzin Passang Fnu, Bachelor of Arts; Tongrui Liu; Elyse Christensen; Raymond Fei; Tanisha Sinha; Sruthi Ravindranathan, PhD, MS; Lily Yang, MD PhD; Edmund K. Waller, MD/PHD; Sarwish Rafiq, PhD |
Cellular Therapies |
CAR T cells;Solid tumors;T cell;Tumor antigens;Tumor microenvironment |
| 311 |
Poster Presentation |
PD-1 blockade protein coupled in 4th generation armored CAR-T cells enhances cytotoxicity effect with in vitro re-challenge system |
Zhifeng Zhao; Jinyan Ma; Tiantian Wang; Ka Fung Noi; Jie Xu; Qingyang Gu |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Solid tumors |
| 312 |
Poster Presentation |
Identification of novel NSC lung cancer Dark Antigens™ with expression in multiple tumor types, as promising targets for immunotherapies |
Rachel J.M. Abbott, DPhil; Okba Alassadi; Matthew Davies; Magdalena Von Essen; Verónica Freire-Benéitez; Vicki Jefferson; Samit Kundu; Prathiba Kurupati; Ralf M. Leonhardt; Samuel Lukowski; Fabio Marino; Giulia Masi; Rayner ML. Queiroz; Hayden Selvadurai; Joana M. Senra; Emily X.C. Tye; Joseph Dukes |
Cellular Therapies |
Adoptive immunotherapy;Bioinformatics;Gene expression;Proteomics;RNA;Solid tumors;T cell;Targeted therapy;Tumor antigens;Vaccine |
| 313 |
Poster Presentation |
EDIT-202, a multiplexed AsCas12a edited iPSC differentiated iNK, displays a mature phenotype, high KIR expression, and ADCC towards multiple solid tumor lines. |
Alex Allen, Ph.D.; Kaitlyn M. Izzo; Mrunali Jagdale; Scott Mordecai; Jared Getgano; Laura Blaha; Abhijit Dandapat; Mark S. Shearman; Kai-Hsin Chang, Ph.D. |
Cellular Therapies |
Adoptive immunotherapy;NK/NKT cell;Solid tumors |
| 314 |
Poster Presentation |
Cell therapy development in oncology requires a collaboration between sponsors and cell therapy experienced CROs |
Jaikrishna Balkissoon, MD, FACS |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Cytokine;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs) |
| 315 |
Oral Presentation |
Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508 |
Michael Ball, PhD; Madison Kremp; Rehman Qureshi; Poonam Sonawane, Ph.D.; Maggie Schmierer; Josh VanDuzer; Michael Lynch; Adam Pfendt; Melissa Christiano; Ken Locke; Ramona Swaby; Daniel Cushing, PhD; Michael Klichinsky, PharmD, PhD; Thomas Condamine, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Monocyte/Macrophage;Myeloid cells;Solid tumors |
| 316 |
Poster Presentation |
Next generation CAR-T incorporating an inhibitory CAR (iCAR) for increased safety in solid tumors |
David Bassan, PhD; Michael R. Weist; Leehee Weinberger; Jason Yi; Gregor Adams; Tanya Kim; Caitlin Schnair; Kristina Vucci; Sarit Tabak; Neta Chaim; Nir Bujanover; Yael Lopesco; Limor Levy-Kanfo; Orit Foord; Jim Johnston; Frank Calzone; Rick Kendell; Adi Sharbi-Yunger |
Cellular Therapies |
CAR T cells;Immune toxicity;Solid tumors |
| 317 |
Poster Presentation |
ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density |
Elisa Bergaggio, Ph.D.; Wei-Tien Tai; Andrea Aroldi; Elisa Landoni; Manuel Nuesch; Ines Mota; Jasna Metovic; Leyuan Ma; Diego Alvarado, Ph.D.; Chiara Ambrogio; Claudia Voena; Rafael B. Blasco; Tongqing Li; Daryl Klein; Darrell J. Irvine, Ph.D.; Mauro Papotti; Barbara Savoldo; Gianpietro Dotti; Roberto Chiarle |
Cellular Therapies |
CAR T cells;Pediatric tumors;Solid tumors;Targeted therapy |
| 318 |
Poster Presentation |
Pre-clinical development of a CAR Monocyte platform for cancer immunotherapy |
Linara Gabitova, PhD; Brett Menchel, MBT; Silvia Beghi, PhD; Larissa Ishikawa, PhD; Rehman Qureshi; Andrew Best, MA; Sabrina DeLong, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD; Daniel Blumenthal, PhD; Michael Klichinsky, PharmD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Monocyte/Macrophage;Myeloid cells;Solid tumors |
| 319 |
Poster Presentation |
Immunometabolic Modulation of Engineered iPSC-NK Cells for Immunotherapy of Solid Tumors |
Shambhavi Borde, MS; Sandro Matosevic, PhD; Kyle Lupo, Ph.D. |
Cellular Therapies |
NK/NKT cell;Solid tumors;Stem cell/cancer-initiating cell |
| 320 |
Poster Presentation |
Rapid identification of a TCR library targeting the HPV E6/E7 oncoproteins to enable multi-TCR T-cell therapies for patients with HPV16+ epithelial cancers |
Magnolia Bostick; John E. Greer; Andrew Conroy; Mark Ting; Allison Xu; Kevin Shao; Claire McHugh; Rakesh Sudhakar; Connie Kong; Taylor Dowdell; Yvonne DaCosta; Shannon Sorn; Justin Win; Noha Elabed; Cheryl Kwan; Craig A. Fett; Evelyn Vilchez; Nimisha Gandhi; George Yam; Benjamin Yuen; Zheng Pan, PhD; Theresa Stueve; Papia Chakraborty; William Lu; Cliff Wang; Eric Stawiski; Stefanie J. Mandl, PhD; Eric Kunkel |
Cellular Therapies |
Adoptive immunotherapy;Bioinformatics;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 321 |
Poster Presentation |
Single mRNA constructs encoding multiple linked antigens allow for a multiantigen-specific CD8+ T cell response driven by SQZ eAPCs |
Ashley A. Brate, PhD; Michael F. Maloney, PhD; Carolyne K. Smith, PhD; Katarina Blagovic, PhD; Andrea A. Silva, BS; Amber Martin, ScM; Jodie Wong, MS; Scott M. Loughhead, PhD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Neoantigens;RNA;T cell;Tumor antigens;Vaccine |
| 322 |
Poster Presentation |
MiNK-413: a Next generation armored allogenic BCMA CAR iNKT product |
Eleni Chantzoura, PhD; Efrat Altman Sharoni; Reed Masakayan; Martyna Popis; Darrian Moskowitz; Paul Ibbett; Sapana Kadel; Moira Pinzan Rossi; Deborah Wright; Burcu Yigit, PhD; Olivier Le Tonqueze, PhD; Xavier Michelet, PhD; Marc A. Van Dijk, PhD |
Cellular Therapies |
CAR T cells;Chemokine;NK/NKT cell;Targeted therapy;Tumor microenvironment |
| 323 |
Poster Presentation |
TALEN-based Gene Edited iPSC-derived NK (iNK) Cells Demonstrate Enhanced Antitumor Activity |
An-Ping Chen; Peng Gao; Preeti Ashok; Marshall Chao Ma; David Zou; Andrea Chambers; Liang Lin; Hao-Ming Chang; Antonio Arulanandam; Justin Eyquem; Elisabetta Burchi; Armin Rath; Stanley Frankel; Alex Boyne; Alexandre Juillerat; Philippe Duchateau; Daniel Teper; Nejmi Dilmac; Wei Li |
Cellular Therapies |
Adoptive immunotherapy;Leukemia/Lymphoma;NK/NKT cell;Stem cell/cancer-initiating cell;Targeted therapy |
| 324 |
Oral Presentation |
Sensitizing poorly differentiated thyroid cancers to TSHR-CART cell therapy with MEK inhibitors |
John A. Copland, PhD; Kendall J. Schick; Justyna J. Gleba, PhD; Truc N. Huynh; James L. Miller; Erin E. MIller; Aylin Alasonyalilar Demirer, PhD; Erin Tapper; Reona Sakemura, MD, PhDs; Elizabeth L. Siegler, PhD, MS; Michelle J. Cox, PhD, MS; Carli M. Stewart; Ismail Can; Ekene J. Ogbodo, PhD; Claudia Manriquez Roman, MS; Bezerra D. Evandro, MD; Cui Gaofeng, PhD; Mer Georges, PhD; Olivier R. Gloria, PhD; Yushi Qui; Robert C. Smallridge, MD; Abba C. Zubair, MD, PhD; Han W. Tun, MD; Saad S. Kenderian, MB, ChB |
Cellular Therapies |
CAR T cells;Immune monitoring;Solid tumors;Targeted therapy |
| 325 |
Poster Presentation |
TALEN-edited SMART CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy |
Shipra sd. Das, PhD; Sonal Dharani; Julien Valton, PhD; Philippe Duchateau; Laurent Poirot, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Carcinogenesis;Checkpoint blockade;Immune suppression;Immune toxicity;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor stroma |
| 326 |
Poster Presentation |
Off-the-shelf iPSC-derived CAR-T cells targeting KLK2 demonstrate prolonged tumor control and survival in xenograft models of prostate cancer |
Charles G. Drake, MD, PhD; Alex J. Garcia, PhD; Chia-Wei Chang, PhD; Bi-Huei Yang, PhD; Samad Ibitokou, PhD; Cameron Pride, BS; Spas Markov, PhD; Angela Liao, MSc; Mochtar Pribadi, PhD; Yijia Pan, PhD; Thomas Dailey, BS; Tom T. Lee, PhD; Szeman (Ruby) Chan, PhD; Michael Ports, PhD; Jode Goodridge, PhD; Ryan Bjordahl, PhD; Joseph Erhardt, PhD; Bahram Valamehr, PhD |
Cellular Therapies |
CAR T cells;Solid tumors |
| 327 |
Poster Presentation |
Clonal expansion of CD22 CAR T-cells following lentiviral vector integration in the PWWP3A gene |
Alka Dwivedi, Ph.D.; Ling Su; Justin M. Mirazee, B.S.; Mehdi Benzaoui, PHARM.D.; Christopher Chien, PhD; Nirali N. Shah, MD; Xiaolin Wu, PhD; Naomi Taylor, M.D., Ph.D. |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Cytokine;Gene expression;Pediatric tumors;T cell |
| 328 |
Poster Presentation |
Promoting NK survival and function within the tumor microenvironment |
Matthew Dysthe, B.S.; Ishwar Navin, MS; Corrine Baumgartner; Stephanie Fetzko, MD; Cliona Rooney, PhD; Robin Parihar, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Pediatric tumors;Tumor microenvironment |
| 329 |
Poster Presentation |
Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment to universally reduce solid tumors |
Shannon L. Ferry; Rachel A. Brog; Courtney Shiebout; Cameron Messier; W J. Cook; Charles Sentman, PhD; H. R. Frost, PhD; Yina H. Huang, PhD |
Cellular Therapies |
CAR T cells;Cytokine;Immune suppression;Monocyte/Macrophage;Regulatory T cell (Treg cell);Solid tumors;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 330 |
Poster Presentation |
Redirecting glucose usage during in vitro expansion improves the in vivo persistence and function of adoptive T cell therapies for cancer |
Andrew Frisch; Yiyang Wang; Yupeng Wang, BS; Konstantinos Lontos, MD, PhD; Greg M. Delgoffe, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Metabolism;T cell;Tumor microenvironment |
| 331 |
Poster Presentation |
A novel small molecule inhibitor of CBL-B shows potent antitumor activity in combination with Pmel-1 adoptive cell transfer in an aggressive mouse melanoma model |
Marilena Gallotta, PhD; Jose Gomez Romo; Serena Ranucci; Austin Tenn-McClellan; Frederick Cohen; Gwenn M. Hansen, PhD; Arthur T. Sands, MD PhD; Ryan Rountree, PhD; Cristiana Guiducci |
Cellular Therapies |
Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs) |
| 332 |
Poster Presentation |
CRISPR/Cas9-based integration of a large and modular cassette into a safe harbor site to improve CAR T cell therapy efficacy and safety |
Brendan D. Galvin, PhD; Grace Zheng; Robby Moot; Michelle Nguyen; Michelle Tan; Rene Sit; Lionel Berthoin; David DeTomaso; Sofia Kyriazopoulou Panagiotopoulou; Shan Sabri; Jun Feng; Manching Ku; Anzhi Yao; Andrea Liu; Jennifer McDevitt; Matt Drever; Stephen Santoro, PhD; Aaron Cooper; Susie Jun; W Nicholas Haining; Tarjei Mikkelsen |
Cellular Therapies |
CAR T cells;Solid tumors;T cell;Targeted therapy |
| 333 |
Poster Presentation |
Novel phytochemicals-based cell culture medium mitigates Natural Killer (NK) cellular exhaustion and enhances mature subpopulations, leading to higher anticancer cytotoxic activity |
Marc A. Gillig, PhD; Rafet N. Amoor, MS; Nicholas S. Ingala; Borom Chean; Rachit Ohri, Ph.D. |
Cellular Therapies |
Biomarkers;NK/NKT cell;Solid tumors;Tumor microenvironment |
| 334 |
Poster Presentation |
Functional Validation of Single Domain Antibody-Derived CD33 Specific CAR-T Cells for the Treatment of Acute Myeloid Leukemia |
Brikena Gjeci, MS; Salar Khan; Julian Scherer, PhD; Tirtha Chakraborty |
Cellular Therapies |
CAR T cells;Leukemia/Lymphoma |
| 335 |
Poster Presentation |
Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells |
Whitney Gladney, PhD; Adina Vultur, PhD; Michael T. Schweizer, MD; Joseph Fraietta, PhD; Andrew Rech, MD, PhD; Carl June; Matthew O'Rourke; Amy Roberts; Hinel Patel; Jamie Rosen; Pam Hufner; Yanping Luo, PhD; David Barrett, MD, PhD; Thomas J. Fountaine, MD; Karen Chagin, MD |
Cellular Therapies |
Biomarkers;CAR T cells;Cytokine |
| 336 |
Poster Presentation |
A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-shelf Cancer Immunotherapy |
Davide Bernareggi; Caryn Gonsalves; Max Schabla; Alejandra Gárate-Carrillo; Mohammad El-Kalay; Dan S. Kaufman, CAMD, PhD; Robert Hollingsworth; Huang Zhu |
Cellular Therapies |
Adoptive immunotherapy;Leukemia/Lymphoma;NK/NKT cell;Solid tumors |
| 337 |
Oral Presentation |
Development of potent iPSC-derived macrophages (iMACs) for off-the-shelf cancer immunotherapy - a new cell type in the EVOcells platform |
Kathrin Haake, Dr.; Michela Mirenda; Julien Bousquet; Philine Scheinpflug; Michael Esquerré; Audrey Holtzinger; Stefanie Pfaender; Michael Paillasse; Daniel Sommermeyer, Dr.; Oriane Bombarde, PhD; Loïc Ysebaert; Fabien Despas; Matthias Austen; Andreas Scheel; Markus Dangl; Monika Braun; Nadja Wagner, Dr. |
Cellular Therapies |
Adoptive immunotherapy;Monocyte/Macrophage;Solid tumors;Tumor microenvironment |
| 338 |
Poster Presentation |
Analysis of chemokine expression profile of normal and tumor tissue for effective adoptive cell therapy |
Do Yeon Han, MS; Jung Han Seo; Cho Rong Hong; Hyeon Jin Lee; Gyung Yub Gong; Hee Jin Lee |
Cellular Therapies |
Adoptive immunotherapy;Chemokine;Tumor infiltrating lymphocytes (TILs) |
| 339 |
Poster Presentation |
Quantitative assessment of CAR-T cell therapy targets using computational pathology |
Nathalie Harder; Markus Schick, PhD; Pallavi Sontakke, PhD; Alma Andoni; Karma DaCosta; Ruppen Nalbandian; Philipp Wortmann; Ansh Kapil, Masters of Informatics; Gordon Moody; Maria Letizia Giardino Torchia; Martin Philip Lloyd; Nicholas Durham, PhD; Eric Tu |
Cellular Therapies |
Biomarkers;CAR T cells |
| 340 |
Poster Presentation |
The Epi-RTM technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function |
Benjamin D. Harris, PhD; Yogin Patel, PhD; Ngoc-Han Ha; Lora Zhao; Sheila Lou; Stefan Siebert; Emily Fu-Sum; Rigel Kishton; Purnima Sundar; Suman Kumar Vodnala; Shobha Potluri |
Cellular Therapies |
Adoptive immunotherapy;Bioinformatics;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 341 |
Poster Presentation |
Novel immune reconstitution model highlights the importance of stealth strategies that potentiate effector cell function and promote functional persistence of next-generation adoptive cell therapies |
Ken L. Hayama, PhD; Alan M. Williams, PhD; Yijia Pan, PhD; Brian Groff; Rina M. Mbofung, PhD; Lauren Fong, PhD; Nicholas Brookhouser, PhD; Ramzey Abujarour, PhD; Tom T. Lee, PhD; Peter Szabo, MD, PhD; Lilly Wong, PhD; Maksim Mamonkin, PhD; Karl-Johan Malmberg, MD, PhD; Ryan Bjordahl, PhD; Jode Goodridge, PhD; Bob Valamehr, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Chemotherapy;Immune tolerance;NK/NKT cell |
| 342 |
Poster Presentation |
KRAS G12V T cell receptor-engineered T cells expressing the durability FAS-41BB switch receptor exhibit a potent, persistent, coordinated CD4/CD8 anti-tumor response in vitro and in vivo |
Xingyue He, PhD; Michelle M. Hoffmann, PhD; Jinsheng Liang; Hongjing Qu; Allison P. Drain, PhD; Hubert Lam, PhD; Shannon K. Oda, PhD; Thomas M. Schmitt, PhD; Aude G. Chapuis, PhD; Philip D. Greenberg, MD; Gary Shapiro, PhD; Loic Vincent, PhD |
Cellular Therapies |
Adoptive immunotherapy;Costimulation;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor microenvironment |
| 343 |
Poster Presentation |
Identification of tumor-reactive T cells targeting melanoma Dark Antigens™ validates this novel class of targets for development of immunotherapies |
Rachel J.M. Abbott, DPhil; Tom Hofland; Thomas M. Hulen; Elizabeth (Els) M. Verdegaal, PhD; Michael D. Crowther; Joseph Dukes; Shawez Khan; Pita de Kok; Giulia Masi; Özcan Met, PhD; Aimilia Schina; Hayden Selvadurai; Marten Visser; Katarzyna Ward; Sjoerd H. van der Burg, Prof.Dr.; George Kassiotis, PhD; Inge M. Svane, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Gene expression;RNA;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 344 |
Poster Presentation |
Comparative assessment of product quality attributes associated with production of Chimeric Antigen Receptor T cells expressing scFv CD-19 and scFv IL-13Ra2 by two manufacturing platforms |
Sujin Hwang, Ph.D.; Heba Degheidy; Mondona McCann; Steven R. Bauer; Raj K. Puri; Bharat H. Joshi |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;T cell;Targeted therapy |
| 345 |
Poster Presentation |
CRS assessment post Fast-Track - CAR T cells application in NSG-SGM3 mouse model |
Arezoo Jamali, PhD; Naphang Ho, MSc.; Angela Braun, MSc.; Elham Adabi, MSc.; Frederic B. Thalheimer, PhD; Christian J. Buchholz, Prof, PhD |
Cellular Therapies |
CAR T cells;Cytokine;Monocyte/Macrophage;Myeloid cells;T cell |
| 346 |
Poster Presentation |
Enhanced anti-tumor activity of HBsAg specific TCR-T (SCG101) in hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) by preventing T cell exhaustion through PD-1/PD-L1 axis blockade |
Pin Xie, Sr., PhD; Tao Jin; Yanzhou Huang; Lu Yang; Karin Wisskirchen; Ulrike Protzer; Ke Zhang |
Cellular Therapies |
Adoptive immunotherapy;Antibody;Checkpoint blockade;Solid tumors;T cell;Tumor microenvironment |
| 347 |
Poster Presentation |
Development of Optimized CAR T Cells for Therapy of Glioblastoma |
Jonathan F. Khan, B.S; Winson Cai, B.S.; Yanhong Yang, Ph.D.; Lauren Dong, BS; Kelsey Hopland, B.S.; Kenny Kwok-Hei Yu, MBBS, Ph.D.; Ruby M. Freeman, B.S.; Terence J. Purdon, M.S.; Viviane Tabar, M.D.; Taha Merghoub, PhD; Jedd D. Wolchok, MD PhD; Renier J. Brentjens, MD, PhD |
Cellular Therapies |
CAR T cells;Checkpoint blockade;Solid tumors |
| 348 |
Poster Presentation |
Defining T cell recognition of a highly conserved fusion neoantigen in fibrolamellar carcinoma |
Allison M. Kirk, MS; Jeremy C. Crawford, PhD; Ching-Heng Chou, PhD; Phuong Nguyen; Walid Awad, MD; E. Kaitlynn Allen, PhD; Xiaoyu Zhang, PhD; Anthony E. Zamora, PhD; Christopher DeRenzo, MD; Scott E. Strome, MD; Paul G. Thomas, PhD |
Cellular Therapies |
Adoptive immunotherapy;Neoantigens;Pediatric tumors;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 349 |
Poster Presentation |
Highly potent Tumor-targeting Optimally Primed Natural Killer cells produced under a feeder-cell free condition in a 50L-scale bioreactor with cytokine-fusion proteins elicits robust anti-tumor response in preclinical study |
Dongwoo Ko, Dr.; Jae Chan Park, Master Degree; Min-Kyong Hyon; Young Hyun Park; Gil-Jung Kim; Jong Beom Ku; Iseul Eom; Su Bin Lee; Jeong Mi Yun; Dan Bee Park; Do Yeon Kim; HyeHyeon Jang; Sora Lim; Do Soo Jang; Sung Yoo Cho; Chun Pyo Hong; Myung Ho Jang |
Cellular Therapies |
Adoptive immunotherapy;Chemokine;NK/NKT cell;Solid tumors |
| 350 |
Poster Presentation |
Harnessing arginine metabolism to overcome hyperthermia-induced metabolic dysfunction of CAR T-cells |
Taisuke Kondo, Ph.D.; Justyn DuSold, B.S.; Sooraj R. Achar, B.S.; Serifat Adebola, B.S.; Pedro Gonzalez-Menendes, Ph.D.; Julie Perrault, M.S.; Bonnie Yates, NP, MS; Hannah Song, Ph.D.; Stephen Fox; Xia Xu; King Chan, Ph.D.; Abdalla Abdelmaksoud; Christopher Chien, PhD; Marie Pouzolles, Ph.D; Haiying Qin, MS; Steven L. Highfill, PhD; Thorkell Andresson, Ph.D.; Nirali N. Shah, MD; Valérie Dardalhon, Ph.D.; Grégoire Altan-Bonnet, Ph.D.; Naomi Taylor, M.D., Ph.D. |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Metabolism;T cell |
| 351 |
Poster Presentation |
Vitamin C treatment prevents CAR T cell exhaustion, maintains stem cell phenotype and enhances antitumor function |
Leonce Kouakanou, Ph.D.; Hanmin Wang, Ph.D.; Grace Sun; Tristan Chan; Jennifer Shepphird, Ph.D.; Darya Alizadeh, PhD; Christine E. Brown, PhD; Leo D. Wang, MD, Ph.D. |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Epigenetics;Leukemia/Lymphoma |
| 352 |
Poster Presentation |
STASH Select, a simple and robust method of purifying cells engineered with multiple vectors using a single selection marker |
Louai Labanieh, PhD; Kaithlen Zen B. Pacheco; Robbie G. Majzner, MD; Chris J. Fisher, MS; Elena Sotillo, PhD; Peng Xu, MD; Jennifer R. Cochran, PhD; Crystal Mackall, MD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell |
| 353 |
Poster Presentation |
Artificial Immune Modulation adoptive cell therapies for virally driven malignancies |
David Langan, PhD; Keshanti D. Tidwell; Alison Farrell; Selome Z. Mitiku; Catrina A. Johnson; Pratima Kunwar, PhD; Ruipeng Wang, PhD; Sojung Kim; Mathias Oelke |
Cellular Therapies |
Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy |
| 354 |
Poster Presentation |
Pulling the lever on all fronts: ICT01, a g9d2 T cell-activating monoclonal antibody, in combination with Venetoclax and 5-Azacytidine as a novel combination therapy for AML |
Elisabeth Wieduwild, PhD; Anne-Charlotte Le Floch; Céline Garulli; Sarah Bourass; Caroline Imbert; Paul A. Frohna, MD, PhD, PharmD; Norbert Vey, MD, PhD; Daniel Olive, MD, PhD; Aude de Gassart, PhD; Loui Madakamutil, PhD |
Cellular Therapies |
Antibody;Chemotherapy;Leukemia/Lymphoma;T cell |
| 355 |
Poster Presentation |
TCR γδ+ TIL from patients with pancreatic cancer recognize autologous tumor cells restricted by CD1d |
Joana R. Lerias, DVM, PhD; Patrícia A. António; Jéssica O. Kamiki, MSc; Rodrigo Eduardo; Sara Cascais; Bernardo Marinheiro; Eric De Sousa; Carolina M. Gorgulho; Andreia Maia; Mireia Castillo-Martin; Markus Buechler; Carlos Carvalho, MD; Antonio Beltran; Sam Jeong; Ridong Chen; Markus J. Maeurer, MD, PhD, FRCP(London) |
Cellular Therapies |
Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 356 |
Poster Presentation |
Generation of GD2-CAR Neutrophils from hPSCs for Targeted Cancer Immunotherapy of Solid Tumors |
Aditi Majumder, PhD; Ho Sun Jung, PhD; Jue Zhang; Kran Suknuntha; James Thomson; Igor Slukvin |
Cellular Therapies |
Adoptive immunotherapy;Granulocyte;Pediatric tumors;Solid tumors;Targeted therapy;Tumor antigens |
| 357 |
Poster Presentation |
Phosphorylation of CD28-Y218 modulates IL-2 secretion and antitumor effect of CAR-T cells, in a preclinical model of pancreatic cancer |
Elena Martinez Planes; Miguel G. Fontela; Cecilia Ramello; Daniel Abate-Daga, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;T cell |
| 358 |
Poster Presentation |
Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the Tumor Microenvironment |
Xavier Michelet, PhD; Martyna Popis; Shannon Boi; Magda Niedzielska; Reed Masakayan; Efrat Altman Sharoni; Paul Ibbett; Deborah Wright; Barbara Barbara Kalinowska; Justin Keith; Bishnu Joshi; Moira Pinzan Rossi; Rachel Smith; Burcu Yigit; Olivier Le Tonqueze, PhD; Eleni Chantzoura, PhD; Marc A. Van Dijk, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Immune suppression;NK/NKT cell;Tumor microenvironment;Tumor stroma |
| 359 |
Poster Presentation |
Hyaluronic acid nanogel based cancer vaccine, in combination with adoptive T cell therapy totally suppresses ICI resistant-tumors |
Hiroshi Shiku, MD, PhD; Fumiyasu Momose, PhD; Takashi Nakai, PhD; Kohei Yabuuchi, MS; Toru Katsumata, PhD; Tsuyoshi Shimoboji, PhD |
Cellular Therapies |
Adoptive immunotherapy;Neoantigens;T cell;TLR;Vaccine |
| 360 |
Poster Presentation |
Novel immunotherapy for prostate cancer combining CAR T cells and myeloid cell STAT3 inhibition |
John P. Murad, PhD; Saul J. Priceman, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Immune suppression;RNA;Solid tumors;T cell;Targeted therapy;TLR;Tumor microenvironment |
| 361 |
Poster Presentation |
Universal Expansion of CBL-B-inhibited Tumor Infiltrating Lymphocytes, DeTIL-0255, from Women with Ovarian Cancer: Process Validation |
Pranav Murthy, MS; Nell Namitha Narasappa, MS; Xiaoyan Liang, PhD; Xianzhu Wu, PhD; Irene Luu, MS; Jeevitha Jeevan, MS; Sagar Sharma; Alison Ross; Caleb Lampenfeld; Sam Zahn; Thomas Musial, MS; Jennifer Bone, PhD; John Nakayama, MD; David Bartlett, MD; Jocelyn S. Chapman, MD; Greta Garrido, PhD; Nicholas P. Shinners, PhD; Arthur T. Sands, MD PhD; Michael Blackton, MBA; Ena Wang, MD MS; Michael T. Lotze, MD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Clinical trial;Dendritic cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 362 |
Poster Presentation |
Defining T cell exhaustion and memory correlates of GD2 CAR T cell expansion in pediatric patients with solid tumor malignancies |
Tara Murty, BS; Sneha Ramakrishna, MD; Sabina Kaczanowska, PhD; Cristina F. Contreras; Caroline Duault, PharmD, PhD; Priyanka Balasubrahmanyam; Warren Reynolds; Reema Baskar, PhD; Aashna Jhaveri; Yang Liu; Jennifer Altreuter, MD; Franziska Michor; Mina Pichavant; Bita Sahaf, PhD; Sean C. Bendall, PhD; Holden T. Maecker, PhD; Melinda Merchant; Crystal Mackall, MD; Rosandra N. Kaplan, MD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Immune contexture;Immune monitoring;Pediatric tumors;Solid tumors;T cell |
| 363 |
Poster Presentation |
Localized interleukin-2 cytokine factories eradicate mesothelioma tumors via activation of adaptive and innate immune cells |
Samira Aghlara-Fotovat, BA; Amanda Nash, BS; Bertha Castillo; Andrea Hernandez; Aarthi Pugazenthi; Hyun-Sung Lee; Hee-Jin Jang; Annie Nguyen; Alexander Lu; Bryan Burt; Ravi Ghanta; Omid Veiseh, Ph.D |
Cellular Therapies |
Checkpoint blockade;Cytokine;Monocyte/Macrophage;T cell |
| 364 |
Poster Presentation |
Antigen abundance and TCR avidity impact T cell-mediated tumor recognition in novel B16F10 ACT model |
Jenna Newman, PhD; John Finnigan, MD; Andrew S. Ishizuka, DPhil; Geoffrey Lynn, PhD; Alexander Rubinsteyn; Timothy O'Donnell; Jeffrey Hammerbacher, BA; Nina Bhardwaj, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 365 |
Poster Presentation |
Comparison of viral vector transduction methods for tumor-infiltrating lymphocytes |
Seung Eon OH; Won Seon Bang; Hee Jae Lee; Hee Jin Lee; Chae Lyul Lim |
Cellular Therapies |
Adoptive immunotherapy;Gene expression;Tumor infiltrating lymphocytes (TILs) |
| 366 |
Poster Presentation |
Synthetic Receptor Enabled Differentiation (ShRED), a novel platform for manufacturing of iPSC-derived cytotoxic innate lymphocytes for 'off-the-shelf' cancer immunotherapies |
Sam O'Hara, PhD; David Vereide, PhD; Teisha Rowland; Ashley Yingst; Dillon Jarrell; Ryan Koning; Cassidy Arnold; Susana Hernandez; Way Wu; Kristen L. Mittelsteadt, PhD; Chris Nicolai, PhD; Wai-Hang Leung, PhD; Laurie Beitz, MD; Shon Green, PhD; Byoung Ryu, PhD; Christopher Garbe; Ryan Crisman, PhD; Andrew Scharenberg, MD; Ryan Larson, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Cytokine;NK/NKT cell;Solid tumors |
| 367 |
Poster Presentation |
CRISPR/Cas9 gene-edited, allogeneic anti-CD83 CAR-T cells demonstrate potent activity in GvHD and AML tumor models |
Ismael Oumzil; Valerie Guerrero; Pooja Smruthi Keerthipati, MS; Jaqlyn Colangelo; Brendan Lawler; Victoria Singson; Aditya Khedkar; Shweta Singh, PhD; Jonathan Terrett, PhD; Daniel Hostetter, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells |
| 368 |
Poster Presentation |
CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis CD19 T cells results in significant tumor killing |
Isabel Monroy, BS; Anthony K. Park, PhD; Colin Cook; Guangyan Xiong; Vivien Chan; Cheng Liu; Saul J. Priceman, PhD; Monil Shah; Nimali Withana; Leslie M.O. Chong; Yuman Fong, BS, MD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors |
| 369 |
Poster Presentation |
Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with immunosuppressive microenvironments |
Carmela Passaro, PhD; Balazs Koscso, PhD; Sean G. Smith, PhD; Violet Young; Theresa Ross; Benjamin Primack, MS; Natasha Ly; Patricia Timpug; Shabnam Davoodi, PhD; Rachel A. Burga, PhD; Gauri Kulkarni; Scott Lajoie; Meghan Langley; Nirzari Shah; Dexue Sun, MS; Dan Jun Li, MD; Raina Duan; Arman Aksoy, PhD; Mithun Khattar, PhD; Jeremy H. Tchaicha, PhD; Dhruv Sethi; Jan H. ter Meulen, MD, PhD; Michelle L. Ols, PhD |
Cellular Therapies |
Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 370 |
Poster Presentation |
The Epi-RTM technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity |
Yogin Patel, PhD; Benjamin D. Harris, PhD; Melissa Bedard, PhD; Joanna Kritikou; Meritxell Galindo Casas; Carson Harms; Melissa DeFrancesco; Purnima Sundar; Nicholas P. Restifo, MD; Gary Lee, Ph.D.; Shobha Potluri, PhD; Suman Kumar Vodnala |
Cellular Therapies |
Adoptive immunotherapy;Epigenetics;Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 371 |
Poster Presentation |
Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy |
Stefano Pierini, PhD; Rashid Gabbasov, PhD; Cecilia Nunes, PhD; Alison Worth, MSc; Yumi Ohtani, PhD; Michael Ball, PhD; Rehman Quereshi, PhD; Olga Shestova; Saar Gill, MD; Serody S. Jonathan, MD; Sascha Abramson, PhD; Thomas Condamine, PhD; Michael Klichinsky, PharmD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Solid tumors |
| 372 |
Poster Presentation |
agenT-797, a native allogeneic 'off-the-shelf' invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment |
Sapana Pokharel, PhD; John Chamberland; Yu Qin; Darrian Moskowitz; Reed Masakayan; Xavier Michelet, PhD; Dhan Chand, PhD; Burcu Yigit; Marc A. Van Dijk, PhD |
Cellular Therapies |
Dendritic cell;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor antigens;Tumor microenvironment |
| 373 |
Poster Presentation |
Combination vaccine, adoptive NK cell transfer and checkpoint blockade reduce murine neuroblastoma progression after bone marrow transplant |
Aicha Quamine, MS; Nicholas R. Mohrdieck; Chloe A. King; Anastasia Griggs; Paul D. Bates; Sean P. Rinella; Katharine E. Tippins; Tyce J. Kearl, MD, PhD; Bryce D. Johnson, PhD; Christian Capitini, MD |
Cellular Therapies |
Adoptive immunotherapy;Antibody;Checkpoint blockade;NK/NKT cell;Pediatric tumors;Solid tumors;Vaccine |
| 374 |
Oral Presentation |
Discovery of a public HPV16-E6 directed T cell response that is associated with overall and progression free survival |
Klaudia A. Szymonowicz; Bo Jiang; Laurene S. Cheung; Weihong Xiao, MD; Alexa J. Halliday; Emily Bontekoe; Keiko Akagi, PhD; Gregory A. Lizee; Kellie N. Smith; Maura L. Gillison, MD, PhD; Nils-Petter Rudqvist, PhD |
Cellular Therapies |
Adoptive immunotherapy;Bioinformatics;Biomarkers;Immune monitoring;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 375 |
Poster Presentation |
In vivo generation of universal CAR T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adapters |
Kristen L. Mittelsteadt, PhD; Isabel Leung, PhD; Kelsey Lynch, PhD; Haiyan Chu, MD-PhD; Chang-Chih Wu, PhD; Seungjin Shin, PhD; Ryan Larson, PhD; Andrew Scharenberg, MD; Byoung Ryu, PhD; Laurie Beitz, MD |
Cellular Therapies |
CAR T cells;Solid tumors;Targeted therapy;Tumor antigens;Tumor microenvironment;Tumor stroma |
| 376 |
Poster Presentation |
Macrophages engineered to express synthetic cytokine switch receptors act as living microenvironment converters |
Chris Sloas, PhD; Yuhao Huangfu, MS, MD; Thomas Condamine, PhD; Michael Klichinsky, PharmD, PhD; Yumi Ohtani, PhD |
Cellular Therapies |
Adoptive immunotherapy;Cytokine;Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment |
| 377 |
Poster Presentation |
Adoptive cell therapy with Cytokine-Induced Killer cells retargeted with immunotools against HER-2 positive breast cancer. |
Roberta Sommaggio, PhD; Elisa Cappuzzello; Annavera Ventura; Sara Perpinello; Anna Dalla Pieta; Emilia Vigolo; Giulia D'Accardio; Pierangela Palmerini; Antonio Rosato |
Cellular Therapies |
Adoptive immunotherapy;Antibody;Bispecifics;Solid tumors;Targeted therapy |
| 378 |
Poster Presentation |
Chimeric Engulfment Receptor (CER) T Cells with a TLR2 Domain Synergize with an EGFR Inhibitor to Target NSCLC Cells In Vitro and Demonstrate APC-like Function |
Sunil Thomas, PhD; Harini Kethar; Linh P. Nguyen, PhD; Brandon Cieniewicz, PhD; Alex Arballo; Priya Baichoo; Damoun Torabi; Ankit Bhatta, MS; Daniel Corey, MD |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;T cell lineages;TLR;Tumor antigens |
| 379 |
Poster Presentation |
Engineering of gamma/delta T cells derived from cord blood for chimeric antigen receptor-T cell therapies |
Chelsia Qiuxia Wang, PhD; Alice Cheung; Andy Hee-Meng Tan |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor microenvironment |
| 380 |
Poster Presentation |
Development and characterization of a CAR T cell potency assay with 3D cancer spheroid models |
Omari Weems; Denise Sullivan; Austin Passaro; Stacie Chvatal; Daniel Millard, PhD |
Cellular Therapies |
CAR T cells;Solid tumors;Tumor microenvironment |
| 381 |
Poster Presentation |
Large-scale expansion and engineering of human NK cells sourced from peripheral blood versus umbilical cord blood |
Michael I. Whang, PhD; Ming-Hong Xie, MD; Kate Jamboretz, MS; Chang N. Kim, BS; Sombeet Sahu, MS; Hadia Lemar; Nafees Rahman, PhD; Ivan H. Chan, PhD; Erik M. Whiteley, PhD; Ralph Brandenberger, PhD; Sasha Lazetic, BA; James B. Trager, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;NK/NKT cell;Targeted therapy |
| 382 |
Poster Presentation |
A novel peripheral blood mononuclear cell humanized mouse model for preclinical efficacy and toxicity evaluation of chimeric antigen receptor T-cell immunotherapy |
Jiwon Yang, PhD; Won Lee; Heather Gustafson; Blair Amrstrong; Katelym Burleigh; Mingshan Cheng; James G. Keck |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Cytokine;Immune toxicity;T cell |
| 383 |
Poster Presentation |
Targeting IgE-producing Blood Cancers Using EMPD-specific Chimeric Antigen Receptor T Cells |
Shenyu Zhang, MS; Zhengyu Ma; Brittany F. Fay |
Cellular Therapies |
B cell;CAR T cells;T cell;Targeted therapy |
| 384 |
Poster Presentation |
Systematic, Antigen-agnostic Discovery of Tumor-Reactive TCRs Powered by Repertoire-Scale TCR Gene Synthesis and The Use of Banked Allogeneic Cancer Cell Lines |
Xi Chen; Yue Zhao, PhD; Ely Porter, PhD; Danielle R. Cook, PhD; Jiekun Xuan; Xiao-Wu Huang; Bin Li; Jingwei Zhang; Lili Ren; Teng Wei; Ning Li |
Cellular Therapies |
Adoptive immunotherapy;Neoantigens;Systems biology;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 385 |
Poster Presentation |
Engineering a TGF-β switch receptor enhances CAR-T cell function in a suppressive TGF-β-enriched tumor microenvironment |
Joe Jiang Zhu, PhD; Criselle DSouza, PhD; Vicky Qin; Niko Thio; Michael H. Kershaw, PhD; Joe A. Trapani, MD; Phillip K. Darcy, PhD; Paul J. Neeson, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Costimulation;Immune suppression;Solid tumors;Tumor microenvironment |
| 386 |
Poster Presentation |
Efficient ex-vivo expansion of adaptive NKG2C+/CD57+ NK cells from CMV-positive donors using dendritic cells derived from the acute myeloid cell line DCOne. |
Haoxiao Zuo, PhD; Remco Bos; Alex Karlsson-Parra, MD, PhD; Satwinder Kaur Singh, PhD |
Cellular Therapies |
Adoptive immunotherapy;Dendritic cell;Immune adjuvant;NK/NKT cell |
| 387 |
Poster Presentation |
Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal cancer (CRC) |
Matthew Beatty, PhD; MacLean Hall, BS; Holly Branthoover; Mary Rau; Jake Nikota, PhD; James Bender, PhD; Jake Ceccarelli, PhD; Timothy J. Langer; Jamie Teer, PhD; Jason Fleming, MD; Shari Pilon-Thomas, PhD |
Cellular Therapies |
Adoptive immunotherapy;Neoantigens;Tumor infiltrating lymphocytes (TILs) |
| 388 |
Poster Presentation |
Targeted ovarian cancer immunotherapy through engineering of follicle stimulating hormone receptor (FSHR) antibody to engage T cells |
Devivasha Bordoloi, PhD; Pratik S. Bhojnagarwala, MS; Alfredo Perales-Puchalt, PhD; Abhijeet J. Kulkarni, MS; Xizhou Zhu; Kevin Liaw, PhD; Ryan P. O’Connell; Daniel H. Park; Daniel Kulp, PhD; Rugang Zhang, PhD; David B. Weiner, PhD |
Cellular Therapies |
Antibody;Bispecifics;Targeted therapy;Tumor antigens;Tumor microenvironment;Vaccine |
| 389 |
Poster Presentation |
Multiplexed TCR-T cell therapy targeting MAGEA1 and PRAME enhances the activity of adoptive T cell therapy in pre-clinical models |
Cagan Gurer, PhD; Gavin MacBeath, PhD; Mollie Jurewicz, PhD; Nancy Nabilsi, PhD; Antoine J. Boudot, PhD; Jenny Tadros; Tary Traore, PhD; Maytal Bowman; Elizabeth M. Hall; Yifan Wang, PhD; Qikai Xu, PhD; Victor Ospina |
Cellular Therapies |
Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 390 |
Poster Presentation |
Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15 therapy) in an allogeneic melanoma PDX model |
Rachel A. Burga, PhD; Zheng Ao, PhD; Arman Aksoy, PhD; Scott Lajoie; Kyle Pedro, PhD; Jack Tremblay; Gauri Kulkarni; Alonso Villasmil Ocando; Benjamin Primack, MS; Meghan Langley; Theresa Ross; Jeremy H. Tchaicha, PhD; Michelle L. Ols, PhD; Jan H. ter Meulen, MD, PhD; Mithun Khattar, PhD |
Cellular Therapies |
Adoptive immunotherapy;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 391 |
Poster Presentation |
Development of a GMP-Compatible, Virus-Free CRISPR CAR T Cell Manufacturing Process |
Dan Cappabianca, BS; Madison Bugel; Sarah Caroline Gomes de Lima; Ross Schwartz; Krishanu Saha; Christian Capitini, MD |
Cellular Therapies |
CAR T cells;Clinical trial;Cytokine;Pediatric tumors;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 392 |
Poster Presentation |
Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies |
Jae Woong Chang, Ph.D.; Joshua Kreuger; Joseph Skeate; Erin Stelljes; Walker Lahr; Nicholas Slipek; Emily Pomeroy; Meghan Walsh; Jennifer Johnson; Charlotte Franco; Simarjot Pabla; Jared Sewell; Eugene Choi; Vipin Suri; Beau Webber; Branden Moriarity |
Cellular Therapies |
NK/NKT cell;Solid tumors |
| 393 |
Poster Presentation |
ATAK receptors, a new class of chimeric antigen receptor that harness innate immunity in myeloid cells to target cancer |
Neha Diwanji; Edward Cochran; Michael Gorgievski; Thomas Prod'Homme; Yuxiao Wang, Ph.D.; Bruce McCreedy; Daniel Getts |
Cellular Therapies |
Adoptive immunotherapy;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;TLR;Tumor antigens;Tumor microenvironment |
| 394 |
Poster Presentation |
Using co-stimulatory CARs in natural killer cells to safely target soft-tissue sarcomas and their inhibitory microenvironments |
Stephanie Fetzko, MD; Ishwar Navin, MS; Matthew Dysthe, B.S.; Tim Sauer, MD; Cliona Rooney, PhD; Robin Parihar, MD, PhD |
Cellular Therapies |
MDSC;NK/NKT cell;Pediatric tumors;Solid tumors;Tumor microenvironment |
| 395 |
Poster Presentation |
Engineering non-activated CAR T cells with enhanced potency against advanced cancers |
Saba Ghassemi, PhD; Joseph S. Durgin, MD; Frederic D. Bushman, PhD; Saar I. Gill, MD, PhD; Roddy S. O'Connor, PhD; Michael C. Milone |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors;T cell |
| 396 |
Poster Presentation |
Investigating the role of the endogenous CD28 co-stimulatory receptor in achieving optimal CAR-T cell therapeutic efficacy |
Mackenzie M. Honikel; Kelvin P. Lee, MD; Scott H. Olejniczak, PhD |
Cellular Therapies |
CAR T cells;Costimulation |
| 397 |
Poster Presentation |
Deep myeloid cell profiling provides new insights into modulators of CAR T cell expansion in patients with solid tumor malignancies |
Sabina Kaczanowska, PhD; Sneha Ramakrishna, MD; Tara Murty, BS; Cristina F. Contreras; Ahmad Alimadadi, PhD; Norma Gutierrez; Aashna Jhaveri; Yang Liu; Jennifer Altreuter, MD; Franziska Michor; Caroline Duault, PharmD, PhD; Priyanka Balasubrahmanyam; Warren Reynolds; Reema Baskar, PhD; Mina Pichavant; Bita Sahaf, PhD; Sean C. Bendall, PhD; Holden T. Maecker, PhD; Melinda Merchant, MD, PhD; Crystal Mackall, MD; Catherine C. Hedrick, PhD; Rosandra N. Kaplan, MD |
Cellular Therapies |
CAR T cells;Clinical study;Immune contexture;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors;T cell |
| 398 |
Poster Presentation |
Expansion of therapeutic NK cell line under hypoxic and hyperbaric culture conditions enhances anti-tumor potency |
James Lim, PhD; Ann Lu, PhD; Yunmin Li, PhD; Yelena Bronevetsky, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Immune suppression;Metabolism;NK/NKT cell;Tumor microenvironment |
| 399 |
Poster Presentation |
Developing a new targeted therapy for pediatric rhabdomyosarcoma: αvβ3 and HER2 as promising targets for bispecific CAR T-cell therapy |
Amanda M. Lulu, PhD; Joseph J. Caruso, BS; Dustin A. Cobb, PhD; Daniel W. Lee, III, MD |
Cellular Therapies |
Bispecifics;CAR T cells;Pediatric tumors;Solid tumors;Tumor evasion |
| 400 |
Poster Presentation |
PDGFRα-specific CAR T cell therapy of pediatric high-grade glioma |
Sara A. Mazrimas, BA; Kathryn Eckholdt, BS; Paul Hauser, PhD; Wafik Zaky, MD; Amer Najjar, Ph.D. |
Cellular Therapies |
CAR T cells;Pediatric tumors |
| 401 |
Poster Presentation |
Hinge length: A novel method of predicting cytotoxicity of CAR constructs against antigen-low leukemia |
Justin M. Mirazee, B.S.; Dongya Jia, Ph.D; Xiang Chen, Ph.D; Sooraj R. Achar, B.S.; Chris D. Chien, Ph.D; Marie Pouzolles, Ph.D; Kniya D. DeDe, B.S.; Philippe Youkharibache, Ph.D; Kylie J. Walters, Ph.D; Grégoire Altan-Bonnet, Ph.D; Naomi Taylor, M.D., Ph.D. |
Cellular Therapies |
CAR T cells |
| 402 |
Poster Presentation |
T cell killing is facilitated by multiple cytotoxic pathways |
Melisa J. Montalvo, BS; Irfan N. Bandey, PhD; Ali Rezvan; Kwan-Ling Wu; Arash Saeedi; Yongshuai Li; Rohan Kulkarni; Xingyue An, BS; Navin Varadarajan, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Immune toxicity;Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy;Tumor evasion |
| 403 |
Poster Presentation |
Rapid and Multiplexed Identification of Novel TCRs for TCR-T Cell Therapy |
Tamson V. Moore, Ph.D.; Bindu Hegde, Ph.D.; John Leonard, PhD; Nathan Katz; Akshay Sharathchandra; Bryan J. Xie, Ph.D.; Joanna Dreux; May Khadilkar; Marvin H. Gee, PhD; Leah V. Sibener, PhD |
Cellular Therapies |
Adoptive immunotherapy;Immune toxicity;T cell;Tumor antigens |
| 404 |
Poster Presentation |
Enrichment of neoantigen reactive TIL in a CRC patient sample by FACS: The TIDAL-01 process |
Jake Nikota, PhD; Larissa Pikor, PhD; Anna Fritzsche; Zachary Jilesen; Sara Fallahi; Barbara Sennino; David Stojdl |
Cellular Therapies |
Adoptive immunotherapy;Antigen presenting cells;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 405 |
Poster Presentation |
A non-canonical role for CCL2 in T cell migration: improving dual-interferon-treated autologous monocytes as a therapy for ovarian cancer. |
Franklin Ning; Thomas Meyer, PhD; Brittney Harrington, PhD; Christina M. Annunziata, MD, PhD |
Cellular Therapies |
Chemokine;Clinical trial;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment |
| 406 |
Poster Presentation |
An unbiased survey of tumor reactivity and transcriptional landscape of 1,000 clones of PD-1hi T-cells from peripheral blood during ICB treatment reveals breath and dynamics of anti-tumor immunity |
Danielle R. Cook, PhD; Immaculada Creus; Andrea Garcia-Garijo; Pierre Levy; Seon Kinrot; Rodrigo Toledo; Elena Garralda, MD, MSc; Ely Porter, PhD; Xi Chen; Alena Gros, PhD |
Cellular Therapies |
Adoptive immunotherapy;Checkpoint blockade;Gene expression;Solid tumors;Systems biology;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 407 |
Poster Presentation |
Mitochondrial transcription is required for the enhanced anti-tumor activity of adoptively transferred stem-like memory T cells |
Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Hannah M. Knochelmann, MD, PhD; Aubrey S. Smith, BS; Anna C. Cole, B.A.; Megan M. Wyatt, MS; Chrystal M. Paulos, PhD; Jessica E. Thaxton, PhD, MS; Shikhar Mehrotra, PhD; Haydn Kissick, PhD; Mark P. Rubinstein, PhD; Gregory B. Lesinski, Ph.D. |
Cellular Therapies |
Adoptive immunotherapy;Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 408 |
Oral Presentation |
Neutralizing oxidative damage at telomeres prevents T cell dysfunction and improves adoptive cell therapy |
Dayana B. Rivadeneira, PhD; Sanjana Thosar; Konstantinos Lontos, MD, PhD; Jessica A. Jana, BSE; Marcel Bruchez; Patricia L. Opresko; Greg M. Delgoffe, PhD |
Cellular Therapies |
Metabolism;T cell;Tumor microenvironment |
| 409 |
Poster Presentation |
Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYLTM PH-762 |
Colin J. Thalhofer, PhD; Simon P. Fricker, PhD; Ryan D. Montler, MBA; Elaine A. Ballinger, PhD; Nick P. Morris, PhD; Jake Moses, BS; Dingxue Yan; Tarsem L. Moudgil, MS; Bernard A. Fox, PhD; Nelson Sanjuan, BS; Eric Tran, PhD; James Cardia, PhD; Andrew D. Weinberg, PhD |
Cellular Therapies |
Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 410 |
Poster Presentation |
Priming of SynNotch CAR T cells via CNS-specific antigen allows spatial and temporal regulation of CAR expression, effective homing and persistence of T cells in the CNS, resulting in the complete eradication of aggresive glioblastoma |
Payal B. Watchmaker, PhD; Milos Simic, PhD; David Diebold; Psalm Pineo-Cavanaugh; Jason Duecker; Wei Yu; Wendell Lim, PhD; Hideho Okada, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Solid tumors |
| 411 |
Poster Presentation |
The multi-omics analyses of 'off-the-shelf' CD19-CAR-T cells identifies the subpopulation complexity and the deep characterization of the anti-tumor properties |
Asma Al Sulaiti, MSC; Mohammed El-Anbari, PhD; Shana Jacob, PhD; Toufiq Mohamed, BSc; Saroja Kotegar Balayya, MSC; Suruchi Mohan, MD; Damilola Olagunju, BSC; Chiara Cugno, MD; Sara Deola, MD; Jean-Charles J. Grivel, PhD; Damien Chaussabel, PhD; Chiara Bonini, MD; Monica Casucci, PhD; Cristina Maccalli, PhD |
Cellular Therapies |
Adoptive immunotherapy;CAR T cells;Gene expression;Leukemia/Lymphoma;RNA;Systems biology;T cell;T cell lineages |
| 412 |
Poster Presentation |
Synthetic PD-1 co-stimulatory molecule preserves a cytolytic CAR T cell immune synapse while reducing tonic signaling |
Rebecca M. Brock, PhD; Jessica Morris; Ahmed Z. Gad, BPharm, MSc; Daniel Landi, MD; Shoba A. Navai, MD; Zeid Y. Nawas; Sujith K. Joseph, PhD; Nabil Ahmed, MD, MPH; Alexandre F. Carisey, PhD; Meenakshi Hegde, MD |
Cellular Therapies |
CAR T cells;Checkpoint blockade;Costimulation;Solid tumors |
| 413 |
Poster Presentation |
Genetic deletion of TIGIT enhances CAR-NK cell function in the solid tumor microenvironment |
Ishwar Navin, MS; Matthew Dysthe, B.S.; Corrine Baumgartner, BS; Robin Parihar, MD, PhD |
Cellular Therapies |
Adoptive immunotherapy;Immune suppression;NK/NKT cell;Pediatric tumors;Solid tumors;Tumor microenvironment |
| 414 |
Poster Presentation |
Target Ephrin A3 on Cancer cells and tumor microenvironment in brain cancer |
Ekene J. Ogbodo, PhD; Reona L. Sakamura, MD PhD; Michael W. Ruff, MD; Claudia M. Roman; Truc Huynh Huynh; James H. Girsch; Olivia L. Sirpilla; Kun Yun; Carli M. Stewart; Ismail Can Can; Mohamad M. Adada; Lionel K. Fonkoua; Mehrdad Hefazi; Elizabeth L. Siegler; Saad S. Kenderian, MB, ChB |
Cellular Therapies |
CAR T cells;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Tumor antigens;Tumor microenvironment |
| 415 |
Poster Presentation |
PD-1 Immune Checkpoint Blockade Enhances Eradication of Disseminated Ovarian Cancer |
Rita E. Serda, PhD |
Cellular Therapies |
Checkpoint blockade;TLR;Vaccine |
| 417 |
Poster Presentation |
Rapid discovery of personalized TCRs through a single-cell transcriptomic signature that predicts tumor reactivity |
Ely Porter, PhD; Yue Zhao, PhD; Danielle R. Cook, PhD; Seon Kinrot; Shuang Mao; Yanzhen Ye; Jiayu Ou; Dandan Hu; Xi Chen |
Cellular Therapies |
Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 418 |
Poster Presentation |
6-gingerol Suppresses Angiogenesis and Promotes T-cell cytotoxicity in Mice Model of Colorectal Cancer. |
Babajide O. Ajayi, PhD; Anuoluwapo A. Adeshina, MD |
Checkpoint Blockade Therapy |
Angiogenesis;Bioinformatics;Carcinogenesis;Checkpoint blockade;Immune monitoring;Inflammation;T cell;T cell lineages;Tumor evasion;Tumor microenvironment |
| 419 |
Poster Presentation |
Combined anti-VEGF, anti-CTLA4 and anti-PDL1 treatment induces strong immune responses in patients with cholangiocarcinoma: results from a clinical trial/in depth correlative studies and mouse studies. |
Reda Benmebarek; Tim F. Greten, MD; Cecilia Monge; Benjamin Ruf, M.D.; Yuta Myojin, MD, PhD; Cihan Oguz; Justin Lack; William Telford; Changqing Xie |
Checkpoint Blockade Therapy |
Immune contexture;Immune monitoring;Immune toxicity;T cell;Tumor microenvironment |
| 420 |
Poster Presentation |
Doxycycline regulatable β-catenin demonstrates inducible immune evasion in a melanoma GEM model. |
Alexandra Cabanov, BS; Thomas F. Gajewski, MD, PhD; Stefani Spranger, PhD; Elen Torres-Mejia |
Checkpoint Blockade Therapy |
Checkpoint blockade;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 422 |
Poster Presentation |
KZR-540 is a novel oral small molecule inhibitor of Sec61 cotranslational translocation that potently and selectively blocks PD-1 expression |
Cristina Delgado-Martin, PhD; Neel K. Anand; Janet L. Anderl; Chengguo Dong; Andrea Fan, PhD; Ying Fang; Christopher J. Kirk, PhD; Tony Muchamuel; Yu Qian; Jinhai Wang; Jennifer A. Whang, PhD; Patricia Zuno-Mitchell |
Checkpoint Blockade Therapy |
Checkpoint blockade;T cell |
| 423 |
Poster Presentation |
Treatment of Relapsed and Refractory Lymphomas with Nivolumab in a Limited Recourse Country |
Lusine Harutyunyan, Dr, MD; Anahit Ter-Grigoryan; Hayk Grigoryan; Marina Kazaryan; Miranush Saaryan; Nerses Ghahramanyan; Artem Oganesyan, MD; Levon Evoyan; Marina Melik-Andreasyan; Anahit Aynajyan; Karapet Hakobyan; Astghik Voskanyan; Karen Meliksetyan; Yervand Hakobyan |
Checkpoint Blockade Therapy |
Checkpoint blockade;Chemotherapy;Leukemia/Lymphoma;Radiotherapy;Targeted therapy |
| 424 |
Poster Presentation |
An allosteric, orally administered CBL-B inhibitor remodels the tumor microenvironment and enhances immune-mediated tumor growth inhibition |
Yilin Qi, Ph.D; Jun Kuai, PhD; Yingzhi Bi; Huadong Sun; Samira Jaeger; David Greco; Ken Carson; Timothy Reilly; Geraldine Harriman; Fang Wang |
Checkpoint Blockade Therapy |
Checkpoint blockade;Costimulation;T cell;Tumor microenvironment |
| 425 |
Poster Presentation |
KVA12.1: an anti-VISTA monoclonal antibody with strong single agent anti-tumor activity and no evidence of cytokine mediated toxicity. |
Thierry Guillaudeux, PhD; Kurt H. Lustig; Emily Frazier; Neda Kabi; Chen Katz; David Peckham; Mei Xu; Shawn Iadonato, PhD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Clinical trial;Cytokine;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment |
| 426 |
Poster Presentation |
ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models |
Xiaofeng Niu, PhD; Chunnian Wang, PhD; Jinfeng Zhao; Yefeng Lu; Yingchao Liu; Rui Gao, PhD; Zhihao Wu, PhD; Yangsheng Qiu, PhD; Zheng Song, PhD; Hongtao Lu, PhD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Immune suppression;Solid tumors;T cell |
| 427 |
Poster Presentation |
Approval Timings and Review Speed of Immune Checkpoint Inhibitors (ICIs) in Cancer Therapy between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) from 2010-2022 |
Numair M. Rizwan, MD; Ali Raza Khaki, MD MS; Aakash Desai, MBBS MPH; Jeremy L. Warner, MD MS; Jonathan Krell, PhD; Mark Lythgoe, MBBS, MRPharmS |
Checkpoint Blockade Therapy |
Checkpoint blockade;Solid tumors |
| 428 |
Poster Presentation |
Diffusing alpha-emitters Radiation Therapy Promotes a Pro-immunogenic Tumor Microenvironment and Synergizes with PD-1 Blockade |
Sara Roumani, PhD; Yossi Nishri; Amit Shai; Margalit Efrati; Itzhak Kelson; Yona Keisari; Vered Domankevich; Robert Den |
Checkpoint Blockade Therapy |
Checkpoint blockade;Gene expression;Myeloid cells;Radiotherapy;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 429 |
Poster Presentation |
Human tumor response to a standard monotherapy checkpoint inhibitor in a humanized HSC-NCG mouse model engrafting adult healthy donor-mobilized human CD34+ hematopoietic stem cells |
Jenny Rowe, PhD; Christoph S. Eberle, PhD; Ann Fiore; Robert Mihalek; Brianna Schoen; Stephen Festin, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 430 |
Poster Presentation |
Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab in a US Community Setting |
Wolfram Samlowski, MD; Phillip K. Chan, PhD; Anna C. Pavlick, MD, MBA; Justin C. Moser, MD; Nicholas Robert, MD; Tayla M. Poreta, PharmD, MPH; Andriy Moshyk, MSc, MD; Leon Sakkal, PharmD; Jennell Palaia, PharmD, MS; Nicole M. Niehoff, PhD; Jonathan Rajkumar, MPH; Asim Amin, MD, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Immune adjuvant;Solid tumors |
| 431 |
Poster Presentation |
Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy. |
Megan Smith-Uffen, MD; John Park; Andrew Parsonson; Anuradha Vasista |
Checkpoint Blockade Therapy |
Checkpoint blockade;Targeted therapy |
| 432 |
Poster Presentation |
Evaluation of novel anti-TIGIT antibody M6223 as a single agent and in combination with avelumab on human natural killer (NK) cell cytotoxicity |
Anton Titov; Nancy Sun; Christie Kelton; Mirek Jurzak; Hong Ma; Chunxiao Xu |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;NK/NKT cell;Targeted therapy;Tumor antigens |
| 433 |
Poster Presentation |
Prevalence of PD-L1 expression among patients with recurrent and metastatic head and neck squamous cell carcinoma in Taiwan |
Chia-Jui Yen; Ming-Yu Lien; Rebecca Cheng; Yu-Wen Su, MD; Han-Nan Lin; Michael Thomas Wong; Song Ling Poon; Chih-Yen Chien; Ruey-Long Hong |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Clinical study;Epidemiology;Solid tumors |
| 434 |
Poster Presentation |
Targeting the expression of Neuropilin-1 by locked nucleic acid modified antisense oligonucleotides results in potent anti-tumor activity in vivo |
Richard Klar, PhD; Clara Seger; Nicole Kirchhammer; André Maaske; Julia Festag; Laura Fernandez Rodriguez; Mélanie Buchi; Monika Schell; Stefanie Raith; Sven Michel; Alfred Zippelius, MD; Frank Jaschinski, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Gene expression;Immune suppression;Tumor microenvironment |
| 435 |
Poster Presentation |
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer |
Namrata S. Patil, Ph.D.; Barzin Y. Nabet, PhD; Sören Müller; Hartmut Koeppen; Wei Zou; Jennifer Giltnane; Jason H. Cheng; Chikara Takahashi; Avantika S. Chitre; Linda Rangell; Sangeeta Jayakar; William E. O’Gorman; Marcus Ballinger; Romain Banchereau; David S. Shames |
Checkpoint Blockade Therapy |
B cell;Checkpoint blockade;Chemotherapy;T cell |
| 437 |
Oral Presentation |
Safety and Efficacy of Immune Checkpoint Inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium |
Talal El Zarif, MD; Amin Nassar, MD; Elio Adib, MD; Bailey Fitzgerald, MD; Jiaming Huang, MS; Tarek H. Mouhieddine; Taylor Nonato, BS; Rana R. McKay, MD; Mingjia Li, MD; Arjun Mittra, MD; Dwight H. Owen, MD, MSc; Michael Lorentsen, MD; Christopher Dittus, DO; Nazli Dizman, MD; Brinda Emu, MD; Adewunmi Falohun, DO; Noha Abdel-Wahab, MD, PhD; Anand Bankapur, MD; Alexandra Reed, BA; Ryan Dobbs, MD; Chul Kim, MD; Aakriti Arora, MD; Neil J. Shah, MBBS; Edward El-Am, MD; Elie Kozaily, MD; Wassim Abdallah, MD; Ahmad Al-Hader, MD; Batool Abu Ghazal, MD; Anwaar Saeed, MD; Claire Drolen, MD; Melissa G. Lechner, MD, PhD; Javier B. Espinar, MD; Caroline A. Nebhan, MD, PhD; Douglas B. Johnson, M.D.; Tarek Haykal, MD; Michael A. Morse, MD; Alessio Cortellini, MD, PhD; David J. Pinato, MD, MRes, PhD; Alessia Dalla Pria, MD; Mark Bower, MD; Evan T. Hall, MD, MPhil; Veli Bakalov, MD; Nathan Bahary, MD, PhD; Aarthi Rajkumar, MD; Ankit Mangla, MD; Vishal Shah, PharmD, MBA; Parminder Singh, MD; Frank Aboubakar Nana, MD; Nerea Lopetegui Lia, MD; Danai Dima, MD; Pauline Funchain, MD; Rabia Saleem, MD; Rachel Woodford, MD; Georgina V. Long AO, BSc PhD MBBS FRACP FAHMS; Alexander M. Menzies, MD; Carlo Genova, MD, MD; Giulia Barletta, MD, MD; Sonam Puri, MD; Vaia Florou, MD; Dame Idossa, MD; Paola Queirolo, MD; Giuseppe Lamberti, MD; Alfredo Addeo, MD; Melissa Bersanelli, MD, PhD; Dory Freeman, BSc; Wanling Xie, MS; Ramya Ramaswami, MD, MPH; Thomas U. Marron, MD, PhD; Toni K. Choueiri, MD; Kathryn Lurain, MD, MPH; Lindsey R. Baden, MD; Guru P. Sonpavde, MD; Abdul Rafeh Naqash, MD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Clinical study;Immune suppression;Immune toxicity |
| 438 |
Poster Presentation |
Interrogation of immune toxicity in patients with thymic epithelial tumors (TETs) |
Meredith J. McAdams, MD; Shannon Swift, RN, BSN; Madison Ballman, BA; Abigail Wong-Rolle, BSc; Renee N. Donahue, PhD; Claudia M. Palena, PhD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; Arun Rajan, MD; Chen Zhao, MD |
Checkpoint Blockade Therapy |
Antibody;Autoimmunity;Biomarkers;Checkpoint blockade;Cytokine;Gene expression;Immune toxicity;Solid tumors |
| 439 |
Poster Presentation |
Healthcare resource utilization in patients with pre-existing autoimmune diseases who received immune checkpoint inhibitors in the Marketscan database |
Jennell Palaia, PharmD, MS; Anna C. Pavlick, MD, MBA; Radhika Pisupati, PharmD; Benjamin C. Fu, PhD, MPH; Keith Wittstock, PharmD, MBA; Ying Zhang, MD, MsPH |
Checkpoint Blockade Therapy |
Autoimmunity;Checkpoint blockade |
| 440 |
Poster Presentation |
Outcomes in patients with pre-existing autoimmune diseases who received immune checkpoint inhibitors: a real-world study |
Anna C. Pavlick, MD, MBA; Jennell Palaia, PharmD, MS; Radhika Pisupati, PharmD; Benjamin C. Fu, PhD, MPH; Keith Wittstock, PharmD, MBA; Ying Zhang, MD, MsPH |
Checkpoint Blockade Therapy |
Autoimmunity;Checkpoint blockade |
| 441 |
Oral Presentation |
Checkpoint inhibitor-associated inflammatory arthritis is comprised of multiple clinical endotypes characterized by distinct transcriptional programs |
Gary D. Reynolds, MBBS PhD; Mazen Nasrallah, MD; Neal P. Smith; Molly Thomas, MD PhD; Leyre Zubiri, MD; Alice Tirard; John McGuire; Kasidet Manakongtreecheep; Jessica Tantivit; Steven Blum, MD; Daniel A. Zlotoff, MD, PhD; Elaina PuiYee Chan; Dejan Juric, MD; Ryan J. Sullivan, MD; Genevieve M. Boland, MD, PhD; Andrew Luster; Sara Schoenfeld; Minna Kohler; Kerry L. Reynolds, MD; Chloe Villani, PhD |
Checkpoint Blockade Therapy |
Autoimmunity;Checkpoint blockade;Immune toxicity;Inflammation;T cell |
| 442 |
Poster Presentation |
Pre-Treatment Interstitial Abnormalities is a Risk Factor for Immune Checkpoint Inhibitor Pneumonitis in Patients with Lung Cancer |
Alexander Wong, MD; Maria Riley, BS; Songzhu Zhao, MS; Jessica Zimmer, BS, BA; Matthew Viveiros, BS; Jing Gennie Wang, MD; Vince Esguerra, MD; Mingjia Li, MD; Gabrielle Lopez, BS; Gregory Otterson, MD; Kari Kendra, MD; Carolyn Presley, MD; Lai Wei, PhD; Dwight H. Owen, MD, MSc; Kevin Ho, MD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Epidemiology;Immune toxicity;Inflammation;Radiotherapy |
| 444 |
Poster Presentation |
TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11 |
Leanne G. Ahronian, PhD; Xinyuan Wu; Minjie Zhang; Chengyin Min; Alice W. Tsai; Jacques Ermolieff; Patrick McCarren; Margaret Wyman; Ye Wang; Alborz Bejnood; Kenjie Amemiya; Brian McMillan; Nikitha Das; Brian Doyon; Andre Mignault; Colin Liang; Vassil Elitzin; Yi Yu, PhD; Samuel Meier; Ashley Choi; John P. Maxwell; Alan Huang, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Epigenetics;MDSC;Regulatory T cell (Treg cell);T cell;Targeted therapy |
| 445 |
Poster Presentation |
Treatment patterns and immunotherapy rechallenge in advanced or metastatic upper gastrointestinal cancer in a US real-world setting |
Jaffer A. Ajani, MD; Marley Boyd; Jenifer Wogen; Ilia Ferrusi; Peyman Nakhaei; Lakshmi Menon-Singh; Ailis Fagan |
Checkpoint Blockade Therapy |
Checkpoint blockade;Chemotherapy;Clinical study;Immune suppression;Solid tumors;T cell;Tumor microenvironment |
| 446 |
Poster Presentation |
HR+ breast cancer: Defining innate and acquired resistance to immune checkpoint inhibitors |
Aitziber Buqué Martinez, PhD; Norma Bloy, PhD; Michal Hensler, PhD; Giulia Petroni, PhD; Ai Sato, MSc; Takahiro Yamazaki, PhD; Bhavneet Bhinder, MS; Jitka Fucikova; Olivier Elemento, PhD; Silvia C. Formenti, MD; Lorenzo Galluzzi, PhD |
Checkpoint Blockade Therapy |
Carcinogenesis;Immune adjuvant;Immune suppression;Immune tolerance;Tumor microenvironment |
| 447 |
Poster Presentation |
Dual targeting of PD-1 and CTLA-4 synergizes with focal radiation to durably increase survival against glioblastoma |
Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Immune suppression;Radiotherapy;Solid tumors;T cell;Tumor microenvironment |
| 448 |
Poster Presentation |
Driver mutation analysis as a selective marker for immunotherapy in patients with pheochromocytoma and paraganglioma |
Katerina Hadrava Vanova, PhD; Ondrej Uher, PhD; Leah Meuter; Suman Ghosal, PhD; Jiri Neuzil, PhD; Karel Pacak, MD, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Gene expression;Genetic polymorphism;Immune monitoring;Solid tumors;Targeted therapy;Tumor microenvironment |
| 449 |
Poster Presentation |
Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors |
Brett Hall, Ph.D.; Anna Travesa, Ph.D.; Amy Yamamura; Amy Axel; Sarah Kolitz, PhD; Jason Funt, Ph.D.; Kevin Fowler, Ph.D.; Matthew Nord, Ph.D.; Praveen Nair, Ph.D.; Scott Barrett, M.D.; Peter J. King, Ph.D.; Benjamin J. Zeskind, PhD, MBA |
Checkpoint Blockade Therapy |
Checkpoint blockade;Targeted therapy |
| 450 |
Poster Presentation |
Increased activity of the ATX/LPA axis diminishes CD8+ T cell cytotoxicity via LPAR5 signaling, driving immune checkpoint blockade resistance in non-small cell lung cancer |
Jessica M. Konen, PhD; B. Leticia Rodriguez; Haoyi Wu; Jared J. Fradette; Lixia Diao; Jing Wang, PhD; Don L. Gibbons, MD, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs) |
| 451 |
Poster Presentation |
Serum albumin predicts outcome in patients with extensive stage small-cell lung cancer (ES-SCLC) receiving first-line combination of PD-(L)1 inhibitors and platinum-etoposide chemotherapy. |
Giuseppe Lamberti, MD; Biagio Ricciuti, MD; Victor R. Vaz; Joao Victor M. Alessi, MD; Federica Pecci, MD; Alessandro Di Federico, MD; Mark Awad, MD, PhD |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Chemotherapy;Solid tumors |
| 452 |
Poster Presentation |
Efficacy and safety of camrelizumab combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma:a retrospective study |
Hong Liu, MD; Shuhuai Niu; Zhaohui Fang; Xi Chen; Siyang Liu; Ge Jin; Yunfeng Guo; Qianying Zhang |
Checkpoint Blockade Therapy |
Checkpoint blockade;Chemotherapy;Clinical study;Radiotherapy |
| 453 |
Poster Presentation |
Pharmacologic tumor PDL1 depletion as a translational approach to inhibit tumor-intrinsic PDL1 signals and create novel treatment vulnerabilities |
Clare E. Murray, B.S.; Haiyan H.B. Bai, PhD; Anand V. Kornepati, PhD; Carlos O. Ontiveros, BS; Yilun Deng, PhD; Alvaro S. Padron; Eva M. Galvan; Myrna G. Garcia, BS; Tyler J. Curiel, MD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Chemotherapy;Solid tumors;Targeted therapy;Tumor microenvironment |
| 454 |
Poster Presentation |
Real-world treatment patterns among patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) in a community oncology setting |
Eric Nadler, MD MPP; Christopher M. Black, PhD; Karthik Ramakrishnan; Wan-Yu Tseng; Chuck Wentworth; John Murphy; Nicole Fulcher; Liya Wang; Melannie Alexander; Gregory Patton |
Checkpoint Blockade Therapy |
Chemotherapy;Radiotherapy;Solid tumors;Targeted therapy |
| 455 |
Poster Presentation |
Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumor models in vivo |
Fredrik G. Oberg, PhD; Sujata Bhoi, PhD; Malene Jensen, PhD; Tom Morris, MD; Karin Tunblad, PhD; Hans Wallberg, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Chemotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 456 |
Poster Presentation |
Patterns and Outcomes of Palliative Radiation Therapy with Immunotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
Logan Roof, MD; Anirudh Yalamanchali, MD; David Buchberger, MD; Shauna Campbell, DO; Shlomo Koyfman, MD; Neil M. Woody, MD; Natalie Silver, MD, MS, FACS; Jessica L. Geiger, MD; Emrullah Yilmaz, MD, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Costimulation;Radiotherapy |
| 457 |
Poster Presentation |
Efficacy of Pembrolizumab as cross-line treatment in advanced non-small cell lung cancer: a multi-center non-interventional study from China |
Kexin Ruan; Jing Zheng; Jianying Zhou; Yuping Li; Xiaodong Lv; Xiaoyu Wu; Liren Ding; Jianya Zhou, MD |
Checkpoint Blockade Therapy |
Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical study |
| 458 |
Poster Presentation |
Characterization of HZ-G206: A potent and oral small molecule PD-L1 inhibitor |
Yizhe Wu, PhD; Xingguo Liu, PhD; Xinxin Jin; Jinglai Huang; Xinglu Zhou |
Checkpoint Blockade Therapy |
Checkpoint blockade;Solid tumors |
| 459 |
Poster Presentation |
Gene therapy with p19Arf and interferon-beta sensitizes cells to PD-1 checkpoint blockade and enhances antitumor immune responses in resistant mouse models |
Ana Domingues, BS; Nayara Tessarollo; Bryan Strauss |
Checkpoint Blockade Therapy |
Checkpoint blockade;Gene expression;Solid tumors |
| 460 |
Poster Presentation |
Discovery of Potent Cbl-b inhibitors Demonstrating Enhanced Immune Cell Activity and Tumor Growth Inhibition in Murine Syngeneic Models |
Silvana Leit, PhD; David Ciccone, PhD |
Checkpoint Blockade Therapy |
B cell;Checkpoint blockade;Cytokine;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell |
| 461 |
Poster Presentation |
Generation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, which binds to a differentiated epitope of TIM-3 |
Eleanor Clancy-Thompson, PhD; Trinity L. Perry; Stacy Pryts; Ashvin Jaiswal, PhD; Vaheh Oganesyan; Nydia van Dyk; Chunning Yang; Andrew Garcia; Wenhan Yu; James R. Moynihan, MS; Caroline Miller; Kathy A. Mulgrew; Mark Cobbold, MD, PhD; Yariv Mazor; Scott A. Hammond, PhD; Kristen N. Pollizzi, PhD |
Checkpoint Blockade Therapy |
Antibody;Bispecifics;Checkpoint blockade;Dendritic cell;Genetic polymorphism;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 462 |
Poster Presentation |
PD-L1/PD-L2 dual-specific cytotoxic antibodies augment survival and mediate tumor regression across immune 'hot' and 'cold' murine cancers |
Coline A. Couillault, PhD; Anupallavi Srinivasamani, MS; Shweta M. Hedge; Qinying Liu; Guillaume Trusz; Ashvin Jaiswal, PhD; Dongxing Zha; Michael A. Curran, PhD |
Checkpoint Blockade Therapy |
Antibody;Bispecifics;Checkpoint blockade;MDSC;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 463 |
Poster Presentation |
Investigating the T cell-intrinsic regulatory role of VISTA in anti-tumor immunity |
Cassandra K. Gilmour, BS; Yikun Wang; Sachin Patnaik, BA; Sarah Stone; Li Wang, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 464 |
Poster Presentation |
Anti-CTLA-4 therapy depletes Tregs and expands ICOS+ T-cells in neuroblastoma tumors with induced DNA mismatch repair deficiency |
Megan Hong, BMSc; Rene Figueredo, MSc; Saman Maleki, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Costimulation;Neoantigens;Pediatric tumors;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 465 |
Poster Presentation |
Synergistic approach to overcome the solid tumor microenvironment of mesothelioma with natural killer cell-focused immunotherapy |
Philippa (Pippa) R. Kennedy, PhD; Quinlan M. Kile; Blake A. Jacobson, PhD; Brianna Ettestad; Sarah E. Miller; Jeffrey S. Miller, MD; Manish R. Patel, DO; Martin Felices |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Costimulation;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment |
| 466 |
Poster Presentation |
Combination therapy with anti-VSIG4 and anti-PD-L1 suppress growth of tumor via conditioning of tumor microenvironment. |
Byoung S. Kwon, PhD; Hye Jeong KIM; Joong Won Lee |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment |
| 467 |
Poster Presentation |
YH38560, a novel bispecific fusion protein targeting 5T4 and CD47 in a tumor-selective manner for the treatment of solid cancers |
Narae Lee, MS; Eunjeong Jeong; Jung-Hoon Pyun; Minji Choi; Young Bong Park; Yoon ha Hwang; Eunjung Lee; Junhwan Kim; Se-Woong Oh |
Checkpoint Blockade Therapy |
Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment |
| 468 |
Poster Presentation |
Application of Organoid-based Discovery Platform for Innovative Screening, Evaluation, and Identification (ODISEI) in Immunotherapy |
Bo Eun Lee, MS; Sarang Kim; Yuri Shin; Hee-Ra Lee; Suyoung Jo; Dong Wook Han; Jongman Yoo |
Checkpoint Blockade Therapy |
B cell;Bispecifics;Checkpoint blockade;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 469 |
Poster Presentation |
Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT |
Karin Lee, PhD; Deepali Malhotra, PhD; Stacy Pryts; Eleanor Clancy-Thompson, PhD; Bilal Omar, PhD; Brian Naiman; Michael Overstreet, PhD; Devon K. Taylor; Chunning Yang; Kathy A. Mulgrew; Zhan Xiao; Yue Wang, PhD; Gordon Moody; Mark Cobbold, MD, PhD; Yariv Mazor; Scott A. Hammond, PhD; Kristen N. Pollizzi, PhD |
Checkpoint Blockade Therapy |
Antibody;Bispecifics;Checkpoint blockade;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 470 |
Poster Presentation |
Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors |
Chloe Delepine, MEng, MS; Daniel L. Levey, PhD; Shanmugarajan Krishnan, PhD; Kwang-Soo Kim, PhD; Adam Sonabend; Margaret Wilkens; Antoine Tanne, PhD; Pilar Garcia-Brocano; Claire H. Galand, PhD; Haiyong Han, PhD; Christopher MacDermaid; Jacky Chow, PhD, MS; Sylvia Vincent; Shalu Karkwal; Yan Sun; Racehl Smith; Xavier Michelet, PhD; Kah Teong; Katherine Rosenthal, RN, MSN, OCN, CCRP; David Savitsky, PhD; Cailin Joyce, PhD; Steven J. O'Day, MD; Joseph E. Grossman, MD; Jaymin M. Patel, MD; Dhan Chand, PhD |
Checkpoint Blockade Therapy |
Antibody;Antigen presenting cells;Checkpoint blockade;Clinical study;Costimulation;Dendritic cell;Gene expression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 471 |
Poster Presentation |
Transient inhibition of cyclin-dependent kinase 4/6 with trilaciclib enhances inhibitory receptor immunotherapy to improve antitumor efficacy |
Kun-Hui Lu; Catherine Dietrich; Sarah Ahn; Subing Cao; John S. Yi, PhD; Shom Goel |
Checkpoint Blockade Therapy |
Checkpoint blockade;Solid tumors;T cell;Tumor microenvironment |
| 472 |
Poster Presentation |
Knockdown of VISTA protein using antisense oligonucleotides promotes superior anti-tumor immunity compared to antibody blockade |
Brittany A. Morrow, BS; Michael A. Curran, PhD; Priyamvada Jayaprakash, PhD; Alexey Revenko; Patrick Younan |
Checkpoint Blockade Therapy |
Checkpoint blockade;Granulocyte;Immune suppression;Immune toxicity;MDSC;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 473 |
Poster Presentation |
PD-1 blockade administered before or at the time of T cell activation enhances anti-tumor immunity |
Jena E. Moseman, BSE; Douglas G. McNeel, MD, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 474 |
Poster Presentation |
First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity |
Akram Obeidat, PhD; Anas Atieh; Alon Vitenshtein; Guy Cinamon, PhD; Keren Paz, PhD; Tihana Roviš; Paola Brilc; Lea Hirsl; Ofer Mandelboim; Stipan Jonjic; Pini Tsukerman, PhD |
Checkpoint Blockade Therapy |
Antibody;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 475 |
Poster Presentation |
Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade |
Namrata S. Patil, Ph.D.; Raymond Meng, PhD; Robert Johnston; Patrick S. Chang; Shyam Srivats; Yoonha Choi; Xiangnan Guan; Barzin Y. Nabet, PhD; Lisa McGinnis; Eugene Chiang; Thinh Pham; Alexis Dunkle; Bill O’Gorman; Ira Mellman, PhD; Ruozhen Hu; John Silva; Joy Han; Amelia Au-Yeung; Chikara Takahashi; Nandini Molden; Pallavi Daggumati; Wendy Connolly; Melissa L. Johnson, MD; Delvys Rodriguez Abreu; Byoung Chul Cho, MD, PhD; Antoine Italiano, MD, PhD; Ignacio Gil Bazo; Enriqueta Felip; Sanjeev Mariathasan, PhD; Carlos Bais; David S. Shames, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Myeloid cells;Regulatory T cell (Treg cell);T cell |
| 476 |
Poster Presentation |
LAIR-1 inhibition enhances anti-PD-1 efficacy |
Yoshiko Takeuchi, MD PhD; Corazon D. Arthur; Heather N. Kohlmiller; James M. White; Betty Lee; Bin Fan; Jiawei Huang; James Sissons; Jonathan Sitrin; Lee Rivera; Robert D. Schreiber, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Neoantigens;Solid tumors |
| 477 |
Poster Presentation |
HBM1047, a novel fully human anti-CD200R1 antagonist antibody with potent anti-tumor efficacy in preclinical model |
Yuhua Wang, Ph.D; Qiumei Du; Hongjie Pan; Geetika Bajpai; Tao Liu; Jason Noon; Yao Lu; Jinqiu He; Yan Li; Qingfang Chen; Yongqiang Wang; Xingxing Jia; Fei Chen; Youhong Wang; Yiping Rong; Yun He; Joe Zhao; Musheng Bao |
Checkpoint Blockade Therapy |
Antibody;Antigen presenting cells;Checkpoint blockade;Coinhibition;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 478 |
Poster Presentation |
Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI) |
Tony Z. Zhuang, MD; Subir Goyal, MBBS, PhD, MSc; Jacqueline T. Brown, MD; Bradley C. Carthon, MD, PhD; Omer Kucuk, MD; Greta R. McClintock, MSN, FNP, DC; Lauren Yantorni, ARNP; Mehmet A. Bilen, MD; Viraj A. Master, MD, PhD; Bassel Nazha, MD, MPH |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Clinical study;Epidemiology;Gene expression;Immune adjuvant;Inflammation;Solid tumors;Targeted therapy;Tumor microenvironment |
| 479 |
Poster Presentation |
Expression of Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) on CD4+/CD8+ T cells may associate with pathological characteristics of different types of cancer |
Dia Roy, PhD; Hieu M. Ta, PhD; Cassandra K. Gilmour, BS; Timothy A. Chan, MD, PhD; Keman Zhang, PhD; Li Wang, PhD; Sarah Stone |
Checkpoint Blockade Therapy |
Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 480 |
Poster Presentation |
Impact of infections in patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving pembrolizumab-based therapies |
Ethan A. Burns, MD; Jiaqiong Xu, PhD; Ryan B. Kieser, MD; Shivan Shah, MD; Ibrahim N. Muhsen, MD; Godsfavour Umoru, PharmD; Charisma Mylavarapu, MD; Yuqi Zhang, MD; Aubrey Crenshaw, DO; Kai Sun, MD; Abdullah Esmail; Carlo Guerrero, MD; Zimu Gong, MD, PhD; Kelly Gee, DO; Kirk Heyne, MD; Monisha Singh, MD; Jun Zhang, MD; Eric Bernicker; Maen Abdelrahim, MD, PhD, Pharm B |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Chemotherapy;COVID and Immunotherapy;Immune toxicity |
| 481 |
Poster Presentation |
An affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade |
Xavier Chauchet, PhD; Sebastien Calloud; Margaux Legrand; Laura Cons; Laurence Chatel; Adeline Lesnier; Nicolas Bosson; Pauline Lloveras; Pauline Malinge; Ulla Ravn; Valery Moine; Bruno Daubeuf; Yves Poitevin; Giovanni Magistrelli; Susana Salgado-Pires, PhD; Dmitry Shchelokov, PhD; Oleg Demin, Jr., PhD; Limin Shang, PhD; Krzysztof Masternak, PhD; Walter Ferlin, PhD |
Checkpoint Blockade Therapy |
Bispecifics;Checkpoint blockade;Solid tumors |
| 482 |
Oral Presentation |
ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking 'don't-eat-me' signal |
Peng Chen; Min Deng; Yun Liu; Jiamei Luo; Rong Guo; Jay Mei; Bo Shan; Bing Hou, Ph.D |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment |
| 483 |
Poster Presentation |
Preclinical evaluation of JTX-1484, an anti-LILRB4 antagonist antibody, for re-programming of immunosuppressive myeloid cells |
Heather Condurso; Amy Mueller; Jessica Jimenez; Lauren Badalucco; Kelly Aldridge; Pauline Sarraf; Michelle Priess; Vikki Spaulding; Sarah Jaffe; Prashanna Balaji Venkatasubramanian; Alexa Diiorio; Geneva Young; Kameron Mori; Karl Wetterhorn; Jeffrey Smith; Morgan Thompson; Jean-Christophe Pignon; Changyun Hu; Brandon Chin; Briana Murphy; Matthew Southard; Katalin Kis-Toth; Monica Gostissa, PhD; Dmitri Wiederschain; Andre P. da Cunha |
Checkpoint Blockade Therapy |
Antibody;Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;Myeloid cells;Solid tumors;Tumor microenvironment;Tumor stroma |
| 484 |
Poster Presentation |
Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen cross-presentation |
Vanessa Gauttier, PhD; Marion Drouin; Isabelle Girault, MD; Irène Baccelli; Sabrina Pengam; Emmanuelle Wilhelm; Javier Saenz; Julien Taurelle; Emmanuel Merieau; Bérangère Evrard; Caroline Mary; Géraldine Teppaz; Ariane Desselle; Virginie Thépénier; Nicolas Poirier; Elise Chiffoleau |
Checkpoint Blockade Therapy |
Antigen presenting cells;Checkpoint blockade;Dendritic cell;Monocyte/Macrophage |
| 485 |
Poster Presentation |
Functional characterization of the inhibitory activity and identification of novel T-cell receptors for the tumor-associated macrophage receptor VSIG4 |
Tim Eitas, PhD; Edward H. van der Horst, PhD; Faith Finley, BS; Thomas Thisted, PhD; Kanam Malhotra, MS; Arnab Mukherjee, PhD; Zuzana Biesova, PhD; Anokhi Cifuentes, MS; Sandra Marder, PhD; Paul Helbling, PhD; Robert H. Pierce, Jr., MD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Coinhibition;Immune suppression;Monocyte/Macrophage;Myeloid cells;Surfaceome;T cell;Targeted therapy;Tumor microenvironment |
| 486 |
Poster Presentation |
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy. |
Silvia Guglietta, PhD; Lukas M. Weber, PhD; Bruno Fosso, PhD; Marinella Marzano; Gary Hardiman; Monica M.M. Olcina, PhD; Mark D. Robinson, PhD; Carsten Krieg, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Inflammation;Microbiome;Solid tumors |
| 487 |
Poster Presentation |
The Role of VSIG4 as an Immuno-Regulatory protein in cancer |
William Huang, BS; Michele Doucet; Rupashree Sen; Andrew M. Pardoll, MD, PhD; Sudipto Ganguly, PhD |
Checkpoint Blockade Therapy |
Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment |
| 488 |
Poster Presentation |
GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy |
Haemi Kim; Kyoung-Jin Kim; Myeong Jin Yoon; Jenny Choih, PhD; Eun Ji Cho; Hak-Jun Jung, PhD; Kwanghyun Lee, PhD; Jayoung Kim; Chae Gyu Park; Sungho Han, PhD; Donggoo Bae; Heungrok Park |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Tumor microenvironment |
| 489 |
Poster Presentation |
NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity |
McKenna Lamb; Yao Wei; Xiaoxin Ren; Rachel O'Connor; Austin Dulak, PhD; Matthew Rausch, PhD; Jamie Strand, PhD; Bijan Etemad-Gilbertson, PhD; Riale Gilligan; Scott Chappel, PhD; Tomonari Shigemura; David McDermott, MD; Gordon J. Freeman, PhD; XingXing Zang, PhD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Coinhibition;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs) |
| 490 |
Poster Presentation |
Galectin-9 drives TIM-3+ natural killer cell dysfunction in head and neck squamous cell carcinoma |
Lazar Vujanovic, PhD; Housaiyin Li; Juncheng Wang; Aditi Kulkarni; Jennifer L. Anderson, M.D., Ph.D.; Lidia M. Arantes; Hridesh Banerjee, PhD; Lawrence P. Kane, PHD; Xin Zhang; Tullia Bruno, PhD; Riyue Bao, PhD; Robert L. Ferris, MD, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Gene expression;Immune suppression;NK/NKT cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 491 |
Poster Presentation |
Preclinical pharmacology modeling of HX009, a clinical stage first-in-class PD-1xCD47 BsAb, for anti-lymphoma applications |
Xiaoyu An, PhD; Henry Li, Ph.D; Hang Ke; Lingxin Xiong, Ph.D; Faming Zhang, Ph.D; Mingfa Zang; Xiaolong Tu, Ph.D; Jingjing Wang, Ph.D; Demi Liu; Cen Chen; Cunxiang Ju; Xianfei He, Ph.D; Lei Zhang, Ph.D |
Checkpoint Blockade Therapy |
Antibody;Bispecifics;T cell |
| 492 |
Poster Presentation |
SIRPα blockade results in tumor intrinsic and immune microenviroment effects resulting in the inhibition of breast-to-brain metastatsis |
Jessica D. Mackert, PhD; Elizabeth R. Stirling, MS, PhD; Steven M. Bronson, DVM; Adam S. Wilson; Mitra Kooshki, MS; Dawen Zhao, MD PhD; Pierre L. Triozzi, MD; Glenn Lesser, MD; David R. Soto-Pantoja, PhD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor evasion;Tumor microenvironment |
| 493 |
Poster Presentation |
PH-804, an INTASYL self-delivering RNAi compound that targets TIGIT enhances NK cell cytotoxicity to tumor cells |
Melissa Maxwell; Dingxue Yan; Brianna Rivest; Andrew Boone; Shenghua Zhou, MD, PhD; Benjamin Cuiffo, PhD; James Cardia, PhD; Simon P. Fricker, PhD |
Checkpoint Blockade Therapy |
Adoptive immunotherapy;Checkpoint blockade;Gene expression;NK/NKT cell;RNA |
| 494 |
Poster Presentation |
CO-1: A Novel Potent Dual Function Anti-CD47 Antibody for Cancer Therapy |
Sittana Matar, Industrial PhD candidate; Seham Skah, PhD; Rolf D. Pettersen, PhD; Kjetil Hestdal, MD, PhD; Nina Richartz, PhD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Immune suppression;Leukemia/Lymphoma;Monocyte/Macrophage;Solid tumors;Tumor evasion |
| 495 |
Poster Presentation |
BYON4228, a pan-allelic SIRPα blocking antibody with a favorable pre-clinical safety profile, enhances anti-tumor immunity in vitro and in vivo |
Mary van Helden; Roel Arends; Seline Zwarthoff; Monique van der Vleuten; Marc Paradé; Karin de Laat-Arts; Hugo Olsman; Ellen Mattaar; Dirk Glaudemans; Daniëlle van Wijk; Lilian Driessen-Engels; Inge Reinieren-Beeren; Paul Boersema; Eva Hanckmann; Gerard Rouwendal; Ruud Ubink; Miranda van der Lee; Gijs Verheijden; Wim Dokter; Timo van den Berg |
Checkpoint Blockade Therapy |
Checkpoint blockade;Myeloid cells |
| 496 |
Poster Presentation |
HCB101: A safe and effective ligand trap therapeutic targeting the CD47-SIRPa signaling pathway for cancer treatment |
Jiin-Tarng Wang; Chi-Ling Tseng; Han-Feng Teng; Pan-Hsien Kuo; Yun-Chih Cheng; Yi-Jing Chen; Yi-Hsuan Lu; Tsai-Kuei Shen; Hong-Fan Wang; Pei-Lun Tsai; Yu-Chen Wu; Chien-Hsin Ho; Wei-Tse Sun; Yen-Cheng Li; Yi-Hsuan Lee; Zong Sean Juo, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Targeted therapy |
| 497 |
Poster Presentation |
Evaluation of the TIGIT+ immune subset depletion effect of the anti-TIGIT antibody M6223 |
Chunxiao Xu; Sireesha Yalavarthi; Clotilde Bourin; Jacques Moisan; Andree Blaukat; Laura Helming |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 498 |
Poster Presentation |
Preclinical characterization of OR502, an anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression |
Meghan E. Zuck, PhD; Myriam N. Bouchlaka, PhD; Huyen Dinh; Kevin Green; Meilyn Sylvestre; Francisco Zapata; Ramya Chandrasekaran, M.S. Ph.D.; Gajendra S. Naika; Lauren Loh; Ray Fox; Darbie Whitman; Tom Graddis; Kamal D. Puri, PhD; Peter Probst, PhD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors |
| 499 |
Poster Presentation |
The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model |
Kathleen Sullivan, PhD; Linda Ertl; Zhenhua Miao; Pingchen Fan; Yibin Zeng; Carolyn Dunlap; Karen Ebsworth; Suprit Gupta; Shijie Chris Li; Ton Dang; Shichang Miao; Israel Charo |
Checkpoint Blockade Therapy |
Checkpoint blockade;Solid tumors;Tumor microenvironment |
| 500 |
Poster Presentation |
INV322, a TME selective CD25 x CTLA4 bispecific antibody approach for depletion of tumor restricted Tregs |
Anna C. Ritter, Ph.D.; Nicholas M. Marshal, PhD; Dileep K. Pulukkunat, PhD; Nikhil Pereira; Alexander L. Rakhmilevich, MD, PhD; Joseph Gawdzik, PhD; Jessica M. Wiwczar, PhD; Jason D. Russell, PhD; Laura J. McCormick; Catherine R. Aversa, PhD; Paul M. Sondel, MD, PhD; Hilario J. Ramos, PhD; Bonnie J. Hammer, PhD; Daniel S. Pereira, PhD |
Checkpoint Blockade Therapy |
Bispecifics;Checkpoint blockade;Regulatory T cell (Treg cell);T cell;Tumor microenvironment |
| 501 |
Poster Presentation |
Anti-PDL2 uses IL17-driven interferon-gamma to treat aged but not young cutaneous melanoma-bearing mice, and treats other tumors in an age- and TME-dependent manner |
Myrna G. Garcia, BS; Yilun Deng, PhD; Clare E. Murray, B.S.; Carlos O. Ontiveros, BS; Alvaro S. Padron; Sladjana Skopelja-Gardner; Kah Teong Soh; Dhan Chand, PhD; Tyler J. Curiel, MD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Costimulation;Solid tumors;Tumor microenvironment |
| 502 |
Poster Presentation |
Transplant Oncology: Utilization of Immunotherapy in the Peri-transplant Setting |
Maen Abdelrahim, MD, PhD, Pharm B; Abdullah Esmail; Ala Abudayyeh, MD; Ashish Saharia, MD; R. Mark Ghobrial, MD |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Immune monitoring;Immune suppression;Targeted therapy |
| 503 |
Poster Presentation |
Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma |
Alexander B. Afeyan, BA; Giacomo Oliveira, PhD; Ann Marie Egloff; Zexiang Zeng, PhD; Rebecca Chernock; Liye Zhou, Ph.D.; Cameron Messier; Patrick Lizotte, PhD; Jacquelyn O. Wolff; Kathleen L. Pfaff, PhD; Kari Stromhaug; Robert Haddad, MD; Glenn J. Hanna, MD; Jonathan Schoenfeld, MD MPH; Laura A. Goguen, MD; Donald J. Annino, MD, DMD; Vickie Y. Jo, MD; Peter Oppelt, MD; Patrik Pipkorn, MD; Ryan Jackson, MD; Sidharth V. Puram; Randal C. Paniello, MD, PhD; Jason T. Rich, MD; Jason Webb; Jose Zevallos; Mena Mansour, MD; Jingxin Fu; Gavin P. Dunn, MD, PhD; Scott J. Rodig, MD, PhD; Jessica Ley; Luc G.T. Morris, MD; Lara A. Dunn, MD; Cloud P. Paweletz, Ph.D.; Dorina Kallogjeri, MD, MPH; Jay F. Piccirillo, MD; Douglas R. Adkins; Catherine J. Wu, MD; Ravindra Uppaluri, MD PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 504 |
Oral Presentation |
PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion |
Zoya Alteber, PhD; Roy Granit; Gady Cojocaru; Amit Novik; Niv Sabath; Assaf Wool; Yossef Kliger; Yu Liang; Natalia Petrenko; Jiang He; Pierre Ferre; Yaron Turpaz; Zurit Levin; Eran Ophir, PhD |
Checkpoint Blockade Therapy |
Antigen presenting cells;Checkpoint blockade;Dendritic cell;Gene expression;Immune contexture;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 505 |
Oral Presentation |
High-dimensional analyses of intratumoral myeloid cells highlights presence of distinct myeloid cell phenotypes in immune checkpoint-sensitive and resistant tumors |
Swetha Anandhan, M.Sc.; Sangeeta Goswami, MD, PhD; Shelley Herbrich, PhD; Yulong Chen, Ph.D.; Padmanee Sharma, MD, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 506 |
Oral Presentation |
FcγRIIB expressed on CD8 T cells limits responsiveness to PD-1 checkpoint inhibition in cancer |
Kelsey B. Bennion, BS; Marvi Tariq, MD; Megan M. Wyatt, MS; Kirsten M. Baecher, MD; Chrystal M. Paulos, PhD; Ragini R. Kudchadkar, MD; Michael Lowe, MD, MA; Mandy L. Ford, PhD |
Checkpoint Blockade Therapy |
Adoptive immunotherapy;Antibody;Biomarkers;Checkpoint blockade;Coinhibition;Costimulation;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 507 |
Oral Presentation |
High endothelial venules control the journey of stem-like CD8+ T cells from lymph node to tumor during cancer immunotherapy with combined anti-PD-1 plus anti-CTLA-4 antibodies |
Lucas Blanchard; Estefania Vina; Dorian Tarroux; Emma Lefrançais; Nathalie Ortega; Jean-Philippe Girard |
Checkpoint Blockade Therapy |
Angiogenesis;Antibody;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 508 |
Poster Presentation |
Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition |
Dante Bortone; Anne Monette, PhD; Nicholas Tschernia; Alexandria Cogdill; Yana G. Najjar, MD; Randy F. Sweis, MD; Sara Valpione, MD, PhD; Erik Wennerberg; Praveen K. Bommareddy, Bpharm, MS, PhD; Cara Haymaker; Uqba Khan; Heather M. McGee; Wungki Park, MD; Houssein A. Sater; Christine N. Spencer, PhD; Maria Ascierto; Valentin Barsan; Vinita Popat, BA; Daniel Wells; Steven Vensko; Sarah Dexheimer; Vesteinn Thorsson; Roberta Zappasodi; Nils-Petter Rudqvist, PhD; Benjamin G. Vincent, MD |
Checkpoint Blockade Therapy |
Bioinformatics;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Systems biology;T cell |
| 509 |
Poster Presentation |
Immune checkpoint blockade boosts anti-tumour B cell responses in lung adenocarcinoma |
Jesse Boumelha, BA; Kevin Ng, BA; Katey Enfield, PhD; Charles Swanton, PhD; George Kassiotis, PhD; Julian Downward, PhD |
Checkpoint Blockade Therapy |
B cell;Checkpoint blockade |
| 510 |
Poster Presentation |
A PD-L1 reporter cell line based on the immune checkpoint protein profiling of ATCC cell lines facilitates cancer immunotherapy drug screening |
Hyeyoun Chang, PhD; Brian Della Fera, BS; Haiyun Liu, PhD; Arunajyothi Bandla, MS; Kevin Tyo, PhD; John G. Foulke, MS; Luping Chen, BS; Zhizhan Gu, MD, PhD; Fang Tian, PhD |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Gene expression;Immune monitoring;Immune suppression;T cell;Targeted therapy;Tumor evasion |
| 511 |
Oral Presentation |
T cell-instructed inflammation drives immune checkpoint inhibitor therapy resistance |
Nam Woo Cho, MD PhD; Sophia Guldberg; Eun Ji Kim; Kamir Hiam-Galvez; Katherine Wai; Lauren Levine; Rachel DeBarge; Jacqueline Yee; Naa Ashitey; Matthew Spitzer, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Cytokine;Granulocyte;Immune suppression;Inflammation;MDSC;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs) |
| 512 |
Poster Presentation |
Time-of-day of pembrolizumab infusion and clinical outcomes of patients with NSCLC: too soon to promote morning infusions |
Alessio Cortellini, MD, PhD; Adriana Barrichello; Joao Victor M. Alessi, MD; Biagio Ricciuti, MD; Victor R. Vatz; Thomas Newsom-Davis; Joanne S. Evans; Giuseppe Lamberti, MD; Federica Pecci, MD; Patrizia Viola; Antonio D'Alessio; Claudia A.M. Fulgenzi; Mark Awad, MD, PhD; David J. Pinato, MD, MRes, PhD |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Clinical study;Immune monitoring |
| 513 |
Poster Presentation |
Overcoming Hedgehog Mediated Anti-PD-1 Resistance in Melanoma through Prostaglandin Inhibition |
Nicholas C. DeVito, MD, Y-Van Nguyen, Nagendra Yarla, PhD, Michael P. Plebanek, PhD, Balamayooran BT. Theivanthiran, PhD, Michael Aksu, Vaibhav Jain, Brent Hanks, MD, PhD |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;NK/NKT cell;Solid tumors;Tumor microenvironment |
| 514 |
Oral Presentation |
Tumor context dictates reliance on TCF1 for response to immunotherapy |
Giulia Escobar, PhD; Katherine Tooley; Joan Pagès Oliveras; Cheng Hanning; Xue Chang; Davide Mangani; Hazel Natanael; Carola Rutigliani; Luca Biasco; Ana Carrizosa Anderson |
Checkpoint Blockade Therapy |
Checkpoint blockade;Immune contexture;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 515 |
Poster Presentation |
Assessing the effect of post-traumatic osteoarthritis on murine tumor growth and responsiveness to immune checkpoint blockade |
Elise F. Gray-Gaillard, MS; Younghwan Choi, PhD; Jin Han, PhD; Helen Nguyen, BS; Katlin Stivers, PhD; Anna Ruta, BS; Andrew M. Pardoll, MD, PhD; Jennifer H. Elisseeff, PhD |
Checkpoint Blockade Therapy |
Angiogenesis;Checkpoint blockade;Solid tumors;Surgery;Tumor stroma |
| 516 |
Poster Presentation |
Clinical Tier Grading of Cancer Stem Cells According to Clinical Characteristics for Immune Checkpoint Inhibitors Guided by mRNA stemness index |
Priya Hays, MS, PhD |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Solid tumors;Stem cell/cancer-initiating cell |
| 517 |
Poster Presentation |
Splenic Tumor-Reactive CD8+ T Cells are Endowed With a Unique Potential for Expansion and are the Dominant Source of Systemic Anti-Tumor Immunity After ICB Therapy |
Brendan L. Horton, PhD; Duncan M. Morgan, Ph.D.; J. C. Love; Stefani Spranger, PhD |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Coinhibition;Gene expression;Solid tumors;T cell;T cell lineages |
| 519 |
Poster Presentation |
Meta-analysis on immunotherapy-related hyperprogressive disease (HPD) incidence across tumor types and HPD definitions |
Min Jeong Kim; Min Jeong Kim, MD; Seung Pyo Hong, MD; Yeonggyeong Park, MD; Allison Belette, MD; Chiwoo Song, MD; Youjin Oh, MD; Sukjoo Cho, MD; Ilene Hong; Young Kwang Chae, MD, MPH, MBA |
Checkpoint Blockade Therapy |
Checkpoint blockade;Tumor microenvironment |
| 520 |
Poster Presentation |
PD-1 Inhibits Bystander T Cell Activation and Protects from Activation Induced Cell Death |
Michael Sheng; Catherine T. Le; Cordelia M. Dunai, MS; Lam T. Khuat; Logan Vick; Kevin Stoffel; Arta M. Monjazeb, MD, PhD; Craig Collins; Robert J. Canter, MD; William J. Murphy |
Checkpoint Blockade Therapy |
Checkpoint blockade;Cytokine;Immune monitoring;T cell;T cell lineages |
| 521 |
Poster Presentation |
AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies |
Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; Chunshan Jin; Xinrong He; Yu Xia; Baiyong Li, Ph.D; Jing Min, Ph.D |
Checkpoint Blockade Therapy |
Antibody;Bispecifics;Checkpoint blockade;Tumor microenvironment |
| 522 |
Poster Presentation |
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer |
Danish Memon; Matthew D. Hellmann, MD; Martin L. Miller, PhD |
Checkpoint Blockade Therapy |
Bioinformatics;Checkpoint blockade;Clinical study;Gene expression;Immune suppression;Systems biology;Tumor evasion;Tumor microenvironment |
| 523 |
Poster Presentation |
Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade |
Barzin Y. Nabet, PhD; Habib Hamidi, PhD; Romain Banchereau, PhD; Stefanie Morris, PhD; Leah Adler; Minu K. Srivastava, PhD; Namrata S. Patil, Ph.D.; Carl M. Gay, MD, PhD; John Minna, M.D.; John V. Heymach, MD, PhD; Joseph M. Chan, MD, PhD; Charles M. Rudin; Lauren A. Byers, MD; Stephen V. Liu, MD; Martin Reck; David S. Shames, PhD |
Checkpoint Blockade Therapy |
Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;Immune contexture;Immune suppression;Monocyte/Macrophage;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 524 |
Poster Presentation |
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer receiving immune check-point inhibitors - applicability and potential caveats |
Line Nederby, MSc, PhD; Sinne S. Brun, MD; Torben S. Hansen, MD; Christa H. Nyhus, MD; Lisbeth Bertelsen, MD; Rikke F. Andersen, MSc, PhD; Anders Jakobsen, MD, DMSc, Professor; Torben F. Hansen, MD, DMSc, Associate Professor |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Solid tumors |
| 526 |
Poster Presentation |
miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma |
Kishore B. Challagundla, PhD; Anup Pathania, PhD; Philip Prathipati, PhD; Omalla A. Olwenyi, PhD; Srinivas Chava, PhD; Oghenetejiri V. Smith, MS; Subash C. Gupta, PhD; Nagendra K. Chaturvedi, PhD; Siddappa N. Byrareddy, PhD; Don W. Coulter, MD |
Checkpoint Blockade Therapy |
Immune suppression;Pediatric tumors;Tumor evasion;Tumor microenvironment |
| 527 |
Poster Presentation |
Spatial proteomic and transcriptomic biomarkers of response to immune checkpoint inhibitors in operable lung cancer |
Jonathan Stauber, PHD; Corinne C.R. Ramos, PhD; Adele Ponzoni; Amandine Gerstenberg |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Immune contexture;Solid tumors;Tumor microenvironment |
| 528 |
Oral Presentation |
Acquired resistance to PD-(L)1 blockade in patients with non-small cell lung cancer (NSCLC) |
Biagio Ricciuti, MD; Giuseppe Lamberti, MD; Joao Victor M. Alessi, MD; Federica Pecci, MD; Alessandro Di Federico; Xinan Wang; Adriana Barrichello; Victor R. Vaz; Andy Pangilinan; Danielle Haradon; Lee Elinton; Mizuki Nishino; Scott J. Rodig, MD, PhD; Lynette M. Sholl, MD; Mark Awad, MD, PhD |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade |
| 529 |
Poster Presentation |
Reduced dendritic cell infiltration in anti-PD-1 resistant head and neck squamous cell carcinoma |
Shin Saito, MD; Hirofumi Shibata; Liye Zhou, Ph.D.; Katie Campbell, PhD; Ann Marie Egloff; Ravindra Uppaluri, MD PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;Dendritic cell;Neoantigens;Tumor infiltrating lymphocytes (TILs) |
| 530 |
Poster Presentation |
B7-H3 is a Checkpoint Immunotherapy Target in Advanced Prostate Cancer Harboring PTEN and TP53 Defects |
Di Zhao, PhD; Wei Shi; Yin Wang |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Immune suppression;Solid tumors |
| 531 |
Poster Presentation |
Identifying genetic factors for resistance and response to immune checkpoint inhibitors (icis) in advanced non-small cell lung cancer (nsclc) patients using real-world data |
Neeraj K. Singh, BTECH; Smita Agrawal, PhD; Babu Narayanan |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;Epigenetics;Solid tumors |
| 532 |
Poster Presentation |
Anti-VISTA antibody HMBD-002 reprograms tumour associated macrophages and promotes cytotoxic T cell response |
Bhushan Dharmadhikari, PhD; Dipti Thakkar, PhD; Olga Zharkova, PhD; Debleena Ray, PhD; Jason Lai, PhD; Konrad Paszkiewicz, PhD; Piers J. Ingram, PhD; Jerome Boyd-Kirkup, PhD |
Checkpoint Blockade Therapy |
Antibody;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;T cell;Tumor antigens;Tumor microenvironment |
| 533 |
Poster Presentation |
A Tumor-Lung NLRP3-TLR4 Distant Signaling Axis Drives Immunotherapy Resistance via G-CSF-dependent Expansion of Circulating PD1+ PMN-MDSCs |
Balamayooran B.T. Theivanthiran, PhD; Nagendra Yarla, PHD; Tarek Haykal, MD; Michael P. Plebanek, PhD; Y-Van Nguyen; Nicholas C. DeVito, MD; Brent Hanks, MD, PhD |
Checkpoint Blockade Therapy |
Granulocyte;Immune suppression;TLR;Tumor evasion |
| 534 |
Poster Presentation |
Sex-Linked Differences in Obesity Markedly Impact the Anti-Tumor Efficacy of PD-1 Blockade |
Logan V. Vick, BA; Logan Vick; Ziming Wang; Craig Collins; Lam T. Khuat; Cordelia M. Dunai, MS; Kevin Stoffel; Sai Yendamuri; Sarbajit Mukherjee; Spencer R. Rosario; Robert J. Canter, MD; Arta M. Monjazeb, MD, PhD; William J. Murphy |
Checkpoint Blockade Therapy |
Biomarkers;Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 535 |
Poster Presentation |
Hydroxychloroquine synergizes with anti-PD-1 immune checkpoint blockade in squamous carcinoma of the head and neck |
Avani Vyas, Ph.D.; Silvia Cruz-Rangel; Nayel Khan, MD; Mikayla Bisignani; Lidia M. Arantes; Nicole Schmitt; Kirill Kiselyov; Robert L. Ferris, MD, PhD; Umamaheswar Duvvuri |
Checkpoint Blockade Therapy |
Checkpoint blockade;Coinhibition;Solid tumors;T cell;Tumor evasion |
| 536 |
Poster Presentation |
Decoupling cytotoxic T lymphocyte and exhausted T lymphocyte transcriptomic signatures enhances immune checkpoint inhibitors response prediction in melanoma |
Binbin Wang, Ph.D.; Kun Wang; Eytan Ruppin; Peng Jiang |
Checkpoint Blockade Therapy |
Bioinformatics;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 537 |
Poster Presentation |
Local immunotherapy with INTASYL™ self-delivering RNAi targeting CTLA-4 provides robust tumor control in vivo |
Benjamin Cuiffo, PhD; Melissa Maxwell; Dingxue Yan; Brianna Rivest; Andrew Boone; Shenghua Zhou, MD, PhD; James Cardia, PhD; Simon P. Fricker, PhD |
Checkpoint Blockade Therapy |
Checkpoint blockade;RNA;Solid tumors;T cell;Targeted therapy |
| 538 |
Poster Presentation |
Comprehensive single cell transcriptomic profiling of untreated resectable lung cancers |
Sydney C. Connor, B.S.E; Jiajia Zhang, MD, MPH; Justina X. Caushi, PhD; Boyang Zhang; Zhen Zeng; Khaled Sanber; Gavin Pereira; Valsamo Anagnostou, MD PhD; Ada Tam; Nicholas Ionta; Franck Housseau; Patrick Forde, MBBCh; Hongkai Ji; Andrew M. Pardoll, MD, PhD; Kellie N. Smith |
Clinical Trials Completed |
Bioinformatics;Checkpoint blockade;Clinical study;Gene expression;Immune monitoring;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 541 |
Oral Presentation |
mregDC/T helper niches enable local reactivation of CD8 T cells upon PD-1 blockade |
Assaf Magen, PhD; Pauline Hamon, PhD; Nathalie M. Fiaschi, PhD; Raquel Deering, PhD; Sacha Gnjatic, PhD; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Gavin Thurston, PhD; Alice O. Kamphorst, PhD; Miriam Merad, MD, PhD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical study;Costimulation;Dendritic cell;Immune adjuvant;Immune monitoring;Systems biology;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 542 |
Poster Presentation |
B-Cell Receptor (BCR) Repertoire is a Dynamic Biomarker of Survival in Sarcoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB) |
Elise F. Nassif, MD, MS; Bin Liu, PhD; Wei-Lien Wang, MD; Alexander J. Lazar, MD, PhD; Davis Ingram; Khalida Wani, PhD; Sheila Duncan; Taylor J. Tate; Grace Mathew; Shadarra Crosby; Kenna Shaw; Monika A. Zelazowska, PhD; Barry W. Feig; Keila E. Torres, MD, PhD; Kelly K. Hunt, MD; B. Ashleigh Guadagnolo; Andrew J. Bishop; Phillip Andrew Futreal, PhD; Jennifer A. Wargo, MD, MMSc; Neeta Somaiah, MD; Kevin McBride, PhD; Christina L. Roland, MD, MS, FACS; Emily Z. Keung, MD, MA |
Clinical Trials Completed |
Antibody;B cell;Bioinformatics;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Surgery;Tumor microenvironment |
| 543 |
Poster Presentation |
Response to checkpoint blockade in HCC is associated with IgG1 skewing |
Robert E. Sweeney, II, MD; Edgar Gonzalez-Kozlova, Ph.D; Alexandra Tabachnikova; Christie Chang; Laura Walker; Assaf Magen, PhD; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Miriam Merad, MD, PhD; Sacha Gnjatic, PhD |
Clinical Trials Completed |
Antibody;B cell;Checkpoint blockade;Clinical study;RNA;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 544 |
Poster Presentation |
Companion diagnostic assays for pembrolizumab in patients with MSI-H/dMMR tumors |
Aurelien Marabelle, MD, PhD; Jeff Cesario; Lixin Lang; Deepti Aurora-Garg; Siddhartha Krishan Mathur; Diane Levitan; Deb Card; Fan Jin; David Adelberg; Thierry André; Amy Wehn |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical study;Solid tumors |
| 545 |
Poster Presentation |
A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 (Cisplatin, Vinblastine) in Early Stage Breast Cancer: the INVINCIBLE Trial |
Angel Arnaout, MD; Susan Robertson, MD; Kianoosh Keyhanian, MD; Arif Awan, MD; Gregory Pond, phD; John Bartlett; Megan Hopkins; Linda Liao; Vida Talebian; Lazlo Radvyani; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Vanessa Lopez Ozuna; Melanie Spears |
Clinical Trials Completed |
Biomarkers;Chemotherapy;Clinical trial;Gene expression;Immune contexture;Immune monitoring;Surgery |
| 546 |
Poster Presentation |
A Phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer |
Mary L. Disis, MD, FACP; Ying Liu; Sasha E. Stanton, MD, Ph.D.; William Gwin; Andrew Coveler; John B. Liao, MD, PhD; Jennifer Childs, MPH; Denise Cecil, PhD |
Clinical Trials Completed |
Clinical trial;Immune adjuvant;Immune monitoring;MDSC;Regulatory T cell (Treg cell);Solid tumors;Stem cell/cancer-initiating cell;T cell;Tumor antigens;Vaccine |
| 547 |
Poster Presentation |
Safety and efficacy of de-escalated neoadjuvant chemoimmunotherapy of triple negative breast cancer (TNBC) using chemokine-modulating regimen (rintatolimod, IFN-α2b, celecoxib) |
Shipra Gandhi; Mateusz Opyrchal; Cayla Ford; Ronald Slomba; Marie Quinn; Tracey O'Connor; Ellis Levine; Pawel Kalinski |
Clinical Trials Completed |
Chemokine;Clinical trial;Immune adjuvant;TLR;Tumor microenvironment |
| 548 |
Poster Presentation |
The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients - immunophenotype results from AWARE-1 study |
Thomas C. Heineman, MD. PhD; Thomas C. Heineman, MD, PhD; Houra Loghmani, PhD; Richard Trauger; Fernando Salvador, PhD; Luis Manso, MD, PhD; Tomás Pascual, MD, PhD; Manel Juan, MD, PhD; Aleix Prat, MD PhD; Joaquín Gavilá, MD, PhD; Matt Coffey, PhD; E. Azucena González-Navarro, PhD |
Clinical Trials Completed |
Adoptive immunotherapy;Chemokine;Clinical trial;NK/NKT cell;Solid tumors;T cell;T cell lineages;Tumor microenvironment |
| 549 |
Poster Presentation |
Booster vaccination of a HER2 helper T-cell vaccine increased HER2 immunity in metastatic HER2 positive breast cancer. |
Sasha E. Stanton, MD, Ph.D.; Jennifer Childs, MPH; Doreen M. Higgins, RN, BSN, OCN; Angela Kask, PhD; Yi Yang, MS; Mary L. Disis, MD, FACP |
Clinical Trials Completed |
Clinical trial;Solid tumors;T cell;Vaccine |
| 551 |
Poster Presentation |
Intratumoral Influenza Vaccine in Early Colorectal Cancer |
Mikail Gögenur, MD; Mustafa Bulut, MD; Lukas Balsevicius, MSc; Anne-Marie Kanstrup Fiehn, MD, Senior Resident; Marianne Bøgevang Jensen, MD; Nesibe Özgur Colak, MD; Tobias Freyberg Justesen, MD; Paulo Cesar Martins Urbano, MSc, PhD; Lasse Bremholm Hansen, MD, PhD; Ismail Gögenur, MD, DMSc |
Clinical Trials Completed |
Clinical trial;Immune suppression;Inflammation;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 552 |
Poster Presentation |
Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial |
H. Duygu Saatcioglu; Juan W. Valle; Teresa Macarulla; Milind Javle, MD; Do-Youn Oh, MD, PhD; Lipika Goyal; Jake Conway; Janani S. Iyer; Fedaa Najdawi; Chintan Shah; Camelia Gliser; Susan Pandya; Scott R. Daigle; Ghassan K. Abou-Alfa, MD; Robin K. Kelley, MD |
Clinical Trials Completed |
Biomarkers;Solid tumors;Tumor microenvironment |
| 553 |
Poster Presentation |
DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial |
Samuel J. Klempner, MD; Jaffer A. Ajani, MD; Joseph Chao, MD; Hope Uronis; Cynthia A. Sirard, MD; Michael Kagey; Jason Baum; Lilin Zhang; In-Ho Kim; Do-Youn Oh, MD, PhD; Byoung Yong Shim, MD, PhD; Sun Jin Sym; Mohamad Sonbol; Mohamedtaki A. Tejani; Zev A. Wainberg; Devalingam Mahalingam, MBBChBAO; Keun-Wook Lee, MD |
Clinical Trials Completed |
Antibody;Clinical trial;Targeted therapy |
| 554 |
Poster Presentation |
Artificial intelligence (AI)-powered immune phenotyping of advanced or metastatic urothelial carcinoma (aUC) clinical trial samples from hematoxylin and eosin (H&E)-stained whole slide images (WSI) |
Jake Conway; Limin Yu; Yash Belhe; Suyog Jain; Hans J. Grote; Mary Lin; Benjamin Trotter; Darpan Sanghavi; Aslihan Gerhold-Ay; XiaoZhe Wang; Sergine Brutus; Thomas Mrowiec |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma |
| 555 |
Poster Presentation |
Clinical and Pharmacodynamic Biomarker Results from PORTER, a multi-cohort Phase 1 Platform Trial of Combination Immunotherapy for Metastatic Castration-Resistant Prostate Cancer Patients |
Matthew D. Galsky, MD; Karen Autio, MS, MD; Kristopher Wentzel, MD; Julie N. Graff, MD; Terence Friedlander, MD; Julie Densmore; Christopher Cabanski; Kristin M. Shotts, PhD; Tim Howes, PhD; Jia Yu, PhD; Elaine Eisenbeisz; Marko Spasic, MD; Stephen Maddock, MD; Diane DaSilva, PhD; Dinesh Kumar, PHD; Jonni Moore, PhD; Richard Schretzenmair; Jennifer Lata, PhD; Arron Xu; Emma Reuschel; Snehal G. Wani; Matthew P. Morrow, PhD; Jeffrey Skolnik, MD; Sandra Santulli-Marotto, PhD; Lacey Padrón, PhD; Lisa H. Butterfield, PhD; Theresa M. LaVallee, PhD; Samantha Bucktrout, PhD; Michael Yellin, MD; Tibor Keler, PhD; Lisa M. Salvador; Jill O'Donnell-Tormey, PhD; Vanessa M. Lucey, PhD, MBA; Justin A. Fairchild, MPH; Ute Dugan, MD, PhD; Nina Bhardwaj, MD, PhD; Sumit K. Subudhi, MD, PhD; Lawrence Fong, MD |
Clinical Trials Completed |
Clinical trial;Dendritic cell;Immune adjuvant;Monocyte/Macrophage;Radiotherapy;Tumor microenvironment;Vaccine |
| 556 |
Poster Presentation |
Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): Analysis from CheckMate 214 |
Saurabh Gupta, PhD; Celine Han, PhD; Bhakti Dwivedi, PhD; Jun Li, PhD; Morten Karsdal, PhD; Robert J. Motzer, MD; Nicholas N.W. Willumsen, PhD; David McDermott, MD; Toni K. Choueiri, MD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors |
| 557 |
Poster Presentation |
The epitope-enhanced TARP peptide can induce specific T cells that can recognize wild-type TARP tetramer by either peptide or peptide-pulsed DC vaccination in patients with prostate cancer. |
Purevdorj B. Olkhanud, M.D., Ph.D.; Refika B. Turnier; Kimberly Dunham; Masaki Terabe, PhD; Seth Steinberg, PhD; Brenda Roberson; Lauren V. Wood, MD; David F. Stroncek, MD; Ira H. Pastan; Jay A. Berzofsky, MD, PhD; Hoyoung M. Maeng, MD |
Clinical Trials Completed |
Clinical trial;Dendritic cell;T cell;Tumor antigens;Vaccine |
| 558 |
Oral Presentation |
CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the Phase 1 COBALT-RCC study |
Sumanta Pal, MD; Ben Tran, MD; John B.A. Haanen; Michael E. Hurwitz, MD, PhD; Adrian Sacher; Neeraj Agarwal, MD; Nizar Tannir; Elizabeth Budde, MD, PhD; Simon Harrison, MBBS, PhD, FRACP; Sebastian Klobuch; Sagar S. Patel, MD; Mary Lee Dequeant, PhD; Verena Karsten, PhD; Kaitlyn Cohen, MS; Ellen B. Gurary, PhD; Henia Dar, PhD; Anna Ma, MS; Anjali Sharma, MD; Samer A. Srour |
Clinical Trials Completed |
CAR T cells;Clinical study;Clinical trial;Solid tumors;T cell |
| 559 |
Poster Presentation |
Biomarker Correlates of Clinical Response with FLT3L/Nivo Backbone Treatment in the Multi-Cohort Phase 1 PORTER Platform Trial in Metastatic Castration-Resistant Prostate Cancer Patients |
Kristin M. Shotts, PhD; Timothy Howes, PhD; Jia Yu, PhD; Julie Densmore; Diane Da Silva; Dinesh Kumar, PHD; Sandra Santulli-Marotto, PhD; Christopher Cabanski; Elaine Eisenbeisz; Geoffrey Ivison, PhD; Aaron Mayer, PhD; Jonni Moore, PhD; Derek Jones; Kimberly A. Kraynyak, PhD; Alex Dolgoter; Richard O. Chen, MD; Lisa H. Butterfield, PhD; Theresa M. LaVallee, PhD; Samantha Bucktrout, PhD; Lacey Padrón, PhD; Ute Dugan, MD, PhD; Michael Yellin, MD; Tibor Keler, PhD; Jill O'Donnell-Tormey, PhD; Justin A. Fairchild, MPH; Lisa M. Salvador; Kristopher Wentzel, MD; Lawrence Fong, MD; Sumit K. Subudhi, MD, PhD; Nina Bhardwaj, MD, PhD; Karen Autio, MS, MD; Matthew D. Galsky, MD; Tim Howes, PhD |
Clinical Trials Completed |
Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Dendritic cell;Monocyte/Macrophage;Proteomics;Radiotherapy;Solid tumors;Vaccine |
| 560 |
Poster Presentation |
Molecular and immunogenomics features associated with complete response and survival after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer |
Wolfgang Beckabir, AB; Alec D. Wilkinson, PhD; Mark G. Woodcock, MD; Mi Zhou, PhD; Hsing-Hui Wang, PhD; Karen P. McKinnon, PhD; Jonathan S. Serody, MD; Tracy L. Rose, MD; Matthew I. Milowsky, MD; William Y. Kim, MD; Benjamin G. Vincent |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Chemotherapy;Clinical trial;Gene expression;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens |
| 561 |
Poster Presentation |
Immune Activation and Clinical Response From Enzalutamide (enza) Alone or with Radium223 (Ra223) In Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Peter D,. Zang, MD; Tanya B. Dorff, MD; Zhang-Xu Liu; Denice D. Tsao-Wei; Susan Groshen, PhD; Cheryl Kefauver; Czarina Patricio; Anishka D'Souza; Sarah Chevalier; Sumanta Pal, MD; Diane DaSilva, PhD; Martin Kast; David I. Quinn |
Clinical Trials Completed |
Clinical study;Cytokine;Radiotherapy;Solid tumors |
| 562 |
Poster Presentation |
Tumor collection and establishment of tumor-initiating cell cultures to serve as the antigen source for AV-OVA-1 dendritic cell vaccines for patients with newly diagnosed advanced ovarian cancer |
Ramez N. Eskander, MD; Lisa A. Abaid, MD; Bradley R. Corr, MD; James R. Mason, MD; Fabio Cappuccini, MD; Richard L. Friedman, MD, PhD; Rockelle M. Robles, BS; Katrina Lopez, BA; Gabriel I. Nistor, MD; Robert O. Dillman, MD |
Clinical Trials Completed |
Clinical trial;Dendritic cell;Neoantigens;Stem cell/cancer-initiating cell;Vaccine |
| 563 |
Poster Presentation |
A Phase I Clinical Trial of Radiation Therapy, Durvalumab and Tremelimumab in Recurrent Gynecologic Cancer |
Larissa Lee, MD; Panagiotis A. Konstantinopoulos; Ursula A. Matulonis, MD; Joyce F. Liu; Neil Horowitz, MD; Elizabeth Lee, MD; Martin King, MD-PhD; Kelly J. Fitzgerald, MD PhD |
Clinical Trials Completed |
Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors |
| 564 |
Poster Presentation |
Safety and clinical activities of the acid pH-sensitive anti-CTLA-4 mAb ONC-392 in ovarian cancer patients |
John Hays, MD; Tianhong Li, MD, PhD; Hui A. Chen, MD; George Zahrah, MD; Richard Frank, MD; John Hamm, MD; Merry-Jennifer Markham, MD; Thomas George, MD; Eric D. Whitman, MD, FACS; Mark G. Goldstein, MD; Kai He, MD, PhD; Rohit Joshi, MD; Dan Chen, MD, PhD; Yang Liu, PhD; Pan Zheng, MD, PhD; David O'Malley, MD |
Clinical Trials Completed |
Checkpoint blockade;Clinical study;Clinical trial |
| 565 |
Poster Presentation |
Leukapheresis to obtain monocytes to produce dendritic cells for manufacturing AV-OVA-1 personal vaccines in a randomized phase II trial in patients with newly diagnosed advanced ovarian cancer |
James R. Mason, MD; Lisa A. Abaid, MD; Bradley R. Corr, MD; Ramez N. Eskander, MD; Fabio Cappuccini, MD; Richard L. Friedman, MD, PhD; Rockelle M. Robles, BS; Katrina Lopez, BA; Gabriel I. Nistor, MD; Robert O. Dillman, MD |
Clinical Trials Completed |
Clinical trial;Dendritic cell;Myeloid cells;Neoantigens;Stem cell/cancer-initiating cell;Vaccine |
| 566 |
Poster Presentation |
ENTPD1 as predictive marker of treatment response to Gemogenovatucel-T (Vigil) in newly diagnosed ovarian cancer |
Rodney Rocconi, MD; Laura Stanbery; Min Tang; Adam Walter; Bradley J. Monk, MD FACOG FACS; Thomas Herzog, MD; Robert L. Coleman, MD; Luisa Manning, MD; Gladice Wallraven; Staci Horvath; Ernest Bognar; Neil Senzer, MD; Scott Brun; John J. Nemunaitis, MD |
Clinical Trials Completed |
Biomarkers;Clinical trial;Tumor antigens;Vaccine |
| 568 |
Poster Presentation |
Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC) |
Maura L. Gillison, MD, PhD; Michelle Williams, MD; Jason M. Johnson, MD; Cheuk H. Leung, MS; Jay Reddy, MD, PhD; Adam S. Garden, MD; Renata Ferrarotto, MD; Frank Mott, MD; Xiuning Le, MD, PhD; Gary B. Gunn, MD; Anna Lee, MD, MPH; Clifton Fuller, MD, PhD; Charles Lu, MD; Amy Moreno, MD; Katherine A. Hutcheson, PhD; Neil Gross, MD; Miriam Lango, MD; Ryan P. Goepfert, MD; Jeffrey N. Myers, MD; Ehab Y. Hanna, MD; Weihong Xiao, MD; Bo Jiang; Nils-Petter Rudqvist, PhD; Jack J. Lee, PhD DDS; Jack Phan, MD, PhD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors;T cell |
| 569 |
Poster Presentation |
A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in head and neck cancer patients |
Jeffrey Houlton, MD; Daniel R. Clayburgh; Ryan Li; Nathan Schauer, PhD; Marc Grenley; Connor Burns; Angela Merrell; Jason Frazier; Jonathan Derry; Emily Beirne; Wendy Jenkins; Allison J. Berger, PhD; Richard Klinghoffer, PhD |
Clinical Trials Completed |
Antigen presenting cells;Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;Immune contexture;Post-translational modifications;Solid tumors;Tumor microenvironment;Tumor stroma |
| 570 |
Oral Presentation |
Cabozantinib plus atezolizumab in advanced head and neck cancer previously treated with platinum-containing chemotherapy: Results from Cohort 17 of the COSMIC-021 Study |
Sylvie Rottey, MD, PhD; Armando Santoro, MD, PhD; Suzanne Arnold; Saad A. Khan, MD; Allen L. Cohn; Bruno Fang, MD; Svetlana Andrianova; Ramu Sudhagoni; Leleesha Samaraweera; Maria Gonzalez-Cao, MD, PhD |
Clinical Trials Completed |
Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy |
| 571 |
Poster Presentation |
Penpulimab for relapsed/refractory (R/R) classical Hodgkin's lymphoma (cHL): Extended follow-up of the multicenter, single-arm, phase 2 study. |
Yuqin Y. Song, MD; Keshu Zhou; Chuan Jin; Zhengzi Qian; Ming Hou; Lei Fan; Fei Li; Kaiyang Ding; Hui Zhou; Xiaoling Li; Bing Chen; Xiuhua Sun; Xianmin Song; Ming Jiang; Qingyuan Zhang; Lihong Liu; Guohua Yu; Yu Hu; Zheng Zhao; Ligen Liu; Hongwei Xue; Jun Luo; Bai He; Zhifang Yao; Fenghua Xu; Min Zhao; Baiyong Li, Ph.D; Yu Xia; Jun Zhu |
Clinical Trials Completed |
Antibody;Checkpoint blockade;Clinical trial |
| 572 |
Poster Presentation |
Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects |
Andrea Facciabene, PhD; Mireia Uribe-Herranz, PhD; Silvia Beghi, PhD; Marco Ruella, MD; Kalpana Parvathaneni, PhD; Guido Ghilrardi, MD; Yung Gu Lee, MD; Noelle Frey; John Scholler; Khatuna Gabunia, Research Specialist; Gary Wu; Elise Chong, MD; David L. Porter, MD; Carl June; Stephen J. Schuster, MD; Vijay Bhoj, MD |
Clinical Trials Completed |
Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Microbiome;Tumor antigens |
| 574 |
Poster Presentation |
Blood-based extracellular matrix biomarkers are correlated with prognostic and fibrotic-related clinical characteristics and liver function markers in patients with advanced hepatocellular carcinoma |
Jaclyn Neely, PhD; Jin Yao, PhD; Christina Jensen; Morten Karsdal, PhD; Nicholas N.W. Willumsen, PhD |
Clinical Trials Completed |
Antibody;Biomarkers;Checkpoint blockade;Clinical study;Immune suppression;Proteomics;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 576 |
Poster Presentation |
Comprehensive single cell sequencing analysis of paired tissue and blood samples from HCC patients treated with neoadjuvant anti-PD-1 therapy reveals treatment-induced clonal T cell dynamics |
Wei Wang; Peter Hawkins; Lianjie Li, MD PhD; Nathalie M. Fiaschi, PhD; Assaf Magen, PhD; Se Jeong; Lauren Boucher; Christina Adler; Min Ni; Nicola C. James; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Elizabeth Miller; Israel Lowy, MD, PhD; Yi Wei; Alice O. Kamphorst, PhD; Miriam Merad, MD, PhD; Gurinder S. Atwal; Gavin Thurston, PhD; Namita T. Gupta, PhD; Raquel Deering, PhD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs) |
| 577 |
Poster Presentation |
The variation of T-Cell receptors (TCR) diversity and genomic Human Leukocyte Antigen (HLA-I) among non-small cell lung cancer (NSCLC) patients expressing high PDL-1 (>=50%) versus those with low or no PDL1 (<50%). |
Afaf Abed, MBBS, FRACP; Aaron Beasley; Anna Reid; Leslie Calapre; Michael Millward, MD; Elin S. Gray |
Clinical Trials Completed |
Biomarkers |
| 578 |
Poster Presentation |
Feasibility of eftilagimod alpha (soluble LAG-3 protein) combined with standard-of-care-therapy in advanced non-small-cell lung cancer (NSCLC) adenocarcinomas. Initial results from INSIGHT‑003 |
Akin Atmaca, MD; Daniel W. Mueller, PhD; Timursah Habibzade, Dr. (Uni Marmara); Marina Schaaf; Jorge Klagges; Regina Eickhoff, PhD; Elke Jaeger, Prof. Dr. med.; Salah-Eddin Al-Batran, Prof. Dr. med.; Thorsten O. Goetze, Prof. Dr. med. |
Clinical Trials Completed |
Adoptive immunotherapy;Antibody;Antigen presenting cells;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors |
| 579 |
Poster Presentation |
Novel digital image approach of multiplex immunofluorescence based PD-L1 expression enables the stratification of advanced NSCLC patients treated with durvalumab |
Nicolas Brieu, PhD; Felix Segerer; Harald Hessel; Ashok Gupta; Ikbel Achour, PhD; Guenter Schmidt, PhD |
Clinical Trials Completed |
Bioinformatics;Biomarkers;Checkpoint blockade |
| 580 |
Poster Presentation |
Host Immune Profiling in First-line Immunotherapy Treated Advanced Stage Non-Small Cell Lung Cancer: Results From the INSIGHT Registry Study |
Hefez Halawani, MD; Eric S. Schaefer, MD; Ray Page, DO, Ph.D; Bassam Ghabach, MD; Wallace L. Akerley, MD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Immune monitoring;Inflammation;Proteomics;Solid tumors |
| 581 |
Poster Presentation |
Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC |
Sukhvinder Johal, PhD; Miguel Miranda; Tina Sarbajna; Xiaojin Shi; Alastair Greystoke; Melissa L. Johnson, MD |
Clinical Trials Completed |
Checkpoint blockade;Clinical trial;Solid tumors |
| 582 |
Poster Presentation |
Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern Cooperative Oncology Group (ECOG) performance status subgroups in EMPOWER-Lung 1 |
Saadettin Kilickap; Ahmet Sezer, MD; Mahmut Gümüs; Igor Bondarenko; Mustafa Ozguroglu; Miranda Gogishvili; Xuanyao He; Giuseppe Gullo; Petra Rietschel; Ruben G.W. Quek |
Clinical Trials Completed |
Antibody;Checkpoint blockade;Chemotherapy |
| 583 |
Poster Presentation |
Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients |
Jan M. Lesniak, PhD; Markus Schick, PhD; Thomas Kunzke, PhD; Pallavi Sontakke, PhD; Thomas Padel, PhD; Anatoliy Shumilov, PhD; Farzad Sekhavati, PhD; Christian C. Sachs, PhD; Federico Pollastri, PhD; Ansh Kapil, Masters of Informatics; Nicolas Brieu, PhD; Carl Barrett; Hadassah Sade, PhD; Guenter Schmidt, PhD; Ross Stewart, PhD |
Clinical Trials Completed |
Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors |
| 584 |
Poster Presentation |
Evaluation of a Composite Immunotherapy Signature in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab |
Khaled Tolba, MD; David R. Gandara, MD; Meagan Montesion, Ph.D.; Barzin Y. Nabet, PhD; Minu K. Srivastava, PhD; Lee Albacker, Ph.D; Mary Redman, Ph.D; David Kozono, MD, PhD; Craig Cummings, PhD; Roy Herbst, MD, PhD; David S. Shames, PhD; David Fabrizio |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Immunoscore |
| 585 |
Poster Presentation |
Phase 1 dose escalation trial of the selective A2B adenosine receptor antagonist PBF-1129 in patients with metastatic non-small cell lung cancer (mNSCLC). |
Dwight H. Owen, MD, MSc; Lai Wei, PhD; Mikhail M. Dikov, PhD; Shankar Suman; Ruohan Wu; Joseph Amann, PhD; Catherine Schweitzer; Sarah Ferguson; Michael B. Smith; Julio Castro; Erin Bertino, MD; Peter Shields, MD; Kai He, MD, PhD; Carolyn Presley, MD; Gregory Otterson, MD; David P. Carbone, MD, PhD |
Clinical Trials Completed |
Clinical trial;Solid tumors |
| 586 |
Poster Presentation |
Durvalumab (D) +- tremelimumab (T) + platinum-etoposide (EP) in extensive-stage small-cell lung cancer (ES‑SCLC): RNA sequencing analysis to explore canonical markers of IO activity in CASPIAN |
Mingchao Xie, PhD; Priti Chugh; Cathy O'Brien; Zhongwu Lai; Ross Stewart, PhD; Luis Paz-Ares; Jonathan W. Goldman; Marina C. Garassino; Charles M. Rudin; J. Carl Barrett, PhD; Yashaswi Shrestha, PhD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical trial;T cell;Targeted therapy |
| 587 |
Poster Presentation |
AMADEUS Trial: Tumor agnostic pre- and on-treatment biomarkers of response to nivolumab plus ipilimumab correlate with on-treatment tumoral T cell infiltration |
Farah A. Alayli, PhD; Kwame Okrah; Apostolia M. Tsimberidou, MD; Alexandra Drakaki; Danny N. Khalil; Saad Khan; Stephen Hodi; David Oh; Meelad Amouzgar; Shikha Guatam; Robin Kageyama; Shannon Pfeiffer; Stefanie Meier; Christopher Cabanski; Diane Da Silva; Dinesh Kumar; Sandra Santulli-Marotto; Michael Tetzlaff; Wai Chin Foo; Travis Hollman, PhD, MD; Yanyun Li, PhD MD; Mathew Adamow; Philip Wong; Marko Spasic, MD; Richard O. Chen, MD; Samantha Bucktrout; Justin Fairchild; Lisa H. Butterfield; Theresa LaVallee; Lacey J. Padrón, PhD; Lisa M. Salvador; Jill O’Donnell-Tormey; Ute Dugan; Padmanee Sharma, MD, PhD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Immunoscore;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 588 |
Poster Presentation |
Phase Ib study of the p38 inhibitor ARRY-614 with nivolumab, ipilimumab or nivolumab+ipilimumab in advanced solid tumors |
Ryan C. Augustin, MD; Andrew Poklepovic, MD; Xin Gao; William E. Gooding, MS; Sarah Brodeur; Julie Urban; Amy Rose, RN; Amy Goodman; Darcy L. Ploucha, MPAS; Roby A. Thomas; Dan P. Zandberg, MD; John M. Kirkwood, MD; Yana G. Najjar, MD; Diwakar Davar, MD; Liza C. Villaruz, MD; Jan H. Beumer, PharmD, PhD; Riyue Bao, PhD; Jason J. Luke, MD |
Clinical Trials Completed |
Antigen presenting cells;Checkpoint blockade;Clinical trial;Immune suppression;T cell;Targeted therapy;Tumor microenvironment |
| 589 |
Poster Presentation |
Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti-PD-1/PD-L1 treatment: results of a dose-optimization, exploratory phase 1b/2 trial |
Emiliano Calvo Aller; Glenn J. Hanna, MD; Maria Vieito Villar; Caroline Even; Victor Moreno, MD, PhD; Chul Kim, MD; Shuchi Gulati, MD, FACP; Daniel Morgensztern; Ana Acuna-Villaorduna; Philippe Cassier; Dennie Jones; Florilene Bouisset; Daniela A. Sahlender; Elisabeth Rouits; Dany Spaggiari; Lars Damstrup; Carlos-Alberto Gomez-Roca |
Clinical Trials Completed |
Antibody;Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy |
| 590 |
Oral Presentation |
Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers |
Manoj Chelvanambi, PhD; Nathaniel Deboever, MD; Elise F. Nassif, MD, MS; Ashish V. Damania, MS; Lili Chen, PhD; Cheuk H. Leung, MS; Emily Z. Keung, MD, MA; Chia-Chin Wu, PhD; Russell G. Witt, MD; Michael G. White, MD; Sarah B. Johnson, MS; Matthew C. Wong, BS; Aditya K. Mishra, PhD; Matthew J. Lastrapes; Neeta Somaiah, MD; Humam Kadara, PhD; Sreyashi Basu; James P. Allison, PhD; Padmanee Sharma, MD, PhD; Kevin McBride, PhD; Wolf H. Fridman, MD, PhD; John V. Heymach, MD, PhD; Boris Sepesi, MD, FACS; Nadim J. Ajami, PhD; Christina L. Roland, MD, MS, FACS; Jennifer A. Wargo, MD, MMSc; Tina Cascone, MD, PhD |
Clinical Trials Completed |
B cell;Checkpoint blockade;Microbiome;Solid tumors |
| 591 |
Poster Presentation |
Immunogenicity of durvalumab: analysis of pooled pan-tumor data |
Anthony B. El-Khoueiry, MD; Diansong Zhou; Mustafa Ozguroglu; Melissa L. Johnson, MD; Ghassan K. Abou-Alfa, MD; Mallory Makowsky; Lee M. Krug; Ashok Gupta; Cecil Chen |
Clinical Trials Completed |
Checkpoint blockade;Clinical trial;Solid tumors |
| 592 |
Poster Presentation |
Phase 1/2a study of the novel nonfucosylated anti-CTLA-4 monoclonal antibody BMS-986218 +- nivolumab in advanced solid tumors: part 1 results |
Claire F. Friedman, MD; Richard D. Carvajal, MD; Diwakar Davar, MD; Eduardo Castanon, MD; Paolo A. Ascierto, MD; Emiliano Calvo; Mark H. O'Hara, MD; Steven F. Powell, MD; Ronnie Shapira-Frommer, MD; Elena Garralda, MD, MSc; Daniel John Renouf, MD; Ruth Perets, MD, PhD; Mona R. Yunan, BA; Palanikumar Ravindran, PhD; Amy Hammell, PhD; Shaun M. O’Brien, PhD; Ke Xu, PhD; Nicholas S. Wilson, PhD; Amy Jhatakia, MS; Anandaroop Mukhopadhyay, PhD; Martin Gutierrez, MD |
Clinical Trials Completed |
Antibody;Checkpoint blockade;Clinical study;Clinical trial;Post-translational modifications;Solid tumors |
| 594 |
Poster Presentation |
Dose Escalation of Next Generation Anti-CTLA-4 antibody ONC-392 in Combination with Fixed Dose of Pembrolizumab in Patients with Advanced Solid Tumors |
Siwen Hu-Lieskovan, MD, PhD; Kai He, MD, PhD; Mei Tang, MD, PhD; Dan Chen, MD, PhD; Yang Liu, PhD; Pan Zheng, MD, PhD; Tianhong Li, MD, PhD |
Clinical Trials Completed |
Checkpoint blockade;Clinical trial;Solid tumors |
| 595 |
Oral Presentation |
Flt3L-primed In Situ vaccination and pembrolizumab induce systemic tumor regressions of bulky tumors in patients with lymphomas and ER/PR+ breast cancer |
Thomas U. Marron, MD, PhD; Julie Fasano, MD; Deborah Doroshow; Dana Ostrowski, BA; Joan Sorich, BA; Martine Van-Voorthuysen; Jennifer Coffey; Erin Moshier; Andres M. Salazar, MD; Michael Yellin, MD; Marshall R. Posner, MD; Joseph Sparano, MD; Jonah Shulman, MD; Paula Klein, MD; Hanna Irie, MD; Seunghee Kim-Schulze, PhD; Sacha Gnjatic, PhD; Miriam Merad, MD, PhD; Joshua Brody, MD; Haley Labo |
Clinical Trials Completed |
Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;Radiotherapy;Solid tumors;TLR;Vaccine |
| 596 |
Poster Presentation |
Results from a Phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab |
Rachel E. Sanborn, MD; Nashat Y. Gabrail, MD; Benedito Carneiro; Mark H. O'Hara, MD; Rodolfo E. Bordoni, MD; Michael S. Gordon, MD; Danny N. Khalil, MD, PhD; Ralph J. Hauke, MD; Cherie Taglienti, PhD; Mark Rogalski; Rachel Styles; Diego Alvarado, Ph.D.; Deena Maurer; Linda Crew; Tibor Keler, PhD; Michael Yellin, MD |
Clinical Trials Completed |
Antibody;Checkpoint blockade;Clinical trial;Solid tumors |
| 597 |
Poster Presentation |
Preliminary safety, efficacy and pharmacokinetic results of the EP4 antagonist INV-1120 from a first-in-human study in subjects with advanced solid tumors |
John Sarantopoulos, MD; Amita Patnaik; Yi Zhu; Zhaopie Zeng; Johannes Nippgen; Yongkui Sun |
Clinical Trials Completed |
Clinical trial;Solid tumors;Tumor microenvironment |
| 598 |
Poster Presentation |
First in human study of S-488210/S-488211, a cancer peptide vaccine, in patients with advanced solid tumours |
Mark D. Linch, FRCP PhD; Paramivir Sawhney, MRCP; Jasmin Waterhouse, MRCP; Kayani Mahaz, MRCP; Anuradha Jayaram, MRCP PhD; Dionysis Papadatos-Pastos; Takahiro Hasegawa; Ide Nobuyuki; Takayuki Kanazawa; Tomohiko Harada |
Clinical Trials Completed |
Clinical trial;Cytokine;Immune toxicity;Solid tumors;Tumor antigens;Vaccine |
| 599 |
Poster Presentation |
Mechanism of Action for OT-101 TGF-ß immunotherapy |
Vuong N. Trieu, PhD; Osmond D'Cruz, PhD |
Clinical Trials Completed |
Checkpoint blockade;Chemotherapy;Clinical trial;Immune suppression;Immune tolerance;Tumor microenvironment |
| 600 |
Poster Presentation |
Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression |
Erika Klohe, BS, MBA; Sunil Suchindran, PhD; Gurpreet S. Kapoor, PhD; Jimson D'Souza, MD; Ellie Corigleano, PhD; Dejka M. Araujo, MD; Sandra P. D'Angelo, MD; Sandra P. D’Angelo, MD |
Clinical Trials Completed |
Biomarkers;Clinical trial;Solid tumors;T cell lineages;Targeted therapy |
| 601 |
Poster Presentation |
Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS) |
Gurpreet S. Kapoor, PhD; Stefan Zajic, PhD; Sunil Suchindran, PhD; Jaegil Kim, PhD; Uma Saxena, BS; Aishwarya Bhaskar, MS; Heather Kaczynski, BS; Michael J. Nathenson, MD; Jimson D'Souza, MD; Benjamin Rich, BS; Sandra P. D'Angelo, MD; Mihaela Druta, MD; Brian A. Van Tine, MD, PhD; Neeta Somaiah, MD; David A. Liebner, MD; Scott Schuetze, MD, PhD; Ioanna S. Eleftheriadou, PhD |
Clinical Trials Completed |
Adoptive immunotherapy;Biomarkers;Clinical trial;Gene expression;Solid tumors;T cell |
| 602 |
Poster Presentation |
Mass spectrometry-based protein biomarker analysis in chemoimmunotherapy combinations identifies unique immune signatures in pancreatic cancer |
Marco Tognetti, PhD; Nigel Beaton, PhD; Kamil Sklodowski, PhD; Roland Bruderer, PhD; Lukas Reiter |
Clinical Trials Completed |
Biomarkers;Post-translational modifications;Proteomics |
| 603 |
Poster Presentation |
A randomized, placebo-controlled, first in human phase I single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy male volunteers of the immunostimulant 7HP349 |
Lionel D. Lewis, MA., MB.BCh., MD; William Schary, PhD; Siddhartha De, PhD; Peter Vanderslice, PhD; Ronald J. Biediger, PhD; Yared Hailemichael, PhD; Darren Woodside, PhD; William W. Overwijk, PhD; Frank Lee, MD; Upendra Marathi, PhD |
Clinical Trials Completed |
Clinical trial;Immune adjuvant |
| 604 |
Poster Presentation |
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial |
Sandra P. D'Angelo, MD; Celeste Lebbé; Laurent Mortier; Andrew S. Brohl, MD; Nicola Fazio; Jean-Jaques Grob, MD; Natalie Prinzi, MD; Glenn J. Hanna, MD; Jessica C. Hassel; Felix Kiecker; Anja von Heydebreck; Gülseren Güzel; Paul T. Nghiem, MD, PhD |
Clinical Trials Completed |
Antibody;Checkpoint blockade;Clinical trial;Immune suppression;Solid tumors;Targeted therapy;Tumor evasion |
| 605 |
Poster Presentation |
Neoadjuvant Vidutolimod (Vidu) and Nivolumab (Nivo) Results in MPR and Immune Activation in High-Risk Resectable Melanoma (MEL): Final Phase II Clinical Trial Results. |
Diwakar Davar, MD; Arivarasan Karunamurthy, MD; Joe-Marc J.M. Chauvin, PhD; Robert Morrison, PhD; Yulong Bai, PhD; Jie Sun, PhD; Hong Wang, PhD; Douglas J. Hartman; Julie E. Stein, MD; Christopher Deitrick, PhD; Riyue Bao, PhD; Jagjit Singh; Quanquan Ding; Wentao Gao, PhD; Drew Hurd, BSc; Ornella Pagliano; Amy Rose, RN; Yana G. Najjar, MD; Jason J. Luke, MD; David Mauro, MD, PhD; Arthur M. Krieg, MD; James E. Wooldridge, MD; Dmitri Bobilev, MD, PhD; John M. Kirkwood, MD; Janis M. Taube, MD; Hyun Jung Park; Hassane Zarour, MD |
Clinical Trials Completed |
Clinical trial;TLR |
| 606 |
Poster Presentation |
Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology |
Sonia Dolfi, PhD; Tracy Tang, PhD; Georgina V. Long AO, BSc PhD MBBS FRACP FAHMS; Paolo A. Ascierto, MD; F. Stephen Hodi, Jr., MD; Evan J. Lipson, MD; Dirk Schadendorf, MD; John B. Wojcik, MD, PhD; Jennifer R. Postelnek, B.A.; Yu Wang, MB, PhD, MSc; Anne Marie Sobiesk, PhD; Kaushal Mishra, PhD; Sarah Keidel, BM BCh; Karen Miller-Moslin, PhD; Hussein Tawbi; Charlie Garnett-Benson, PhD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 607 |
Oral Presentation |
MCGRAW Trial: Evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients |
Isabella Glitza Oliva; Omid Hamid, MD; Patrick A. Ott; Genevieve M. Boland, MD, PhD; Ryan J. Sullivan, MD; Kenneth Grossmann; Christopher Desjardins; Nathan Hicks; Brian Weiner; Farah A. Alayli, PhD; Christine N. Spencer, PhD; Shikha Guatam; Christopher Loo; Benjamin Kamphaus; Julie Densmore; Christopher Cabanski; Diane Da Silva; Jennifer A. Wargo, MD, MMSc; Justin Fairchild; Marko Spasic; John Aunins; Kelly Brady; Elizabeth M. Burton, MBA; Jennifer Wortman; Theresa LaVallee; Mathew Henn; Hussein Tawbi |
Clinical Trials Completed |
Antibody;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Metabolism;Microbiome;Solid tumors;Tumor microenvironment |
| 608 |
Poster Presentation |
Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) |
Georgina V. Long AO, BSc PhD MBBS FRACP FAHMS; Tracy Tang, PhD; Abraham Apfel, PhD; David J. Paulucci, MS; Scott D. Chasalow, PhD; Daniel J. Tenney, PhD; Gina Fusaro, PhD; Dirk Schadendorf, MD; Hussein Tawbi; F. Stephen Hodi, Jr., MD; Pratik K. Thakkar, MPharm; James Larkin, MD; Jedd D. Wolchok, MD PhD; Megan Wind-Rotolo, PhD; Shu-Pang Huang, Ph.D.; Peter Mohr, Dr.; Caroline Robert, MD, PhD; Christoph Hoeller, MD; Jean-Jacque Grob; Helen Gogas, MD, PhD; Jeffrey S. Weber, MD, PhD; Han Chang, PhD; Rebecca A. Moss, MD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 609 |
Poster Presentation |
Nitric oxide dependent improved relapse free survival to ipilimumab therapy in melanoma patients |
Joseph Markowitz, MD, PhD; Saurabh K. Garg, PhD; James Sun, MD; Youngchul Kim, PhD; Junmin Whiting, PhD; Jose Conejo-Garcia, MD, PhD; Mitch A. Phelps, PhD; Jeffrey S. Weber, MD, PhD; James J. Mule, PhD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Clinical study;Immune monitoring;Post-translational modifications |
| 610 |
Poster Presentation |
Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors |
Kevin Harrington; Pablo Nenclares; Isla Leslie; Ari M. VanderWalde, MD, MPH, MBioeth; Tawnya L. Bowles; Joseph J. Sacco; Anna C. Olsson-Brown, MD; Jiaxin Niu; Katy K. Tsai; Jason A. Chesney, MD, PhD; Bartosz Chmielowski, MD, PhD; Adel Samson, PhD; Terence Rhodes, MD, PhD; Gino K. In, MD, MPH; Anna C. Pavlick, MD, MBA; Trisha M. Wise-Draper, MD, PhD; Miguel F. Sanmamed, MD, PhD; Laxminarasimha R. Donthireddy; Yawei Zhang; Jeannie Hou; Praveen K. Bommareddy, Bpharm, MS, PhD; Robert S. Coffin, PhD; Mark R. Middleton, MD, PhD; Mohammed M. Milhem, MBBS |
Clinical Trials Completed |
B cell;Immune monitoring;Immune suppression;Inflammation;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 611 |
Poster Presentation |
Biodistribution and shedding analysis following treatment with RP1 oncolytic immunotherapy in the skin cancer patients from the IGNYTE clinical trial |
Mohammed M. Milhem, MBBS; Ari M. VanderWalde, MD, MPH, MBioeth; Tawnya L. Bowles; Joseph J. Sacco; Anna C. Olsson-Brown, MD; Jiaxin Niu; Katy K. Tsai; Jason A. Chesney, MD, PhD; Bartosz Chmielowski, MD, PhD; Adel Samson, PhD; Terence Rhodes, MD, PhD; Gino K. In, MD, MPH; Anna C. Pavlick, MD, MBA; Trisha M. Wise-Draper, MD, PhD; Miguel F. Sanmamed, MD, PhD; Alireza Kalbasi; Colin Love; Aaron Clack; Jeannie Hou; Praveen K. Bommareddy, Bpharm, MS, PhD; Robert S. Coffin, PhD; Mark R. Middleton, MD, PhD; Kevin Harrington |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Immune monitoring;Inflammation;Systems biology;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 612 |
Poster Presentation |
Peripheral immune signature of responsiveness to adoptive cell therapy with ex vivo expanded TILs using high dimensional single cell analysis |
Cecilie Oelvang Madsen, BSc; Marta Velasco Santiago, MSc; Troels Holz Borch, MD, PhD; Inge Marie Svane, MD; Morten Hansen, PhD |
Clinical Trials Completed |
Adoptive immunotherapy;Biomarkers;Clinical trial;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 613 |
Oral Presentation |
Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma |
Brian M. Olson, PhD; Crystal Mallow, BS; Christine Reilly, BS; Jacklyn N. Hammons, BS; Jayden Kim; Brian G. Burns; Agnes Harutyunyan; Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Maurice Zauderer, PhD; Keith Delman, MD; Melinda Yushak, MD, MPH; Ali Mokhtari, MD; Douglas C. Parker, MD; Chrystal M. Paulos, PhD; Gregory B. Lesinski, Ph.D.; Michael Lowe, MD, MA |
Clinical Trials Completed |
B cell;Biomarkers;Checkpoint blockade;Clinical trial;Immune monitoring;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 614 |
Oral Presentation |
Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients |
Bertrand Routy; John G. Lenehan; Brendan Daisley; Meriem Messaoudene; Kait Al; Corentin Richard; Wilson Miller, Jr.; Rahima Jamal; Scott Ernst; Diane Logan; Karl Belanger; Luara Martinez-Gili; Benjamin H. Mullish; Panteleimon Takis; Cecilia Hermosilla Samayoa; Marina Ninkov; Seema Nair Parvathy; Caroline Lambert; Arielle Elkrief; Rejean Lapointe, PhD; Mansour Haeryfar; Jeremy Burton; Michael Silverman; Saman Maleki, PhD |
Clinical Trials Completed |
Biomarkers;Checkpoint blockade;Microbiome;T cell |
| 615 |
Oral Presentation |
Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (r/r) melanoma |
Alexander N. Shoushtari, MD; Lone H. Ottesen, MD, PhD; Victor Levitsky, MD, PhD; Thomas Birkballe Hansen; Thomas J. Hornyak, MD; Anthony Olszanski, MD, RhP; Martha Nyakas, MD; Jedd D. Wolchok, MD PhD |
Clinical Trials Completed |
Checkpoint blockade;Clinical study;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 616 |
Poster Presentation |
Understanding molecular consequences of immunotherapy on the germinal center axis |
Sabrina Solis, BS; Tomoaki Muramatsu, PhD; Sophie Gray-Gaillard, BA; Ramin Herati, MD |
Clinical Trials Completed |
Antibody;Autoimmunity;B cell;Biomarkers;Checkpoint blockade;Clinical trial;Immune toxicity;RNA;T cell;Targeted therapy |
| 617 |
Poster Presentation |
Neoadjuvant intratumoral TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma |
Ahmad A. Tarhini, MD, PhD, MS; Zeynep Eroglu, MD; Amod A. Sarnaik, MD, FACS; Jonathan S. Zager, MD; Ricardo J. Gonzalez, MD; Deanryan B. De Aquino, BS; Edith Abraham, APRN; Justin A. Martin, MS; Allison Richards, MS; Yian Ann Chen, PhD; Denise Kalos, MS; Jessica Lloyd; Jonathan Hanna; Erica Browning, BS; David A. Canton, PhD; Kenneth Y. Tsai, MD, PhD; Jane L. Messina, MD; Pei-Ling Chen, MD; Vernon K. Sondak, MD |
Clinical Trials Completed |
Checkpoint blockade;Clinical trial;Immune monitoring |
| 618 |
Poster Presentation |
Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade |
Raymond S. Traweek, MD; Russell G. Witt, MD; Elise F. Nassif, MD, MS; Nadim J. Ajami, PhD; Aditya K. Mishra, PhD; Ashish V. Damania, MS; Manoj Chelvanambi, PhD; Wei-Lien Wang, MD; Alexander J. Lazar, MD, PhD; Emily Z. Keung, MD, MA; Keila E. Torres, MD, PhD; Christopher P. Scally, MD; Xiaotao Zhang, MD, PhD; Carrie R. Daniel-MacDougall, MPH, PhD; Jennifer A. Wargo, MD, MMSc; Neeta Somaiah, MD; Christina L. Roland, MD, MS, FACS |
Clinical Trials Completed |
B cell;Checkpoint blockade;Microbiome;Solid tumors;Surgery;T cell;Tumor microenvironment |
| 619 |
Poster Presentation |
Tebentafusp induced T and B cell epitope spread in patients with advanced melanoma |
Alexander Greenshields Watson, PhD; Camille Britton-Rivet, MSc; Sarah Stanhope, PhD; Laura Collins, MSc; Koustubh Ranade, PhD; Adel Benlahrech, BSc PhD |
Clinical Trials Completed |
Antibody;B cell;Bispecifics;T cell;Tumor antigens |
| 620 |
Poster Presentation |
Molecular features in tumors at time of progression on tebentafusp associated with overall survival (OS) |
Emma Leach, PhD; Laura Collins, MSc; Alexander Greenshields Watson, PhD; Shaad E. Abdullah, MD, FACP; Sarah Stanhope, PhD; Koustubh Ranade, PhD |
Clinical Trials Completed |
Bispecifics;Clinical trial;Solid tumors;T cell;Tumor evasion;Tumor microenvironment |
| 621 |
Poster Presentation |
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria:Trial in progress |
Maen Abdelrahim, MD, PhD, Pharm B; Abdullah Esmail; Ashish Saharia, MD; Gonzalo Sapisochin, MD; Grainne O. Kane, MD; Sudha Kodali, MD; David Victor, MD; Kirk Heyne, MD; Rafik M. Ghobrial, MD |
Clinical Trials In Progress |
Clinical study;Clinical trial;Immune monitoring;Immune suppression;Immune toxicity;Targeted therapy;Tumor microenvironment |
| 622 |
Poster Presentation |
A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors |
David J. Pinato, MD, MRes, PhD; Ruth Plummer; Martin Gutierrez, MD; Jeffrey Yachnin, MD, PhD; Aglaia Schiza; Martin Hojgaard; Knut B. Smeland; William Edenfield; Hans Prenen; Lars Ny, MD, PhD; Alan Anthoney; Nuria Kotecki, MD; Stefan N. Symeonides, MD PhD; Louis Viviers; Jeannie Daniel; Jennifer Pulini; Udai Banerji |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Solid tumors;T cell lineages;Targeted therapy |
| 623 |
Poster Presentation |
Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies |
Tom Haber, PhD; Jessica L. Symons; Bhushan Dharmadhikari, PhD; Thomas Müller, PhD; Dipti Thakkar, PhD; Jordi Ahnert Rodon, MD; Joshua J. Gruber, M.D., PhD; Melinda Telli, MD; Monica Mita, MD; Alain Mita, MD; Meera Patel, MD; Daniel Y. Wang, MD; Joseph W. Kim, MD; Shalini S. Yadav, PhD; Padmanee Sharma, MD, PhD; Leah DiMascio, PhD; Eric K. Rowinsky, MD; Piers J. Ingram, PhD; Jerome Boyd-Kirkup, PhD |
Clinical Trials In Progress |
Antibody;Biomarkers;Checkpoint blockade;Clinical study;Immune suppression;MDSC;Tumor microenvironment |
| 624 |
Poster Presentation |
A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy |
Omar H. Butt, MD, PhD; Yu Tao, MD; Jiayi Huang, MD; Jingquin Luo, PhD; Alice Y. Zhou, MD, PhD; Christopher Abraham; Ruth G. Katumba; Se Hwan Yang; Byung H. Lee; Michael P. Rettig, PhD; George Ansstas, MD; Tanner M. Johanns, MD, PhD; Milan G. Chheda, MD; Jian L. Campian, MD, PhD |
Clinical Trials In Progress |
Clinical study;Cytokine;T cell |
| 625 |
Poster Presentation |
A phase 1 single ascending dose study evaluating the safety, tolerability, and pharmacodynamic effects of MDK-703, an IL-7 mimetic with extended half-life |
Richard Friend; Bryan Baxter; Inkyung Angie Park, Ph.D.; Steven Cwirla; Ronald Barrett |
Clinical Trials In Progress |
Clinical trial;Cytokine;T cell;T cell lineages |
| 626 |
Poster Presentation |
Trial in progress: An intravenously administered second-generation STING agonist, BI 1703880 with a novel lead-in design in combination with ezabenlimab |
Kevin Harrington; Elizabeth Dowling; Robert Latek; Michael Schmohl; Patricia Lorusso, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Clinical trial;Solid tumors |
| 627 |
Poster Presentation |
Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy |
Mark Lythgoe, MBBS, MRPharmS; Benjamin H. Mullish; Adam E. Frampton; Paola Dama; Emily Pickford; Laura Tookman; Paula Cunnea; Christina Fotopoulou; Ian B. Jeffery; Gayle Fyvie; Alexander Stevenson, PhD; Jonathan Krell, PhD |
Clinical Trials In Progress |
Clinical trial;Microbiome;Solid tumors |
| 628 |
Poster Presentation |
Trial in progress: Phase I dose-escalation study of VSV-GP (BI 1831169) monotherapy and with ezabenlimab (BI 754091) in patients with locally advanced or metastatic solid tumors |
Mercedes M. Porosnicu, MD; Anne-Marie Quinson; Abi MacKay; Stephan Luecke; Ulrich M. Lauer |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Clinical trial;Solid tumors |
| 629 |
Poster Presentation |
Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma |
Nicholas J. Venturini, BA; Thomas U. Marron, MD, PhD; Maria Casanova-Acebes, Ph.D; John Mandeli, PhD; Deborah Doroshow; Natalie Lucas; Kathy Wu; Olivia Hapanowicz; Paula King; Pauline Hamon, PhD; Jessica Le Berichel; Diane Del Valle; Clotilde Hennequin; Seunghee Kim-Schulze, PhD; Sacha Gnjatic, PhD; Miriam Merad, MD, PhD; Zhen Zhao; Stephen Ward; Maria Isabel Fiel, MD; Mary B. Beasley; Edward Kim; Kirema Garcia-Reyes; Udit Chaddha; Timothy Harkin; David Yankelevitz; Ganesh Gunasekaran; Parissa Tabrizian; Myron E. Schwartz, MD; Andrew Kaufman; Daniel Nicastri; Andrew Wolf; Raja Flores |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Granulocyte;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors |
| 631 |
Poster Presentation |
Phase I dose escalation study in patients with advanced solid tumors with ANV419, a novel fusion protein selective for IL-2Rβ/γ |
Christoph Bucher, MD; Guzman Alonso, Dr; Juanita Lopez; Emiliano Calvo; Markus Joerger, MD; Vicky Sanchez Perez, MD; Elena Corral, MD; Daniela Di Blasi, PhD; Kirsten Richter, PhD; Christoph Huber, PhD; Julie Mouton; Silvio Costanzo; Sangeeta Jethwa, MD; Elena Gerralda, MD; Heinz Läubli, MD PhD |
Clinical Trials In Progress |
Antibody;Clinical study;Cytokine;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell |
| 632 |
Poster Presentation |
Clinical update from a Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients with Metastatic Solid Tumours and Haematologic Malignancies |
Rohit Joshi; Jeffrey Goh; Sharron E. Gargosky, PhD; Warren Joubert, MD; Vineet Kwarta, MD; Meena Okera, MD; Sarwan Bishnoi; Jim Lederer, PhD; Frank Borriello, MD, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;Clinical study;Clinical trial;NK/NKT cell;Solid tumors;T cell |
| 633 |
Poster Presentation |
A Phase 1, First in Human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors. |
Kim A. Reiss; Naoto Ueno, M.D.; Yuan Yuan, MD, PhD; Melissa L. Johnson, MD; E. Claire Dees, M.D.; Joseph Chao, MD; Mathew Angelos; Ramona F. Swaby, M.D.; Daniel Cushing, PhD; Amy Ronczka; Thomas Condamine, PhD; Debora Barton, MD; Michael Klichinsky, PharmD, PhD; Yara Abdou, MD |
Clinical Trials In Progress |
CAR T cells;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment;Tumor stroma |
| 634 |
Poster Presentation |
A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors. |
Kim A. Reiss; Yuan Yuan, MD, PhD; Naoto Ueno, M.D.; Melissa L. Johnson, MD; E. Claire Dees, M.D.; Mathew Angelos; Joseph Chao, M.D.; Saar I. Gill, MD, PhD; Olga Shestova; Jonathan S. Serody, MD; Saul J. Priceman, PhD; Amy Ronczka; Rehman Qureshi; Poonam Sonawane, Ph.D.; Daniel Cushing, PhD; Debora Barton, MD; Michael Klichinsky, PharmD, PhD; Thomas Condamine, PhD; Ramona F. Swaby, M.D.; Yara Abdou, MD |
Clinical Trials In Progress |
CAR T cells;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment;Tumor stroma |
| 635 |
Oral Presentation |
KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer |
Roy Herbst, MD, PhD; Wei-Sen Lam; Matthew D. Hellmann; Matthew A. Gubens; Charu Aggarwal, MD MPH; Daniel Shao Weng Tan; Enriqueta Felip; Joanne W.Y. Chiu; Jong-Seok Lee; James Chih-Hsin Yang; Edward B. Garon; Giovanna Finocchiaro; Myung-Ju Ahn; Alexander Luft; Gregory A. Landers; Andrea Basso; Hua Ma; Julie Kobie; John Palcza; Razvan Cristescu; Lawrence Fong; Alexandra Snyder; Jianda Yuan; Martin Gutierrez, MD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors |
| 636 |
Poster Presentation |
A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers |
Steven P. Margossian, MD, PhD; John D. Powderly, II, MD; Nashat Y. Gabrail, MD; Yvonne M. Saenger, MD; J. Eva Selfridge; Nataliya Uboha; Jun Gong; Brian A. Van Tine, MD, PhD; Olatunji B. Alese, MD; Dae Won Kim, MD; Wen W. Ma; Tanios S. Bekaii-Saab, MD; Jeremy C. Jones; Angela T. Alistar, MD; Laura Agensky; Apollina Goel, PhD; Reena Lynam; Raymond J. Moniz, PhD; Steve N. Quayle, PhD; Cynthia Rajan; Kenneth J. Pienta, MD; Matteo Levisetti |
Clinical Trials In Progress |
Clinical study;Clinical trial;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 637 |
Poster Presentation |
Phase IIa combining NEO-201 with Pembrolizumab in adults with chemo-resistant solid tumors |
Princess Mark-Adjeli; Christina M. Annunziata, MD, PhD; Christopher B. Cole; Maria Pia Morelli; Ann McCoy; Massimo Fantini, PhD; Sharon A. Mavroukakis; Anjum Zaki; Kwong Y. Tsang, PhD; Philip M. Arlen |
Clinical Trials In Progress |
Antibody;Checkpoint blockade;Clinical trial;Immune suppression;Neoantigens;Post-translational modifications;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor microenvironment |
| 638 |
Poster Presentation |
COMMANDER-001: A Phase 1/2, First-in-Human, Multicenter, Open Label Study of SQZ-eAPC-HPV as Monotherapy and with Pembrolizumab in Patients with HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors (Trial in Progress) |
Meredith S. Pelster, MD, MSCI; Michael S. Gordon, MD; Justin C. Moser, MD; Trisha M. Wise-Draper, MD, PhD; Jong Chul Park, MD; Wade T. Iams, MD; Ricardo F. Zwirtes, MD; Julia J. Jennings; Nathan Miselis, PhD; Rui Ru Ji, PhD; Scott M. Loughhead, PhD; Howard Bernstein, MD, PhD; Armon Sharei, PhD; Antonio Jimeno, MD, PhD |
Clinical Trials In Progress |
Antigen presenting cells;Checkpoint blockade;Clinical trial;RNA;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 639 |
Poster Presentation |
BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated TmodTM; CAR T-cell therapy |
Diane M. Simeone, MD; Maria Pia Morelli; J. Randolph Hecht, MD; Sandip P. Patel, MD; Marwan G. Fakih, MD; Kedar Kirtane; Theodore H. Welling; Sally Lau; Yi Lin, MD PhD; Mitesh J. Borad, MD; Edward B. Garon; Sarah Larson, MD; Shumei Kato; Peter Vu; Frederick L. Locke, MD; Dae Won Kim, MD; John B. Sunwoo, MD; David B. Miklos, MD; Matthew J. Frigault; Marcela V. Maus, MD, PhD; Sarah Nikiforow; Caron A. Jacobson, MD, MMSc; Kirstin B. Liechty; Armen Mardiros; Ariane Lozac'hmeur; Karl Beutner; John S. Welch; Eric W. Ng, MD; William Y. Go; David G. Maloney, MD, PhD; Scott Kopetz, PhD; Julian R. Molina, MD, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor evasion |
| 640 |
Poster Presentation |
Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against treatment-refractory glioblastoma |
Thomas Look; Emanuele Puca, PhD; Riccardo Stucchi, PhD; Roberto De Luca, phD; Dario Neri; Michael Weller; Teresa Hemmerle, PhD; Tobias Weiss |
Clinical Trials In Progress |
Antibody;Chemotherapy;Clinical trial;Cytokine;Targeted therapy;Tumor stroma |
| 641 |
Poster Presentation |
Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1-18/ROSALIE study |
Ana Maia; Hélène Toussaint; Joao Gamelas Magalhaes; David Reardon, MD; Ahmed Idbaih; Maria Vieito; Ghazaleh Tabatabai; Agostina Stradella; François Ghiringhelli; Michael C. Burger; Iris Mildenberger; Ulrich Herrlinger; Macarena González; Alice Hervieu; Marta GilMartin; Mirjam Renovanz; Mehdi Touat; Patrick Y. Wen; Antje Wick; Laurent Chene; Cécile Gouttefangeas; Christophe Bonny; Jan Fagerberg; Wolfgang Wick |
Clinical Trials In Progress |
Immune monitoring;T cell;Tumor antigens;Vaccine |
| 642 |
Oral Presentation |
EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study |
David Reardon, MD; Ahmed Idbaih; Maria Vieito; Ghazaleh Tabatabai; Agostina Stradella; François Ghiringhelli; Michael Burger; Iris Mildenberger; Ulrich Herrlinger; Macarena González; Marta GilMartin; Mirjam Renovanz; Mehdi Touat; Patrick Y. Wen; Antje Wick; Cecile Gouttefangeas, PhD; Ana Maia; Chistophe Bonny; Jan Fagerberg, MD; Wolfgang Wick |
Clinical Trials In Progress |
Clinical trial;Immune monitoring;T cell;Vaccine |
| 643 |
Poster Presentation |
Spatial-transcriptomic Analysis of Neoadjuvant Checkpoint Immunotherapy in Recurrent Glioblastoma |
Michael J. Schachter, PhD; Lu Sun; Wesley Kwong; Samantha I. Liang, PhD; Sandra Santulli-Marotto, PhD; Lacey J. Kitch, PhD; Willy Hugo; Robert M. Prins, PhD, MS; Dinesh Kumar, PHD |
Clinical Trials In Progress |
Angiogenesis;Bioinformatics;Checkpoint blockade;Clinical trial;Gene expression;Inflammation;Myeloid cells;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 644 |
Oral Presentation |
Major pathologic response after a single radiotherapy fraction + a single pembrolizumab dose given preoperatively in patients with cT1N0 triple negative breast cancer (TNBC) - preliminary results of a phase 1b/2 study (NCT04454528) |
Julia Tchou, MD PhD; Amy S. Clark; Neil Taunk; Gary Freedman; Nucleus H. Xu; Andy J. Minn, MD, PhD; Angela Bradbury; Angela Demichele Gross; Susan Domchek, MD; Hayley Knollman; Rachel Jankowitz; Payal D. Shah, MD; Oluwadamilola Fayanju; Anupma Nayak; Joseph Fraietta, PhD; Alexander Huang, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors;Surgery |
| 645 |
Poster Presentation |
Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC) |
Hyo S. Han, MD; Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Hatem Soliman; Hung Khong; Aixa Soyano; Ricardo Costa; Loretta Loftus; Kimberley T. Lee; Avan Armaghani; Hien Liu; Frederick L. Locke, MD; Alexandria Shrewsbury, MS; Jessica Malka; Lavakumar Karyampudi; Maurice Zauderer, PhD; Brian Czerniecki, MD, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;Clinical trial;Dendritic cell;Vaccine |
| 646 |
Poster Presentation |
Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC) |
Sasha E. Stanton, MD, Ph.D.; Sasha Stanton; Lisa D. MacDonald, MSc; Stephan Fiset, MSc, MBA; Heather Hirsch; Kabir Mody, MD; Jeremy R. Graff, PhD; Aurelio S. Lobo, MSc; Danielle Lanroue; Heather Torrey, PhD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Tracy L. Kelly; David B. Page, MD; Kristina H. Young, MD, PhD |
Clinical Trials In Progress |
Solid tumors;Vaccine |
| 647 |
Poster Presentation |
Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma |
Don Stevens; Clifton Mo; Benjamin Garmezy; John Hamm, MD; Benedito Carneiro; Breelyn A. Wilky, MD; Rachel E. Sanborn, MD; Anthony El- Khoueiry; Alexa Buffa; Sonia De Munari; Burcu Yigit; Marco Purbhoo; Mark Exley; David J. Einstein, MD |
Clinical Trials In Progress |
Clinical study;Clinical trial;NK/NKT cell;Solid tumors;T cell |
| 648 |
Poster Presentation |
Autologous macrophage-based immunotherapy Induces a pro-inflammatory state in GBM tumor microenvironment - (TEM-GBM) |
Gaetano Finocchiaro; Bernhard Gentner; Marica Eoli; Francesca Farina; Alessia Capotondo; Elena Anghileri; Matteo Barcella; Valentina Brambilla; Maria Grazia G. Bruzzone; Matteo G. Carrabba; Valeria Cuccarini; Giorgio G. D'Alessandris; Francesco Di Meco; Valeria Ferla; Alberto Franzin; Paolo Ferroli; Filippo Gagliardi; Federico Legnani; Stefania Mazzoleni, Ph.D.; Pietro Mortini; Matteo Maria Naldini; Alessandro Olivi; Roberto Pallini; Monica Patanè; Rosina Paterra; Bianca Pollo; Marco Saini; Silvia Snider; Andrew Zambanini; Naldini Luigi; Carlo Russo; Fabio Ciceri |
Clinical Trials In Progress |
Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment |
| 649 |
Poster Presentation |
Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19) |
Marco Purbhoo; Burcu Yigit; Xavier Michelet, PhD; Rachel Smith; Darrian Moskowitz; Maurice Kirby; Alexa Buffa; Sonia De Munari; Waldo Ortuzar Feliu; Koen Van Besien; Don Stevens; Mark Exley; Terese C. Hammond, MD |
Clinical Trials In Progress |
Adoptive immunotherapy;Clinical study;Clinical trial;COVID and Immunotherapy;Cytokine;Inflammation;NK/NKT cell;T cell |
| 650 |
Poster Presentation |
Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients - Interim results from the GOBLET study |
Dirk Arnold, MD, PhD; Maike Collienne, MD; Alexander Stein, MD, PhD; Guy Ungerechts, MD, PhD; Eray Goekkurt, MD; Jack Chater; Houra Loghmani, PhD; Matt Coffey, PhD; Richard Trauger; Uwe M. Martens, MD, PhD; Thomas C. Heineman, MD, PhD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 651 |
Poster Presentation |
Phase 2 trial of AGEN1423, an Anti-CD73-TGFβ-Trap Bifunctional Antibody, in Combination with Balstilimab, with or without Chemotherapy in Subjects with Advanced Pancreatic Cancer |
Bruno Bockorny, MD; Joseph E. Grossman, MD; Jaymin M. Patel, MD; Bonnie L. Bullock, PhD; Benjamin Morin, PhD; Lilian Gaynor; Manuel Hidalgo |
Clinical Trials In Progress |
Checkpoint blockade;Chemotherapy;Clinical study;Coinhibition;Solid tumors |
| 652 |
Poster Presentation |
A Phase 1 Dose Escalation Study of GCC19CART a Novel CoupledCAR Therapy for Subjects With Metastatic Colorectal Cancer |
Naifei Chen; Chengfei Pu; Lingling Zhao; Ning Li; Chang Wang; Yusheng Huang; Suxia Luo; Xun Li; Zhenzhou Yang; Jun Bie; Ruihong Zhu; Xi Huang; Haiyang Tang; Tingting Liang; Yizhuo Wang; Beibei Jia, Master; Dongqi Chen; Eugene Kennedy; Zhao Wu; Yongping Song; Lei Xiao; Jiuwei Cui; Victor Lu |
Clinical Trials In Progress |
Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 653 |
Poster Presentation |
APN401, a novel EPiC-based anti-cancer cell therapy, case report: Cbl-b silenced, autologous PBMCs induced stable disease in an appendix carcinoma patient |
Romana Gugenberger, PhD; Alexander Dohnal; Andreas Tanzmann; Beate Pribitzer; Felix Batrina; Stefan Bunka; Sophia Spagl; Manuela Branka; Sarah Bischof; Kathrin Thell; Mario Kuttke; Maria Urban; Hannes Muehleisen; Bernhard Peball; Markus Raderer; Gerald Prager; Nina Worel |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical study;Clinical trial |
| 654 |
Poster Presentation |
Personalised tumour-trained lymphocytes derived from regional lymph nodes for treatment of colorectal cancer |
Anne-Laure Joly, PhD; Sofia Berglund, MD PhD; Erwan Le Maitre, PhD; Ana Lukic, PhD; Luigi Notari, PhD; Ola Nilsson, PhD; Guro Gafvelin, PhD, Associate Professor; Hans Grönlund, PhD, Associate Professor |
Clinical Trials In Progress |
Adoptive immunotherapy;Clinical trial;Solid tumors;T cell |
| 655 |
Poster Presentation |
Pivotal screening and proposed treatment algorithm for immune checkpoint inhibitor‑induced cardio/myotoxicities in neoadjuvant-treated rectal cancer patients: experience from the CHINOREC trial |
Johannes Laengle, MD, PhD; Jutta Bergler-Klein, MD; Simon Hametner, MD; Ellen Gelpi, MD; Irene Kuehrer, MD; Branka Petricevic, MD; Askin Kulu; Clemens Bittermann, MD; Anton Stift, MD; Friedrich Laengle, MD; Klaus Machold, MD; Stephan Blueml, MD; Michael Bergmann, MD |
Clinical Trials In Progress |
Clinical trial;Immune toxicity;Radiotherapy |
| 656 |
Poster Presentation |
Exploratory Platform Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION) |
Jaclyn P. Lyman, MSc; Eileen M. O'Reilly, MD; Zev A. Wainberg; George A. Fisher, MD, PhD; Robert A. Wolff, MD; Andrew H. Ko, MD; Mark H. O'Hara, MD; Harshabad Singh, MBBS; Ravi K. Amaravadi, MD; Alec C. Kimmelman, MD, PhD; Eric A. Collison, MD; Danny N. Khalil, MD, PhD; Rosemarie Schmidberger, MS; Christopher Cabanski; Stephen Maddock, MD; Marko Spasic, MD; Deena M. Maurer, PhD; Diane Da Silva; Christopher Perry, BS; Jia Xin Yu, PhD; Lacey J. Padrón, PhD; Samantha L. Bucktrout, PhD; Lisa H. Butterfield, PhD; Ramy Ibrahim, MD; Justin Fairchild; Theresa LaVallee; Thomas Lillie, MD, PhD; William A. Hoos, MBA, MS; Silvia Boffo, PhD; Ute Dugan; Jill O'Donnell-Tormey, PhD; Robert H. Vonderheide, MD, DPhil |
Clinical Trials In Progress |
Antigen presenting cells;Biomarkers;Checkpoint blockade;Chemotherapy;Clinical trial;Immune monitoring;Microbiome;Solid tumors;Tumor antigens;Tumor microenvironment |
| 657 |
Oral Presentation |
NT-I7, a long-acting IL-7, plus pembrolizumab favors CD8 T-cell infiltration in liver metastases of heavily pre-treated, immunologically cold, MSS-colorectal and pancreatic cancer |
Aung Naing, MD; Sara Ferrando-Martinez, PhD; Michael B. Ware, PhD; Cara Haymaker; Allison Bierly, PhD; Jack B. Goon; Marya F. Chaney, PhD; Swati Dhar; Chan-Young Ock, MD, PhD; Siyoung Lee; Kyunghyun Paeng; Taeseob Lee; Tolani Adebanjo; Se Hwan Yang, PhD; Byung Ha Lee, PhD; Richard D. Kim, MD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical trial;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 658 |
Poster Presentation |
A Phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer |
Paul D. Rhee, Ph.D.; Do-Youn Oh, MD, PhD; Min Hee Ryu, MD, PhD; Jun-Eul Hwang, MD, PhD; Jaeyong Cho, MD, PhD; Dae Young Zang, MD, PhD; Sang Cheul Oh, MD, PhD; Jeeyun Lee, MD, PhD; Keun-Wook Lee, MD, PhD; Sun Young Rha, MD, PhD; Byoung Yong Shim, MD, PhD; William Y. Ho, MD, PhD; Taewan Kim; Eunhye Baek; SeungJae Baek, MD, PhD; Michael Chisamore |
Clinical Trials In Progress |
Chemokine;Clinical study;Clinical trial;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment |
| 659 |
Oral Presentation |
COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases |
Drew Rasco; Ecaterina E. Dumbrava, MD; Manish R. Sharma, MD; Dale Shepard, MD PhD; Daniel Vaena; Gini Fleming, MD; Bartosz Chmielowski, MD, PhD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Kyriakos P. Papadopoulos, MD; Amita Patnaik; Eran Ophir, PhD; Gady Cojocaro, BS, PhD; Chet Bohac, MD, PharmD, MS; Adeboye H. Adewoye, MD; Manish R. Patel, MD; Michael J. Overman, MD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical trial;Immune monitoring;NK/NKT cell;Proteomics;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 660 |
Poster Presentation |
Clinicopathologic Characteristics of Patients with Metastatic Colorectal Cancer with Molecular Responses Following Treatment with an Individualized Neoantigen Vaccine Regimen |
Chih-Yi Liao, MD; Benny Johnson; Alexander I. Spira, MD, PhD, FACP; David P. Carbone, MD, PhD; Brian S. Henick; Michael J. Overman, MD; Blase N. Polite; Sameek Roychowdhury; Amit Mahipal; Daniel Ahn; Melissa L. Johnson, MD; Desiree Schenk; Kyounghwa Bae; Matthew Davis; Karin Jooss, PhD; Andrew R. Ferguson, PhD; Benjamin Solomon |
Clinical Trials In Progress |
Clinical trial;Gene expression;Neoantigens;RNA;T cell;Tumor antigens;Vaccine |
| 661 |
Poster Presentation |
Initial results from a Phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma |
David H. Aggen, MD, PhD; Meredith McKean, MD; Nehal J. Lakhani, MD; Babar Bashir, MD, MS; Jean Hoffman-Censits; Omar Alhalabi, MD; Elizabeth A. Guancial; Isaac A. Bowman; Alan Tan, MD; Trupti Lingaraj, B.S.; Marissa Timothy, MS; Nerymar Ortiz-Otero; Wilmin Bartolini; Katherine Kacena; Karim Malek; Sergio L. Santillana, MD, MSc, MBA; Jason J. Luke, MD |
Clinical Trials In Progress |
Biomarkers;Clinical study;Clinical trial;Solid tumors;Targeted therapy;Tumor microenvironment |
| 663 |
Poster Presentation |
Phase 2 multi-cohort clinical study evaluating Disitamab Vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress) |
Matthew D. Galsky, MD; Peter H. O'Donnell; Earle Burgess; Michiel Van der Heijden; Laurence Krieger; Andrea Necchi; Evan Y. Yu; Nobuaki Matsubara; Matthew T. Campbell; Saikrishna Gadde; Jeanny B. Aragon-Ching; Vadim S. Koshkin; Wei Zhang; Kevin Sokolowski; Thomas Powles |
Clinical Trials In Progress |
Antibody;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy |
| 664 |
Poster Presentation |
A phase I trial of Tremelimumab, Durvalumab (MEDI4736) and Belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE) |
Sumati Gupta, MD; Benjamin L. Maughan, MD, PharmD; Manish Kohli; Bradley Cairns; Umang Swami; Neeraj Agarwal, MD |
Clinical Trials In Progress |
Angiogenesis;Checkpoint blockade;Clinical trial;Epigenetics;Solid tumors;Targeted therapy |
| 665 |
Poster Presentation |
JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma |
Jean Hoffman-Censits; Petros Grivas; Thomas T. Powles, MBBS, MD, MRCP; Danko Martincic; Jessica Hawley; Karin Tyroller; Sonja Seeberger; Silke Guenther; Natalia Jacob; Keyvan Tadjalli Mehr; Noah M. Hahn, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Targeted therapy |
| 666 |
Oral Presentation |
Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) |
Roger Li, MD; Gary Steinberg; Edward Uchio; Donald Lamm; Shah Paras; Ashish Kamat; Trinity Bivalacqua Bivalacqua; Vignesh Packiam Packiam; Michael Chisamore; John McAdory; Paola Grandi; Nataliya Hnat; James Burke |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Gene expression;Solid tumors;Targeted therapy |
| 667 |
Poster Presentation |
A Phase 1, multiple-dose study to evaluate the safety and tolerability of XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (RCC) |
Sumanta Pal, MD; Sreeni Yalamanchili; Huajiang Li; Jitendra Kanodia; Raphael Clynes, MD, PhD; Zequn Tang, MD, PhD; Benjamin Garmezy |
Clinical Trials In Progress |
Antibody;Bispecifics;Clinical study;Clinical trial;Immune monitoring;Immune toxicity;Solid tumors;T cell;Targeted therapy |
| 668 |
Poster Presentation |
A Phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer |
Mark N. Stein, MD; Oscar B. Goodman, Jr., MD; Tanya B. Dorff, MD; Vivek Narayan, MD, MSCE; Jose Avitia, MD; Rana R. McKay, MD; Luke T. Nordquist, MD, FACP; Matthew Rettig, MD; Michael T. Schweizer, MD; Roby A. Thomas, MD; Michael H. Silverman, MD; Li Yao, PhD; Raphael Clynes, MD, PhD; Jolene S. Shorr |
Clinical Trials In Progress |
Antibody;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors |
| 669 |
Poster Presentation |
Use of HPV16 circulating tumor DNA detected in liquid biopsies to predict response in patients with advanced HPV16-positive cervical cancer |
Paula A. Bousquet, PhD; Milena Blaga; Berit Nicolaisen; Karsten Bruins Slot, MD, PhD; Agnete B. Fredriksen, PhD; Karoline Schjetne, PhD |
Clinical Trials In Progress |
Biomarkers;Clinical trial;Vaccine |
| 670 |
Poster Presentation |
Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts |
Lucy Gilbert, MD, MSc, FRCOG; Kathleen N. Moore; Vanessa Samouëlian; Cara Mathews, MD; Maria-Pilar Barretina-Ginesta; Janet S. Rader; Anna V. Tinker; Adriano Gravina; Joanna Pikiel, Dr n. med.; Grace Antony; Eleftherios Zografos; Jennifer Veneris; Ana Oaknin, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Solid tumors |
| 671 |
Poster Presentation |
A Phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies |
Eugenia Girda, MD; Emese Zsiros, MD, PhD; John Nakayama, MD; Sarah Whelan, PhD; Srinand Nandakumar; Seema Rogers; Beverly Benson; Michael T. Lotze, MD; Robert J. Brown; Robert M. Wenham |
Clinical Trials In Progress |
Clinical trial;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 672 |
Poster Presentation |
Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer (OVCA) |
Robert M. Wenham, MD, MS, FACS, FACOG; Marco L. Davila, M.D., Ph.D.; Daniel Abate-Daga, PhD; Melissa McGettigan, MD; Xuefeng Wang, PhD; Theresa Boyle, PhD, MD; Pamela D. Garzone, PhD; Amit Kumar, PhD; Jose Conejo-Garcia, MD, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;CAR T cells;Clinical trial;Solid tumors;T cell;Targeted therapy |
| 673 |
Poster Presentation |
Efficacy and Safety of Zimberelimab (GLS-010) Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase II Study |
Xiaohua Wu; Lingfang Xia; Jing Wang; Chunyan Wang; Qingming Zhang; Jianqing Zhu; Qunxian Rao; Huijun Cheng; Zheng Liu; Yongmei Yin; Xiaohong Ai; Kurban Gulina; Hong Zheng; Xiaoyong Luo; Baoping Chang; Li Li; Haiyan Liu; Yunxia Li; Ge Lou; Qi Zhou; Yanling Zhu; Zemin Xiao; Jiandong Tong; Ke Wang; Jie Chen; Xia Wang; Lijie Song; Zhixia Wei; Yijing Ye; Jiman Zhu |
Clinical Trials In Progress |
Checkpoint blockade |
| 674 |
Poster Presentation |
IMMUNOCERV, an ongoing Phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers |
Kyoko Yoshida-Court, PhD; Olsi Gjyshi, MD, PhD; Madison O’Hara, BS; Lilie L. Lin, MD; Anuja Jhingran, MD; Melissa M. Joyner, MD, MBA; Tatiana Cisneros Napravnik; Erica J. Lynn; Lauren E. Colbert, MD, MSCR; Jagannadha K Sastry, PhD; Ann H. Klopp, MD, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;Clinical study;Clinical trial;T cell |
| 675 |
Poster Presentation |
TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma |
Irene Brana, MD; Valerii Cheshuk; Claus Andrup Kristensen; Maria Eugenia Ortega; Brieuc Sautois; Antonio López-Pousa; Judith Christian; Willem Lybaert; Julio Peguero, MD; John Park, BSc(Med), MBBS, MPH, FRACP; Robert Metcalf; Lisle Nabell; Bernard Doger de Spéville; Jordi Rubió Casadevall; Ainara Soria Rivas; Martin Forster; Frederic Triebel, MD, PhD |
Clinical Trials In Progress |
Antibody;Antigen presenting cells;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;Immune monitoring;Solid tumors;T cell |
| 676 |
Poster Presentation |
A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04 |
Ezra Cohen, MD; Kevin Harrington; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting; Bhumsuk Keam, MD, PhD; Beatriz B. Cirauqui, MD; Annette M. Lim; Keun-Wook Lee, MD; Tim Welliver, MD, PhD; Christine Ju; Feng Jin; Alison J. Forgie, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Athanasios C. Tsiatis, MD |
Clinical Trials In Progress |
Antigen presenting cells;Checkpoint blockade;Chemotherapy;Clinical trial;Coinhibition;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 677 |
Poster Presentation |
A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti-PD-1) in recurrent or metastatic head and neck squamous cell carcinoma |
Rom Leidner, MD; Robert Haddad, MD; Nawel Bourayou, MD; Sonia Ioannidis; Feng Zhou; Zhiwan Dong, PhD; Ezra Cohen, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy |
| 678 |
Poster Presentation |
A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03 |
Kevin Harrington; Ezra Cohen, MD; Bhumsuk Keam, MD, PhD; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting; Brett G.M. Hughes, MD; Jong Chul Park, MD; Tim Welliver, MD, PhD; Christine Ju; Feng Jin; Alison J. Forgie, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Athanasios C. Tsiatis, MD |
Clinical Trials In Progress |
Clinical trial;Costimulation;Dendritic cell;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 679 |
Poster Presentation |
NT-I7 for the treatment of locally recurrent squamous cell carcinoma of head and neck undergoing salvage surgery: A clinical trial in progress |
Hyunseok Kang, MD, MPH; Matthew Spitzer, PhD; Mi-Ok Kim, PhD; Patrick Ha, MD; Daniel Johnson, PhD; Byung Ha Lee, PhD; Se Hwan Yang, PhD |
Clinical Trials In Progress |
Clinical trial;Cytokine;Tumor infiltrating lymphocytes (TILs) |
| 680 |
Poster Presentation |
A Phase 1b open-label, single-arm dose expansion study of IK-175, an oral AHR inhibitor, in combination with nivolumab in patients with primary PD-1 inhibitor resistant advanced head and neck cancer |
Trupti Lingaraj, B.S.; Marissa Timothy, MS; Nerymar Ortiz-Otero; Wilmin Bartolini; Katherine Kacena; Karim Malek; Sergio L. Santillana, MD, MSc, MBA |
Clinical Trials In Progress |
Biomarkers;Clinical study;Clinical trial;Solid tumors;Targeted therapy;Tumor microenvironment |
| 681 |
Poster Presentation |
A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer |
Christine H. Chung, MD; Dimitrios Colevas, MD; Douglas R. Adkins; Jong Chul Park, MD; Cristina P. Rodriguez, MD; Michael K. Gibson, MD PhD; Ammar Sukari, MD; Barbara A. Burtness, MD; Faye M. Johnson, MD, PhD; Ricklie A. Julian, MD; Nabil F. Saba, MD; Lara A. Dunn, MD; Tanguy Y. Seiwert, MD; Francis P. Worden; Rami Y. Haddad, MD; Nashat Y. Gabrail, MD; Julie E. Bauman, MD, MPH; Laura Agensky; Apollina Goel, PhD; Reena Lynam; Steven P. Margossian, MD, PhD; Raymond J. Moniz, PhD; Steve N. Quayle, PhD; Cynthia Rajan; Kenneth J. Pienta, MD; Matteo Levisetti; Sara I. Pai, MD PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Clinical trial;Cytokine;T cell;Targeted therapy;Tumor microenvironment |
| 682 |
Poster Presentation |
Changing the Radiation and Immune-Oncology Paradigm with the Radioenhancer NBTXR3: Overcoming resistance to anti-PD-1 blockade from the bench to the clinic |
Ari Rosenberg, MD; Jessica Frakes, MD; Jiaxin Niu; Jared Weiss, MD; Jimmy Caudell; Patricia Said; Pavel Tyan; Sebastien Paris; Tanguy Y. Seiwert, MD; Colette Shen; Sergio Szyldergemajn; Omar Vivar, PhD; Leonard A. Farber, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors;T cell |
| 683 |
Poster Presentation |
CD8 T cell repertoire analysis of patients with resectable head and neck cancer enrolled in a phase II neoadjuvant study of α-PD1 administered alone or in combination with α-CTLA4 or α-LAG3 |
Patricia M. Santos, PhD; Aditi Kulkarni; Housaiyin Li; Jie Chen; Lazar Vujanovic, PhD; Seungwon Kim; Umamaheswar Duvvuri; Dan P. Zandberg, MD; Robert L. Ferris, MD, PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 684 |
Poster Presentation |
NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation Phase I trial (Study 1100) |
Colette Shen; Jessica Frakes, MD; Jiaxin Niu; Jared Weiss, MD; Jimmy Caudell; Tanguy Y. Seiwert, MD; Patricia Said; Mickael Guedj; Pavel Tyan; Omar Vivar, PhD; Sergio Szyldergemajn; Leonard A. Farber, MD; Ari Rosenberg, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors |
| 685 |
Poster Presentation |
Preliminary Results of MT-401 in Post-Transplant MRD+ AML Patients |
Mythili Koneru, MD, PhD; Juan Vera, M.D.; Shukaib Arslan; Hongtao Liu, MD, PhD; Margarida Magalhaes-Silverma, MD; Nelli Bejanyan; Antonio DiStasi; Betul Oran, MD, MS; Jingmei Hsu; Robin McCallum; Silvia Quintero; Gerald M. Garrett; Karrie Wang; Eric A. Smith, PhD; Tsvetelina Hoang, PhD; Tara Shahim; Jeannette Crisostomo; Anna Wilga-Savitski; Jennifer Pickering; Laura Angelo; Anastasiya Smith, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;Biomarkers;Clinical study;Clinical trial;Immune monitoring;Leukemia/Lymphoma;T cell;Tumor antigens |
| 686 |
Poster Presentation |
Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager (bsTCE), confirmed in the clinical setting |
Roeland Lameris; Jurjen M. Ruben; Rob Roovers; Arnon P. Kater; Thilo Riedl; Victoria Iglesias; Annemiek Broijl; Ilse Tuinhof; Sanjana Umarale; Anton E.P. Adang; Tanja D. de Gruijl, PhD; Paul Parren; Benjamin Winograd, MD, PhD; Hans J. Van der Vliet, MD, PhD |
Clinical Trials In Progress |
Bispecifics;Clinical trial;NK/NKT cell;T cell;Targeted therapy |
| 687 |
Poster Presentation |
Proteomic profiling in blood identifies novel pretreatment and mechanistic markers related to inflammatory adverse events in relapsed/refractory large B-cell lymphoma after axicabtagene ciloleucel |
Kelly Speth, PhD; Gayatri Tiwari; Sabina Adhikary; Qinghua Song; Justin Chou; Frederick L. Locke, MD; Caron A. Jacobson, MD, MMSc; David B. Miklos, MD; Olalekan O. Oluwole, MBBS, MPH; Marie José Kersten; Max S. Topp, MD; Jenny J. Kim, MD, MS; Adrian Bot |
Clinical Trials In Progress |
Biomarkers;CAR T cells;Clinical study;Clinical trial;Immune toxicity;Inflammation;Leukemia/Lymphoma;Proteomics |
| 688 |
Poster Presentation |
Prediction of HCC response to neoadjuvant immunotherapy using multiparametric magnetic resonance imaging: a preliminary study. |
Octavia Bane, PhD; Enamul Bhuiyan, PhD; Paul Kennedy, PhD; Muhammed Shareef, MD; Pauline Hamon, PhD; Mark Buckup, PhD; Sacha Gnjatic, PhD; Stefanie Hectors, PhD; Hung Kam Cheung; Elizabeth Miller; Maria Isabel Fiel, MD; Stephen Ward; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Miriam Merad, MD, PhD; Bachir Taouli, MD, MSHA |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Immune adjuvant;Solid tumors;T cell |
| 689 |
Poster Presentation |
PRELIMINARY RESULTS OF A PILOT STUDY OF INTRATUMORAL INJECTION OF AUTOLOGOUS DENDRITIC CELLS AFTER HIGH-DOSE CONFORMAL EXTERNAL BEAM RADIOTHERAPY IN UNRESECTABLE PRIMARY LIVER CANCERS |
Lionel A. Kankeu Fonkoua, MD; Panwen Wang, Ph.D.; Christopher L. Hallemeier, M.D.; Thomas D. Atwell, MD; Nguyen H. Tran, M.D.; Amit Mahipal, MBBS; Elham Babadi, M.D.; Svetlana Bornschlegl, M.S.; Anatilde M. Gonzalez Guerrico, Ph.D.; Kodi Martinez; Gabrielle McCoy; Kevin M. Regan; Zuoyi Shao, Ph.D.; Henan Zhang; Junwen J. Wang, Ph.D.; Ying Li, PhD; Allan B. Dietz, Ph.D.; Haidong Dong, MD, PhD; Yi Lin, MD PhD; Sean S. Park, M.D.Ph.D; Lewis R. Roberts, M.B.,Ch.B., Ph.D. |
Clinical Trials In Progress |
Adoptive immunotherapy;Antigen presenting cells;Clinical trial;Dendritic cell;Radiotherapy;Solid tumors;Vaccine |
| 690 |
Poster Presentation |
Correlates of poor response to neoadjuvant anti-PD-1 therapy in hepatocellular carcinoma (HCC) include WNT pathway activation and loss of HLA expression |
Kunal Kundu, PhD; Nathalie M. Fiaschi, PhD; Wei Wang; Baijun Kou, PhD; Assaf Magen, PhD; Pauline Hamon, PhD; Sacha Gnjatic, PhD; Myron E. Schwartz, MD; Alice O. Kamphorst, PhD; Thomas U. Marron, MD, PhD; Miriam Merad, MD, PhD; Chunguang Guo, PhD; Gavin Thurston, PhD; Namita T. Gupta, PhD; Kamil J. Cygan, PhD |
Clinical Trials In Progress |
Bioinformatics;Checkpoint blockade;Solid tumors;Tumor evasion;Tumor microenvironment |
| 691 |
Poster Presentation |
Immune pressure in an advanced hepatocellular cancer patient following treatment with personalized neoantigen DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab) |
Mark Yarchoan, MD; Edward J. Gane, MD; Renzo Perales, PhD; Alfredo Perales-Puchalt, MD, PhD; Gabor Bartha, PhD; Sarah Rochestie; Neil Cooch; Joann Peters; Ildiko Csiki, MD, PhD; Jian Yan, PhD; Niranjan Y. Sardesai, PhD |
Clinical Trials In Progress |
Clinical study;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 692 |
Poster Presentation |
Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab) |
Renzo Perales, PhD; Alfredo Perales-Puchalt, MD, PhD; Gabor Bartha, PhD; Josette Northcott; Richard O. Chen, MD; John Lyle; Dan Norton; Neil Cooch; Edward J. Gane, MD; Mark Yarchoan, MD; Thomas U. Marron, MD, PhD; Sarah Rochestie; Joann Peters; Ildiko Csiki, MD, PhD; Jian Yan, PhD; Niranjan Y. Sardesai, PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 693 |
Oral Presentation |
Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab as second-line (2L) treatment for advanced hepatocellular carcinoma (HCC) |
Edward J. Gane, MD; Mark Yarchoan, MD; Thomas U. Marron, MD, PhD; Sarah Rochestie; Renzo Perales, PhD; Neil Cooch; Jian Yan, PhD; Joann Peters; David B. Weiner, PhD; Ildiko Csiki, MD, PhD; Alfredo Perales-Puchalt, MD, PhD; Niranjan Y. Sardesai, PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 694 |
Poster Presentation |
An Open-Label Phase I Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of VG161 in Patients with Advanced Primary Liver Cancer |
Yinan Shen, MD; Guoming Shi; Xingmei Liang; Xinyan Jin; Youlei Wang; Guyue Wei; Yi Chen; Xiaoyong Huang; Jiacheng Lu; Huiqun Xia; Miao Xiao; Shah Rahimian; Ronghua Zhao; Yuwei Li, MD; Danni Lin; Tian Fang; Wei Chen; Tao Ma; Xueli Bai; Tingbo Liang |
Clinical Trials In Progress |
Clinical trial;Solid tumors |
| 695 |
Poster Presentation |
Immune correlates associated with clinical benefit in patients with immune checkpoint refractory HPV-associated malignancies treated with triple combination immunotherapy |
Meghali Goswami, PhD; Julius Strauss, MD; Yo-Ting Tsai, PhD; Caroline Jochems, MD, PhD; Jennifer L. Marte, MD, MPH; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical study;Immune monitoring;Solid tumors;T cell;Vaccine |
| 696 |
Poster Presentation |
Abatacept For Immune Checkpoint Inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Trial |
Kerry L. Reynolds, MD; Meghan J. Mooradian, MD; Daniel A. Zlotoff, MD, PhD; Paul Ridker, MD, MPH; Tomas Neilan, MD MPH On Behalf Of The ATRIUM Investigators |
Clinical Trials In Progress |
Clinical study;Immune toxicity |
| 697 |
Poster Presentation |
A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC) |
Lauren A. Byers, MD; John V. Heymach, MD, PhD; Don L. Gibbons, MD, PhD; Jianjun Zhang, MD, PhD; Alberto Chiappori, MD; Erik Rasmussen, MS; Benjamin E. Decato, PhD; Marie-Anne D. Smit, MD, MS; Nooshin Hashemi Sadraei, MD |
Clinical Trials In Progress |
Adoptive immunotherapy;Biomarkers;CAR T cells;Clinical trial;Solid tumors;T cell;Targeted therapy |
| 698 |
Poster Presentation |
A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial) |
Ming Chen; Honglian Ma, MD; Xianghui Du; Yujin Xu; Yongling Ji; Zhengbo Song |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Radiotherapy |
| 699 |
Poster Presentation |
Interim Results from a Phase IB, First-in-Human Study of a Novel Complement Factor H Inhibitor (GT103) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) |
Jeffrey M. Clarke, MD; Thomas E. Stinchcombe, MD; Jeffrey Crawford, MD; Hirva M. Mamdani, MD; Lin Gu; Neal Ready, MD, PhD; Andrew Nixon, PhD; Stephen Baleviic; Michael Campa; Liz Gottlin; Ryan Bushey; James Herndon; Scott Antonia; Edward Patz; George Simon, MD; Jeffrey Clarke, MD |
Clinical Trials In Progress |
Antibody;Clinical trial;Solid tumors |
| 700 |
Poster Presentation |
LuCa-MERIT-1: First-in-human open label dose confirmation trial evaluating safety, tolerability, and efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer |
Patrick Forde, MBBCh; Akin Atmaca, MD; Neru Munshi; Malgorzata Kaczorowska, M.D.; Patrick Brueck, MD, MBA; Thomas Schell; Oezlem Tuereci, MD; Ugur Sahin |
Clinical Trials In Progress |
Antigen presenting cells;Clinical study;Clinical trial;Dendritic cell;RNA;Solid tumors;T cell;Tumor antigens;Vaccine |
| 701 |
Poster Presentation |
Brightplex TCE and Brightplex MDSC assays combination improves advanced NSCLC patients' stratification under anti-PD1/L1 immunotherapy in the PIONeeR project |
Lamia Ghezali, PhD; Marcellin Landri; Florence Monville, PhD; Vanina Leca, PhD; Théo Vasse; Chafik Hamdad; Margaux Mercadal; Laurent Vanhille, PhD; Alboukadel Kassambara, PhD; Thomas Sbarrato, PhD; Maryannick Le Ray, PharmD; Marie Roumieux, PhD; Richard Malkoun; Noémie Resseguier; Arnaud Boyer, MD; Clarisse Audigier-Valette, MD; Stephanie Martinez, MD; Hervé Pegliasco, MD; Patrice Ray, MD; Lionel Falchero, MD; Antoine Serre, MD; Nicolas Cloarec, MD; Louisiane Lebas, MD; Stéphane Hominal, MD; Patricia Barré, MD; Sarah Zahi, MD; Ahmed Frikha, MD; Pierre Bory, MD; Lilian Laborde; Julien Mazières, MD, PhD; Virginie Martin; Maurice Pérol, MD; Laurent Greillier, MD, PhD; Fabrice Barlesi, MD, PhD; Jacques Fieschi, PhD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical study;Granulocyte;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs) |
| 702 |
Poster Presentation |
Tertiary lymphoid structures (TLS) observed in non-small cell lung cancer (NSCLC) tumors treated with Pulsed Electric Fields |
Jeff S. Iding, MD; Paul VanderLaan, MD, PhD; Marcelo F. Jimenez, MD, PhD; José M. Fernández García-Hierro, MD; Javier Flandes Aldeyturriaga, MD, PhD; Erik H. F. M. van der Heijden, MD, PhD; Calvin S. H. Ng, MD, FRCSEd, FCSHK, FHKAM; Rainbow W. H. Lau, MBChB, FRCS(CTh), FHKAM, FCSHK; Maria D. Ludeña, MD; Rafael Carías, MD; Oderay M. Cedeño, MD; Alicia Moreno-Gonzalez, PhD; Beryl A. Hatton, PhD; William Krimsky, MD, FCCP, DAABIP |
Clinical Trials In Progress |
B cell;Clinical study;Clinical trial;Inflammation;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor microenvironment |
| 703 |
Poster Presentation |
First-line Tumor Treating Fields (TTFields; 150 kHz) therapy plus pembrolizumab for advanced or metastatic intrathoracic non-small cell lung cancer: the phase 2 EF-36/KEYNOTE B36 pilot study |
Rupesh Kotecha, MD; Corey J. Langer; Vinicius Ernani; Anne Tsao, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Clinical trial;Solid tumors |
| 704 |
Poster Presentation |
Phase I study of tislelizumab in combination with bevacizumab and pemetrexed in first-line treatment for advanced elderly non-squamous non-small cell lung cancer: trial in progress |
Xiubao Ren, MD; Liang Liu, MD |
Clinical Trials In Progress |
Angiogenesis;Checkpoint blockade;Chemotherapy |
| 705 |
Poster Presentation |
Phase 2 study of SEA-CD40 combination therapies in advanced malignancies (SGNS40-002, trial in progress) |
April Salama, MD; Meredith McKean, MD; Thaddeus Beck, MD; Omid Hamid, MD; Sandeep Mashru, MD; Sapna P. Patel, MD; Timothy Kuzel, MD, FACP; Michael Castine, MD; Vincent T. Ma, MD; Keenan Fenton; Jonathan Hayman, MD; Adil Daud, MD |
Clinical Trials In Progress |
Chemotherapy;Clinical trial;Solid tumors;Targeted therapy |
| 706 |
Poster Presentation |
NOUS-PEV, a Novel Personalized Viral-based Prime/Boost Cancer Immunotherapy Targeting Patient-Specific Neoantigens: Interim Results from the First Subjects in the Phase 1b Study |
Oliver Bechter, MD; Juan Martin-Liberal; Anna M. D'Alise, PhD; Guido Leoni, PhD; Gabriella Cotugno, PhD; Loredana Siani, PhD; Rosa Vitale, PhD; Valentino Ruzza, PhD; Elisa Micarelli, PhD; Irene Garzia, PhD; Thea Faivre, PhD; Sven Gogov, PhD; Patricia Delaite, MD; Stefano Colloca, MD; Maria Ambrosio, PhD; Rossella Merone, PhD; Elisa Scarselli, MD; Stefan N. Symeonides, MD PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Neoantigens;T cell;Vaccine |
| 707 |
Poster Presentation |
A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers |
Emanuela Romano, MD, PhD; Jacques Medioni, MD; Thibault De La Motte Rouge, MD; Nicolas Fischer, PhD; Clélia Bardonneau; Walter Ferlin, PhD; Dirk Hose, MD, PhD; Anja Seckinger, MD; Matteo Simonelli, MD; Giuseppe Curigliano, MD, PhD |
Clinical Trials In Progress |
Antibody;Bispecifics;Checkpoint blockade;Clinical study;Monocyte/Macrophage;Solid tumors;Targeted therapy;Tumor antigens |
| 708 |
Poster Presentation |
MEDI1191 (IL-12 mRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (C/SC) lesions |
Michael Abadier, PhD; Emily Jennings; Jim Eyles; Philip Martin, PhD, MS, DVM; Fernanda Pilataxi; Yuling Wu, PhD; Xiaoru Chen; Analia Azaro; Benjamin Ridgway; Marc Phillips; Benedito A. Carneiro, MD; Omid Hamid, MD; Thomas U. Marron, MD, PhD; Dmitriy Zamarin; Eduardo Castañón; Sandip P. Patel, MD; Elena Garralda, MD, MSc; Vivek Subbiah; Anthony B. El-Khoueiry, MD; Paula G. Fraenkel; Nicholas Durham, PhD |
Clinical Trials In Progress |
Biomarkers;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor microenvironment |
| 709 |
Poster Presentation |
Phase II Study to Assess the Safety and Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination with PD-1 blockade in Patients with Advanced Solid Tumors - BEXCOMBO |
Petri Bono, PhD; Juho M. Jalkanen; Inka Pawlitzky; Marie-Louise H. Fjaellskog; Cecilia Ahlin, MD |
Clinical Trials In Progress |
Antibody;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 710 |
Poster Presentation |
Safety and survival results from a phase 1/2 trial of intratumoral agent INT230-6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers |
Jacob S. Thomas, MD; Anthony B. El-Khoueiry, MD; Diana L. Hanna, MD; Anthony Olszanski, MD, RhP; Nilofer Azad, MD; Giles Whalen, MD; Matthew Ingham, MD; Luis H. Camacho, MD; Franco Abbate, Ph.D.; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Lillian L. Siu |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 711 |
Poster Presentation |
Interim Results of a Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR) Cancers Resistant to Prior PD-(L)1 Inhibition |
Katherine M. Bever, MD; Hao Wang, PhD; Jennifer Durham, PhD; Colleen Apostol; Nilofer Azad, MD; Ilene Browner, MD; Stephanie Gaillard, MD PhD; Daniel A. Laheru, MD; Valerie Lee, MD; William H. Sharfman, MD; Mark Yarchoan, MD; Qingfeng Zhu, PhD; Robert A. Anders, MD, PhD; Andrew M. Pardoll, MD, PhD; Suzanne L. Topalian, MD; Nicolas J. Llosa, MD; Elizabeth M. Jaffee, MD; Dung T. Le, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Solid tumors |
| 712 |
Poster Presentation |
Retrospective Tumor Microenvironment Analysis from a Personalized neoTCR-T Cell Therapy Clinical Trial and Its Potential Applications for Off-the-Shelf HPV TCRs |
Eric Stawiski; Chad Smith; Tyler Borrman; Zheng Pan, PhD; Stefanie J. Mandl, PhD; Vinnu Bhardwaj |
Clinical Trials In Progress |
Adoptive immunotherapy;Bioinformatics;Clinical trial;Gene expression;Immune suppression;Neoantigens;Solid tumors;T cell;Tumor microenvironment |
| 713 |
Poster Presentation |
The PRAME opportunity - high peptide copy numbers, homogenous expression and high prevalence to address a broad patient population across different solid cancers with TCR-based therapeutics |
Cedrik M. Britten; Dejka M. Araujo, MD; Linus Backert; Carsten Bokemeyer; Richard D. Carvajal, MD; Manik Chatterjee; Asim Dash; Lena K. Freudenmann; Jens Fritsche, PhD; David Fuhrmann; Valentina Goldfinger; Tobias AW. Holderried; Franziska Hoffgaard; Jens Hukelmann; Amir A. Jazaeri, MD; Ahmed O. Kaseb, MD; Florian Köhler; Daniel Kowalewski; Jason J. Luke, MD; Van Morris; Shivani Mukhi; Martina Ott; Ran Reshef, MD, MSc; Michael Römer; Lida Rostock; Swapna Satam; Arun Satelli; Christoph Schräder; Merline Thambi; Apostolia M. Tsimberidou, MD; Maike Wagner; Martin Wermke, MD; Heiko Schuster; Oliver Schoor; Toni Weinschenk |
Clinical Trials In Progress |
Adoptive immunotherapy;Biomarkers;Bispecifics;Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 714 |
Poster Presentation |
ATOR-1017, a 4-1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies. |
Ana Carneiro, MD PhD; Sumeet V. Ambarkhane, MBBS, MD; Karin Enel Smith, PhD; Gustav J. Ullenhag, PhD, MD; Lena Schulz; Tova Landstrom; Peter Ellmark, PhD; Malin Carlsson; Jeffrey Yachnin, MD, PhD |
Clinical Trials In Progress |
Antibody;Antigen presenting cells;Biomarkers;Clinical trial;Costimulation;Cytokine;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 715 |
Poster Presentation |
Emerging results from the use of an Oncolytic Adenovirus armed with TNFa and IL-2 (TILT-123) in different Phase I Solid Tumor Clinical trials |
Victor Cervera-Carrascon, PhD, PharmD; Inge M. Svane, MD, PhD; Katriina Peltola; Tuomo Alanko; Riitta Korpisaari; Susanna Juteau; Marjut Jaakkola; Jorma Sormunen; Juha Kononen; Eva Ellebaek Steensgaard, MD, PhD; Tine Monberg; Marco Donia, MD, PhD; Amir Khammari; Brigitte Dreno; Joao M. Santos, MS; Suvi Sorsa; Riikka Havunen; Akseli Hemminki, MD, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 716 |
Poster Presentation |
AURELIO-04: A phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors |
Stephane Champiat, MD, PhD; Aurelien Marabelle, MD, PhD; Diwakar Davar, MD; Peter Grell, MD; Kaissa Ouali, MD; Anna Patrikidou, MD; Andreu Schoenenberger; Lenka Palova Jelinkova, PhD; Irena Adkins, PhD; Sascha Tillmanns, PhD; Joachim Kiemle-Kallee, MD; Richard Sachse, MD; Elena Garralda, MD, MSc |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;NK/NKT cell;Solid tumors;Tumor microenvironment |
| 717 |
Poster Presentation |
Interim clinical update of the Phase 1b trial of ATRC-101 as monotherapy or in combination with pembrolizumab for select advanced solid tumors |
Bartosz Chmielowski, MD, PhD; John Weroha, MD, PhD; Susanna Ulahannan, MD, MMED; John D. Powderly, II, MD; Frances Valdes-Albini; Tanios S. Bekaii-Saab, MD; Deborah Doroshow; Alejandro Recio-Boiles; Jordan Berlin, MD; Yan Xing, MD, PhD; Sudha Khurana, PhD; Jonathan Benjamin, MD, PhD; Steven Isakoff; Benjamin Weinberg, MD |
Clinical Trials In Progress |
Antibody;B cell;Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy |
| 718 |
Poster Presentation |
Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and/or metastatic solid tumors |
Byoung Chul Cho, MD, PhD; Sang J. Shin, MD; Jae Lyun Lee; Byoung Y. Shim; Hyo J. Lee, PhD, MD; Nari Yun, PhD; Mina Ham, MS; YunHee Jeong, MS; Wooyul Lee, MD, PhD; Hyunjin Kang, MS; Jisoo Kim, PhD; Myoung Ho Jang, PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Cytokine;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell |
| 719 |
Poster Presentation |
Phase 1 study of the Porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor Nivolumab in patients with advanced solid tumours |
Natalie Cook; Sarah P. Blagden; Juanita Lopez; Debashis Sarker; Alastair Greystoke; Saira Bashir; Aglaia Skolariki; Salma ElBadri; Cienne Morton; Ana OrtegoFranco; Shybi MohamedKhan; Catherine Eagle; Eimear Flanagan; Louise Goodwin; Caroline Phillips; Jane Robertson, MD; Craig Tilston; Helen Timmis, MBChB; Simon A. Woodcock; Ruth Plummer |
Clinical Trials In Progress |
Biomarkers;Clinical study;Cytokine;Immune monitoring;Immune toxicity;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell |
| 720 |
Poster Presentation |
Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, γ9δ2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial |
Johann De Bono; Stephane Champiat, MD; Francois-Xavier Danlos, MD; Martin Wermke, MD; Volker Kunzmann, MD, PhD; Aude de Gassart, PhD; Emmanuel Valentin, PhD; Marina Iche; Maelle Mairesse, PhD; Patrick Brune; Daniel Olive, MD, PhD; Paul A. Frohna, MD, PhD, PharmD |
Clinical Trials In Progress |
Clinical study;Cytokine;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 721 |
Poster Presentation |
Pixatimod (P) in Combination with Nivolumab (N) +/- low-dose Cyclophosphamide (Cy) in Advanced Cancers: A Phase IIA Basket Trial. |
Diwakar Davar, MD; Hong Wang, PhD; Sarah Behr, BSc; Aubrey Murano; Sarah Johnson; Amy Rose, RN; Darryn Bampton; Keith Dredge, PhD; Hassane Zarour, MD; John Rhee, MD; Liza C. Villaruz, MD; Yana G. Najjar, MD; Jason J. Luke, MD |
Clinical Trials In Progress |
Clinical study;Monocyte/Macrophage;Solid tumors;TLR |
| 722 |
Poster Presentation |
Cbl-b silenced, autologous PBMCs as a novel anti-cancer therapy using the closed cell processing platform EPiC - a phase 1b trial with APN401 |
Romana Gugenberger, PhD; Alexander Dohnal; Kathrin Thell; Sarah Bischof; Mario Kuttke; Bernhard Peball; Hannes Muehleisen; Maria Urban; Andreas Tanzmann; Beate Pribitzer; Felix Batrina; Stefan Bunka; Sophia Spagl; Manuela Branka; Markus Raderer; Gerald Prager; Thorsten Fuereder; Nina Worel |
Clinical Trials In Progress |
Adoptive immunotherapy;Biomarkers;Checkpoint blockade;Clinical study |
| 723 |
Poster Presentation |
A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti-PD1 and anti-LAG-3 antibody, in patients with select advanced malignancies |
Sarina A. Piha-Paul, MD; Nawel Bourayou, MD; Richard Schaub; Yan-ou Yang; Wendy Wei; Patrick Mayes, PhD; Tara C. Gangadhar, MD |
Clinical Trials In Progress |
Bispecifics;Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy |
| 724 |
Poster Presentation |
A phase I study of HCW9218, a bifunctional TGF-β Antagonist/IL-15 protein complex, in advanced solid tumors |
Melissa A. Geller, MD, MS, FACOG; Manish R. Patel, DO; Hing C. Wong; Peter R. Rhode; Philip M. Arlen; Pallavi Chaturvedi; Jack O. Egan; Giles M. Leclerc; Martin Felices; Shannon Lunn; Bethany Hanke; Deepa Kolseri; Rose Wangen; Jeffrey S. Miller, MD |
Clinical Trials In Progress |
Chemokine;Clinical study;Cytokine;NK/NKT cell;Solid tumors |
| 725 |
Poster Presentation |
Phase I safety and preliminary efficacy of PM8002 in subjects with advanced solid tumors, a bispecific antibody targeting PD-L1 and VEGF-A |
Ye Guo; Suxia Luo; Yanru Qin; Yongmei Yin; Guiling Li; Jingfen Wang; Yongsheng Li; Jun Guo; Feng Zhang; Yi Huang; Hong Luo; Dongqing Lv; Cheng Ying; Chunyan Wang; Chuan-Chu Chou, PhD; Chundan Gong; Ruixia Chang; Jing Liu; Guoqiang Hu |
Clinical Trials In Progress |
Angiogenesis;Antibody;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Tumor microenvironment |
| 726 |
Poster Presentation |
Phase I results of FT516, an off-the-shelf, iPSC-derived NK cell therapy expressing a high-affinity, non-cleavable CD16 (hnCD16) combined with avelumab in patients with advanced solid tumors |
Martin Gutierrez, MD; Manish R. Patel, DO; Feng Liu, PhD; Peter Szabo, MD, PhD; Bob Valamehr, PhD; Yu-Waye Chu, MD; Brandon Beagle, PhD; Jeffrey Chou, MD, PhD; David S. Hong, MD |
Clinical Trials In Progress |
Adoptive immunotherapy;Antibody;Checkpoint blockade;Clinical trial;NK/NKT cell;Solid tumors |
| 727 |
Poster Presentation |
Interim Phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors |
Martin Gutierrez, MD; Melissa L. Johnson, MD; David Sommerhalder, MD; Wells A. Messersmith, MD, FACP, FASCO; Haeseong Park, MD, MPH; Muhammad Furqan, MD; Jason A. Chesney, MD, PhD; Ryan Bjordahl, PhD; Lingmin Zeng, PhD; Peter Szabo, MD, PhD; Yu-Waye Chu, MD; Brandon Beagle, PhD; Bob Valamehr, PhD; Jeffrey Chou, MD, PhD; David S. Hong, MD |
Clinical Trials In Progress |
Adoptive immunotherapy;Antibody;Checkpoint blockade;Clinical trial;NK/NKT cell;Solid tumors |
| 728 |
Poster Presentation |
Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers |
Jason Henry, M.D.; David Oh; Jeff D. Eskew, PhD; Joaquina Baranda, MD; Ildefonso Ismael Rodriguez Rivera, MD; Ecaterina E. Dumbrava, MD; Ezra Cohen, MD; Rajesh Belani, MD; Joanne McCaigue; Devon J. Shedlock, PhD; Julia Coronella, Ph.D.; Christopher E. Martin, PhD; Hamid Namini, PhD; Ann Murphy; Eric M. Ostertag, Ph.D. M.D. |
Clinical Trials In Progress |
Adoptive immunotherapy;CAR T cells;Clinical trial;Solid tumors |
| 729 |
Poster Presentation |
Targeting epidermal growth factor receptor (EGFR)-expressing solid tumors with AFM24, a novel CD16A bispecific innate cell engager: Comprehensive correlative science findings from a Phase 1 study |
Gabriele Hintzen, PhD; Susanne Wingert; Michael Emig; Pilar Nava-Parada; Kerstin Pietzko; Laura Kohlhas; Uwe Reusch, PhD; Melissa M. Berrien-Elliott; Todd A. Fehniger, MD, PhD; Mark Foster; Paolo Nuciforo; Ester Castillo Andreo; Sina Staeble; Paulien Ravenstijn; Bettina Rehbein; Erich Rajkovic; Arndt Schottelius; Joachim Koch, Prof. |
Clinical Trials In Progress |
Antibody;Bispecifics;Solid tumors;Targeted therapy |
| 731 |
Poster Presentation |
A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: Interim results of a Phase 1 study (SGNB6A-001) |
Antoine Hollebecque; Juanita Lopez; Sarina A. Piha-Paul, MD; Afshin Dowlati; Amita Patnaik; Vladimir Galvao; Bruno Buckorny; Kartik Sehgal; Edwin Kingsley; Rachel E. Sanborn, MD; Solange Peters; Yan Sun; Gabriela Patilea-Vrana; Natalya Nazarenko; Emiliano Calvo |
Clinical Trials In Progress |
Antibody;Biomarkers;Clinical study;Clinical trial;Solid tumors;Targeted therapy |
| 732 |
Poster Presentation |
First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21-1480, an affinity-balanced PD-L1x4-1BBxHSA trispecific antibody: Results of Phase 1 dose escalation |
David S. Hong, MD; Jason J. Luke, MD; Melissa Johnson, MD; Shirish M. Gadgeel, MD; Alexander I. Spira, MD, PhD, FACP; James C.H. Yang, MD, PhD; Jennifer M. Johnson, MD; Taryn R. Losch-Beridon; Daniel Snell, PhD; Stefan Warmuth, PhD; Maureen Cleaver; Elmar vom Baur, PhD; David M. Urech, PhD; Peter Lichtlen, MD, PhD |
Clinical Trials In Progress |
Antibody;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;T cell;Tumor microenvironment |
| 733 |
Poster Presentation |
A Phase 2 study of vudalimab (XmAb20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer |
June Hou; Oscar Goodman, MD; David Berz, MD; Li Yao, PhD; Nital Soni, MS |
Clinical Trials In Progress |
Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;T cell |
| 734 |
Poster Presentation |
A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors |
Hans Prenen; Thierry Lesimple; Marie Robert; Brant Delafontaine; Jean-Pascal Machiels, MD, PhD; Tarek Meniawy; Eric Van Cutsem, MD, PhD; Nuria Kotecki, MD; Sarina A. Piha-Paul, MD; Michael T. Schweizer, MD; Shirish M. Gadgeel, MD; Jeannie Daniel; Louis Viviers; Jason Howe; Antoine Italiano, MD, PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy |
| 735 |
Poster Presentation |
A Phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Initial dose-escalation results |
Melissa L. Johnson, MD; Nehal J. Lakhani, MD; Eugenia Girda, MD; Anthony Olszanski, MD, RhP; Lawrence Fong, MD; Hyunsil Han, PhD; Kerry A. Casey, PhD; Siyu Li, PhD; Jennifer E. Visich, PhD; Dmitris Skokos, PhD; Frank Seebach, MD; Israel Lowy, MD, PhD; Matthew G. Fury, MD, PhD; Melissa Mathias, MD; Neil H. Segal, MD |
Clinical Trials In Progress |
Antibody;Bispecifics;Checkpoint blockade;T cell |
| 736 |
Poster Presentation |
A clinical stage engineered toxin body (ETB) targeting PD-L1 (MT-6402) induces peripheral pharmacodynamic responses unique from PD-L1 monoclonal antibodies |
Swati Khanna, Ph.D.; Rachael M. Orlandella, PhD; Elizabeth P. Saputra; Sydney Matthews; Lydia Navarrete-Galvan; Sara LeMar; Joseph D. Dekker, Ph.D.; Eric Poma, Ph.D.; Chris B. Moore, Ph.D. |
Clinical Trials In Progress |
Angiogenesis;Checkpoint blockade;Clinical trial;Cytokine;Immune suppression;MDSC;Solid tumors;Tumor microenvironment |
| 737 |
Poster Presentation |
Interim results of a first-in-human Phase 1 dose-escalation trial of TAK-102, a glypican-3 targeted armored chimeric antigen receptor T-cell immunotherapy in patients with advanced solid tumors |
Takafumi TK. Koyama, MD, PhD; Toshio Shimizu; Toshihiko Doi; Noboru Yamamoto; Shunsuke Kondo; Abood Okal, PhD; Aman Singh; Janet Markman; Takenori Akaike; Hideaki Kagehara; Yasutoshi Kuboki |
Clinical Trials In Progress |
CAR T cells;Clinical trial;Cytokine;Solid tumors;T cell;Tumor microenvironment |
| 738 |
Poster Presentation |
Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2) |
Nehal J. Lakhani, MD; Amita Patnaik; Meredith McKean, MD; Justin F. Gainor, MD; Cathy Vo Buu; Amanda Enstrom; Rupert Davies; Stacey R. Dillon; Hany Zayed; Michael Chisamore; James Michael Pluda; Allison L. Naumovski; Stanford L. Peng |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Coinhibition;Costimulation;Solid tumors;T cell |
| 739 |
Poster Presentation |
A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI naïve advanced or metastatic solid tumors |
Han Myint, MD, FRCPath, FRCP; Eric Christenson, MD; Siqing Fu, MD, PhD; Martin Gutierrez, MD; Ashley Martz; Stephanie Zeidan, M.S.; Megan M. Nelson, MS; Alina Barbu, Ph.D.; Aaron Morawski; Chelsea Zhou, PhD; Zachary Cusumano, Ph.D.; Rachel O’Neill, Ph.D.; Ron Copeland, Ph.D.; Dallas B. Flies, PhD; Solomon Langermann, PhD; Julia W. Cohen; Dung T. Le, MD |
Clinical Trials In Progress |
Antibody;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Tumor microenvironment;Tumor stroma |
| 740 |
Poster Presentation |
A first-in-human trial of hSTC810 (anti-BTN1A1 Ab), a novel immune checkpoint with a mutually exclusive expression with PD-1/PD-L1, in patients with relapsed/refractory solid tumors |
Soohyeon Lee, MD PhD; Sangjoon Shin; Lynn Howie; Hyunjin Jung; Steven S. Yoo; David S. Hong, MD |
Clinical Trials In Progress |
Antibody;Checkpoint blockade;Clinical trial;Solid tumors |
| 741 |
Poster Presentation |
First in humaun phase I trial of DT-9081, a selective EP4 receptor antagonist in patients with recurrent andor metastatic solids tumors |
Jean-Pierre Delord, MD; Christophe Le Tourneau, MD; Nuria Kotecki, MD; Patricia Zerr, PHD; Claire Jouffroy Zeller, Pharm D; Samira El Farouk, PhD; Asmaa AB. Boudribila, MD; Jean-Pascal Machiels, MD, PhD |
Clinical Trials In Progress |
Clinical study;Clinical trial;Solid tumors;Targeted therapy |
| 742 |
Poster Presentation |
A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors |
Bradley McGregor, MD; Toni K. Choueiri, MD; Neil J. Shah, MBBS; Aung Bajaj; Jad Chahoud; Bert O’Neil; Joel Michalski; Benjamin Garmezy; Lixian Jin, MD, MPH; Usman Aziz; Fiona Xu; Robert J. Motzer, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy |
| 743 |
Poster Presentation |
Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting Beta-only IL-2 Agonist |
Minh D. To, PhD; Nina Merchant; Melissa Coello; Carole Galligan; Kritika Mehta; Victoria G. Atkinson, MD; Martin Bexon, MD; Jim Coward; Jenny Lee; Charlotte R. Lemech, MBBS BSc(med) FRACP MD(res); Peter Lloyd; Jesus F. Antras; Arash Yavari; Fahar Merchant, PhD |
Clinical Trials In Progress |
Clinical trial;Cytokine;NK/NKT cell;T cell |
| 744 |
Poster Presentation |
Interim single-agent safety and anti-tumor activity from dose escalation phase of ABILITY study on MDNA11, a long-acting beta-only IL-2 agonist. |
Minh D. To, PhD; Fahar Merchant, PhD; Victoria G. Atkinson, MD; Martin Bexon, MD; Jim Coward; Jenny Lee; Charlotte R. Lemech, MBBS BSc(med) FRACP MD(res); Jesus F. Antras; Peter Lloyd; Arash Yavari; Melissa Coello; Nina Merchant |
Clinical Trials In Progress |
Clinical trial;Cytokine;Solid tumors |
| 745 |
Poster Presentation |
IMP-MEL: A phase 1 first-in-human dose-finding study of a novel invariant natural killer T-cell agonist (iNKT) IMM60 in advanced melanoma and non-small-cell lung cancer (NSCLC) |
Nicholas Coupe, MD, PhD; Ian B. Walters, MD, MBA; Justin A. Fairchild, MPH; Matthew Parkes, PhD; David Thomspson; Robert A. Kramer, PhD; Uzi Gileadi, DPhil; Mark R. Middleton, MD, PhD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;MDSC;Myeloid cells;NK/NKT cell;Solid tumors;Tumor microenvironment |
| 746 |
Poster Presentation |
AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR+) solid tumors: Initial results from the Phase 1 dose-escalation study |
Omar Saavedra Santa Gadea, MD, MSc; Daniela Morales-Espinosa; Juanita Lopez; Eric Christenson, MD; Anthony B. El-Khoueiry, MD; Andrés Cervantes; Christa Raab; Ulrike Gärtner; Kerstin Pietzko; Laura Kohlhas; Daniel Schütz; Gabriele Hintzen, PhD; Paulien Ravenstijn; Michael Emig; Pilar Nava-Parada |
Clinical Trials In Progress |
Antibody;Bispecifics;Checkpoint blockade;Clinical trial;NK/NKT cell;Solid tumors;Targeted therapy |
| 747 |
Poster Presentation |
A Phase 1 Trial of IO-202, An Antagonist Antibody Targeting Myeloid Checkpoint LILRB4 (ILT3), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors |
Aung Naing, MD; John D. Powderly, II, MD; Meredith S. Pelster, MD, MSCI; Alexander I. Spira, MD, PhD, FACP; Reva E. Schneider, MD; Paul H. Woodard, MD; Luke E. Chung, MD; Elizabeth Wieland, MS; Sydney Ray, MS; Kyu Hong, MS; Tao Huang, PhD; X. Charlene Liao, PhD; Hong Xiang, PhD; Wen Hong WL. Lin, MD, MS; Heinz-Josef Lenz, MD, FACP |
Clinical Trials In Progress |
Clinical trial;Myeloid cells;Solid tumors |
| 748 |
Poster Presentation |
A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors |
Han Myint, MD, FRCPath, FRCP; Satish Shah, MD; Martin Gutierrez, MD; Emese Zsiros, MD, PhD; Megan M. Nelson, MS; Stephanie Zeidan, M.S.; Nadia Myrthil, MBA; Aaron Morawski; Alina Barbu, Ph.D.; Jahangheer S. Shaik, Ph.D.; Chelsea Zhou, PhD; Chrysi Kanellopoulou, Ph.D.; Ron Copeland, Ph.D.; Zachary Cusumano, Ph.D.; Dallas B. Flies, PhD; Solomon Langermann, PhD; Patricia Lorusso, MD; Kunle Odunsi, MD PhD |
Clinical Trials In Progress |
Antibody;Biomarkers;Clinical study;Clinical trial;Solid tumors |
| 749 |
Poster Presentation |
Use of positron emission tomography for the diagnosis of immune checkpoint inhibitor myocarditis |
Nicolas L. Palaskas, MD; Yang Lu, MD; Rebecca Caldwell; Praise Oderinde; Gaspar Pina; Abdelrahman Ali; Khatera Shah; Cezar Iliescu; Syed Wamique Yusuf; Efstratios Koutroumpakis; Shaden Khalaf; Ihab Hamzeh; Bilal A. Siddiqui, MD; Sumit K. Subudhi, MD, PhD; Anita Deswal |
Clinical Trials In Progress |
Immune toxicity;Inflammation |
| 750 |
Poster Presentation |
TWT-101: A First-In-Clinic, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies |
Kyriakos P. Papadopoulos, MD; Siqing Fu, MD, PhD; Erika P. Hamilton, MD; Alexander I. Spira, MD, PhD, FACP; Scott Laurie, MD; Judy S. Wang, MD; Brigette Ma, MD; Anna Spreafico, MD PhD; Manish R. Sharma, MD; Quincy Chu, MD; Mark R. Bray; Glenn Michelson; Dih-Yih Chen; Linh Nguyen; Emily Roberts-Thomson, MMSc; Omid Hamid, MD |
Clinical Trials In Progress |
Clinical study;Clinical trial;Cytokine;Regulatory T cell (Treg cell);Targeted therapy |
| 751 |
Poster Presentation |
PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME. |
Cheon Ho H. Park, PhD; Sang Soon Byun; Ki Dae Kim; Hye Rim Han; Weon Sup Lee |
Clinical Trials In Progress |
Adoptive immunotherapy;Antibody;Antigen presenting cells;Checkpoint blockade;Clinical study;MDSC;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 753 |
Poster Presentation |
A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObodyTM ADG116 Monotherapy and in Combination with Toripalimab (Tori; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors |
John Park, BSc(Med), MBBS, MPH, FRACP; Matthew NC. Hsien; Gary Richardson; Anthony W. Tolcher, MD; Hong Jae Chon; Sang Joon Shin; Ho Yeong Lim; Anis Hamid; Daneng Li, MD; Kristine Shi; Songmao Zheng; Guizhong Liu; Ai Li; Lvyu Zhu; Ruby Dai; Wei Peng; Dana D.H. Lowe, PhD; Peter Luo; Jiping Zha, MD, PhD |
Clinical Trials In Progress |
Antibody;Checkpoint blockade;Clinical study;Clinical trial |
| 754 |
Poster Presentation |
A phase 1/2 study of ASP1570 in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies |
Manish R. Patel, MD; David J. Park; Stefano Tarantolo; Afshin Dowlati; Daniel J. Olson, MD; Yuichiro Kaneko; Mei Tang; Serguei A. Soukharev; Masaomi Takizawa; Yohei Okada; Christine Fredericks; Derek Smith; Teresa Flegel; Tsubasa Watanabe; Sue Lee; Jason J. Luke, MD |
Clinical Trials In Progress |
Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 755 |
Poster Presentation |
Results of a Phase I trial of FT500, a first-in-class, off-the-shelf, iPSC‑derived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors |
Sandip P. Patel, MD; Manish R. Patel, DO; Martin Gutierrez, MD; Marlisa Anderson, MPH; Peter Szabo, MD, PhD; Bob Valamehr, PhD; Yu-Waye Chu, MD; Brandon Beagle, PhD; Jeffrey Chou, MD, PhD; David S. Hong, MD |
Clinical Trials In Progress |
Adoptive immunotherapy;Antibody;Checkpoint blockade;Clinical trial;Leukemia/Lymphoma;NK/NKT cell;Solid tumors |
| 756 |
Poster Presentation |
INCLINE-101, A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in Patients with Select Advanced or Metastatic Solid Tumors |
Cesar A. Perez, MD; Jason Henry, M.D.; Timothy G. Humphries, MD; Sunnie Kim, MD; Adi Diab; Ons Harrabi, BA; Feng Jin, PhD; Hong I. Wan, PhD; Candy Bermingham, PhD; Anthony B. El-Khoueiry, MD |
Clinical Trials In Progress |
Antibody;B cell;Clinical study;Clinical trial;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs) |
| 757 |
Poster Presentation |
A Phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with lorigerlimab in patients with advanced solid tumors (AST) |
John D. Powderly, II, MD; Patrick Kaminker, PhD; Enxu Zhao, MS; Denise Casey, MD; Eugene Shenderov, MD, PhD |
Clinical Trials In Progress |
Antibody;Checkpoint blockade;Clinical trial;Coinhibition;Solid tumors;Targeted therapy |
| 758 |
Poster Presentation |
A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies |
Drew Rasco, MD; Albiruni R. Razak; Maike Schmidt, PhD; Sariah Kell; Dylan Glatt, PhD; Erin Belshaw; Sophia R. Majeed, PharmD, PhD; Shivaani Kummar, MBBS |
Clinical Trials In Progress |
Antibody;Checkpoint blockade;Clinical trial;Genetic polymorphism;Solid tumors;T cell |
| 759 |
Poster Presentation |
Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors |
Jordi Rodon; Marya F. Chaney, PhD; Justine V. Cohen, DO; Tina Garyantes; Jessica J. Lin, MD; Patricia Lorusso, MD; Alain Mita, MD; Monica Mita, MD; Carolyn Muller, MD; Christopher Natale, PhD; Marlana Orloff, MD; Kyriakos P. Papadopoulos, MD; Sapna P. Patel, MD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical trial;Genetic polymorphism;Solid tumors;Targeted therapy |
| 760 |
Poster Presentation |
A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors |
Benjamin L. Schlechter, MD; Daniel Olson, MD; Samuel Saibil, MD; Mridula George, MD; Riemke Bouvier; Jessica McKinley; Brooke Pieke, MS; Jill Geisburger; Nathan J. Ternus, BS; Kara Moss; Deyaa Adib, MD; Ecaterina E. Dumbrava, MD |
Clinical Trials In Progress |
CAR T cells;Clinical study;Cytokine;Solid tumors;T cell;Targeted therapy |
| 761 |
Poster Presentation |
Pharmacokinetic and pharmacodynamic data from a Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumors |
Randolph Noelle; Melissa L. Johnson, MD; Jordi Rodon; Marjorie Zauderer; Lionel Lewis; Mariano Severgnini; Jefferson Parker; Maureen Lane; Reinhard von Roemeling; Alex S. Martin; Michael Molloy; Robert E. Martell; Tong Dai |
Clinical Trials In Progress |
Antibody;Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Cytokine;Immune monitoring;Solid tumors |
| 762 |
Poster Presentation |
First-in-human Phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR) |
George Simon, MD; Vivek Subbiah; Lee Rosen, MD; Heinz-Josef Lenz, MD; Haeseong Park, MD, MPH; Minesh Patel; David Miles; Stephanie Wallis; Vladimir Evilevitch; David Krige, PhD; Mark Powell; Tom Lillie |
Clinical Trials In Progress |
Clinical study;Cytokine;Solid tumors;T cell;Tumor microenvironment;Tumor stroma |
| 763 |
Oral Presentation |
Phase 1/2 Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies: Initial Results From Dose Escalation |
Diwakar Davar, MD; Morteza Aghmesheh, MD, GradDipSc, PhD, FRACP; Alain P. Algazi, MD; David Bajor, MD; Vinod Ganju, MBBS, FRACP; Douglas E. Laux, MD; Alexander I. Spira, MD, PhD, FACP; Elizabeth S. Ahern; Jaspreet S. Grewal, MD, PhD, MPH; Jamie Rand, MD; Randy F. Sweis, MD; Mette Kriegbaum, PhD; Jens-Jakob Karlsson, PhD; Yang Wu, PhD; Tuan-Anh Tran, PhD; Stina M. Singel, MD, PhD; Nashat Y. Gabrail, MD |
Clinical Trials In Progress |
Clinical study;Clinical trial;Solid tumors;TLR |
| 764 |
Poster Presentation |
First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim Data |
Brian A. Van Tine, MD, PhD; Eugene Ahn, MD; John D. Powderly, II, MD; Herbert L. Duvivier, MD, JD; Drew Rasco; Rebecca A. Redman, MD; Steven F. Powell, MD; Agnes Rethy; Chris B. Moore, Ph.D.; Amy Yuet; Rachael M. Orlandella, PhD; Swati Khanna, Ph.D.; David R. Spigel, MD; Angela Georgy; Joseph D. Dekker, Ph.D. |
Clinical Trials In Progress |
Antibody;Checkpoint blockade;Clinical trial;Monocyte/Macrophage;T cell;Targeted therapy;Tumor microenvironment |
| 766 |
Poster Presentation |
Phase I/II Evaluation of the Combination of Entinostat, M9241 and Bintrafusp Alfa in Patients with Advanced HPV Related Malignancies |
Julius Strauss, MD; Charalampos Floudas, MD, DMSc, MS; Danielle Pastor, DO, Ph.D.; Jason M. Redman, MD; Deneise Francis, BSN, RN, OCN, CCRP; Elizabeth Lamping, RN; Lisa Cordes, PharmD, BCACP, BCOP; Jennifer L. Marte, MD, MPH; Renee N. Donahue, PhD; Caroline Jochems, MD, PhD; Sofia R. Gameiro, PharmD, PhD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Clinical trial;Solid tumors |
| 767 |
Poster Presentation |
Safety and Preliminary Efficacy of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36γ for Intratumoral (ITu) Injection, and durvalumab (IV) in TNBC, HNSCC, and Melanoma |
Randy F. Sweis, MD; Daniel J. Olson, MD; Adil Daud, MD; Ronnie Shapira-Frommer, MD; Antonio Jimeno, MD, PhD; Patrick Reagan, MD; Shivaani Kummar, MBBS; Raghad Abdul-Karim, M.D.; Salomon Stemmer; Meredith McKean, MD; Ravit Geva, MD; Ruth Perets, MD, PhD; Manish R. Patel, MD; Thomas U. Marron, MD, PhD; Shilpa Gupta; Anupam Desai, M.D.; Jeffrey S. Weber, MD, PhD; Kim A. Margolin, MD, FACP, FASCO; Jong Chul Park, MD; Sima Zacharek, PhD; Andressa Sodre Laino, PhD; Joshua Frederick; Oleg Milberg; Lili Zhu; Kinjal Mody; Natalia Lopez; Praveen Aanur, MD; Robert S. Meehan, MD; Lisa Johansen; Sara Lavoie; Khanh T. Do, MD; Ryan J. Sullivan, MD |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Clinical trial;Costimulation;Cytokine;Inflammation;Solid tumors;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 768 |
Poster Presentation |
Peripheral pharmacodynamic (PD) effects of ociperlimab (OCI) in combination with tislelizumab (TIS) in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study |
Wei Tan; Yang Shi; Han Yan; Zhirong Shen; Nageshwar Budha; Ahsan Rizwan; Ruiqi Huang; Hao Zheng; Rang Gao; Sophia Frentzas; Steven Kao; Tarek Meniawy; Yun Zhang |
Clinical Trials In Progress |
Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Cytokine;Regulatory T cell (Treg cell);Solid tumors;Tumor evasion |
| 769 |
Poster Presentation |
Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors |
Emil deGoma, MD; Gonzalo Tapia-Rico; Joanne Lundy, MBBS FRACP; Gary Richardson; Niky Zhao; Karen Ebsworth; Huibin Yue; Shichiang Miao; Rita Jain; Thomas Schall; Kathleen Sullivan; Penglie Zhang; Paul de Souza, MBBS, MPH, PHD, FRACP |
Clinical Trials In Progress |
Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Solid tumors;T cell |
| 770 |
Poster Presentation |
Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors |
Anthony W. Tolcher, MD; Desamparados Roda-Perez; Kai He, MD, PhD; Victor Moreno, MD, PhD; Carlos Gomez-Roca, MD; Jean-Pascal Machiels, MD, PhD; Albiruni R. Razak; Mohammad Sahtout; Xiaowen Guan; Stacy Jaryno-Daly; Rachel Leibman; Martha E. Blaney, PharmD; James P. O'Brien, MD; Patricia Lorusso, MD; John D. Powderly, II, MD; Talia Golan; Kathy Miller, MD; Jordi Bruix |
Clinical Trials In Progress |
Antibody;Clinical trial;Cytokine;Regulatory T cell (Treg cell);Solid tumors |
| 771 |
Poster Presentation |
A phase 1, first in human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors |
Lei Chen, MD; Anthony W. Tolcher, MD; Nashat Y. Gabrail, MD; Minal A. Barve, MD; Xiaohua Wu; Jian Zhang; Michael Shi, MD; Chuan Qi, MD; Steven Yu, PhD; Jenny Yao; Jianming Wang; Christopher T. Cavanaugh |
Clinical Trials In Progress |
Antibody;Bispecifics;Checkpoint blockade;Clinical trial;Immune suppression;Solid tumors |
| 772 |
Poster Presentation |
A Phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01) |
Manish R. Sharma, MD; Deanne Lathers, PhD; Melissa L. Johnson, MD; Jason J. Luke, MD; Igor Puzanov, MD, MSCI, FACP; Brendan D. Curti, MD; Christopher Chen; Anthony B. El-Khoueiry, MD; Brian S. Henick; Margaret K. Callahan, MD, PhD; Mario Sznol, MD; Sandip P. Patel, MD; Dawn Wilson; Melissa Ricker; Lizhi Cao; Pushpa Jayaraman; Jenny Che; Li Peng, PhD; David Feltquate; Anthony W. Tolcher, MD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Glycoproteomics;Immune suppression;Solid tumors;T cell |
| 773 |
Poster Presentation |
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEOBodyTM ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update |
Anthony W. Tolcher, MD; John D. Powderly, II, MD; Kristine Shi; Songmao Zheng; Guizhong Liu; Jin Shang; Xinwei Wang; Wenda Li; Dana D.H. Lowe, PhD; Michael Chisamore; Peter Luo; Jiping Zha, MD, PhD |
Clinical Trials In Progress |
Antibody;Checkpoint blockade;Clinical study;Clinical trial |
| 774 |
Poster Presentation |
A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors |
Christophe Le Tourneau, MD; Sarina A. Piha-Paul, MD; Hans Prenen; Brant Delafontaine; David J. Pinato, MD, MRes, PhD; Armando Santoro, MD, PhD; Rebecca Kristeleit, MD PhD; Kristen R. Spencer, DO, MPH; Tara C. Gangadhar, MD; Howard Burris, III; Nuria Kotecki, MD; Bristi Basu; Donna M. Graham; Anna Maria Di Giacomo; Solmaz Sahebjam, MD; Massimo Di Nicola; Carlos Gomez-Roca, MD; Pascale Tomasini; Paolo A. Ascierto, MD; Giuseppe Curigliano, MD, PhD; Thomas Karasic; Ryan Geschwindt, BS; Jeannie Daniel; Eric Van Cutsem, MD, PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy |
| 775 |
Poster Presentation |
Initial results from dose escalation of a phase 1/2 first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25, in patients with solid tumors |
James R. Vasselli, MD; Paul de Souza, MBBS, MPH, PHD, FRACP; Sophia Frentzas; Andrew Weickhardt, MD; Timothy L. Wyant, PhD; Jenny Tang, MS; Lori Richards; Aron Knickerbocker, B.Sc., M.B.A.; Inbar Amit; Yanay Ofran, Ph.D. |
Clinical Trials In Progress |
Adoptive immunotherapy;Antibody;Clinical study;Clinical trial;Costimulation;Cytokine;Immune contexture;Solid tumors;T cell;Targeted therapy |
| 776 |
Poster Presentation |
ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor |
Jeffrey P. Ward, MD Ph.D.; Armin Ghobadi, MD; John B. Liao, MD, PhD; Adam Schoenfeld; Scott S. Tykodi; Yizhou Jiang, PhD; John Le Gall, MD, MBA; Ruben Alvarez-Rodriguez; Marika Sherman; Tiffany Singson; Jeffrey McLeroy |
Clinical Trials In Progress |
Clinical study;Clinical trial;Costimulation;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 777 |
Poster Presentation |
Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies |
Sarah Whelan, PhD; Christopher Karim; Jordan Ye; Timothy Ingallinera; Ganesh Cherala; Katherine Jameson; Anja Williams; Adam Sharp; Matthew G. Krebs, MD, PhD; Simon Pacey; Sarah P. Blagden; Ruth Plummer; Daniel Hochhauser; Jeff Evans; Johann De Bono; Janine Powers |
Clinical Trials In Progress |
Biomarkers;Chemokine;Clinical study;Clinical trial;Cytokine;Solid tumors;T cell |
| 778 |
Oral Presentation |
Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in 'cold' and I-O refractory metastatic solid tumors |
Breelyn A. Wilky, MD; Anthony B. El-Khoueiry, MD; Andrea J. Bullock, MD; Apostolia M. Tsimberidou, MD; Daruka Mahadevan, MD, PhD; Kim A. Margolin, MD, FACP, FASCO; Jonathan C. Trent, MD, PhD; Bruno Bockorny, MD; Justin C. Moser, MD; Peter J. Hosein, MD; Marwan G. Fakih, MD; Benjamin L. Schlecter, MD; Jacob S. Thomas, MD; Ani S. Balmanoukian, MD; Rachel E. Sanborn, MD; Ghassan K. Abou-Alfa, MD; Gary K. Schwartz, MD; Diana L. Hanna, MD; Waldo Ortuzar Feliu, MD; Joseph E. Grossman, MD; Katherine Rosenthal, RN, MSN, OCN, CCRP; James L. Godwin, MD; Jaymin M. Patel, MD; Bonnie L. Bullock, PhD; Justin Stebbing, MD, PhD, FRCP, FRCPath; Bhupendra Rawal, MS, MS; Hunter Cole, MPH; Chloe Delepine, MEng, MS; Jacky Chow, PhD, MS; Ross C. Walker, PhD, MS; Chris MacDermaid, PhD; Dhan Chand, PhD; Michael S. Gordon, MD; Heinz-Josef Lenz, MD, FACP; Steven J. O'Day, MD |
Clinical Trials In Progress |
Antibody;Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Coinhibition;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell |
| 779 |
Poster Presentation |
A Phase I, Dose Escalation and Expansion Study of PT199, a Next Generation CD73 Monoclonal Antibody, Administered Alone and in Combination with a PD-1 Inhibitor in Adult Patients with Advanced Solid Tumors |
Ramzi Melhem, MD; Harold M. Wright, PhD; Hui Zou, PhD; Claudia Ramos; Jack Li, PhD; Ming Wang, PhD |
Clinical Trials In Progress |
Antibody;Checkpoint blockade;Clinical trial;Coinhibition;Solid tumors;Tumor microenvironment |
| 780 |
Poster Presentation |
SRK-181, a latent TGFβ1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors |
Timothy A. Yap, MD; Justin F. Gainor, MD; Meredith McKean, MD; Melissa Johnson, MD; Bruno Bockorny, MD; Minal A. Barve, MD; Randy F. Sweis, MD; Ulka Vaishampayan, MD; Ahmad A. Tarhini, MD, PhD, MS; Deepak Kilari; Yawen Ju; Si-Tuen Lee-Hoeflich; Stephen DeWall; Lan Liu; Nisha Shah; Ann Marie Kennedy; Lu Gan, MD, PhD |
Clinical Trials In Progress |
Clinical study |
| 781 |
Poster Presentation |
DELTA-2: A phase 1, open-label, multicenter study of ITIL-168, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, with pembrolizumab in patients with advanced solid tumors |
Oladapo Yeku, MD, PhD; Daniel Olson, MD; Jeffrey P. Ward, MD Ph.D.; Sandip P. Patel, MD; Jeff Aycock, BSc; Amber C. Donahue; Yizhou Jiang, PhD; John Le Gall, MD, MBA; Zachary J. Roberts, MD, PhD; Rubén Alvarez-Rodríguez; Judy Seng; Tong Shen; Nishi Kothari |
Clinical Trials In Progress |
Adoptive immunotherapy;Clinical study;Clinical trial;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 782 |
Oral Presentation |
Intratumoral sotigalimab with pembrolizumab activates antigen-presenting cells and induces local and distant anti-tumor responses in first-line metastatic melanoma: Results of a phase I/II study |
Salah-Eddine Bentebibel, PhD; Daniel H. Johnson, MD; Barbara M. Pazdrak; Daniel J. McGrail, PhD; Srisuda Lecagoonporn, PhD DPharm; Cara Haymaker; Dzifa Y Duose; Khalida Wani, PhD; Heather Sonnemann; Houssein Safa, MD; Jared K Burks; Patrick Hwu; Cho Sungnam; Chantale Bernatchez, PhD; Suhendan Ekmekcioglu, PhD; Gregory Lizée; Adi Diab |
Clinical Trials In Progress |
Antibody;Antigen presenting cells;B cell;Biomarkers;Checkpoint blockade;Clinical trial;Dendritic cell;Immune monitoring;Solid tumors |
| 783 |
Poster Presentation |
Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1-inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC |
Allison Betof, MD, PhD; Trisha M. Wise-Draper, MD, PhD; Kai He, MD, PhD; Amod A. Sarnaik, MD, FACS; Jonathan R. Thompson, MD; Friedrich G. Finckenstein, MD; Parameswaran Hari; Madan Jagasia; Anjali Desai; Akiko Suzuki; Xiao Wu; Jason A. Chesney, MD, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;Checkpoint blockade;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 784 |
Poster Presentation |
Immune profiling of patients with advanced Melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies - results of a Phase I trial expansion |
Paula L. Codó, Dr.Sc.Nat.; Marina Gonzalez; Peter Wengenmayer; Igor Samoylenko, MD. PhD; Sebastian Ochsenreither, P.D. Dr.; Erika Richtig, MD; Ioannis Thomas, MD; Michael Erdmann, MD; Celeste Lebbe, MD, PhD; Juan Martin-Liberal, MD PHD; Patrick Terheyden, P.D. Dr. med.; Artem Poltoratskiy, MD; Marina Sekacheva, MD; Yuliya Semiletova, MD; Thomas Eigentler, MD; Beate Schmitt-Bormann, Dr.; Dominik Vahrenhorst; Sarah-Katharina Kays, PhD; Tobias Seibel, II, PhD; Gianluca Quintini, PhD; Birgit Scheel, Dr.; Martin H. Falk, MD PhD; Ulrike Gnad-Vogt, Dr. med. |
Clinical Trials In Progress |
Biomarkers;Clinical study;Clinical trial;Gene expression;Immune monitoring;RNA;Solid tumors;TLR;Tumor microenvironment |
| 785 |
Poster Presentation |
A phase I study of intralymphatic (IL) administration of ipilimumab (IPI) with intravenous nivolumab (NIVO) using the Sofusa DoseConnect™ device in patients with advanced melanoma. |
Anastasios Dimou, MD; Vera Suman; Kristina Denic; Lisa Kottschade; Heather Montane; Heidi D. Finnes; Kristina Franta; Jill Schimke; Yiyi Yan; Robert McWilliams; Matthew Block; James Jakub; Joel Reid; Svetomir N. Markovic, MD, PhD |
Clinical Trials In Progress |
Clinical study;Immune toxicity |
| 786 |
Poster Presentation |
Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from ongoing expansion part in study 008 |
Thomas Eigentler, MD; Igor Samoylenko, MD, PhD; Sebastian Ochsenreither, P.D. Dr.; Erika Richtig, MD; Ioannis Thomas, MD; Michael Erdmann, MD; Celeste Lebbe, MD, PhD; Juan José Soto-Castillo, MD; Patrick Terheyden, P.D. Dr. med.; Artem Poltoratskiy, MD; Marina Sekacheva, MD; Yuliya Semiletova, MD; Janina Henze, Dr.; Beate Schmitt-Bormann, Dr.; Paula L. Codó, Dr.Sc.Nat.; Martin H. Falk, MD PhD; Ulrike Gnad-Vogt, Dr. med. |
Clinical Trials In Progress |
Clinical study;Clinical trial;RNA;Solid tumors;TLR |
| 787 |
Poster Presentation |
DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma |
Brian Gastman, MD; Amod A. Sarnaik, MD, FACS; Donald P. Lawrence, MD; Anthony Olszanski, MD, RhP; Bartosz Chmielowski, MD, PhD; Jose Lutzky, MD; Marcus O. Butler, MD; Omid Hamid, MD; Pippa Corrie, PhD, FRCP; Evidio Domingo-Musibay, MD; Sajeve S. Thomas, MD; Fiona Thistlethwaite, MD, PhD; Gregory A. Daniels, MD, PhD; Thomas R.J. Evans, MD, MBBS, FRCP; Andrew J.S. Furness, MD PhD; Geoffrey Gibney, MD; Mark Harries, MA, FRCP, PhD; Theresa M. Medina, MD; Daniel Olson, MD; Lalit Pallan, MBchB, PhD; Eric D. Whitman, MD, FACS; Melissa Wilson, MD, PhD; Jeff Aycock, BSc; Robert E. Hawkins, MBBS, PhD, FRCP; Yizhou Jiang, PhD; Audrey Kennedy, BSc; Paul B. Robbins, PhD; Zachary J. Roberts, MD, PhD; John Le Gall, MD, MBA |
Clinical Trials In Progress |
Adoptive immunotherapy;Clinical study;Clinical trial;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 788 |
Poster Presentation |
A Phase 1b study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of neoadjuvant use of PH-762 administered intratumorally in subjects with advanced melanoma |
Simon P. Fricker, PhD; Caroline Robert, MD, PhD; François-Xavier Danloss, MD; Emilie Routier, MD; Benjamin Cuiffo, PhD; James Cardia, PhD |
Clinical Trials In Progress |
Checkpoint blockade;Clinical trial;RNA;Solid tumors;Surgery;Tumor microenvironment |
| 789 |
Oral Presentation |
Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study) |
Amod A. Sarnaik, MD, FACS; Karl D. Lewis, MD; Harriet Kluger, MD; Omid Hamid, MD; Eric D. Whitman, MD, FACS; Sajeve S. Thomas, MD; Martin Wermke, MD; Mike Cusnir, MD; Evidio Domingo-Musibay, MD; Giao Q. Phan, MD; John M. Kirkwood, MD; Jessica C. Hassel; Marlana Orloff, MD; James Larkin, MD; Jeffrey S. Weber, MD, PhD; Andrew J.S. Furness, MD PhD; Nikhil I. Khushalani, MD; Theresa M. Medina, MD; Friedrich G. Finckenstein, MD; Madan Jagasia; Parameswaran Hari; Giri Sulur; Wen Shi, MD, PhD; Xiao Wu; Jason A. Chesney, MD, PhD |
Clinical Trials In Progress |
Adoptive immunotherapy;Clinical study;Clinical trial;Neoantigens;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 790 |
Oral Presentation |
Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab |
Jens Tijtgat, MD; Julia Katharina Schwarze, MD, MSc; An-Sofie Vander Mijnsbrugge, MD; Steven Raeymaeckers, MD, PhD; Ivan Van Riet, PhD; Xenia Geeraerts, PhD; Latoya Stevens, PhD; Sandra Tuyaerts, PhD; Bart Neyns, MD, PhD |
Clinical Trials In Progress |
Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;Immune adjuvant;Solid tumors;Vaccine |
| 791 |
Poster Presentation |
Immune checkpoint blockade enhances Cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model |
Mariam M. George, PhD; Allison Betof, MD, PhD; Taha Merghoub, PhD; Linda Hamadene, MD; Daniel Hirschhorn; Alan N. Houghton, MD; Jedd D. Wolchok, MD PhD |
Combination Immunotherapies |
Checkpoint blockade;Chemotherapy |
| 792 |
Poster Presentation |
Natural killer T cell immunotherapy combined with fusogenic oncolytic virus and PD-1 blockade enhances survival in a mouse model of spontaneous lung adenocarcinoma |
Jordan D. Lukacs, BSc |
Combination Immunotherapies |
Adoptive immunotherapy;Carcinogenesis;Checkpoint blockade;NK/NKT cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 793 |
Poster Presentation |
Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity |
Xiaofeng Niu, PhD; Chunnian Wang, PhD; Jinfeng Zhao; Haiying Wang; Li Zhang; Jiahui Hu; Jingfeng Yu; Yefeng Lu; Xiaoli Guo; Haixia Jiang; Rui Gao, PhD; Zhihao Wu, PhD; Yangsheng Qiu, PhD; Quan Qiu, PhD; Zheng Song, PhD; Dawei Sun, PhD; Hongtao Lu, PhD |
Combination Immunotherapies |
Antibody;Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors |
| 794 |
Poster Presentation |
TKM-011, Anti-CD20 Antibody Confers Multi-Properties Against Burkitt's Lymphoma in Comparable Efficacy to Rituximab and Obinutuzumab |
Jutatip Panaampon, PhD; Seiji Okada, MD, PhD |
Combination Immunotherapies |
Antibody;Monocyte/Macrophage;NK/NKT cell |
| 795 |
Poster Presentation |
STAT3 signaling as a checkpoint for TLR9-driven epigenetic reprogramming of acute myeloid leukemia into antigen-presenting cells |
Dongfang Wang, PhD; Priyanka Duttagupta, PhD; Yu-Lin Su, PhD; Haiqing Li; Mingye Feng; Bin Zhang; Ya-Huei Kuo; Guido Marcucci, MD; Marcin Kortylewski, PhD |
Combination Immunotherapies |
Leukemia/Lymphoma;Myeloid cells;TLR;Tumor evasion |
| 796 |
Poster Presentation |
Repurposing NSAIDs for cancer immunotherapy: mechanisms beyond COX inhibition |
Gang Zhou, PhD; Nada S. Aboelella; Md Ye. Gazi; Gary A. Piazza |
Combination Immunotherapies |
Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Chemotherapy;Inflammation;Myeloid cells;T cell;Tumor microenvironment |
| 797 |
Poster Presentation |
Real-world treatment duration of atezolizumab+carboplatin+etoposide among older patients with extensive-stage small cell lung cancer (ES-SCLC) and the impact of performance status and brain metastases |
Husam Albarmawi, PhD; Scott Robinson, MPH, MA; Kevin Dietz; Kris Norris; Nindhana Paranthaman, MD; Sarika Ogale, PhD; Taylor T. Schwartz, MPH |
Combination Immunotherapies |
Solid tumors |
| 798 |
Poster Presentation |
Real-World Overall Survival among Patients Receiving First-Line (1L) Pembrolizumab in the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the United States |
Christopher M. Black, PhD; Liya Wang; Karthik Ramakrishnan; Gleicy Hair; Daisuke Goto |
Combination Immunotherapies |
Checkpoint blockade;Chemotherapy;Solid tumors |
| 799 |
Poster Presentation |
Real-World Use of Pembrolizumab Combination Regimens in First-Line Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma |
Christopher M. Black, PhD; Liya Wang; Karthik Ramakrishnan; Daisuke Goto |
Combination Immunotherapies |
Checkpoint blockade;Chemotherapy;Solid tumors |
| 800 |
Poster Presentation |
Clinicopathological and molecular predictive factors of survival in non-small cell lung cancer patients treated with first-line immunotherapy with or without chemotherapy: a systematic review and meta-analysis |
Alessandro Di Federico, MD; Francesco Gelsomino; Andrea De Giglio, MD; Francesca Sperandi; Barbara Melotti; Andrea Ardizzoni |
Combination Immunotherapies |
Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial |
| 801 |
Poster Presentation |
The anti-tumor efficacy of immunogenic chemotherapy is enhanced by the dual A2aR/A2bR antagonist etrumadenant, relieving the necessity for an extended chemotherapy regimen |
Daniel DiRenzo; Dana Piovesan, MSc; Ferdie Soriano, BS; Livia Yamashiro; Janine Kline; Dillon H. Miles, PhD; Ehesan Sharif; Manmohan R. Leleti; Matthew Walters |
Combination Immunotherapies |
Chemotherapy;Immune suppression;Tumor microenvironment |
| 802 |
Poster Presentation |
Eliciting calreticulin-mediated 'eat me' phagocytic signal is additive/synergistic with CD47 blockade in enhancing tumor associated macrophage phagocytosis of tumor cells and deceasing xenograft tumor growth in Ewing sarcoma |
Wen Luo, PhD; Mitchell S. Cairo; Janet Ayello, MS, MT(ASCP); Timothy P. Cripe; Kevin A. Cassady; Hai Hoang |
Combination Immunotherapies |
Antibody;Chemotherapy;Monocyte/Macrophage;Pediatric tumors;Solid tumors;Tumor microenvironment |
| 803 |
Poster Presentation |
Enhhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-tocopheryloxacetic acid-lysine |
Emmanuel T. Akporiaye, Ph.D.; William L. Redmond, Ph.D.; Melissa Kasiewicz, B.S. |
Combination Immunotherapies |
Chemotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 804 |
Poster Presentation |
Novel AI-derived approach to identify Lomitapide as an anticancer agent inducing autophagic cell death in colorectal cancer |
Seung Ju Park; Seulgi Lee; Boah Lee |
Combination Immunotherapies |
Bioinformatics;Checkpoint blockade;Chemotherapy;Coinhibition;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 805 |
Poster Presentation |
Multiple combinational strategies of immunotherapy for urothelial carcinoma in one institution |
Jo-Pai Chen, MD; Sung-Hsin Kuo, MD PhD; Wei-Chen Lu |
Combination Immunotherapies |
Checkpoint blockade |
| 807 |
Poster Presentation |
Selective depletion of tumor-specific regulatory T cells in combination with low dose chemotherapy with or without PD-1 blockade improves anti-tumor T cell responses in solid tumors |
Dorothèe Saddier Axe; Michelle R. Kuhne, PhD; Renu Jain, PhD; Brian M. Weist, PhD |
Combination Immunotherapies |
Antibody;Checkpoint blockade;Chemokine;Chemotherapy;Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 808 |
Poster Presentation |
Blocking 'don't-eat-me' signal of CD47-SIRPα by anti-SIRPα antibody enhances anti-tumor efficacy of trastuzumab deruxtecan |
Mayumi Sue, PhD; Takuya Tsubaki, PhD; Yoko Ishimoto; Shinko Hayashi; Saori Ishida; Yoshitaka Isumi, PhD; Jun Ishiguro, PhD; Reimi Kawaida; Toshiaki Ohtsuka; Teiji Wada, PhD; Toshinori Agatsuma, PhD; Norihito Kawasaki, PhD |
Combination Immunotherapies |
Antibody;Antigen presenting cells;Checkpoint blockade;Chemotherapy;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy |
| 809 |
Poster Presentation |
Anti-CLDN18.2 antibody ZL-1211 enhances anti-tumor activities in combination with chemotherapy in gastric cancer models |
Anthony Cao, PhD; Qiuping Ye, PhD; Karl Hsu, MD; Hua Gong; Jiaqing Yi, PhD; Haiying Zhou, PhD; Xinyan Tang, PhD |
Combination Immunotherapies |
Antibody;Chemotherapy;NK/NKT cell;Solid tumors;Tumor antigens |
| 810 |
Poster Presentation |
Novel Renal Cell Carcinoma Immunotherapy Combining TLR9-Targeted STAT3 Antisense Oligonucleotide with PD-1 blockade |
Marice Alcantara, PhD; Alexander Chehrazi-Raffle, MD; Nazli Dizman, MD; Wilson Tang, BS; Luis Meza, MD; Zeynep Zengin, MD; Dongfang Wang, PhD; Dayson Moreira, PhD; Alan Horsager, PhD; JoAnn Hsu, BS; Sumanta Pal, MD; Marcin Kortylewski, PhD |
Combination Immunotherapies |
Checkpoint blockade;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 811 |
Poster Presentation |
PD1 and LAG3 synergize on CD8+ T cells to hinder IFNγ-dependent anti-tumor immunity |
Lawrence P. Andrews, PhD; Carly Cardello; Jian Cui, PhD; Creg Workman, PhD; Dario A. Vignali, PhD |
Combination Immunotherapies |
Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs) |
| 812 |
Poster Presentation |
Development of BCMA-targeted immunotherapy using vaccine-induced antigen-specific memory CD8+ T cells for treating patients with multiple myeloma |
Jooeun Bae; Derin Keskin, Ph.D.; Yueyi Huang, M.S.; Sean Rowell, BS; Sarah Nikiforow; Gerry MacDonald; Jerome Ritz; Nikhil Munshi; Kenneth Anderson |
Combination Immunotherapies |
T cell |
| 813 |
Poster Presentation |
Cancer vaccine triple synergistic combination immunotherapy enhances anti-cancer efficacy |
Jay A. Berzofsky, MD, PhD; William Becker, Ph.D.; Purevdorj B. Olkhanud, M.D., Ph.D. |
Combination Immunotherapies |
Checkpoint blockade;Coinhibition;Costimulation;Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 814 |
Poster Presentation |
DT-9081, a selective EP4 receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models |
Anne-Laure Blayo, PhD; Claire Jouffroy-Zeller; Nathalie Lenne; Imane Nafia; Patricia Zerr; Stéphan Schann, PhD; Xavier Leroy, PhD |
Combination Immunotherapies |
Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;T cell;Tumor microenvironment |
| 815 |
Poster Presentation |
CRB-601, a selective integrin avβ8 blocking antibody, exhibits potent anti-tumor activity in anti-PD-1 resistant models |
Daqing Wang, Ph.D; Vaishali Shinde; Maneesh Singh, Ph.D; Rachael Brake, Ph.D; Andrew Kolodziej, Ph.D |
Combination Immunotherapies |
Antibody;Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 816 |
Poster Presentation |
Blockade of SIRPα on macrophages to enhance CAR T activity against glioblastoma |
Rebecca M. Brock, PhD; Alesandra S. Echeandia-Marrero; Matthew Dysthe, B.S.; Robin Parihar, MD, PhD; Nabil Ahmed, MD, MPH; Meenakshi Hegde, MD |
Combination Immunotherapies |
Antibody;CAR T cells;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment |
| 817 |
Poster Presentation |
Engineered toxin body targeting CTLA-4 (MT-8421) depletes Tregs in the tumor microenvironment and synergizes with αPD-1 to enhance T cell immunity |
Lauren R. Byrne; Swati Khanna, Ph.D.; Rebecca Martin, Ph.D.; Caleigh Howard; Lilia A. Rabia, Ph.D.; Michaela M. Sousares; Jay Zhao, Ph.D.; John Majercak, Ph.D.; Eric Poma, Ph.D.; Chris B. Moore, Ph.D. |
Combination Immunotherapies |
Antibody;Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 818 |
Poster Presentation |
Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma |
Anthony R. Cillo, PhD; Carly Cardello; Lilit Karapetyan; Feng Shan, MS; Cindy Sander, BS; Elizabeth Rush, BS; Aofei Li; Arivarasan Karunamurthy, MD; Sheryl R. Kunning; John M. Kirkwood, MD; Tullia Bruno, PhD; Dario A. Vignali, PhD |
Combination Immunotherapies |
Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;Systems biology;T cell;Tumor microenvironment |
| 819 |
Poster Presentation |
Intratumoral administration of High-Concentration Nitric Oxide and Anti PD-1 treatment leads to higher tumor regression rates and prolonged survival in CT26 tumor-bearing mice |
Hila Confino; David Greenberg, Prof.,MD; Selena Chaisson; Jedidiah Mercer Monson, MD; Steve Lisi; Amir Avniel; Ido Wolf, MD. PhD; Yana Epshtein |
Combination Immunotherapies |
Adoptive immunotherapy;B cell;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 820 |
Poster Presentation |
Linear DNA amplicons as a novel antiviral and cancer vaccine strategy |
Luigi Aurisicchio, PhD; Antonella Conforti; Mirco Compagnone; Erika Salvatori; Lucia Lione; Eleonora Pinto; Clay Shorrock; James Hayward; Brian Viscount; Fabio Palombo; Yuhua Sun; Ben Minghwa Liang |
Combination Immunotherapies |
Neoantigens;Tumor antigens;Vaccine |
| 821 |
Poster Presentation |
The potential clinical usage of Fc-optimized anti-CCR8 therapeutic antibodies as a monotherapy or combined with other promising immune-modulating agents beyond PD-1/L1 |
Shuang Dai; Weifeng Huang; Longjun Yan; Shaogang Peng; Shihui Zhou; Zhijun Yuan; Chao Wang; Chuan-Chu Chou, PhD; Andy Tsun; Tianhang Zhai |
Combination Immunotherapies |
Antibody;Bispecifics;Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 822 |
Poster Presentation |
Overcoming the suppressive tumor microenvironment with a live bacterial immunotherapy |
Andrew C. Scott, PhD; Matthieu Besneux, PhD; Oluwatobiloba Oke; Mary Chol; Claudia Prevosto, PhD; Nicholas Glanville, PhD; Livija Deban, PhD |
Combination Immunotherapies |
Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR;Tumor microenvironment |
| 823 |
Poster Presentation |
IMM20059, a novel anti-EPN1 antibody, in combination with Atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy |
John P. Dowling; John P. Dowling, PhD; Pavel A. Nikitin; Cezary R. Swider; Chris Nicolescu; Halley Shukla; Jamie L. Bingaman-Steele; Nirja B. Patel; Eden L. Sikorski; Benjamin C. Harman; Jillian M. DiMuzio; Karen Lundgren; Yumi Ohtani; Michael J. Morin; Matthew K. Robinson; Fang Shen |
Combination Immunotherapies |
Antibody;B cell;Checkpoint blockade;Chemokine;Solid tumors;Tumor microenvironment |
| 824 |
Poster Presentation |
NX-1607, a small molecule inhibitor of the CBL-B E3 ubiquitin ligase, promotes T and NK cell activation and enhances NK-mediated ADCC in a mouse lymphoma tumor model |
Marilena Gallotta, PhD; Jennifa Gosling; Austin Tenn-McClellan; Serena Ranucci; Jose Gomez Romo; Frederick Cohen; Gwenn M. Hansen, PhD; Arthur T. Sands, MD PhD; Cristiana Guiducci; Ryan Rountree, PhD |
Combination Immunotherapies |
Leukemia/Lymphoma;NK/NKT cell;Regulatory T cell (Treg cell);T cell |
| 826 |
Poster Presentation |
IL7R TME expression correlates with immunotherapy response and is associated with T-cell stemness with decreased apoptosis |
Nicolas Poirier; Isabelle Girault, MD; Aurore Morello, PhD; Justine Durand; Margaux Seite |
Combination Immunotherapies |
Bioinformatics;Cytokine;Immune monitoring;T cell |
| 827 |
Poster Presentation |
The Role of Combination Immune Checkpoint Inhibitors as Salvage Therapy for PD-1/PD-L1-resistant Merkel Cell Carcinoma |
Tarek Haykal, MD; Georgia Beasley, MD, MHSc; April Salama, MD; Brent Hanks, MD, PhD |
Combination Immunotherapies |
Checkpoint blockade;Clinical study;Immune adjuvant;Solid tumors |
| 828 |
Poster Presentation |
Combination of Flt3L and STING agonism sensitizes non-T cell-inflamed tumors to checkpoint blockade therapy |
Emily F. Higgs, PhD; Thomas F. Gajewski, MD, PhD |
Combination Immunotherapies |
Antigen presenting cells;Dendritic cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs) |
| 829 |
Poster Presentation |
In situ vaccination utilizing intratumoral electroporation of plasmids expressing IL-12 and CD40 ligand (CD154) has efficacy against murine tumors. |
Gregory W. Ho, BA; Steven Fiering, BS, MS, PhD |
Combination Immunotherapies |
Cytokine;Solid tumors;Targeted therapy;Tumor microenvironment |
| 830 |
Poster Presentation |
Targeting B cell Suppression to Improve the Efficacy of Immunotherapies in Brain Cancer |
David Hou, BA; Brandyn Castro, MD; Andrew Zolp; Mark Dapash, MD; Victor A. Arrieta, MD, PhD; Jana Biermann, PhD; Johannes C. Melms, PhD; Maciej S. Lesniak, MD; Benjamin Izar, MD, PhD; Jason M. Miska, PhD; Junfei Zhao, PhD; Catalina Lee-Chang, PhD |
Combination Immunotherapies |
B cell;Checkpoint blockade;Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 831 |
Poster Presentation |
Targeting tumor oxidative metabolism to overcome hypoxia-induced immunotherapy resistance in prostate cancer |
Priyamvada Jayaprakash, PhD; Michael A. Curran, PhD; Brittany A. Morrow, BS; Joseph R. Marszalek; Krithikaa Rajkumar Bhanu; Meghan Rice; Jason P. Gay; Christopher P. Vellano; Benjamin Cowen; Dean J. Welsch, PhD |
Combination Immunotherapies |
Checkpoint blockade;Immune suppression;MDSC;Metabolism;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 832 |
Poster Presentation |
Antigen spread mediated by oncolytic adenovirus Delta-24-RGDOX during intratumoral adoptive T cell therapy in immunocompetent mice with disseminated tumors |
Hong Jiang, PhD |
Combination Immunotherapies |
Adoptive immunotherapy;CAR T cells;Immune suppression;Inflammation;Solid tumors;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 833 |
Poster Presentation |
Blockade of human LILRB4/ILT3 inhibits the formation of lung metastasis in melanoma model. |
Darya Khantakova, BS; Martina Molgora, PhD; Julie M. Roda, PhD; Geoffrey Stone, PhD; Susan Gilfillan, PhD; Tihana Trsan, PhD; Marina Cella, MD; Alan Kutach, PhD; Daniel Kaplan, PhD; Jer-Yuan Hsu, PhD; Marco Colonna, MD |
Combination Immunotherapies |
Antibody;Immune suppression;Myeloid cells |
| 834 |
Poster Presentation |
Integrin αvβ8 inhibitor improves immune checkpoint therapy in advanced ovarian cancer model and its activity can be monitored in blood |
Natalia J. Reszka-Blanco; Megan Krumpoch; Huidong Chen; Lia Luus; Michaela Mentzer; Aleksey Molodtsov; Adrian S. Ray; Vinod Yadav; Matthew Clark; Ian Gerken; Justin Snider; Blaise Lippa; Bruce N. Rogers; Gerard Bain |
Combination Immunotherapies |
Biomarkers;Checkpoint blockade;Immune suppression;Immune tolerance |
| 835 |
Poster Presentation |
AZD4820 Oncolytic Vaccinia Virus Encoding IL-12 Mediates Anti-tumor Activity Through Oncolysis and Tumor-specific Immunity |
Cheyne Kurokawa; Sonia Agrawal; Abhisek Mitra; Elena Galvani; Shannon Burke; Ankita Varshine; Raymond Rothstein; Johann Foloppe; Nathalie Silvestre; Eric Quemeneur; Puja Sapra; Carl Barrett; Scott Hammond; Jason Laliberte; Nicholas Durham, PhD; Michael Oberst; Maria Broggi |
Combination Immunotherapies |
Targeted therapy;Tumor antigens |
| 836 |
Poster Presentation |
Activating the Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas |
Sara Labiano, PhD; Reyes Hernández-Osuna; Virginia Laspidea; Marc Garcia-Moure, PhD; Javier Marco-Sanz; Iker Ausejo; Montserrat Puigdelloses, PhD; Oren J. Becher, MD; Ana Patiño-Garcia, PhD; Candelaria Gomez-Manzano, MD, PhD; Juan Fueyo, MD, PhD; Marta M. Alonso, PhD |
Combination Immunotherapies |
Antibody;Antigen presenting cells;Costimulation;Dendritic cell;Immune contexture;Immune monitoring;Pediatric tumors;Solid tumors;Tumor microenvironment;Tumor stroma |
| 837 |
Poster Presentation |
Redirecting IL-7-induced bystander tumor-infiltrating lymphocytes by bispecific T-cell engager augments antitumor response |
Kun-Joo Lee; Nara Tae; Yeon-Woo Kang; Dain Moon; Youngsik Oh; Ji-Hae Kim, BS; Minji Lee; Ha Won Song; Sun Shim Choi; Donghoon Choi; Dae Hee Kim; Seung-Woo Lee |
Combination Immunotherapies |
Adoptive immunotherapy;Bispecifics;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 838 |
Poster Presentation |
Combination MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation |
June Li; Karen Millerchip; Carlos Ramos, BS; Edwin Parra, MD, PhD; Luisa Solis; Alex Stevenson; Aurelie Couturier; Gayle Fyvie; Michael Chisamore; Rahul Parikh; Eric Bernicker; Diwakar Davar, MD; Arvind Chaudhry; Nizar Tannir; Shubham Pant; Cara Haymaker |
Combination Immunotherapies |
Biomarkers;Checkpoint blockade;Dendritic cell;Immune monitoring;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell |
| 839 |
Poster Presentation |
Selective Targeting of GARP-LTGFß Axis in the Tumor Microenvironment Augments PD-1 Blockade via Enhancing CD8+ T Cell Anti-Tumor Immunity |
Anqi Li, MD; Yuzhou Chang; No-Joon Song, PhD; Xingjun Wu; Dongjun Chung; Brian P. Riesenberg, PhD; Maria Velegraki, MD, PhD; Hyunwoo Kwon; Karthik Chakravarthy, BS; Chelsea M. Bolyard; Yi Wang; Qin Ma; Zihai Li, MD, PhD |
Combination Immunotherapies |
Antibody;Regulatory T cell (Treg cell);T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 840 |
Poster Presentation |
Triple-drug oral immunotherapy targeting myeloid cells for treatment of metastatic osteosarcoma evaluated in spontaneous canine model |
Cheryl London, DVM, PhD; Dan Regan, DVM, PhD; Lyndah Chow, PhD; Kristen Weishaar, DVM; Heather Gardner, DVM, PhD; Doug Thamm, VMD; Steven Dow, DVM, PhD |
Combination Immunotherapies |
Granulocyte;Inflammation;Monocyte/Macrophage;Myeloid cells;Tumor microenvironment |
| 841 |
Poster Presentation |
XTX202, a tumor-selective protein-engineered IL-2, exhibited enhanced anti-tumor activity in combination with checkpoint inhibition in mice |
Wilson D. Guzman, A.B; Uli Carl Bialucha; Hanumantha Rao Madala; Haley Duprey; Manoussa Fanny; Stephanie Hsiao; Parker Johnson; Jake Taylor; Rebekah O’Donnell; Magali Pederzoli-Ribeil; Benjamin Nicholson; Jennifer O’Neil; Caitlin O’Toole |
Combination Immunotherapies |
Checkpoint blockade;Cytokine;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 842 |
Poster Presentation |
Development of a multiplex test for predicting response to combined immunotherapies in patients with metastatic melanoma |
Gabriele Madonna, MS; Pedro Machado Almeida, PhD; Mariaelena Capone, MD; Vito Vanella, MD; Lucia Festino, MD; Antonio Sorrentino, PhD; Marco Cassano, PhD; Benjamin Pelz, PhD; Diego G. Dupouy, PhD; Paolo A. Ascierto, MD |
Combination Immunotherapies |
Biomarkers;Checkpoint blockade;Immune contexture;Proteomics;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 843 |
Poster Presentation |
Lag3 blockade in combination with GITR improves anti-tumor immune responses in a preclinical melanoma model |
Rachana Maniyar, PhD; Roberta Zappasodi, PhD; Yuval Elhanati; Samantha St.Jean; Sebastian Carrasco; Benjamin D. Greenbaum, PhD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD |
Combination Immunotherapies |
Antibody;B cell;Biomarkers;Checkpoint blockade;T cell;Tumor microenvironment |
| 844 |
Poster Presentation |
Combined immunotherapy efficacy on a multifocal hepatocellular carcinoma model based on hydrodynamic oncogene transfer |
Maria C. Ochoa; Sandra Sanchez-Gregorio; Alvaro Teijeira, PhD; Saray Garasa, BS; Carlos E. De Andrea, MD; Maria Villalba; Iñaki Etxeberria; Ignacio I.M. Melero, MD, PhD |
Combination Immunotherapies |
Checkpoint blockade;Immune monitoring;Solid tumors |
| 845 |
Poster Presentation |
Identifying patient subsets for CTLA4 and GITR depletion strategies in poorly T cell infiltrated tumors |
Arjun Mittal, BS; Jason J. Luke, MD; Riyue Bao, PhD |
Combination Immunotherapies |
Bioinformatics;Biomarkers;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 846 |
Poster Presentation |
Trastuzumab, an anti-HER2 antibody Modulates Cytotoxicity Against Cholangiocarcinoma (CCA) via Multiple Mechanisms. |
Seiji Okada, MD, PhD; Jutatip Panaampon, PhD |
Combination Immunotherapies |
Antibody;Solid tumors;Targeted therapy |
| 847 |
Poster Presentation |
CF33-CD19t Oncolytic Virus (onCARlytics) in Combination with Off-the-shelf Allogeneic CyCART-19 T Cells Targeting de novo CD19+ Solid Tumors |
Anthony K. Park, PhD; Isabel Monroy; Colin Cook; Shuyang He; Kathy Karasiewicz; Monil Shah; Nimali Withana; Leslie M.O. Chong; Robert Hariri, MD PhD; Yuman Fong, BS, MD; Saul J. Priceman, PhD |
Combination Immunotherapies |
CAR T cells;Solid tumors;T cell;Targeted therapy |
| 848 |
Poster Presentation |
Impact of immunotherapy time-of-day infusion on overall survival in patients with metastatic renal cell carcinoma |
Jimmy S. Patel; Amber S. Draper; Yena Woo; Layla Dhabaan; Pretesh Patel, MD; Ashesh Jani; Bradley C. Carthon, MD, PhD; Viraj A. Master, MD, PhD; Haydn Kissick, PhD; Mehmet A. Bilen, MD; Zachary Buchwald, MD PhD; David C. Qian, MD, PhD |
Combination Immunotherapies |
Clinical study;Immune tolerance |
| 849 |
Poster Presentation |
NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model |
Yee Peng Phoon, PhD; Kang Kai, PhD; Alexandra A. Wolfarth, PhD; Sara Ferrando-Martinez, PhD; Byung Ha Lee, PhD; Brian Gastman, MD |
Combination Immunotherapies |
Adoptive immunotherapy;Checkpoint blockade;Immune adjuvant;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 850 |
Poster Presentation |
Interim results for Phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies |
Ruth Plummer; Mikael H. Sodergren, MD, PhD; Brid Ryan; Ilian Tachkov; Vikash Reebye; Tim Meyer; David J. Pinato, MD, MRes, PhD; Debashis Sarker; Bristi Basu; Sarah P. Blagden; Natalie Cook; Jeff Evans; Jeffrey Yachnin; Cheng-Ean Chee; Daneng Li, MD; Anthony B. El-Khoueiry, MD; Maria Diab; Kai-Wen Huang; Antonio D'Alessio; Claudia A.M. Fulgenzi; Marcus Noel; Bridget P. Keenan, MD, PhD; Devalingam Mahalingam, MBBChBAO; Nina Raulf; Rose Hogson; Choon Ping Tan; Joanna Nicholls; Alison Adderkin; Julia Vassiliadou; Robert Habib; John Rossi; Nagy Habib |
Combination Immunotherapies |
Checkpoint blockade;Clinical study;Immunoscore;MDSC;Monocyte/Macrophage;T cell;Tumor microenvironment |
| 851 |
Poster Presentation |
Voyager V1 (VV1) oncolytic virus combined with immune checkpoint therapy boosts CTL responses to multiple tumor antigens and correspondingly deepens tumor responses in murine models of melanoma, lung and colon cancer. |
Priyanka Ram; Navpreet Tung, PhD; Himani Sharma; Ben Fulton, PhD; Kah-Whye Peng, PhD; Stephen J. Russell, MD, PhD; Markus Mohrs, PhD; Gavin Thurston, PhD; Christos Kyratsous, PhD; Alina Baum, PhD; Jessica R. Kirshner, PhD; John Lin, MD, PhD; Saida Dadi-Mehmetaj, PhD |
Combination Immunotherapies |
Checkpoint blockade;Neoantigens;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 852 |
Poster Presentation |
Investigating The Functional Role of GPNMB in Glioblastoma And The Tumor Immune Microenvironment And Its Targeted Elimination Using CAR-Ts |
Neil Savage, BSc; Franz J. Zemp; Nick Mikolajewicz, PhD; Hong Han, PhD; Chitra Venugopal, PhD; Chirayu Chokshi, PhD; Nazanin Tatari, PhD; Thomas Kislinger, PhD; Jason Moffat, PhD; Doug Mahoney, PhD; Sheila K. Singh, PhD, MD |
Combination Immunotherapies |
Adoptive immunotherapy;CAR T cells;Glycoproteomics;Monocyte/Macrophage;Proteomics;Solid tumors;Stem cell/cancer-initiating cell;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 853 |
Poster Presentation |
Novel CEAxCD47 (NILK-2401) and CEAxCD3 (NILK-2301) kl bispecific antibodies for multimodal immunotherapy of CEA-expressing solid cancer |
Anja Seckinger, MD; Vanessa Buatois, PhD; Valéry Moine; Lise Nouveau; Bruno Daubeuf; Sara Majocchi, PhD; Ulla Ravn; Nicolas Bosson; Krzysztof Masternak, PhD; Yves Poitevin; Giovanni Magistrelli; Pauline Malinge; Limin Shang, PhD; Nicolas Fischer, PhD; Klaus Strein, MD, PhD; Walter Ferlin, PhD; Dirk Hose, MD, PhD |
Combination Immunotherapies |
Antibody;Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 854 |
Poster Presentation |
HPK1 inhibition relieves suppression downstream of TCR activation to drive enhanced cytokine production and antigen-specific killing, an effect that is further enhanced by immune checkpoint blockade |
Rajesh K. Singh, PhD; Bindi Patel; Rameshwari Rayaji; Sachie Marubayashi; Sean Cho; Stefan Garrido-Shaqfeh; Joseph Kulusich; Cesar Meleza; Nidhi Tibrewal; Joice Thomas; Pradeep Nareddy; Ehesan Sharif; Sharon Zhao; Dave Green; Manmohan R. Leleti; Jay P. Powers; Matt J. Walters; Daniel DiRenzo |
Combination Immunotherapies |
Checkpoint blockade;Coinhibition;Cytokine;T cell |
| 855 |
Poster Presentation |
Diacylglycerol kinase alpha and zeta dual inhibitors enhance T cell responses and promote robust and durable anti-tumor T cell immunity |
Marcos W. Steinberg, PhD; Darina Spasova; Danelle Eto; AnneMarie Pferdekamper; Phuong Nguyen; Brian Le; Zachary Naiman; Susan Murphy; Maricel Gozo; James Skipper; Taylor Ismaili; Xikui Liu; Sunil Sahdeo; Xiao Hu; Isharat Yusuf; Kristen Taylor Meadows; Laura Carter |
Combination Immunotherapies |
Costimulation;Immune suppression;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 856 |
Poster Presentation |
SNS-101, a highly pH-selective VISTA:PSGL-1 inhibitory antibody, potentiates anti-PD-1 sensitivity, expands memory T-cells and enhances tumor infiltration of CD8 T-cells |
Thomas Thisted, PhD; Tim Eitas, PhD; Kanam Malhotra, MS; Yuliya Kleschenko, PhD; Faith Finley, BS; Zhi-Gang Jiang, PhD; Arnab Mukherjee, PhD; Zuzana Biesova, PhD; Anokhi Cifuentes, MS; Robert H. Pierce, Jr., MD; Edward H. van der Horst, PhD |
Combination Immunotherapies |
Antibody;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 857 |
Poster Presentation |
Identifying novel immunotherapy targets under the pressure of Inhibitory cytokine TGF-β1. |
Liangzhe Wu; Nicholas Gascoigne; Ling Wu, Ph.D.; Vivian Tan, BSc.; Manoj N. Krishnan; Unnikrishnan Unniyampurath; Benson Chua; Liangzhe Wu, B.Sc |
Combination Immunotherapies |
Adoptive immunotherapy;Cytokine;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor microenvironment |
| 858 |
Poster Presentation |
HBM7008 (B7H4x4-1BB HBICE) Synergizes HBM7004 (B7H4xCD3 HBICE) for Solid Tumor Therapy |
Xiaodong Wu, PhD; Yongqiang Wang; Gezi Jia; Bing Huang, Ms., Ph.D.; Yunxing Yang; Yun He; Yiping Rong |
Combination Immunotherapies |
Antibody;Bispecifics;Solid tumors;T cell |
| 859 |
Poster Presentation |
Combination of HER2 ADC and lemzoparlimab elicits enhanced efficacy in both HER2 high-and low-expressing breast and gastric cancers |
Yanni Zhang, Ph.D; Yu Pang; Ao Li; Ke Xu; Ming Yang; Zhengyi Wang, PhD; Andrew Zhu |
Combination Immunotherapies |
Antibody;Biomarkers;Monocyte/Macrophage;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 860 |
Poster Presentation |
In vivo effectiveness of Tumor Treating Fields (TTFields) concomitant with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) |
Yiftah Barsheshet; Tali Voloshin; Boris Brant; Gadi Cohen; Lilach Avigdor; Roni Blatt; Shay Cahal; Tharwat Haj Khalil; Efrat Zemer-Tov; Rom Paz; Anat Klein-Goldberg; Catherine Tempel-Brami; Sara Jacobovitch; Alexandra Volodin; Tal Kan; Bella Koltun; Cfir David; Adi Haber, PhD, MBA; Moshe Giladi, PhD; Uri Weinberg, MD PhD; Yoram Palti |
Combination Immunotherapies |
Checkpoint blockade;Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 861 |
Poster Presentation |
Combined irreversible electroporation and local CD40 agonism stimulate neoantigen specific systemic immune responses that inhibit liver metastasis in an orthotopic pancreatic cancer model. |
Jayanth Shankara Narayanan, PhD; Rebekah White, M.D.; Tomoko Hayashi, MD PhD; Dennis A. Carson, MD; Stephen P. Schoenberger, PhD |
Combination Immunotherapies |
Antigen presenting cells;Dendritic cell;Neoantigens;Solid tumors;Surgery;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 862 |
Poster Presentation |
Administration of intratumoral hu14.18-IL2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma |
Mark R. Albertini, MD; Cindy L. Zuleger, PhD; Erik A. Ranheim, MD, PhD; Oyewale Shiyanbola, MD; Andrew Kosharek, B.A.; Paul M. Sondel, MD, PhD; Zachary S. Morris, MD, PhD; Jens Eickhoff, PhD; Michael A. Newton, PhD; Irene M. Ong, PhD; Rene Welch Schwartz, PhD; Rubi Hayim, BS; Sarah Adrianowycz, DVM; Rachel Uyehara, DVM; Ilene D. Kurzman, PhD; Michelle Turek, DVM; David M. Vail, DVM |
Combination Immunotherapies |
Checkpoint blockade;Immune monitoring;Radiotherapy;Solid tumors;T cell;Vaccine |
| 866 |
Poster Presentation |
Potentiating radiotherapy-induced abscopal immunity by ATR abrogation and CTLA-4 blockade in colorectal cancer |
Rodney Cheng-En Hsieh, MD, PhD; Ricardo Alexandre De Azevedo; Pham Hong Anh Cao; Arthur J. Liu, BS; Akash R. Boda, MS; Michelle Winkler, BS; Broderick Turner; Michael A. Curran, PhD |
Combination Immunotherapies |
Antigen presenting cells;Checkpoint blockade;Solid tumors;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 867 |
Poster Presentation |
Deciphering of radiotherapy-induced immunomodulation effect synergized with immunotherapy in hepatocellular carcinoma by spatial multi-omics profiling |
Mai Chan Lau; Lisda Suteja; Lawrence Cheung; Jeffrey C. Lim; Chun Jye Lim; Xinru Lim; Neslihan A. Kaya; Jiang Feng Ye; Felicia Wee; Han Chong Toh; Su Pin Choo; Suat Ying Lee; Joycelyn Jie Xin Lee; Jin Liu; Tony Kiat Hon Lim; Weiwei Zhai; David Tai; Joe Poh Sheng P. Yeong, MD, PhD |
Combination Immunotherapies |
Bioinformatics;Biomarkers;Immune contexture;Radiotherapy;T cell;Tumor microenvironment |
| 868 |
Oral Presentation |
CD122-directed IL-2/anti-IL-2 complexes massively expand stem-like tumor-specific T cells and enhance abscopal responses to radiation and anti-PD-1 |
Kateryna Onyshchenko; Ren Luo, PhD; Liqun Wang, MD; Gabriele Niedermann |
Combination Immunotherapies |
Checkpoint blockade;Cytokine;Radiotherapy;T cell |
| 869 |
Poster Presentation |
NBTXR3-enhanced proton beam immunoradiotherapy reshapes tumor immune microenvironment and improves abscopal effect in an anti-PD1-resistant lung cancer |
Yun Hu, PhD; Sebastien Paris; Narayan Sahoo; Genevieve Bertolet; Qi Wang; Qianxia Wang; Hampartsoum Barsoumian; Jordan Da Silva; Ailing Huang; Claudia S. Kettlun Leyton; Tiffany A. Voss; Ethan Y. Hsu; Fatemeh Masrorpour; Carola Leuschner; Nahum Puebla Osorio; Quynh N. Nguyen; Saumil Gandhi; Jing Wang; Maria A. Cortez; James Welsh, MD |
Combination Immunotherapies |
Antibody;Checkpoint blockade;Immunoscore;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 870 |
Poster Presentation |
High-dose radiation is required for effective combination with tumor-specific vaccination in a prostate cancer model |
Hemanth K. Potluri, BA; Carolina A. Ferreira, PhD; Joseph Grudzinski, PhD; Christopher Massey; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD |
Combination Immunotherapies |
Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 871 |
Poster Presentation |
Irradiation potentiates NK cells for surveillance against parental and cancer stem cells of hepatocellular carcinoma through LFA-1/ICAM-1 axis. |
Tung Uong Nguyen Thanh, MSc; Huy Nguyen Phuoc Quang, MSc; Mee Sun Yoon, MD PhD |
Combination Immunotherapies |
Adoptive immunotherapy;Cytokine;NK/NKT cell;Radiotherapy;Stem cell/cancer-initiating cell |
| 872 |
Poster Presentation |
Liposomal doxorubicin enhances the radiation-induced abscopal effect by promoting the release of tumor cell mitochondrial DNA |
Liqun Wang, MD; Ren Luo, PhD; Kateryna Onyshchenko; Gabriele Niedermann |
Combination Immunotherapies |
Chemotherapy;Dendritic cell;Radiotherapy;T cell |
| 873 |
Poster Presentation |
Radiation-induced dynamic alterations in PD-1/PD-L1 activity and relevant immune cell profiles depending on treatment response status in mouse tumor models |
Yi Na Yoon, Ph.D.; Yu Jin Lim; Jae-Sung Kim |
Combination Immunotherapies |
Immune monitoring;Immune suppression;MDSC;Monocyte/Macrophage;Radiotherapy;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 874 |
Poster Presentation |
Optimizing a combination radio-immunotherapy regimen in a preclinical model of treatment-resistant, high-risk neuroblastoma |
Lauren K. Zebertavage, PhD; Amy K. Erbe, PhD; Taylor Aiken, MD; Allison Schopf; Megan Nielsen; Sydney Katz; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD |
Combination Immunotherapies |
Chemotherapy;Pediatric tumors;Radiotherapy |
| 875 |
Poster Presentation |
Targeting CCR8-expressing tumor infiltrating Tregs in combination with radiotherapy enhances anti-tumor immunity |
Yurun Zhang, PhD; Vikash Bhagwandin, PhD; Sandra V. Hatcher; Ziyun Ding, PhD; Liang Tang; Ricky A. Sharma, MD, PhD; Sophia X. Pfister, PhD |
Combination Immunotherapies |
Radiotherapy;Regulatory T cell (Treg cell);Tumor microenvironment |
| 876 |
Poster Presentation |
Volumetric muscle loss injury impacts murine tumor growth and response to immune checkpoint blockade therapy |
Anna Ruta, BS; Jordan Garcia, MD; Locke Davenport Huyer, PhD; Joscelyn Mejias, PhD; Kavita Krishnan, BS; Helen Nguyen, BS; Elise F. Gray-Gaillard, MS; Jin Han, PhD; Andrew M. Pardoll, MD, PhD; Jennifer H. Elisseeff, PhD |
Combination Immunotherapies |
Checkpoint blockade;Surgery |
| 877 |
Oral Presentation |
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression |
Sofia Bruni, MS; Mara De Martino, PhD; Florencia L. Mauro, MS; Maria F. Mercogliano; Cecilia J. Proietti; Rosalia Cordo-Russo; Patricia V. Elizalde, PhD; Roxana Schillaci, PhD |
Combination Immunotherapies |
Antibody;Biomarkers;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 878 |
Poster Presentation |
BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade via DNA damage-induced STING/NF-κB/type I IFN signaling |
Kiranj Chaudagar, PhD; Marguerite Li; Christina J. Hong; Srikrishnan Rameshbabu; Raymond Chen; Alison J. Thomas; Brian M. Olson, PhD; Akash Patnaik, MD, PhD, MMSc |
Combination Immunotherapies |
Checkpoint blockade;Immune suppression;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 879 |
Poster Presentation |
Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer |
Akash Patnaik, MD, PhD, MMSc; Kiranj Chaudagar, PhD; Hanna Hieromnimon; Taghreed Hirz; Shenglin Mei, PhD; David Sykes, MD, PhD |
Combination Immunotherapies |
Biomarkers;Checkpoint blockade;Coinhibition;Immune suppression;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment |
| 880 |
Poster Presentation |
Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) |
Alexander Chehrazi-Raffle, MD; Marice Alcantara, PhD; Nazli Dizman, MD; Wilson Tang, BS; Luis Meza, MD; Zeynep Zengin, MD; Dongfang Wang, PhD; Dayson F. Moreira, PhD; Daniela Castro; Ameish Govindarajan, MD; Alan Horsager; JoAnn Hsu, BS; Sumanta Pal, MD; Marcin Kortylewski, PhD |
Combination Immunotherapies |
Biomarkers;Coinhibition;Cytokine;Myeloid cells;Targeted therapy;Tumor evasion |
| 881 |
Poster Presentation |
Significant Therapeutic Effects of Anti-ROR1 CAR NK Against Neuroblastoma by Oncolytic virus Armored with IL-21 in-vitro and in-vivo |
Yaya Chu, PhD; Meijuan Tian, PhD; Uksha Saini, PhD; Dean A. Lee, MD, PhD; Timothy P. Cripe, MD PhD; Elaine R. Mardis, PhD; Gregory Behbehani, MD PhD; Stanley Riddell, MD; Kevin A. Cassady, MD; Mitchell S. Cairo |
Combination Immunotherapies |
Adoptive immunotherapy;Cytokine;NK/NKT cell;Pediatric tumors;Solid tumors;Targeted therapy |
| 882 |
Poster Presentation |
Using Oncogenic Pathway Agonism to Sensitize RAS Mutant Cancers to Immunotherapy |
Alvaro De Mingo Pulido, PhD; Charles H. Adelmann, PhD; Kim T. Nguyen; Cynthia Dixey; Francisca Beato; Karol Prieto, PhD; Marco Napoli, PhD; Elsa Flores, PhD; Karen Mann, PhD; Jason Fleming, MD; Kenneth Y. Tsai, MD PhD |
Combination Immunotherapies |
Checkpoint blockade;Chemokine;Cytokine;Inflammation;T cell;Targeted therapy;Tumor microenvironment |
| 883 |
Poster Presentation |
MCLA-145, an anti CD137×PD-L1 Bispecific antibody, induces T cell activation and proliferation in ex vivo models of hepatocellular carcinoma |
Jyaysi Desai, PhD; Lissane Noordam; Patrick Boor, PhD; Rachid Bouzid; Diana Mittag; Paul Tacken; Jeroen Lammerts van Bueren; Cecile Guijen; Jaap Kwekkeboom; Dave Sprengers; Sonja Buschow |
Combination Immunotherapies |
Adoptive immunotherapy;Checkpoint blockade;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 884 |
Poster Presentation |
PERK inhibitor HC-5404 demonstrates immune-activation and anti-tumor efficacy in combination with anti-PD1 immune checkpoint inhibitor antibody |
Anissa S.H. Chan, PhD; Jeremy Drees, PhD; Yunfang Li; Takashi O. Kangas; Weiyu Zhang, PhD; Maria Fumagalli; Iman Dewji; Xiaohong Qiu; Nick Collette; Ben Harrison; Ashley LaCayo; Veronica Calvo Vidal, PhD; Crissy Dudgeon, PhD; Michael Stokes, PhD; Eric Lightcap, PhD; David Surguladze, PhD; Nandita Bose, PhD |
Combination Immunotherapies |
Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor microenvironment |
| 885 |
Poster Presentation |
Enhancing immune checkpoint inhibitor efficacy with anti-angiogenics in ovarian cancer |
Sarah B. Gitto, PhD; Sergey Medvedev; Veethika Pandey, PhD; Dalia K. Omran; Matthew J. Anderson; Lauren E. Schwartz, MD; Fiona Simpkins, MD; Daniel J. Powell, Jr., PhD |
Combination Immunotherapies |
Angiogenesis;Antibody;Checkpoint blockade;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 886 |
Poster Presentation |
Combined allogeneic NK cell and Herzuma is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity |
Yong W. Moon, MD, PhD; Mithun Gosh; Hee-Jung An; Tae Hoen Kim; Sa Deok Hong; Nar Bahadur Katuwal; Minsil Kang |
Combination Immunotherapies |
Adoptive immunotherapy;NK/NKT cell |
| 887 |
Poster Presentation |
Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1-specific immune checkpoint blockade |
Marcin Kortylewski, PhD; Chia-Yang Hung, PhD |
Combination Immunotherapies |
Myeloid cells;T cell;TLR;Tumor microenvironment |
| 888 |
Poster Presentation |
Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models |
Kana Ichikawa; Ammar Adam; Hsin-Jung Wu; David L. Lahr; Lan Xu; Brandon Antonakos; Liv Johannessen; Steven F. Bellon; Ryan Kruger; Richard C. Centore; Martin Hentemann |
Combination Immunotherapies |
Checkpoint blockade;Epigenetics |
| 889 |
Poster Presentation |
IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that directly targets solid tumours and breaks immune tolerance |
Giusy Di Conza, PhD; Lars Van der Veen; Chiara Tarantelli; Francesco Bertoni; Amy Fraser; Pritom Shah; Simon Tiede; Laura Tesmer; Gerhard Hummer; Oscar Vadas; Michael Lahn; Nomanbhoy Tyzoonn; Zoe Johnson, PhD |
Combination Immunotherapies |
Checkpoint blockade;Immune suppression;Immune toxicity;Leukemia/Lymphoma;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor microenvironment |
| 890 |
Poster Presentation |
Using intratumor microdevices to identify highly synergistic combinations between targeted agents and immunotherapies in breast cancer |
Oliver Jonas |
Combination Immunotherapies |
Biomarkers;Solid tumors;Tumor microenvironment |
| 891 |
Poster Presentation |
Immune related vulnerabilities of non-neuroendocrine small cell lung cancer |
Ryan Kowash; Mingrui Zhu, B.S.; Benjamin Drapkin, M.D., Ph.D.; John Minna, M.D.; Luc Girard, PhD; Esra Akbay, PhD |
Combination Immunotherapies |
Antibody;Checkpoint blockade;Immune monitoring;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor antigens;Tumor evasion |
| 892 |
Poster Presentation |
The novel telomerase-directed telomere-targeted anticancer agent 6-thio-dG (THIO) demonstrates potent activity and induces antitumor immunity in hepatocellular carcinoma (HCC) models |
Ilgen Mender, Ph.D.; Silvia Siteni, Ph.D.; Mihail Obrocea; Vlad Vitoc; Sergei Gryaznov, PhD; Jerry Shay, Ph.D. |
Combination Immunotherapies |
Checkpoint blockade;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor microenvironment |
| 893 |
Poster Presentation |
Myeloid derived suppressive cells attenuate the anti-tumor efficacy of androgen deprivation therapy and targeted radionuclide therapy in a murine prostate cancer model. |
Anusha Muralidhar, MS; Carolina Ferreria, PhD; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD |
Combination Immunotherapies |
Immune contexture;Immune suppression;MDSC;Myeloid cells;Radiotherapy;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 894 |
Poster Presentation |
A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models. |
Ravikumar Muthuswamy, PhD; Steve Thorne, PhD; Carly Carter, PhD; Ming Zhang, PhD; Dan Byrd, PhD |
Combination Immunotherapies |
Biomarkers;Immune adjuvant;Immune contexture;Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma;Vaccine |
| 895 |
Poster Presentation |
Enhanced anti-tumor efficacy by combination of checkpoint immunotherapy and antibody-drug conjugates utilizing the topoisomerase I inhibitor linker-payload AZ'0133 |
Bilal Omar, PhD; Steve Arbitman; Kalyani Daita; Ana Paucarmayta; Huiyanangel Chow; Judith Anderton; Raymond Rothstein; Allison Gerber; Kathy A. Mulgrew; Leslie Wetzel; Edward Rosfjord; Nadia Luheshi, PhD; Krista Kinneer; Scott A. Hammond, PhD |
Combination Immunotherapies |
Antigen presenting cells;Bispecifics;Checkpoint blockade;T cell;Targeted therapy;Tumor antigens |
| 896 |
Poster Presentation |
ONCOLYTIC HERPES SIMPLEX VIRUS IMMUNO-VIROTHERAPY IN COMBINATION WITH TIGIT IMMUNE CHECKPOINT BLOCKADE TO TREAT GLIOBLASTOMA |
Eleni Panagioti, PhD; Hunter J. Kelley, MSC; William F. Goins, PhD; Keith L. Ligon, MD, PhD; Karen O. Dixon, PhD; Ana C. Anderson, PhD; Vijay Kuchroo; Antonio E. Chiocca, MD, PhD |
Combination Immunotherapies |
Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;T cell lineages;Tumor evasion;Tumor microenvironment;Vaccine |
| 897 |
Poster Presentation |
Partners for Bispecifics: combinatorial approaches to augment T-cell function and mitigate exhaustion |
Nora Philipp; Marion Subklewe, Prof. Dr. med.; Amelie Muth; Michael Von Bergwelt-Baildon, MD, PhD; Veit Bücklein |
Combination Immunotherapies |
Bispecifics;Checkpoint blockade;Leukemia/Lymphoma;T cell |
| 898 |
Poster Presentation |
Triple therapy (binimetinib, bevacizumab, pembrolizumab) modulates the tumor immune microenvironment in microsatellite stable colorectal cancer PDXs in a humanized mice model |
Julie Lang, PhD; Adrian Dominquez; Matthew Lewis, MS; Sarah J. Hartmann, MS; Jordi M. Lanis, PhD; Hannah Strassburger; Wells A. Messersmith, MD, FACP, FASCO; S. Lindsey Davis, MD; Alexis D. Leal, MD; Sunnie Kim, MD; Kimberly R. Jordan, PhD; Tyler Friedrich, MD; Christopher Lieu, MD; Todd Pitts, PhD |
Combination Immunotherapies |
Checkpoint blockade;Immune contexture;Immune monitoring;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 899 |
Poster Presentation |
BET inhibitors synergize with anti-PD1 by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells |
Kyle Romine, PhD; Kevin MacPherson; Hyun-jun Cho; Yoko Kosaka, PhD; Patrick Flynn; Kaelan H. Byrd; Jesse L. Coy; Matthew T. Newman; Jamie Scott; Andrew C. Adey; Evan F. Lind, PhD |
Combination Immunotherapies |
Checkpoint blockade;Immune suppression;Leukemia/Lymphoma;T cell |
| 900 |
Poster Presentation |
Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation. |
Sheila Dakhel Plaza, PhD; Giulia Rotta; Samuele Cazzamalli, PhD; Ettore Gilardoni, PhD; Riccardo Stucchi, PhD; Christian Pellegrino, PhD; Jacqueline Mock, PhD; Roberto De Luca, phD; Emanuele Puca, PhD; Dario Neri, Professor |
Combination Immunotherapies |
Antibody;Cytokine;Immune toxicity;Solid tumors;Targeted therapy;Tumor microenvironment |
| 901 |
Poster Presentation |
Inhibition of GAS6/MerTK signaling by novel MerTK antibody, 20A77, exerts significant anti-tumor efficacy with little retinal degeneration in mice |
Atsushi Sawada; Masayoshi Toyoura; Aki Takaiwa; Toshikazu Inoue; Koji Nakamura |
Combination Immunotherapies |
Antibody;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 902 |
Poster Presentation |
NKX019, an Off-the-Shelf CD19 CAR-NK Cell, mediates improved anti-tumor activity and persistence in combination with CD20-directed therapeutic mAbs |
Mira Tohmé, PhD; Tina Davis, MS; Max Zhang; Hadia Lemar; Bao Duong, PhD; Joanne Tan, PhD; James B. Trager, PhD |
Combination Immunotherapies |
CAR T cells;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy |
| 903 |
Poster Presentation |
APR-246 induces an increase in tumor immunogenicity in a p53 independent manner |
Divya Venkatesh, Ph.D.; Judith Michels, MD PhD; Cailin Lu, MD; Sadna Budhu, PhD; Mariam M. George, PhD; Ouathek Ouerfelli, PhD; Lars Abrahmsen, PhD; Roberta Zappasodi, PhD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD |
Combination Immunotherapies |
Antigen presenting cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 904 |
Poster Presentation |
LDH inhibition improves response to CTLA-4 blockade by enhancing effector T cell activity and impairing regulatory T cell suppression |
Svena Verma, BS; Inna Serganova, PhD; Sadna Budhu, PhD; Lauren Dong, BS; Levi M. Mangarin, BS; Myat K. Ko; Ronald Blasberg; Roberta Zappasodi, PhD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD |
Combination Immunotherapies |
Checkpoint blockade;Metabolism;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 905 |
Poster Presentation |
Broad anti-tumor activity of a potent and selective small molecule antagonist of PD-L1 ABSK043 in combination with other agents in preclinical models |
Haiyan Ying, PhD; Yongxian Zhang; Fei Yang; Wenqun Xin; Jie Wang; Jie Zhang; Zhui Chen |
Combination Immunotherapies |
Checkpoint blockade;Chemotherapy;Immune suppression |
| 906 |
Poster Presentation |
Telomere dysfunction mediates anti-tumor immunity in small cell lung cancer |
Mingrui Zhu, B.S.; Buse Eglenen-Polat, M.D.; Matthew Bender, B.S.; Ilgen Mender, Ph.D.; Silvia Siteni, Ph.D.; Benjamin Drapkin, M.D., Ph.D.; Jerry Shay, Ph.D.; Esra Akbay, PhD |
Combination Immunotherapies |
Checkpoint blockade;Coinhibition;T cell;Targeted therapy |
| 907 |
Poster Presentation |
Blockade of VEGF, Angiopoietin-2, and PD1 reprograms dysfunctional endothelial cells in glioblastoma to quasi-antigen-presenting cells |
Zohreh Amoozgar, PharmD, PhD; Jun Ren; Nancy Wang; Patrik Andersson; Gino Ferraro; Shanmugarajan Krishnan; Pin-Ji Lei; Sonu Subudhi; Kosuke Kawaguchi; Rong En Tay; Igor L. Gomes-Santos; Peigen Huang; Hye-Jung Kim; Dai Fukumura; Rakesh K. Jain, PhD |
Combination Immunotherapies |
Angiogenesis;Antigen presenting cells;Solid tumors;T cell;Tumor antigens |
| 908 |
Poster Presentation |
Tumor-intrinsic p38 signaling as a therapeutic target to overcome non-T cell-inflamed tumors and immunotherapy resistance |
Rebekah Dadey, PhD; Shannon Winski, PhD; Patrice A. Lee, PhD; Sarah Brodeur; Tullia Bruno, PhD; Heath Skinner, PhD; Robert L. Ferris, MD, PhD; Jason J. Luke, MD; Riyue Bao, PhD |
Combination Immunotherapies |
Bioinformatics;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 909 |
Poster Presentation |
Overcoming resistance to NK-mediated lysis in enzalutamide-resistant prostate cancer cells |
Madeline Dahut, BS; Kristen N. Fousek, PhD; Lucas A. Horn, PhD; Haiyan Qin; Jeffrey Schlom, PhD; Claudia M. Palena, PhD |
Combination Immunotherapies |
NK/NKT cell;Solid tumors;Tumor evasion;Tumor microenvironment |
| 910 |
Poster Presentation |
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer |
Liya Ding; Qiwei Wang; Antons Martincuks; Michael J. Kearns; Tao Jiang; Ziying Lin; Xin Cheng; Changli Qian; Hye-Jung Kim; Inga-Maria Launonen; Anniina Färkkilä; Thomas M. Roberts; Joyce F. Liu; Panagiotis A. Konstantinopoulos; Ursula A. Matulonis, MD; Hua E. Yu, PhD; Jean Zhao, PhD |
Combination Immunotherapies |
Antigen presenting cells;Checkpoint blockade;Chemokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment |
| 911 |
Poster Presentation |
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice |
Xinyue Dong; Jun Ren; Zohreh Amoozgar, PharmD, PhD; Meenal Datta; Somin Lee; Sylvie Roberge; Mark Duquette; Dai Fukumura; Rakesh K. Jain, PhD |
Combination Immunotherapies |
Adoptive immunotherapy;Angiogenesis;CAR T cells;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 912 |
Poster Presentation |
Epigenetic remodeling enhances therapeutic responses to STING agonism in vivo |
Rana Falahat, PhD; Anders Berglund, PhD; Patricio Perez-Villarroel; Shari Pilon-Thomas, PhD; Glen N. Barber, PhD; James J. Mule, PhD |
Combination Immunotherapies |
Epigenetics;Immune adjuvant;Immune suppression;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 913 |
Poster Presentation |
Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab. |
Heather Torrey, PhD; Walead Ebrahimizadeh, PhD; Valarmathy Kaliaperumal, MSc; Aurelio S. Lobo, MSc; Barry Kennedy, PhD; Tran Ngo, BSc; Lisa D. MacDonald, MSc; Stephan Fiset, MSc, MBA; Jeremy R. Graff, PhD; Heather A. Hirsch |
Combination Immunotherapies |
B cell;Gene expression;Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor microenvironment;Vaccine |
| 914 |
Poster Presentation |
Regulating negative immune regulators to enhance immune checkpoint blockade antitumor potential |
Yared Hailemichael, PhD; Glenn Winn; Michael A. Davies, MD, PhD |
Combination Immunotherapies |
Checkpoint blockade;Chemokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor microenvironment;Tumor stroma |
| 915 |
Oral Presentation |
Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 blockade therapy in small cell lung cancer |
Evelyn M. Nguyen, BA; Andrew Chow, MD, PhD; Charles M. Rudin, MD, PhD; Triparna Sen, PhD; Hirokazu Taniguchi, MD, PhD |
Combination Immunotherapies |
Checkpoint blockade;Epigenetics;Targeted therapy |
| 916 |
Poster Presentation |
Acquired resistance to immune checkpoint blockade by phenotypic plasticity of melanoma |
Emily J. Robitschek, BS; Arnav Mehta, M.D., Ph.D.; Jia-Ren Lin, Ph.D.; Dennie Frederick; Alvin Shi, PhD; Ana B. Larque, MD, PhD; Benchun Miao, Ph.D; Rumya Raghavan; Tatyana Sharova; John Shin, M.D.; Manolis Kellis, Ph.D; Nir Hacohen, PhD; Keith Flaherty, MD; Genevieve M. Boland, MD, PhD; Ivan Chebib, MD; David Liu, MD, MPH, MS; Ryan J. Sullivan, MD |
Combination Immunotherapies |
Bioinformatics;Checkpoint blockade;Epigenetics;Gene expression;Immune contexture;Tumor evasion;Tumor microenvironment |
| 917 |
Poster Presentation |
Reversing the immune-excluded ('cold') tumor immune microenvironment in oral squamous cell carcinoma |
Yewen Shi, MD PhD; Alanis E. Rodriguez-Rosario; Tongxin Xie; Frederico O. Gleber-Netto; Curtis R. Pickering; Abdullah A. Osman; Andrew Sikora, MD, PhD; Jeffrey N. Myers, MD; Roberto Rangel, PhD |
Combination Immunotherapies |
Checkpoint blockade;Chemokine;Cytokine;Gene expression;Immune suppression;Inflammation;Monocyte/Macrophage;Solid tumors;Tumor evasion;Tumor microenvironment |
| 918 |
Poster Presentation |
Treatment-related adverse event (TRAE)-related discontinuation rate of immunotherapy alone (IO-only) compared to immunotherapy combined with chemotherapy (chemo-IO): a meta-analysis |
Seunghwan Shin, MD; Sumin Lee; Huijeong Kim; Chiyoon Oum; SooIck Cho; Yoojoo Lim; Ken Nesmith; Chan-Young Ock, MD, PhD |
Combination Immunotherapies |
Checkpoint blockade;Immune toxicity |
| 919 |
Poster Presentation |
Acute Respiratory Failure and the Risk Immunotherapy Related Pneumonitis during the Covid Pandemic |
Scott Amrhein, MD; Andrew Faucheux, MD; Lara Khoury, MD; John Kalada, MD; Greg Russell, MS; Thomas W. Lycan, Jr., DO |
COVID and Immunotherapy |
COVID and Immunotherapy;Immune toxicity |
| 920 |
Poster Presentation |
Alteration of T cell responses against SARS-CoV-2 omicron variant after vaccination with mRNA booster in lung cancer patients |
Karthik Chakravarthy, BS; No-Joon Song, PhD; Chelsea M. Bolyard; Kelsi Reynolds; Kevin P. Weller; Sarah Reisinger; Yi Wang; Anqi Li, MD; Mark P. Rubinstein, PhD; Peter Shields, MD; Zihai Li, MD, PhD |
COVID and Immunotherapy |
Checkpoint blockade;COVID and Immunotherapy;Solid tumors;T cell;T cell lineages |
| 922 |
Poster Presentation |
Effect of COVID-19 vaccination status on adverse events and outcomes in advanced non-small cell lung Cancer (aNSCLC) patients Treated with Immunotherapies |
Rohini George, PhD; Babu Narayanan, PhD; Smita Agrawal, PhD |
COVID and Immunotherapy |
COVID and Immunotherapy;Vaccine |
| 923 |
Poster Presentation |
Deep single-cell, proteogenomic insights from SARS-CoV-2 infected lung tissues |
Arutha Kulasinghe; Chin Wee Tan; Ning Liu; James Monkman; Emily Killingbeck; Youngmi Kim, PhD; Liuliu Pan, PhD; Tony Blick; Dharmesh Bhuva; Kristen Feher; Michael Leon; Mark Gregory; Kirsty Short, PhD; Fernando Guimaraes; Michael Rhodes, PhD; Gabrielle Belz; Melissa Davis |
COVID and Immunotherapy |
Biomarkers;COVID and Immunotherapy;Gene expression;Immune monitoring;Proteomics |
| 924 |
Poster Presentation |
Barcode Enabled Antigen Mapping (BEAM) and Single-Cell sequencing enables next-generation systems immunology analysis of the post-COVID-19 immune landscape |
Peter Finnegan, BS; Bruce Adams, PhD; Daniel Reyes, MS; Sean Marrache, PhD; Payam Shahi, PhD; FuNien Tsai, PhD; Thomas Vollbrecht, PhD; Micheal Stubbington, PhD |
COVID and Immunotherapy |
B cell;COVID and Immunotherapy;Gene expression;T cell;Targeted therapy |
| 925 |
Poster Presentation |
PhenoComb, a tool for evaluating complex phenotypes in high-dimension cytometry datasets. |
Ann M. Strange; David M. Woods, PhD; Brian Thompson; Carol M. Amato, MS; Paulo E. Burke |
Data Sharing, Handling and Access |
Bioinformatics |
| 926 |
Poster Presentation |
Evaluating diverse deconvolution methods for tumor spatial transcriptomic datasets |
Guangyuan(Frank) Li, BS; Amir Bayegan; Joon Sang Lee, PhD; Donald G. Jackson, PhD; Jack Pollard, PhD |
Data Sharing, Handling and Access |
Bioinformatics;Gene expression;Systems biology;Tumor microenvironment |
| 927 |
Poster Presentation |
Streamlining cancer immunotherapy research with the CRI iAtlas data resource and web portal |
Vésteinn Thorsson; Carolina Heimann; Andrew E. Lamb; David L. Gibbs; Dante Bortone; Sarah Dexheimer; Steven Vensko; Yooree Chae; Ilya Shmulevich; Benjamin G. Vincent; James A. Eddy |
Data Sharing, Handling and Access |
Bioinformatics;Checkpoint blockade;Gene expression;Immune contexture;Systems biology;Tumor microenvironment |
| 928 |
Poster Presentation |
Standardizing the analysis of spatial imaging features in tumor samples |
Jason L. Weirather, PhD; Ian Dryg, PhD; Madison Turner; Ann-Elizabeth Le, MS; Anne E. Carlisle, PhD; Kathleen L. Pfaff, PhD; F. Stephen Hodi, Jr., MD; Scott J. Rodig, MD, PhD |
Data Sharing, Handling and Access |
Bioinformatics;Tumor microenvironment;Tumor stroma |
| 929 |
Poster Presentation |
The Data Management and Resource Sharing Center for the Cancer Moonshot Immuno-Oncology Translational Network |
Alan D. Hutson, PhD; Himangi Marathe, PhD; Martin Morgan; Kunle Odunsi, MD PhD; Song Liu, PhD |
Data Sharing, Handling and Access |
Adoptive immunotherapy;Bioinformatics;Biomarkers;CAR T cells;Gene expression;Systems biology;Tumor microenvironment |
| 930 |
Poster Presentation |
Provider insights on managing patients on immunotherapy, barriers to clinical trials, and biomarker testing preferences |
Tariqa Ackbarali, MS, PhD; Joel Neal, MD, PhD; Yelena Janjigian, MD; Michael J. Overman, MD |
Education and Treatment Management |
Biomarkers;Checkpoint blockade;Clinical trial;Immune toxicity;Solid tumors |
| 931 |
Poster Presentation |
Targeting the lymphocyte-activation gene-3 (LAG-3) immune checkpoint in patients with cancer: awareness and confidence among oncology healthcare professionals (HCP) |
Marie N. Becker, PhD; Timothy A. Quill, PhD; Tian Zhang, MD; Evan J. Lipson, MD |
Education and Treatment Management |
Checkpoint blockade;Solid tumors |
| 932 |
Poster Presentation |
Immunotherapy efficacy and tolerability in advanced hepatocellular carcinoma (HCC) in a diverse and underserved population in the United States - Importance of baseline liver function and screening |
Fernand Bteich, MD; Kush Desai; Chenxin Zhang; Charlotte McGuckin; John Yan, MD; Sharmin Sultana; Lawrence Leung, PhD; Andreas Kaubisch, MD; Milan Kinkhabwala, MD; Sarah Bellemare, MD; Adebola Adedimeji, Ph.D., M.B.A., M.P.H., M.S.; Clara Tow; Yvonne M. Saenger, MD |
Education and Treatment Management |
Checkpoint blockade;Clinical study;Immune toxicity;Solid tumors |
| 933 |
Poster Presentation |
Real-world treatment patterns and clinical outcomes in patients with metastatic NSCLC after receiving first-line pembrolizumab with pemetrexed/platinum chemotherapy in The US Oncology Network |
Jerome H. Goldschmidt, MD; Srinivas Annavarapu, MBBS, PhD; Divea Venkatasetty, MPH; Melissa L. Santorelli, PhD, MPH; Thomas Burke, PharmD, PhD; Nathan A. Pennell, MD, PhD |
Education and Treatment Management |
Checkpoint blockade |
| 934 |
Poster Presentation |
Immunotherapy-Based Strategies for Advanced Non-Small Cell Lung Cancer: Identifying and Reducing Clinician Knowledge Gaps with Online Education |
Elizabeth J. Heller, PhD; Keira P. Smith; Eden ED. Maack, PhD; Lyn Brook; Sarah A. Williams, MAT; Beth Sandy, MSN, CRNP |
Education and Treatment Management |
Checkpoint blockade;Immune toxicity;Solid tumors |
| 935 |
Poster Presentation |
A Case Report of Pediatric Adenoviral Reactivation after CAR T-cell Therapy |
Jimmy Maiarana, MD; Saara Kaviany, DO; Jim Connelly, MD; Carrie Kitko, MD; Richard H. Ho, MD |
Education and Treatment Management |
CAR T cells;Clinical study;Immune monitoring;Immune suppression;Immune toxicity;Leukemia/Lymphoma;Pediatric tumors |
| 936 |
Poster Presentation |
Assessing educational needs for immune-related adverse events curriculum in clinical practice |
Gong He, MD; Austin Wesevich, MD, MPH; Pankti Reid, MD, MPH |
Education and Treatment Management |
Immune toxicity;Solid tumors |
| 937 |
Poster Presentation |
Post-immunotherapy survivorship in advanced melanoma (aMEL): routine versus symptom-based imaging surveillance, a retrospective review in a large integrated healthcare network, Kaiser Permanente Northern California (KPNC) |
Juraj Kavecansky, Md; Richie H. Xu; Lue-Yen Tucker; Jahan Tavakoli; Alexander Menter; Thach-Giao Truong |
Education and Treatment Management |
Checkpoint blockade;Epidemiology;Immune adjuvant;Solid tumors |
| 939 |
Oral Presentation |
Augmentation of CD8 T cell memory via CDK4/6 inhibition can be sequentially combined with PD-1 blockade to avoid toxicities |
Lestat Ali, MD; Ana Garrido-Castro, MD; Sara Tolaney; Stephanie Dougan, PhD |
Immune Cell Types and Biology |
Adoptive immunotherapy;Bioinformatics;Checkpoint blockade;Clinical trial;Immune toxicity;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 940 |
Poster Presentation |
siRNA screen of upregulated genes identifies targets for a multiantigen polyepitope vaccine to prevent HNSCC |
Fnu Alka, Ph.D.; James Annis; Brady M. Bernard, PhD; Sasha E. Stanton, MD, Ph.D. |
Immune Cell Types and Biology |
Carcinogenesis;Immune monitoring;RNA;T cell;Tumor antigens;Vaccine |
| 941 |
Poster Presentation |
Botensilimab modulates innate and adaptive gene expression programs resulting in superior immune stimulation relative to a first-generation anti-CTLA-4 antibody |
Shanmugarajan Krishnan, PhD; Jacky Chow, PhD, MS; Kah Teong Soh, PhD; Kayla Ostergard; Christopher MacDermaid; Marc Van Dijk; Dennis Underwood; Dhan Chand, PhD; Cailin Joyce, PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Bioinformatics;Biomarkers;Checkpoint blockade;Dendritic cell;Gene expression;Myeloid cells;Systems biology |
| 942 |
Poster Presentation |
Flow cytometry immunophenotyping of neck lymph nodes sampled by fine needle aspiration (FNA) in patients suffering from advanced cutaneous squamous cell carcinoma: a pilot study |
Vilma Lagebro; Krzysztof Piersiala; Gregori Margolin, MD PhD; Susanna Kumlien Georén, PhD; Lars-Olaf Cardell, Professor, Senior Physician |
Immune Cell Types and Biology |
Checkpoint blockade;Immune monitoring;Immune suppression;T cell;T cell lineages |
| 943 |
Poster Presentation |
Harnessing Anti-Tumor Metabolic Sensing Switch GPR84 on Macrophages for Cancer Immunotherapy |
Gang Xin; Ruohan Zhang; Bao Zhao; Cankun Wang; Wantong Li; Nuo Sun; Qin Ma; Jianying Li, MS; Haitao Wen; William Carson, III; Zihai Li, MD, PhD; Anjun Ma |
Immune Cell Types and Biology |
Bioinformatics;Monocyte/Macrophage;Myeloid cells;Targeted therapy |
| 944 |
Oral Presentation |
Targeting of Notch ligand Jagged2 in lung cancer cells drives anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages |
J. Mandula; Rosa Sierra-Mondragon; Darwin C. Chang; Rachel Jimenez; Eslam Mohamed; Jimena Trillo; Alyssa Obermayer; Carlos Moran-Segura; Das Satyajit; Julio Vazquez-Martinez; Timothy Shaw; Jose Conejo-Garcia, MD, PhD; Paulo Rodriguez |
Immune Cell Types and Biology |
Adoptive immunotherapy;Antigen presenting cells;Bioinformatics;Gene expression;Monocyte/Macrophage;RNA;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 945 |
Poster Presentation |
Overlapping and Distinct Patterns of LILRB Receptors Support Complementary Targeting Approach in Cancer |
Jeffrey Smith; Amy Mueller; Vikki Spaulding; Michelle Priess; Krithi Bala, PhD; Andrew Dunn; Sarah Jaffe; Morgan Thompson; Jean-Christophe Pignon; Alexa Diiorio; Andre Cunha, PhD; Heather Condurso; Kristin O'Malley, BSc; Olivia Petrillo, MS; Prashanna Balaji Venkatasubramanian; Geneva Young; Christina Meyer, PhD; Michael Meehl, PhD; Katalin Kis-Toth; Monica Gostissa, PhD; Dmitri Wiederschain, PhD; Ben Umiker, PhD; Yasmin L. Hashambhoy-Ramsay, PhD |
Immune Cell Types and Biology |
Bioinformatics;Gene expression;Immune contexture;Monocyte/Macrophage;Myeloid cells;Proteomics;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 946 |
Poster Presentation |
Dissecting myeloid cell-mediated mechanisms of resistance to immune checkpoint blockade in bladder cancer |
Michelle Tran, MD PhD Candidate; Adam M. Farkas, PhD; Kristin G. Beaumont, PhD; Amir Horowitz, PhD; John Sfakianos; Matthew D. Galsky, MD; Nina Bhardwaj, MD, PhD |
Immune Cell Types and Biology |
Checkpoint blockade;Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;Tumor microenvironment |
| 947 |
Poster Presentation |
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche |
Judith Agudo, PhD; Pilar Baldominos |
Immune Cell Types and Biology |
Adoptive immunotherapy;Dendritic cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 948 |
Poster Presentation |
Developing engineered animal models to investigate tumor-specific T cell responses and immune-related adverse events after immunotherapy |
Martina Damo; Noah Hornick; Nikhil Joshi, PhD |
Immune Cell Types and Biology |
B cell;T cell;T cell lineages;Tumor microenvironment |
| 949 |
Poster Presentation |
INOVATIVE IN VIVO (IN OVO) CAM MODEL TO PREDICT EFFICACY AND MODE OF ACTION OF A NEW ANTITUMOR VACCINE STC-1010 ON HUMAN COLORECTAL ADENOCARCINOMA |
Yan Wang; Corinne Tortorelli, Pharm.D, Ph.D; Arnaud Peyronnier; Benoit Pinteur; Lionel Chalus; Paul Bravetti; Jean Viallet; François Ghiringhelli |
Immune Cell Types and Biology |
Biomarkers;Cytokine;Dendritic cell;Immune monitoring;Neoantigens;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 950 |
Poster Presentation |
TNFR2 HuGEMMTM murine model for evaluation of hTNFα-hTNFR2 signaling effect on induced regulatory T cell differentiation |
Demi Liu; Xuefei Yan |
Immune Cell Types and Biology |
Adoptive immunotherapy;Antibody;Immune suppression;T cell |
| 951 |
Oral Presentation |
Spatial Atlases of Immunological Development within the Lymph Node |
Tyler D. Hether, PhD; Stephanie Zimmerman, PhD; Zachary Lewis, PhD; Shanshan He, MD, PhD; Liang Zhang, PhD; Kathy Ton; Liuliu Pan, PhD; Wei Yang, PhD; Stefan Phelan, MS; Charles Glaser; Andy Nam; Emily Brown; Michael Patrick; Gary Geiss, PhD; Sarah E. Church, PhD; Michael Rhodes, PhD; Yan Liang, MD PhD; Jason W. Reeves, PhD; Joseph M. Beechem, PhD |
Immune Cell Types and Biology |
Adoptive immunotherapy;Antigen presenting cells;B cell;Costimulation;Gene expression;Monocyte/Macrophage;RNA;T cell |
| 952 |
Poster Presentation |
The temporal contribution of interferon-γ in driving T-cell exhaustion and response to immune checkpoint blockade. |
Vaishali Aggarwal, PhD; Chang Liu, PhD; Lawrence P. Andrews, PhD; Madhu Malinee; Carly Cardello; Creg Workman, PhD; Dario A. Vignali, PhD |
Immune Cell Types and Biology |
Checkpoint blockade;Cytokine;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 953 |
Poster Presentation |
Treatment with SQ3370, a doxorubicin-based therapeutic, corresponds with immunomodulation of the tumor microenvironment |
Masa Aleckovic, PhD; Sangeetha Srinivasan, PhD; Jesse M. McFarland, PhD; Leslie Priddy, B.S; Matthew Tso, MS; Jose M. Mejia Oneto, MD, PhD |
Immune Cell Types and Biology |
Chemotherapy;Clinical trial;Dendritic cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 954 |
Poster Presentation |
SQ2270, a Novel MMAE-based Therapeutic, Promotes Tumor Growth Inhibition and Extensive Immune Cell Infiltration in the RENCA Cancer Model |
Masa Aleckovic, PhD; Sangeetha Srinivasan, PhD; Jesse M. McFarland, PhD; Leslie Priddy, B.S; Matthew Tso, MS; George Coricor, PhD; Jose M. Mejia Oneto, MD, PhD |
Immune Cell Types and Biology |
T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 955 |
Poster Presentation |
Gingivo-buccal oral cancer: Inferring prognosis from immune contextures of tumor and surrounding margin. |
Ankita Chatterjee, PhD; Partha P. Majumder; Nidhan K. Biswas; Arindam Maitra; Arnab Ghosh |
Immune Cell Types and Biology |
Gene expression;Immune contexture;Immune suppression;Solid tumors;Tumor microenvironment |
| 956 |
Oral Presentation |
Spatial clustering reveals immune hub interaction with reservoir of stem-like CD8 T cells and predicts immunotherapy response in lung cancer patients. |
Jonathan H. Chen; Linda T. Nieman; Maxwell Spurrell; Mari Mino-Kenudson, MD; Justin F. Gainor, MD; Nir Hacohen, PhD |
Immune Cell Types and Biology |
Immune contexture;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 957 |
Poster Presentation |
Assessment of the spatial distribution and cell-to-cell interactions into the tumor micro-environment, within and between serial slides stained with Brightplex, a sequential chromogenic multiplex assay |
Aurelie Collignon; Alboukadel Kassambara; Alex Trinh; Maité Chamourin; Georgia Culley; Marion Olive; Clemence Jaume; Assil Benchaaben; Jerome Galon; Jacques Fieschi, PhD |
Immune Cell Types and Biology |
Biomarkers;Immune contexture;Immune monitoring;Immune suppression;Immunoscore;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 959 |
Poster Presentation |
PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors |
Rebekka Duhen, PhD; Olivier Fesneau, PhD; Kimberly Samson; Alexandra Frye; Michael F. Beymer; Venkatesh Rajamanickam; David Ross; Eric Tran, PhD; Brady M. Bernard, PhD; Andrew D. Weinberg, PhD; Thomas Duhen, PhD |
Immune Cell Types and Biology |
Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor microenvironment |
| 960 |
Poster Presentation |
TT-816, a novel small molecule immune checkpoint inhibitor targeting cannabinoid CB2 receptor, stimulates innate and adaptive immunity for cancer therapy |
Peidong Fan, PhD; Elfatih Elzein, PhD; Lina Yao, MD, PhD |
Immune Cell Types and Biology |
Checkpoint blockade;Dendritic cell;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment |
| 961 |
Poster Presentation |
Tumor-infiltrating mucosal-associated invariant T cells (MAIT) from patients with pancreatic cancer recognize shared tumor antigens in an MR1-restricted fashion |
Jéssica O. Kamiki, MSc; Patrícia A. António; Rodrigo Eduardo; Sara Cascais; Bernardo Marinheiro; Andreia Maia; Eric De Sousa; Joana R. Lerias, DVM, PhD; Carolina M. Gorgulho; Mireia Castillo-Martin; Markus Buechler; Antonio Beltran; Carlos Carvalho, MD; Ridong Chen; Sam Jeong; Markus J. Maeurer, MD, PhD, FRCP(London) |
Immune Cell Types and Biology |
Adoptive immunotherapy;Gene expression;Immune monitoring;Inflammation;Microbiome;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 962 |
Poster Presentation |
IFI16 promotes immune responses through IFN-γ pathway activation in metastatic cutaneous melanomas |
Yuta Kobayashi, MD, PhD; Matias A. Bustos, PhD; Qiang Yu, PhD; Dave Hoon, MSc, PhD |
Immune Cell Types and Biology |
Chemokine;Cytokine;Gene expression;Immune suppression;Monocyte/Macrophage;RNA;Tumor microenvironment |
| 963 |
Poster Presentation |
Significantly different immune microenvironment between triple-negative breast cancer with and without neoadjuvant chemotherapy through multiplex immunohistochemistry |
Miseon Lee, MD.PhD, MD,PhD; Hyun Lee, MD; Gyungyub Gong; Hee Jin Lee |
Immune Cell Types and Biology |
Tumor microenvironment |
| 964 |
Poster Presentation |
Dynamic immune landscapes during melanoma progression reveal a role for endogenous opioids in driving T cell dysfunction |
Davide Mangani; Linglin Huang; Meromit Singer; Ruitong Li; Rocky Barilla; Giulia Escobar, PhD; Katherine Tooley; Hanning Cheng; Conor Delaney; Kathleen Newcomer; Jackson Nyman; Nemanja Marjanovic; James Nevin; Orit Rozenblatt-Rosen; Vijay Kuchroo; Aviv Regev; Ana C. Anderson, PhD |
Immune Cell Types and Biology |
Checkpoint blockade;Immune suppression;Immune tolerance;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 965 |
Oral Presentation |
Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway to generate TCF1+ progenitor CD8 T cells to improve efficacy of PD-1 checkpoint blockade. |
Geoffrey J. Markowitz, PhD; Yi Ban, Ph.D.; Diamile Tavarez; Michael Crowley, Ph.D.; Liron Yoffe, Ph.D.; Mitchell Martin; Tito Sandoval, Ph.D.; Dingcheng Gao, Ph.D.; Juan Cubillos-Ruiz, Ph.D.; Timothy E. McGraw, Ph.D.; Nasser K. Altorki, M.D.; Vivek Mittal, Ph.D. |
Immune Cell Types and Biology |
Adoptive immunotherapy;Checkpoint blockade;Gene expression;Metabolism;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 966 |
Poster Presentation |
Multispectral Immunohistochemistry reveals an immunosuppressive tumour microenvironment in Esophageal Adenocarcinoma |
Charles J. Rayner, MB BS MRCS; Tyler F. Wooldridge, BSc (Hons); Sunny Sunshine; Izhar Bagwan, MBBS, MD, FRCPath; Shaun R. Preston, MD FRCS; Hardev S. Pandha, PhD, FRCP, FRACP, FR; Nima Abbassi-Ghadi, PhD FRCS; Nicola E. Annels, BSc, PhD |
Immune Cell Types and Biology |
Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors;Surgery;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 967 |
Poster Presentation |
Unfavorable neoantigen architectures blunt anti-tumor T cell responses in a mouse model of lung adenocarcinoma |
Malte Roerden, MD, PhD; Kim B. Nguyen, B.A.; Nory G. Klop-Packel; Christopher J. Copeland; Nishant Singh; Michael Birnbaum, PhD; Stefani Spranger, PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor evasion |
| 968 |
Poster Presentation |
Improved antitumoral activity of antigen-specific CD8+T cells in comparison to unspecific activated CD8+T cells in a 2D T cell killing assay targeting HER2+ breast cancer |
Ina Rohleff; Matthias Bleisch; Kanstantsin Lashuk; Julia Schueler, DVM PhD |
Immune Cell Types and Biology |
Checkpoint blockade;Solid tumors;T cell;Tumor antigens |
| 969 |
Poster Presentation |
Next-generation immunotherapy using patient-derived APC |
Zhen Bian, Ph.D; Lei Shi, PhD; Harry Stylli; Yuan Liu; Jane Zen |
Immune Cell Types and Biology |
Antigen presenting cells;Myeloid cells |
| 970 |
Poster Presentation |
Exhausted T cells are characterized by inappropriate lipid accumulation |
Kellie Spahr, BS; Nicole E. Scharping, PhD; Greg M. Delgoffe, PhD |
Immune Cell Types and Biology |
Immune suppression;Metabolism;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 971 |
Poster Presentation |
VISTA regulates the differentiation and function of myeloid-derived suppressor cells |
Keman Zhang, PhD; Amin Zekeri, PhD; Juan Dong, PhD; Sarah Stone; Li Wang, PhD |
Immune Cell Types and Biology |
Gene expression;MDSC;Monocyte/Macrophage;Myeloid cells |
| 972 |
Poster Presentation |
Enrichment of atypical memory double negative (CD27- IgD-) tumour infiltrating B cells following neoadjuvant chemotherapy for early-stage breast cancer |
Esme Carpenter, MRes; Thanussuyah Alaguthurai; Farhana Hossain; Rosalind Graham; Helen Kakkassery, MRes; Sean Keane; Sheeba Irshad, MD PhD |
Immune Cell Types and Biology |
B cell;Chemotherapy;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 973 |
Poster Presentation |
Extrafollicular Expansion and Differentiation of B Cells Drives Anti-Tumor Responses in Metastatic Cancer |
Noor E. Nader, BS; Dongyan Liu; Hye Mi Kim, BS; Ayana Ruffin, PhD; Sheryl R. Kunning; Xiaron Zhang, MD, MS; Daniel Dunlap, MD; Roy Semaan, MD; Rajeev Dhupar, MD, MBA, FACS; Adam C. Soloff, PhD; Tullia Bruno, PhD |
Immune Cell Types and Biology |
Antibody;Antigen presenting cells;B cell;Solid tumors;Tumor antigens;Tumor microenvironment |
| 974 |
Poster Presentation |
Regulatory B cells producing IL-10 are increased in human tumour draining lymph nodes. |
Krzysztof Piersiala, MD; Krzysztof Piersiala; Pedro Farrajota Neves da Silva; Vilma Lagebro; Gregori Margolin; Susanna Kumlien Georén, PhD; Lars Olaf Cardell |
Immune Cell Types and Biology |
B cell;Immune monitoring;Immune suppression;Solid tumors |
| 975 |
Poster Presentation |
Characterization of signaling and metabolic differences between γδ and αβ CAR T cells |
Xiomar E. Bustos, MS; Daniel Abate-Daga, PhD; Leticia Tordesillas, PhD |
Immune Cell Types and Biology |
Adoptive immunotherapy;CAR T cells;Metabolism;Proteomics;T cell;T cell lineages |
| 976 |
Poster Presentation |
T-cell metabolic activity is impacted by the nutrient composition within the tumor microenvironment |
Jesse Bucksot, PhD; Dorys A. Lopez-Ramos, PhD; Tushar Pandey; Anuja K. Antony, MD; Joseph R. Peterson, PhD; Daniel J. Cook |
Immune Cell Types and Biology |
Metabolism;Systems biology;T cell;Tumor microenvironment |
| 977 |
Poster Presentation |
Highly cytotoxic resilient CD8+ T cells avoid exhaustion by lowering ROS through ME1 upregulation |
Joanina K. Gicobi, BS; Haidong Dong, MD, PhD; Cindy Liu |
Immune Cell Types and Biology |
Checkpoint blockade;Metabolism;T cell |
| 978 |
Poster Presentation |
Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity |
Santiago Acero-Bedoya, MS; Thomas F. Gajewski, MD, PhD; Emily F. Higgs, PhD |
Immune Cell Types and Biology |
Dendritic cell;Genetic polymorphism;Myeloid cells;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 979 |
Poster Presentation |
Compound screen identifies inhibitor of apoptosis proteins (IAP) antagonist as an inducer of T cell proliferation after cross-presentation by dendritic cells |
Esmee Hoefsmit, MSc; Paula T. van Royen; Disha Rao; Johanna A. Stunnenberg; Petros Dimitriadis; Cor Lieftink; Ben Morris; Elisa A. Rozeman; Irene L.M. Reijers; Ruben Lacroix; Huma Shehwana; Maarten A. Ligtenberg; Roderick L. Beijersbergen; Daniel S. Peeper; Christian U. Blank |
Immune Cell Types and Biology |
Antigen presenting cells;Checkpoint blockade;Dendritic cell;T cell |
| 980 |
Poster Presentation |
In-depth characterization of cDC1 ex vivo and in vitro models: development and comparison of conventional dendritic cell culture systems for industry |
Anna Licht; Tamera Ashworth; Laura L. Goodfield; Hannah Gardner; Johanna Lahdenranta, PhD; Philip E. Brandish, PhD; Kevin McDonnell, PhD; Nicholas Keen, PhD |
Immune Cell Types and Biology |
Dendritic cell |
| 981 |
Poster Presentation |
Peritumoral stromal remodeling licenses cDC1 through CD40 to elicit T-cell inflammation |
Athanasios Papadas, MD; Alexander P. Cicala; Alejandro Rizo; Chelsea Hope; Katerina Politi, PhD; Christian Capitini, MD; Kristina Matkowskyj; Scott I. Abrams, PhD; Fotis Asimakopoulos, MD PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Dendritic cell;Glycoproteomics;Immune contexture;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 982 |
Poster Presentation |
cDC1 cells are required to sustain CD8 T cell stemness in cancer and for the success at the onset of various immunotherapies. |
Alvaro Teijeira, PhD; Carlos Luri; Saray Garasa, BS; Assunta Cirella; Ignacio I.M. Melero, MD, PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Checkpoint blockade;T cell |
| 983 |
Poster Presentation |
BCL-2 inhibition mediates Treg to TH17 plasticity through inhibition of FOXO1 |
Rosy Liao, BS; Anika T. Thomas-Toth; Joshua McKeever; Andrew Koh, PhD; James L. LaBelle, MD, PhD |
Immune Cell Types and Biology |
Cytokine;Gene expression;Regulatory T cell (Treg cell);T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 984 |
Poster Presentation |
MEK1 within extracellular vesicles inhibits tumor growth by promoting anti-tumor immunity |
Jack D. Bui, MD, PhD; Stephen Searles, PhD; Jarrod Yee, MS; Preston Lee, MS; Christine Caron, MS; Calvin Lee, MS; Irina Matei, PhD; David C. Lyden, MD, PhD |
Immune Cell Types and Biology |
Extracellular vesicles/exosomes;Monocyte/Macrophage;Tumor microenvironment |
| 985 |
Poster Presentation |
Inhibition of fibroblast growth factor receptor 4 (FGFR4) signaling activates tumor interferon (IFN) signaling in hepatocellular carcinoma (HCC) |
Nannan Zhang, PhD; Zhui Chen; Bin Shen; Zhixuan Zhu; Jueping Shi; Jiacheng Zhang; Pan Liang; Jie Wang |
Immune Cell Types and Biology |
Solid tumors;T cell;Targeted therapy;Tumor microenvironment |
| 986 |
Poster Presentation |
Local and lymphoid immune surveillance mechanisms in 'exceptional survivors' of stage IV breast cancers following standard of care chemo- and targeted therapies |
Helen Kakkassery, MRes; Thanussuyah Alaguthurai; Rosalind Graham; Esme Carpenter, MRes; Farhana Hossain; Sean Keane; Sheeba Irshad, MD PhD |
Immune Cell Types and Biology |
Immune monitoring;NK/NKT cell;Solid tumors;T cell;T cell lineages |
| 987 |
Poster Presentation |
Comprehensive immunophenotyping and genomics from single blood tube for T-cell dynamics in clinical trials |
Manling Ma-Edmonds, MS; Gregg Masters; Omar J. Jabado, PhD; Lisa Grimm, MS; Mahesh B. Bachu, PhD; Matthew Loya, BS; Gabrielle Suppa, MS; Jordan M. Blum, PhD; David Soong, PhD; Han Si, PhD; Brandon Higgs; Nicole Bottrel, MS; Erin Henitz, MS; Christopher Chiu, PhD; Kate Sasser; Mark Fereshteh |
Immune Cell Types and Biology |
Bioinformatics;Biomarkers;Clinical trial;Gene expression;Immune monitoring;RNA;Surfaceome;Systems biology;T cell;T cell lineages |
| 988 |
Poster Presentation |
B-Cell Receptor (BCR) Repertoire and Antibody Recognition Analysis of Melanoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB) |
Monika A. Zelazowska, PhD; Somnath Paul, PhD; Joshua B. Plummer; Manoj Chelvanambi, PhD; Beth A. Helmink, MD PhD; Russell G. Witt, MD; Michael G. White, MD; Shalaka R. Lotlikar, PhD; Melissa Simper, PhD; Sarah B. Johnson, MS; Alexandra L. Hebertson; Bin Liu, PhD; Jennifer A. Wargo, MD, MMSc; Kevin McBride, PhD |
Immune Cell Types and Biology |
Antibody;B cell;Bioinformatics;Checkpoint blockade;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 989 |
Poster Presentation |
A luciferase-based method to assess antigen-specific T cell responses and antigen presentation to evaluate immunomodulatory checkpoints and therapeutics |
Jimena Alvarez Freile, MSc; Yuzhu Qi; Lisa Jacob; Maria Franceskin Lobo; Harm Jan Lourens; Gerwin Huls; Edwin Bremer |
Immune Cell Types and Biology |
Antibody;Antigen presenting cells;Checkpoint blockade;Immune monitoring;Immune suppression;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor microenvironment |
| 990 |
Poster Presentation |
Heterogeneity in glioblastoma tumor microenvironment: strategies for cancer-associated fibroblast targeting |
Jonathan Stauber, PHD; Corinne C.R. Ramos, PhD; Sandra Delebecq; Adele Ponzoni; Lisa Guzzi |
Immune Cell Types and Biology |
Biomarkers;Solid tumors;Tumor microenvironment;Tumor stroma |
| 991 |
Poster Presentation |
AB598, a therapeutic anti-human CD39 antibody, binds and inhibits CD39 enzymatic activity in vivo to promote anti-tumor immunity |
Kaustubh Parashar; Julie Clor; Amy E. Anderson, PhD; Urvi Vani; Jaskirat Singh; Enzo Stagnaro; Ferdie Soriano, BS; Angelo Kaplan; Janine Kline; Lisa Seitz, MS; Stephen W. Young; Nigel P. Walker, PhD; Matthew Walters; Ester Fernandez-Salas; Christine Bowman, PhD |
Immune Cell Types and Biology |
Antibody;Antigen presenting cells;Chemotherapy;Cytokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment |
| 992 |
Poster Presentation |
Intratumoral S100A8-to-CD8 ratio in inflamed Merkel cell carcinoma tumors correlates with response to PD-1 pathway blockade |
Shira Tabachnick-Cherny, PhD; Thomas Pulliam; Haroldo J. Rodriguez Chevez, BS; Kimberly S. Smythe, BS; Rima Kulikauskas; Kristina Lachance; Daniel Hippe; Paul T. Nghiem, MD, PhD |
Immune Cell Types and Biology |
Biomarkers;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment |
| 993 |
Poster Presentation |
InteractPrint predicts clinically meaningful interactions between cancer epithelial cells and immune cells: Lessons from a single-cell breast cancer atlas |
Lily Xu, B.A.; Kaitlyn Saunders, B.A.; Hildur Knutsdottir, PhD; Kenian Chen, PhD; Julia Maués; Christine Hodgdon; Evanthia Roussos Torres; Sangeetha M. Reddy; Lin Xu, PhD; Isaac Chan, MD, PhD |
Immune Cell Types and Biology |
Bioinformatics;Tumor microenvironment |
| 994 |
Poster Presentation |
Investigating the ability of tumor cell-derived type I interferon to potentiate anti-ovarian cancer immune responses |
Fiona Chatterjee, BA; Ellen Duong, PhD; Arjun Bhutkar, PhD; Stefani Spranger, PhD |
Immune Cell Types and Biology |
Cytokine;Dendritic cell;Solid tumors;T cell |
| 995 |
Poster Presentation |
V domain immunoglobulin suppressor of T cell activation (VISTA) re-programs macrophage biology and promotes phagocytosis and M2c-differentiation |
Yusheng Lin, PhD candidate; Ghizlane Choukrani; Lena Dubbel; Lena Rockstein; Jimena A. Freile; Yuzhu Qi; Harm Jan Lourens; Nienke Visser; Valerie Wiersma; Hao Zhang; Emanuele Ammatuna; Tom V. Meerten; Gerwin Huls; Edwin Bremer |
Immune Cell Types and Biology |
Cytokine;Immune suppression;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells |
| 996 |
Poster Presentation |
Functional and transcriptomic profiling of myeloid cells in pediatric solid tumors to inform next generation immunotherapy |
Cristina F. Contreras; Sabina Kaczanowska, PhD; Francesca Buffa; Rosandra N. Kaplan, MD |
Immune Cell Types and Biology |
Gene expression;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors |
| 997 |
Poster Presentation |
T cell immunotherapies trigger neutrophils to eliminates heterogenous tumors |
Daniel Hirschhorn; Sadna Budhu, PhD; David Redmond; Jacob Ricca; Billel Gasmi; Mathieu Gigoux, PhD; Cailian Liu, MD; Yanyun Li, PhD MD; Czrina Cortez, BS; David Schroder, MD; Arshi Arora; Travis Hollman, PhD, MD; Lukas kraehenbuehl; Hyejin Choi, PhD; Sara Schad; Isabell Schulze; Rebekka Duhen, PhD; Andrew D. Weinberg, PhD; Andrew Chow, MD, PhD; Mikala Egeblad, PhD; Katherine S. Panageas, PhD; Gabrielle A. Rizzuto; Olivier de Henau; Aliya Holland; Jean Albrengues, PhD; Linda Hamadane; David Ng; Xue-Yan He; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD |
Immune Cell Types and Biology |
Checkpoint blockade;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 998 |
Poster Presentation |
Neutrophil subsets in head and neck cancer |
Sandra SE. Ekstedt, PhD; Krzysztof Piersiala; Magnus Starkhammar, MD; Gregori Margolin, MD, PhD; Susanna Kumlien Georén, PhD; Lars Olaf Cardell, MD, PhD |
Immune Cell Types and Biology |
Granulocyte;Solid tumors;Tumor microenvironment |
| 999 |
Poster Presentation |
Investigating the immunomodulatory role of innate lymphoid cells in epithelial ovarian carcinoma |
Douglas C. Chung, Bsc; Kathrin Warner, PhD; Jehan Vakharia, BSc; SeongJun Han, PhD; Maryam Ghaedi, PhD; Carlos Garcia-Batres, MSc; Nicolas Jacquelot, PhD; Azin Sayad, MSc; Sarah Ferguson, MD, FRCSC; Pamela S. Ohashi, PhD |
Immune Cell Types and Biology |
Bioinformatics;Cytokine;Gene expression;Immune contexture;Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1000 |
Poster Presentation |
Melanoma Lymph Node Metastases are Associated with Hypoxia and Immunologic Dysfunction |
Dustin McCurry, MD; Chistopher Deitrick; Yan Zang; Arivarasan Karunamurthy, MD; Theresa L. Whiteside, PhD; Diwakar Davar, MD; Hassane Zarour, MD; Jason J. Luke, MD; John M. Kirkwood, MD; Riyue Bao, PhD; Yana G. Najjar, MD |
Immune Cell Types and Biology |
Bioinformatics;Checkpoint blockade;Immune suppression;Metabolism;Monocyte/Macrophage;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 1001 |
Poster Presentation |
Immunophenotyping of brain tumors identifies interferon enriched phagocytes in human gliomas |
Pravesh Gupta, PhD; Minghao Dang, Ph.D.; Dapeng Hao, PhD; Krishna Bojja, BS; Tuan M. Tran, PhD; Huma Shehwana, PhD; Carlos Kamiya-Matsuoka, MD; Jianzhuo Li, PhD; Alessandra Audia, PhD; Cynthia Kassab, PhD; Martina Ott, PhD; Joy Gumin, PhD; Sanaalarab Alenazy, PhD; Alicia Goldman, MD; Sameer A. Seth, MD; Atul Maheshwari, MD; Veerakumar Balasubramaniyan, PhD; Brian Vaillant, MD; John F. de Groot, MD; Antonio Iavarone, MD; Frederick F. Lang, MD; Nicholas E. Navin, PhD; Amy B. Heimberger, M.D.; Linghua Wang, PhD; Krishna Bhat, PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Immune contexture;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment |
| 1002 |
Poster Presentation |
Circulating myeloid states induced with anti-PD-1 and GM-CSF combination therapy are associated with treatment resistance in human biliary cancer |
Bridget P. Keenan, MD, PhD; Elizabeth McCarthy; Arielle Ilano; Diamond Luong; Hai Yang; Li Zhang, PhD; Kathryn Allaire; Zenghua Fan, PhD; Tony Li; David S. Lee; Yang Sun, PhD; Alexander Cheung; Hewitt Chang; Brandon Chen; Brenna Sheldon; Robin K. Kelley, MD; Chun Jimmie Ye, PhD; Lawrence Fong, MD |
Immune Cell Types and Biology |
Checkpoint blockade;Monocyte/Macrophage;Solid tumors;T cell |
| 1003 |
Poster Presentation |
Macrophage adhesion to tumor cells positively impacts tumor growth |
Jovan Nikolic, PhD; Joseph Ackerman, PhD; Sarah Taheraly; Thierry Rose, PhD; Ouardia Aït-Mohamed, PhD; Martine Ben Amar, PhD; Jean-François Joanny, PhD; Philippe Benaroch, PhD |
Immune Cell Types and Biology |
Monocyte/Macrophage;Myeloid cells;Tumor microenvironment |
| 1004 |
Poster Presentation |
Signaling pathways inducing tumoricidal phagocytosis in pancreatic cancer |
Li Qiang, Ph.D.; Stephanie Dougan, PhD; Samantha Liu; Gabrielle Ro; Michael Dougan, MD, PhD; Lestat Ali, MD; Patrick Lenehan; Felix Hambitzer |
Immune Cell Types and Biology |
Monocyte/Macrophage;Tumor microenvironment |
| 1005 |
Poster Presentation |
PD-L1 knockout Natural Killer cells as a cellular product for therapeutic use in combination with humanized ADCC-competent anti-PD-L1 |
Tayler J. Croom-Perez, PhD; Jeremiah L. Oyer; Md Faqrul Hasan, Masters; Thomas A. Dieffenthaller; Liza D. Robles-Carrillo; Alicja J. Copik, PhD |
Immune Cell Types and Biology |
Adoptive immunotherapy;Checkpoint blockade;NK/NKT cell |
| 1006 |
Poster Presentation |
Single-cell functional genomics of natural killer cell evasion in blood cancers |
Olli Dufva; Sara Gandolfi; Jani Huuhtanen; Olga Dashevsky; Khalid Saeed; Jay Klievink; Petra Nygren; Jonas Bouhlal; Jenni Lahtela; Anna Näätänen; Bishwa Ghimire; Tiina Hannunen; Pekka Ellonen; Hanna Duàn; Jason Theodoropoulos; Essi Laajala; Jouni Härkönen; Petri Pölönen; Merja Heinäniemi; Shizuka Yamano; Ryosuke Shirasaki; David Barbie; Jennifer Roth; Rizwan Romee; Michal Sheffer; Harri Lähdesmäki; Dean A. Lee; Ricardo De Matos Simoes; Matti Kankainen; Constantine S. Mitsiades; Satu Mustjoki |
Immune Cell Types and Biology |
Adoptive immunotherapy;Biomarkers;Gene expression;Leukemia/Lymphoma;NK/NKT cell;Systems biology;Tumor evasion |
| 1007 |
Poster Presentation |
Microglia recruit and activate natural killer cells to control tumor progression in breast cancer brain metastasis |
Timothy P. McMullen, BA; Aaron Longworth; Dennis Ma; Devon A. Lawson, PhD; Katrina Evans |
Immune Cell Types and Biology |
Bioinformatics;Immune suppression;Myeloid cells;NK/NKT cell;Tumor evasion |
| 1008 |
Poster Presentation |
Cross-Species Characterization of Splenic Natural Killer (NK) Cells Reveals Organ-Specific Heterogeneity with Implications for Cancer Immunotherapy |
Lauren E. Farley, BS; Khurshid Iranpur, BS; Aryana M. Razmara, MS; Sylvia M. Cruz; Marshall Lammers, BS; Cyrus J. Sholevar, MD; Robert M. Rebhun, DVM PhD; Michael S. Kent, DVM; William Culp, VMD; Richard J. Bold, MD; Sean J. Judge, MD; William J. Murphy; Robert J. Canter, MD |
Immune Cell Types and Biology |
NK/NKT cell |
| 1009 |
Poster Presentation |
Knockout of the inhibitory receptor TIGIT enhances anti-tumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-competent TIGIT antibodies |
Md Faqrul Hasan, Masters; Tayler J. Croom-Perez, PhD; Jeremiah L. Oyer; Thomas A. Dieffenthaller; Liza D. Robles-Carrillo; Alicja J. Copik, PhD |
Immune Cell Types and Biology |
Adoptive immunotherapy;Checkpoint blockade;NK/NKT cell |
| 1010 |
Poster Presentation |
A Single-Cell Transcriptomic Atlas of Human NK Cells to Guide Cancer Immunotherapy |
Ryan J. King, PhD; Azim Amirabad, PhD; Amir Bayegan; Joachim Theilhaber; Nicole Acuff; Shannon McGrath; Ziangming Li; Franck Rapaport, PhD; Jack Pollard, PhD; Donald G. Jackson, PhD |
Immune Cell Types and Biology |
Bioinformatics;NK/NKT cell;RNA;Tumor microenvironment |
| 1011 |
Poster Presentation |
Antibody targeting NKG2D ligands MICA/B to unleash anti-tumor immunity of NK and ILC1 cells |
Sizhe Liu, BS; Tyler A. Smith, PhD; Lisha Zhu, PhD; Payal Dhar, PhD; Jennifer D. Wu, PhD |
Immune Cell Types and Biology |
Antibody;Immune contexture;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 1012 |
Poster Presentation |
Fibroblast activation protein regulates human natural killer cell migration. |
Rachael E. Maynard, MD, PhD Candidate; Allison Fitzgerald; Apsra Nasir; Eric Glasgow, PhD; Sandra Jablonski, PhD; Pieter Van Der Veken; Gray Pearson, PhD; Emily Mace, PhD; Louis M. Weiner, MD |
Immune Cell Types and Biology |
NK/NKT cell;Solid tumors |
| 1013 |
Poster Presentation |
Prognostic value of Natural Killer cell activity and derived neutrophils-to-lymphocytes ratio in non-small cell lung cancer patients receiving immune checkpoint inhibitors |
Line Nederby, MSc, PhD; Sara W.C. Wen, MD; Torben S. Hansen, MD; Christa H. Nyhus, MD; Lisbeth Bertelsen, MD; Rikke F. Andersen, MSc, PhD; Anders Jakobsen, MD, DMSc, Professor; Torben F. Hansen, MD, DMSc, Associate Professor |
Immune Cell Types and Biology |
Biomarkers;Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors |
| 1014 |
Poster Presentation |
Complement C3 deficiency increases the anti-tumor immunity of NK cells and controls tumor growth |
Girdhari Lal, PhD; PRADIPTA PAL, M.Sc (Integrated Biotechnology); Sourav Paul; Heikrujam Thoihen Meitei; Praneet Wahi; Arvind Sahu, PhD |
Immune Cell Types and Biology |
Cytokine;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1015 |
Poster Presentation |
Natural Killer cells in immunotherapy-induced MHC-I tumor escape |
Eric Miao; Jennifer Poursine-Laurent; Kathleen CF. Sheehan; Robert D. Schreiber, PhD; Wayne M. Yokoyama; Sytse J. Piersma, PhD |
Immune Cell Types and Biology |
Checkpoint blockade;Immune suppression;Neoantigens;NK/NKT cell;Solid tumors;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1016 |
Poster Presentation |
IL-2 expanded tumor infiltrated Natural Killer (TINK) cells from canine sarcomas possess potent anti-tumor cytotoxicity |
Weiqing Jing, PhD; Himaly Shinglot; Juliana Chi Kei Ng; Ali Zhang; Bernard Seguin; Jeffrey Bryan; Timothy Fan; Jennifer D. Wu, PhD; Seth M. Pollack |
Immune Cell Types and Biology |
NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 1017 |
Poster Presentation |
A tumor model in the humanized immuno-reconstituted hIL15 transgenic mice revealed the impact of other immune components on the development and function of NK cells against malignancies |
Li Yang; Chunlei Dai; Hongmei Xu; Hui Qi; Xuzhen Tang; Qingyang Gu; Qunsheng Ji, PhD |
Immune Cell Types and Biology |
Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1018 |
Poster Presentation |
Multifunctional Natural Killer Cell Engager Releasing CXCL10 Augments Natural Killer Cell Recruitment and Anti-tumor Efficacy against Glioblastoma |
Xue Yao, Master; Sandro Matosevic, PhD |
Immune Cell Types and Biology |
Antibody;Bispecifics;Chemokine;Cytokine;NK/NKT cell;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1019 |
Oral Presentation |
CSF1R+PD-L1+ Tumor-associated Macrophages Trigger MAIT Cell Dysfunction at the HCC Invasive Margin |
Benjamin Ruf, M.D.; Matthias Bruhns, M.Sc.; Sepideh Babaei, Ph.D.; Noemi Kedei, MD; Chi Ma, MD, PhD; Lichun Ma, Ph.D.; Mahler Revsine; Bernd Heinrich, MD; Varun Subramanyam, B.Sc; Jonathan Qi, B.Sc.; Simon Wabitsch, M.D.; Benjamin Green, M.D.; Kylynda C. Bauer, Ph.D.; Yuta Myojin, MD, PhD; Mohamed-Reda Benmebarek, Ph.D.; Layla Greten; Justin McCallen, M.D.; Patrick Huang, D.V.M.; Marie Pouzolles, Ph.D; David Kleiner, M.D. Ph.D.; William Telford, Ph.D.; Kimia Dadkhah, Ph.D.; Allison Ruchinskas; Merrill Stoffroff; Jiman Kang, M.D.; Kesha S. Oza, M.D.; Mathuros Ruchirawat, Ph.D.; Alexander Kroemer, M.D.; Xin W. Wang, PhD; Manfred Claassen, Ph.D.; Firouzeh Korangy, Ph.D.; Tim F. Greten, MD |
Immune Cell Types and Biology |
Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Proteomics;Solid tumors;Systems biology;T cell;T cell lineages;Tumor microenvironment |
| 1020 |
Poster Presentation |
Targetting TIM-3 on T regulatory cells make Nonresponsive cold Melanoma, more responsive to immune mediated tumor control. |
Hridesh Banerjee, PhD; Hector N. Rosado; Benjamin M. Murter, BS; Lawrence P. Kane, PhD |
Immune Cell Types and Biology |
Antigen presenting cells;CAR T cells;Cytokine;Immune monitoring;Immune toxicity;Inflammation;Metabolism;T cell;Tumor evasion;Tumor microenvironment |
| 1021 |
Poster Presentation |
A pan-cancer signature identifies tumor-reacting CD8+ TILs and reveals their functional heterogeneity |
Christopher A. Chamberlain, MSc; Arianna Draghi, MD; Shawez Khan; Katja Harbst, PhD; Mario Presti, MD; Aimilia Schina; Agnete Witness Præst Jensen, MSC; Anne-Christine Kiel Rasmussen, MSc; Torben Lorentzen, MD; Jakob Vasehus Schou, MD; Göran B. Jönsson, Professor, PhD; Inge M. Svane, MD, PhD; Marco Donia, MD, PhD |
Immune Cell Types and Biology |
Bioinformatics;Chemokine;Cytokine;Gene expression;Immune monitoring;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 1022 |
Poster Presentation |
Tumor-infiltrating CXCR6-expressing tissue-resident memory HPV-specific CD8+ T cells are terminally exhausted in HPV-associated head and neck squamous cell carcinoma |
Yang Cheng, PhD; Kathleen Atkinson; Talia Saal; Jean S. Campbell, PhD; Sara I. Pai, MD PhD |
Immune Cell Types and Biology |
Immune monitoring;Solid tumors;Systems biology;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1023 |
Poster Presentation |
The signal strength of signal 2 and 3 during T cell priming affect the functional fate of an anti-tumor T cell response. |
Duncan M. Morgan, Ph.D.; Vidit Bhandarkar, BS; Emi Lutz; K. D. Wittrup; Stefani Spranger, PhD; Teresa Dinter, BS |
Immune Cell Types and Biology |
Checkpoint blockade;Costimulation;Cytokine;T cell;T cell lineages |
| 1024 |
Poster Presentation |
Illuminating stem memory T cell (Tscm) heterogeneity in human cancer: Characterization of a unique CD45RO+ Tscm population in human ovarian cancer |
Erica G. Brown, BS; Monika Eiva; Veethika Pandey; Alexander Benton, BA; Stacy K. Thomas; Wenzhao Meng; Aaron M. Rosenfeld; Eline T. Luning Prak; Daniel J. Powell, Jr., PhD |
Immune Cell Types and Biology |
Stem cell/cancer-initiating cell;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1025 |
Poster Presentation |
Single Cell Evaluation of Costimulatory and Coinhibitory Receptors and Their Ligands Across Solid Tumor Indications |
Shawn P. Fahl, PhD; Kerri Colwell; Cavin Ott; Casey Smith; Kayla Williams; Alex Moore |
Immune Cell Types and Biology |
Coinhibition;Costimulation;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 1027 |
Poster Presentation |
Chronic antigen in solid tumors drives a distinct program of T cell residence |
Noah V. Gavil, BA; Milcah Scott, BS; Eyob Weyu; Olivia Smith; Stephen D. O'Flanagan; Sathi Wijeyesinghe, MD, PhD; Sahar Lotfi-Emran, MD, PhD; Stephen L. Shiao, MD, PhD; Vaiva Vezys, PhD; David Masopust, PhD |
Immune Cell Types and Biology |
Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1028 |
Poster Presentation |
IL-12 and IL-27 upregulate CD39 expression on CD8+ T-cells and differentially affect CD39+CD8+ T-cell effector function |
Lara Gerhardt, BSc; Rene Figueredo, MSc; Saman Maleki, PhD |
Immune Cell Types and Biology |
Cytokine;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1029 |
Poster Presentation |
Engineering of T cells with CCR10 for enhanced trafficking of adoptive cell therapy |
Jong Moo Hong; Hee Jin Lee; Gyung Yub Gong; Kwang Hee Kim, PhD |
Immune Cell Types and Biology |
Adoptive immunotherapy;Chemokine;T cell |
| 1030 |
Poster Presentation |
PSGL-1-deficiency suppresses tumor growth of orthotopic pancreatic ductal adenocarcinoma tumors and enhances immune cell infiltration and CD8+ T cell responses |
Jennifer L. Hope, PhD; Yijuan Zhang, PhD; Ashley B. Palete; Hannah A. Faso; Sreeja Roy, PhD; Dennis C. Otero, PhD; Swetha Maganti; Cosimo Commisso, PhD; Linda M. Bradley, PhD |
Immune Cell Types and Biology |
Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 1031 |
Poster Presentation |
Acetyl CoA Carboxylase Inhibition Rewires T cell Fate and Tumor Immunotherapy Outcome |
Katie Hurst; Brian P. Riesenberg, PhD; Elizabeth Hunt, BS; Alex M. Andrews, PhD; Megan Tennant, MS; Evelyn Gandy; Peng Gao; Lauren Ball, PhD; Emily Wallace; David Corcoran; Jessica E. Thaxton, PhD, MS |
Immune Cell Types and Biology |
Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1032 |
Poster Presentation |
Uncoupling CD39 and T cell antigen specificity in brain tumors |
Jordan F. Isaacs; Sierra A. Kleist; Shawn C. Musial; Hanna N. Degefu; Pamela C. Rosato, PhD |
Immune Cell Types and Biology |
Immune suppression;Inflammation;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 1033 |
Poster Presentation |
Stem-like CD8 T-cells residing in antigen presenting immune niches are prognostic for local control in brain metastases and are sustained following radiation therapy |
Caroline S. Jansen, PhD; Prasanthi Chappa; Nataliya Prokhnevska, BS; Maria Cardenas; Roshan Prabhu; Jim Zhong; Kimberly B. Hoang; Subir Goyal, MBBS, PhD, MSc; Suzanna Logan; Jeffrey Olson; Edjah K. Nduom, MD; Luke del Balzo; Kirtesh R. Patel, MD; Stuart Burri; Anthony Asher; Scott Wilkinson, PhD; Ross Lake; Kristin Higgins; Pretesh Patel; Vishal Dhere; Mylin Torres; Adam G. Sowalsky, PhD; Mohammad K. Khan; Haydn Kissick, PhD; Zachary Buchwald, MD PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Biomarkers;Dendritic cell;Immune contexture;Immunoscore;Radiotherapy;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1034 |
Poster Presentation |
Analysis of factors associated less differentiated T cells in breast cancer for improvement of adoptive T cell therapy |
Sung Wook Jung; Jeong-Han Seo, PhD candidate; Hyeonjin Lee; Gyungyub Gong; Hee Jin Lee |
Immune Cell Types and Biology |
Adoptive immunotherapy;Gene expression;T cell |
| 1035 |
Poster Presentation |
High-dimensional Immune Profiling of Peripheral Epstein-Barr Virus-specific T cells in Nasopharyngeal Carcinoma |
Nandita Kumar, BS; Hugh R. MacMillan, PhD; Joe Poh Sheng P. Yeong, MD, PhD; Melvin L. Chua, MBBS, FRCR, PhD, FAMS; Amit Jain, MBBS, MRCP, MMed; Evan W. Newell, PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Biomarkers;Immune monitoring;T cell;Tumor antigens |
| 1036 |
Poster Presentation |
Ron kinase as potential immunotherapeutic target for augmenting T cell activity in breast cancer metastasis |
Alicia S. Lai, PhD; Alana Welm, PhD |
Immune Cell Types and Biology |
Immune suppression;T cell;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs) |
| 1037 |
Poster Presentation |
Single cell evaluation of antigen specificity, clonal dynamics and transcriptional signatures of CD8+ T cells in Head and Neck Squamous Carcinoma |
Housaiyin Li; Patricia M. Santos, PhD; Aditi Kulkarni; Alok V. Joglekar, PhD; Lazar Vujanovic, PhD; Robert L. Ferris, MD, PhD |
Immune Cell Types and Biology |
Checkpoint blockade;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1038 |
Poster Presentation |
Loss of PD-1 signals improves CD8+ TIL function in a cell intrinsic and cell extrinsic manner |
Samuel C. Markson, PhD; Kristen E. Pauken; Vikram Juneja; Osmaan Shahid; Kelly P. Burke; Jared Rowe; Jacklyn Long; Megan Fung; Jacob M. Luber; Jennifer Judge; Alison Ringel; Marcia C. Haigis, PhD; Meromit Singer; Arlene H. Sharpe |
Immune Cell Types and Biology |
Bioinformatics;Checkpoint blockade;T cell |
| 1040 |
Oral Presentation |
A population of ectoenzyme expressing T-cells with an immunosuppressive phenotype are associated with checkpoint immunotherapy resistance in metastatic melanoma patients. |
David M. Woods, PhD; Carol M. Amato, MS; Ann M. Strange; Brian Thompson; Jeffrey S. Weber, MD, PhD; Ankita Mitra |
Immune Cell Types and Biology |
Biomarkers;Checkpoint blockade;Immune suppression;Solid tumors;T cell;T cell lineages |
| 1041 |
Poster Presentation |
PIK3IP1/TrIP Immune Regulation on CD8+ T Cells Restricts Anti-Tumor Immunity |
Benjamin M. Murter, BS; Hridesh Banerjee, PhD; Sean C. Robinson; Andrea L. Szymczak-workman, PhD; Lawrence P. Kane, PHD |
Immune Cell Types and Biology |
Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1042 |
Poster Presentation |
The dual function of the adenosine pathway in the liposarcoma tumor microenvironment |
Jacqueline Oliva; Younghee Lee; Rebeca Rodriguez; Katarzyna Tomczak; Davis Ingram; Xiao Zhou; Vinod Ravi; Anthony Conley; John Livingston; Joseph Ludwig; Neeta Somaiah, MD; Cara Haymaker |
Immune Cell Types and Biology |
Cytokine;Immune suppression;Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1043 |
Poster Presentation |
High VISTA expression on tumor-infiltrating lymphocytes is prognostic of poor survival in patients with endometrial cancer |
Sachin Patnaik, BA; Cassandra K. Gilmour, BS; Stefanie Avril, MD; Andrelie Branicky; Ajay Zalavadia, PhD; Judith Drazba, PhD; Li Wang, PhD |
Immune Cell Types and Biology |
Biomarkers;Immune suppression;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1044 |
Poster Presentation |
Proteasome mediated protein catabolism fuels antitumor immunity |
Brian P. Riesenberg, PhD; Elizabeth G. Hunt; Megan Tennant, MS; Katie E. Hurst, MPH; Alex M. Andrews, PhD; Lee Leddy, MD, MsCR; David M. Neskey, MD; Elizabeth G. Hill, PhD; Guillermo O. Rangel Rivera; Chrystal M. Paulos, PhD; Peng Gao; Jessica E. Thaxton, PhD, MS |
Immune Cell Types and Biology |
Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1045 |
Poster Presentation |
High dimensional profiling of Merkel cell polyomavirus-specific T cells in response to anti-PD-1 immunotherapy |
Heeju Ryu, Ph.D.; Timothy Bi; Korok Sarkar; Candice Church, Ph.D.; Nirasha Ramchurren, PhD; Thomas Pulliam; Steven P. Fling, PhD; Paul T. Nghiem, MD, PhD; Evan W. Newell, PhD |
Immune Cell Types and Biology |
Biomarkers;Checkpoint blockade;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 1046 |
Poster Presentation |
Targeting Novel Pathways in Chronically Activated T Cells Prevents Functional Exhaustion |
Justyna Rzepecka, PhD; Andrew Hall, PhD; Mark Barbour; Emma Mallon; Marija Bedaj; Lucia Janicova; Xabier Cortes-Lavaud; Frances Acklam; Joanne Hay; Hayley Gooding; Darryl Turner; Preeti Singh; Aaron Crawford |
Immune Cell Types and Biology |
Checkpoint blockade;Coinhibition;T cell;Tumor microenvironment |
| 1047 |
Poster Presentation |
From exhaustion to memory: altering T cell fate improves immunotherapeutic responses to cancer |
Nicole E. Scharping, PhD; Allison Cafferata; Maximilian Heeg, MD; Quynhanh Nguyen; Ananda W. Goldrath, PhD |
Immune Cell Types and Biology |
Adoptive immunotherapy;Proteomics;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) |
| 1048 |
Poster Presentation |
Interplay of IL-12 and IFNg to induce Treg fragility within the tumor microenvironment |
Ellen N. Scott, B.S.; Angela M. Gocher, PhD, MS; Creg Workman, PhD; Dario A. Vignali, PhD |
Immune Cell Types and Biology |
Cytokine;Regulatory T cell (Treg cell);Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1049 |
Oral Presentation |
Reconstruction of gene regulatory networks dissects transcriptional control of intratumoral regulatory T cells |
Feng Shan, MS; Anthony R. Cillo, PhD; Carly Cardello; Daniel Yuan; Sheryl R. Kunning; Jian Cui, PhD; Robert L. Ferris, PhD; Tullia Bruno, PhD; Creg Workman, PhD; Panayiotis V. Benos, PhD; Dario A. Vignali, PhD |
Immune Cell Types and Biology |
Bioinformatics;Biomarkers;Gene expression;Immune suppression;Regulatory T cell (Treg cell);Systems biology;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1050 |
Poster Presentation |
Single cell transcriptome and epigenome profiling reveals the diversity of T cell states in ex vivo grown tumor-infiltrating lymphocytes from malignant pleural mesothelioma |
Katarzyna Tomczak; Carlos Ramos, BS; Nathaniel Deboever, MD; Nicolas Zhou, DO, MSc; Jacqueline Liszeth Oliva, PhD; Chang-Jiun Wu, PhD; Chad D. Strange, MD; Annikka Weissferdt, MD; David C. Rice, MB, BCh, BAO, FRCSI; Reza J. Mehran, CD, MDCM, MSc, FRCSC, FACS; Jianjun Zhang, MD, PhD; Mehmet Altan, MD; Anne Tsao, MD; Boris Sepesi, MD, FACS; Cara Haymaker |
Immune Cell Types and Biology |
Epigenetics;Gene expression;Immune tolerance;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1051 |
Poster Presentation |
Radiation dose-related temporal changes in STING-associated immune genes in murine CD8 T cells |
Ana Torres, BA; Amanda G. Shea, BS; Wonjong Jin, PhD; Caroline Kerr; Kaleb Schroeder; Paul A. Clark, PhD; Zachary S. Morris, MD, PhD |
Immune Cell Types and Biology |
Gene expression;Radiotherapy;T cell;T cell lineages |
| 1052 |
Oral Presentation |
Tissue-specific interferon-gamma drives regulatory T-cells to restrain DC1-mediated priming of cytotoxic T-cells against lung cancer |
Maria Zagorulya, B.S.; Leon Yim, B.S.; Duncan M. Morgan, Ph.D.; Austin Edwards; Elen Torres-Mejia; Noor Momin, Ph.D.; Chloe V. McCreery; Izabella L. Zamora; Brendan L. Horton, PhD; K. D. Wittrup; J. C. Love; Stefani Spranger, PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Checkpoint blockade;Costimulation;Cytokine;Dendritic cell;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor evasion |
| 1053 |
Poster Presentation |
Identification of distinct immune landscapes of infiltrating T cells in colon cancer using multiplex immunofluorescence staining |
Hehuan Zhu, MSc; Jessica Roelands, MSc; Eiman Ahmed; Imke Stouten; Rachel Hoorntje; Ronald Vlierberghe; Marieke Ijsselsteijn; Noel Miranda; Rob Tollenaar; Wouter RL. Hendrickx, PhD; Davide Bedognetti, MD, PhD; Peter Kuppen |
Immune Cell Types and Biology |
Immunoscore;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1054 |
Poster Presentation |
Myeloid and T cell subsets defined in bladder cancer using single-cell RNA sequencing and paired protein profiling |
Viktor Sincic, MSc; Ashfaq Ali, PhD; Alar Aab, PhD; Thoas Fioretos, PhD; Carl Borrebaeck, PhD; Fredrik Liedberg, PhD; Kristina Lundberg, PhD |
Immune Cell Types and Biology |
Antigen presenting cells;Dendritic cell;Gene expression;Immune suppression;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1055 |
Poster Presentation |
Immune cell subtypes associated with the level of tumor-infiltrating lymphocytes in breast tumor microenvironment |
Su Min Cha; Jeong-Han Seo, PhD candidate; Jung-Wook Park, PhD candidate; Hee Jae Lee, PhD; Hee Jin Lee |
Immune Cell Types and Biology |
Bioinformatics;Gene expression;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1056 |
Poster Presentation |
ZG033, a novel CD137 agonist, induces superior anti-tumor activity without hepatotoxicity rely on Fc-mediated crosslinking |
Liansheng Cheng; Wenting Liu; Dayan Zhang; Xiaoli Zeng; Guodong Shen |
Immune-stimulants and immune modulators |
Antibody;Costimulation;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 1057 |
Poster Presentation |
HBM7008, a first-in-class bispecific antibody targeting both B7-H4 and 4-1BB, exhibits robust anti-tumor immunity and low toxicity through B7-H4-directed 4-1BB activation |
Bing Huang, Ms., Ph.D.; Fangfang Du; Xiaocheng Lv; Jianxun Zhao; Fei Chen; Zailian Lu; Yang Zhang; Victor Chen; Xin Gan; Jiuqiao Zhao; Yun He; Xiaodong Wu, PhD; Yiping Rong |
Immune-stimulants and immune modulators |
Bispecifics;Checkpoint blockade;Costimulation;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1058 |
Poster Presentation |
YH32364 (ABL104), a novel EGFR/4-1BB bispecific antibody exhibits potent antitumor efficacy with an excellent safety profile |
Eunjung Lee, PhD; Hyejin Chung; Yangsoon Lee; Young Bong Park; Eun-Jung Lee; Hyunmo Koo; Mikyeong Ju; Ju Young Park; Sujin Ahn; Junhwan Kim; Kyeongsu Park; Wonjun Son; Jaehyun Eom; Hanbyul Lee; Jaeho Jung; Jonghwa Won; Se-Woong Oh |
Immune-stimulants and immune modulators |
Bispecifics;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 1059 |
Poster Presentation |
ON203: A new antibody targeting the oxidized form of macrophage migration inhibitory factor (oxMIF) exerts antitumorigenic activity and modulates the tumor microenvironment. |
Barbara Maurer, PhD; Irina Mirkina, PhD; Julia Mayer, MSc; Christine Landlinger, PhD; Alexander Schinagl, PhD; Michael Thiele, PhD; Randolf J. Kerschbaumer, PhD |
Immune-stimulants and immune modulators |
Antibody;Cytokine;Immune contexture;NK/NKT cell;Solid tumors;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 1060 |
Poster Presentation |
EVOLVETM: a novel costimulatory T cell engager platform engineered for the treatment of immune suppressive tumors |
Jeremy Myers, Ph.D.; Mohosin Sarkar; Eric M. Tam; Abudukadier Abulizi; Guixian Jin; Xingyue An; Evelyn Teran; Shu Shien Chin; Danielle M. Klaskin; Nana Adjoa Pels; Maria Hackett; Oksana A. Sergeeva; Hayden Karp; Julio Rodriguez; Sonali Dhindwal; Changqing Yuan; Zengzu Lai; Jennifer Zeiger; Amber Fearnley; Louis Matis; Jay Fine |
Immune-stimulants and immune modulators |
Costimulation |
| 1061 |
Poster Presentation |
CLN-617 is an intratumorally injected and locally retained fusion of IL-2 and IL-12 that drives systemic anti-tumor activity |
Mehta K. Naveen, PhD; Kavya Rakhra; Kristan Meetze; Irina Shapiro; Karl D. Wittrup; Patrick A. Baeuerle, PhD; Jennifer S. Michaelson |
Immune-stimulants and immune modulators |
Bispecifics;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1062 |
Poster Presentation |
ES009, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation |
Xiaofeng Niu, PhD; Chunnian Wang, PhD; Jinfeng Zhao; Jiahui Hu; Yanfen Hu; Jun Sun; Xiaoyan Zheng, PhD; Yuting Qiu, PhD; Zhihao Wu, PhD; Yangsheng Qiu, PhD; Quan Qiu, PhD; Hongtao Lu, PhD |
Immune-stimulants and immune modulators |
Antibody;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor microenvironment |
| 1063 |
Poster Presentation |
Anti-4-1BB x PD-1, a bispecific anti-cancer therapeutics. |
Byoung S. Kwon, PhD; Hanna Lee; Jin Sung Park; SeungHee Han; Sungmin Park; Sun Woo X. Im; HyunTae Son; Joseph H. Jeong |
Immune-stimulants and immune modulators |
Antibody;Bispecifics;Costimulation;T cell;Tumor antigens |
| 1064 |
Poster Presentation |
Exercise induced hormone irisin inhibits Integrin αv-TGF-β axis in tumor microenvironment to improve CD8+ T cell mediated tumor control |
No-Joon Song, PhD; Yuzhou Chang; Anqi Li, MD; Yi Wang; Kelsi Reynolds; Kevin P. Weller; Chelsea M. Bolyard; Gang Xin; Qin Ma; Zihai Li, MD, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell |
| 1065 |
Poster Presentation |
ACTM-838, a microbial-based immunotherapy that enriches in solid tumors after IV dosing, reverses the immunosuppressive TME to promote durable anti-tumor immunity, alone and in combination with anti-PD1 in mice |
Akshata R. Udyavar, MS, PhD; Hailey He; John Brandenburg; Julie Janes; Oanh Pham, PhD; Sara Tribble; Ryan Daroy; Keith Cheung, PhD; Haixing Kehoe, MS; Bret Peterson, PhD; Emily Miyashita-Lin, PhD; Omkar Joshi, PhD; Nick Eisele, PhD; Christopher D. Thanos, PhD; Chan C. Whiting, PhD |
Immune-stimulants and immune modulators |
Antigen presenting cells;Checkpoint blockade;Cytokine;Immune monitoring;Immune suppression;Monocyte/Macrophage;Myeloid cells;T cell;TLR;Tumor microenvironment |
| 1066 |
Poster Presentation |
Pharmacologic inhibition of DGKα activates T cells and enhances anti-tumor immunity |
Adele Y. Wang, Dr., PhD; Jean-Philippe Belzie; Lance Stapleton; Weimei Xing; Gladys Muiru; Dmytro Kornyeyev; Edward Hsieh; Albert Liclican; Pamela Toy; Mengshu Xu; Kei Kim; Jacob S. Lee; Michelle R. Kuhne, PhD; Latesh Lad |
Immune-stimulants and immune modulators |
Checkpoint blockade;Solid tumors;T cell |
| 1067 |
Poster Presentation |
Synergistic combination of Natural Killer cell engagers (NKEs) with proinflammatory cytokines |
Tian Zhang, PhD; Matthew S. Faber, PhD; Erik Pong, BS; Ke Liu, PhD; Matthew J. Bernett, PhD; Christine Bonzon, PhD; Juan E. Diaz, PhD; Dong Hyun Nam; Kendra N. Avery, PhD; Jing Qi, PhD; Rumana Rashid, PhD; Rena Bahjat, PhD; John R. Desjarlais, PhD; Katrina Bykova, PhD |
Immune-stimulants and immune modulators |
Antibody;Bispecifics;NK/NKT cell;Solid tumors;T cell |
| 1068 |
Poster Presentation |
A ROR1 specific CD3 bispecific T-cell Engager engineered for solid tumors with an expanded therapeutic window |
Brian Rabinovich, PhD; Xueyuan Zhou, PhD; Jeffrey Takimoto, PhD; Paul Y. Song; Evren Alici, MD, PhD; Nikhita Khanna, MS |
Immune-stimulants and immune modulators |
Antibody;Solid tumors;T cell;Targeted therapy |
| 1069 |
Poster Presentation |
OX40/CD137 dual agonism potentiates anti-tumour immunity by driving functional reprogramming and instability of regulatory T (Treg) cells |
Charlotte Imianowski; Paula Kuo; Edmund Poon; Matthew A. Lakins, PhD; Michelle Morrow, PhD; Rahul Roychoudhuri, MBBS., PhD |
Immune-stimulants and immune modulators |
Antibody;Bispecifics;Checkpoint blockade;Costimulation;Cytokine;Immune tolerance;Regulatory T cell (Treg cell);T cell |
| 1070 |
Poster Presentation |
HexaBody-CD27 enhances T-cell activation, proliferation, cytokine secretion and cytotoxic activity independently of Fc gamma receptor-mediated crosslinking |
Isil Altinas; Kristina B. Nürmberger; Andrea Imle; Aras Toker; Kristin Strumane; Sina Fellermeier-Kopf; Andreea Ioan-Facsinay; Alexander Muik; Mustafa Diken; Frank J. Beurskens; Rob N. De Jong; Sebastian Kreiter, MD; David P.E. Satijn, PhD; Friederike Gieseke; Janine Schuurman; Tahamtam Ahmadi; Oezlem Tuereci, MD; Kate Sasser; Esther C.W. Breij, PhD; Ugur Sahin |
Immune-stimulants and immune modulators |
Antibody;Costimulation;Cytokine;Dendritic cell;Immune adjuvant;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1071 |
Poster Presentation |
Autologous tumor cell immunotherapeutic platform induces stress-correlated immunogenic cell death leading to immune activation within the draining lymph nodes |
Christopher Cultrara, PhD; Kenneth Kirby; Essam Elrazaq; Christopher Uhl, PhD; Amelia Zellander, PhD; Lorenzo Galluzzi, PhD; Mark A. Exley, PhD; Jenny Zilberberg, PhD |
Immune-stimulants and immune modulators |
Antigen presenting cells;Dendritic cell;T cell;Tumor antigens;Vaccine |
| 1072 |
Poster Presentation |
Intravenous BCG administration in mice stimulates NK and T cell-mediated antitumor immunity in the lung and overcomes resistance to immunotherapy |
Eduardo Moreo Lapieza, Degree in Biotechnology; Santiago Uranga; Carlos Martín, PhD, MD; Nacho Aguiló |
Immune-stimulants and immune modulators |
Antigen presenting cells;Checkpoint blockade;Dendritic cell;Inflammation;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 1073 |
Poster Presentation |
Costimulatory CD28 trispecific antibodies targeting PDL1 and PDL2 enhance T cell activation in solid tumors |
Veronica G. Zeng, PhD; Juan E. Diaz, PhD; Jing Qi, PhD; Thuy Truong, PhD; Matthew Dragovich, PhD; Rumana Rashid, PhD; Christine Bonzon, PhD; Panida Lertkiatmongkol, PhD; Ruschelle Love, MS; Michael Hackett, PhD; Kendra N. Avery, PhD; Norman J. Barlow, PhD, DVM, MBA; John R. Desjarlais, PhD; Michael Hedvat, PhD; Gregory L. Moore, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 1074 |
Poster Presentation |
A novel fully human CD28 antibody that cross-reacts with CTLA-4 and mouse CD28 for potential applications in cancer immunotherapy |
Abdullah Elsayed, MSc; Frederik Peissert; Louis Plüss; Franziska Ulrich; Emanuele Puca, PhD; Roberto De Luca, phD; Cornelia Halin; Dario Neri, Professor |
Immune-stimulants and immune modulators |
Antibody;Bispecifics;Checkpoint blockade;Costimulation;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 1075 |
Poster Presentation |
HBM1020 Is A Fully Human Novel Anti-B7H7 Antibody with Excellent Preclinical Efficacy and Safety Profile |
Xiaodong Wu, PhD; Yongqiang Wang; Jonna Liu; Xiaocheng Lv; Fei Chen; Izzie Wang; Jiuqiao Zhao; Yiping Rong |
Immune-stimulants and immune modulators |
Antibody;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 1076 |
Poster Presentation |
Anchored immunotherapy with intratumorally administered aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response |
Sailaja Battula, PhD; Gregory Papastoitsis; Howard L. Kaufman, MD; K. D. Wittrup; Michael M. Schmidt, PhD |
Immune-stimulants and immune modulators |
Costimulation;Cytokine;Immune toxicity;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment |
| 1077 |
Poster Presentation |
Development of a molecular targeted cytokine that specifically expands Vgamma9Vdelta2 T cells and potentiates anti-tumor activity |
Bryan R. Becklund, PhD; Kaitlyn Robinson; Kyle Jones; Angelica Sanabria; Elisebeth Torretti; Andrew Eckles; Abrahim Hussain; Sae Jeong Ahn; Rajay Pandit; Florian J. Sulzmaier, PhD; John C. Timmer, PhD; Brendan P. Eckelman, PhD |
Immune-stimulants and immune modulators |
Antibody;Costimulation;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 1078 |
Poster Presentation |
Conditionally Activatable Interferon-alpha 2b Improves Tolerability and Exhibits Preferential Activity in Tumors |
Alexey Berezhnoy, PhD, DVM; Hsin Wang; Nicole Lapuyade; Na Cai; Carol LePage; Michael Winter, PhD; Michael Krimm; Kenneth R. Wong, MA; Robert T. Dunn II, PhD; Sean McAlister, PhD; Leila Boustany, PhD; Madan Paidhungat, PhD; Marcia Belvin, PhD; Erwan Le Scolan, PhD; Dylan L. Daniel, PhD |
Immune-stimulants and immune modulators |
Cytokine;Immune adjuvant;Inflammation;Tumor microenvironment;Tumor stroma |
| 1079 |
Poster Presentation |
LAG3-targeted IL15/IL15Rα-Fc (LAG3 x IL15) fusion proteins for preferential TIL expansion via cis delivery of IL15 to LAG3+ cells |
Matthew J. Bernett, PhD; Suzanne Schubbert, PhD; Michael Hackett, PhD; Lukasz Ochyl, PhD; Lizett E. Scott, MS; Christine Bonzon, PhD; Rumana Rashid, PhD; Kendra N. Avery, PhD; Nicole Rodriguez, PhD; Irene Leung, PhD; Norman J. Barlow, PhD, DVM, MBA; Rena Bahjat, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD |
Immune-stimulants and immune modulators |
Antibody;Bispecifics;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 1080 |
Poster Presentation |
Using site-specific chemical conjugation to generate superior half-life extended or PD-1-targeted formats of a potent IL-18 variant resistant to IL-18 binding protein |
Jean Ph. Carralot, PhD; Camille Delon, MSc; Rubén Alvarez Sanchez, PhD; Roy Meoded, PhD; Philipp Moosman, PhD; Kea Martin, PhD; Arnaud Goepfert, PhD; Andrew S. Chi, MD PhD; Vijaya R. Pattabiraman, PhD; Bertolt D. Kreft, PhD |
Immune-stimulants and immune modulators |
Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 1081 |
Poster Presentation |
Exenokine-2: a half-life extended no-α-IL-2 with improved preclinical pharmacological properties supports first-in-human clinical development |
Lili Cheng, Ph.D; Fan Ye, Ph.D; Sandra Chen; Jianing Huang; Jenny Jiang; Henry He; Shirley Shi; Mingxing Yang; Qiang Fu; Ark Xia; Yudan Hong; Wang Xin; Karen Yuan; Hongchuan Liu; Hui Feng; Eugene Liu; Ziyang Zhong |
Immune-stimulants and immune modulators |
Cytokine;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment |
| 1082 |
Poster Presentation |
IL-27 expressed in the tumor microenvironment is correlated with PD-L1 levels and can induce PD-L1 expression on immune and tumor cells |
Karin Golan, PhD; Ricard Masia, M.D., Ph.D.; Yu Yang, M.S.; Yue Ren, Ph.D.; Kerry F. White, B.A.; Benjamin H. Lee, M.D., Ph.D.; Vito J. Palombella, PhD; Jonathan A. Hill, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Clinical trial;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment |
| 1083 |
Poster Presentation |
AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that mediates potent anti-tumor activity, cytotoxicity, and expansion of memory CD8+ T cells |
Renee Greer, Ph.D.; Henry Nguyen, Ph.D.; Paul Mesko; Ruth Lan, Ph.D.; Wei Wei Prior; Hussein M. Sultan, PhD; Meghana Sukthankar; Irene Ni; S. Michael Chin; Kelly D. Moynihan, Ph.D.; Ton N. Schumacher, PhD; Robert D. Schreiber, PhD; Andy Yeung, Ph.D.; Ivana Djuretic, Ph.D. |
Immune-stimulants and immune modulators |
Antibody;Antigen presenting cells;Bispecifics;Cytokine;Immune toxicity;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1084 |
Poster Presentation |
NTX-0250, a multimodal mRNA-based immunotherapy, eradicates large established tumors in a stringent mouse model of HPV16-driven cancer |
Ole W. Haabeth, PhD; Diane DaSilva, PhD; Colin J. McKinlay, PhD; Weiqun Liu, PhD; Edward E. Lemmens, PhD; Christopher S. Rae, PhD; Adrienne Sallets; Daniel O. Frimannsson, PhD; Sangeeta Nath, PhD; Nicole E. Peck, PhD; Ou Li, PhD; Nicole Fay, PhD; Ruben Prins, BsC.; Meredith L. Leong; W. Martin Kast, PhD; Samuel Deutsch, PhD |
Immune-stimulants and immune modulators |
Costimulation;Cytokine;RNA;Solid tumors;T cell |
| 1085 |
Poster Presentation |
The NAD+ Dependent Deacetylase Sirt2 is a Negative Regulator of the JAK/STAT Pathway in Effector T cells. |
Imene Hamaidi, PhD; Lin Zhang, MD. PhD; Pingyan Cheng, MD; Min-Hsuan Wang; Erika Johnson; Bin Fang, PhD; Sungjune Kim, MD PhD |
Immune-stimulants and immune modulators |
Cytokine;Post-translational modifications;T cell |
| 1086 |
Poster Presentation |
NKTR-288, a polymer-conjugated interferon gamma mutein for the treatment of solid tumors |
Damon Hamel; Marlene Hennessy; Sarah Ingersoll; Olga Zemska; Phi Quatch; Rhoneil Pena; Thomas Chang; David Doherty; Guifen Xu; Arkopal Choudhury; Danni Yu; Werner Rubas; Christie Fanton; Brian Vuillemenot; Saul Kivimae; Takahiro Miyazaki; Jonathan Zalevsky |
Immune-stimulants and immune modulators |
Antigen presenting cells;Checkpoint blockade;Cytokine;Myeloid cells;Neoantigens;Solid tumors;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1087 |
Poster Presentation |
Addition of IL-2 Overcomes Lung Tumor Resistance to IL-12 by Coordinating Cytotoxic and Regulatory T Cell Responses |
Brendan L. Horton, PhD; Maria Zagorulya, B.S.; Noor Momin, Ph.D.; Yash Agarwal, B.Sc.; K. D. Wittrup; Stefani Spranger, PhD |
Immune-stimulants and immune modulators |
Cytokine;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment |
| 1088 |
Poster Presentation |
A highly potent anti-LAG-3-IL-2c that selectively targets tumor-specific CD8+ T cells |
Zoey Huang; Jianing Huang; Fan Ye; Sandra Chen; Danny Huang; Michael Hua; Ella Li; Jenny Jiang; Hanna Lin; Shirley Shi; Bella Yue; Henry He; Mingxing Yang; Qiang Fu; Ziyang Zhong |
Immune-stimulants and immune modulators |
Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1089 |
Poster Presentation |
Immunopheresis: A novel immunotherapy platform for extracorporeal removal of soluble target molecules in oncology |
Steven Josephs, PhD; Robert Segal, MD, FACP; Steve Prince; Mathew Ong; Amir Jafri; Lawrence Florin; Victoria Manax, MD; Michael Matho, PhD; Sameera Bilgrami, PhD; Annette Marleau, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Cytokine;Immune suppression;Inflammation |
| 1090 |
Poster Presentation |
Overcoming systemic toxicity of IL-12-based immunotherapy by tumor-targeting and IL-12 attenuation |
Jihoon Chang, Ph.D; Donggeon Kim, DVM,PhD; Dahea Lee; Dongsu Kim; Soomin Ryu; Byoung C. Lee |
Immune-stimulants and immune modulators |
Antibody;Cytokine;Immune toxicity;Tumor microenvironment |
| 1091 |
Poster Presentation |
CGC-601, a novel βγ-only IL-2 variant, enhances moderate immune activation without Treg expansion, and exhibits a superior safety evidence in vivo |
Lei Zhao, Ph.D.; Rong Wang; Chuan Feng; Yongji Jiang; Patrick Liu; Yuan Liu, Ph. D |
Immune-stimulants and immune modulators |
Cytokine;Regulatory T cell (Treg cell);Solid tumors |
| 1092 |
Poster Presentation |
The CD8+ T cell selectivity of AB248 is essential for optimal anti-tumor activity and safety in nonclinical models |
Kelly D. Moynihan, Ph.D.; Danielle C. Pappas; Hussein M. Sultan, PhD; Terrence Park; Manu Kumar, Ph.D.; Ruth Lan, Ph.D.; Irene Ni; Jessie Chen; Michael Chin; Ton N. Schumacher, PhD; Andy Yeung, Ph.D.; Robert D. Schreiber, PhD; Ivana Djuretic, Ph.D. |
Immune-stimulants and immune modulators |
Cytokine;T cell |
| 1093 |
Poster Presentation |
A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment of cancer |
Lisa Nadal; Frederik Peissert; Abdullah Elsayed, MSc; Tobias Weiss; Thomas Look; Michael Weller; Geny Piro; Carmine Carbone; Giampaolo Tortora; Mattia Matasci; Nicholas Favalli; Riccardo Corbellari; Cesare Di Nitto; Eleonora Prodi; Chiara Libbra; Simone Galeazzi; Claudiopietro Carotenuto; Cornelia Halin; Emanuele Puca, PhD; Dario Neri, Professor; Roberto De Luca, phD |
Immune-stimulants and immune modulators |
Antibody;Cytokine;Targeted therapy;Tumor antigens;Tumor microenvironment;Tumor stroma |
| 1094 |
Poster Presentation |
Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first in human clinical development |
Guillaume Carmona, PhD; Amanda Nash, BS; Ryan Newman; Jake Schladenhauffen; Maria Jarvis; Samira Aghlara-Fotovat; Sudip Mukherjee; Andrea Hernandez; Andrew Hecht; Peter Rios; Shirin Nouraein; Rahul A. Sheth, MD; Weiyi Peng, MD PhD; Jose Oberholzer; Amir A. Jazaeri, MD; Omid Veiseh, Ph.D |
Immune-stimulants and immune modulators |
Cytokine;T cell |
| 1095 |
Poster Presentation |
IL-12-Based Cytokine Factories Modulate Tumor Microenvironment to Eradicate Pancreatic Tumors in Mice and are Well Tolerated in Non-human Primates |
Amanda Nash, BS; Samira Aghlara-Fotovat, BA; Andrea Hernandez; Sofia Ghani; Ira Joshi; Douglas Ira; Peter Rios; Omid Veiseh, Ph.D |
Immune-stimulants and immune modulators |
Cytokine;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1096 |
Poster Presentation |
mWTX-330, an IL-12 INDUKINE molecule, Selectively Activates Tumor Infiltrating Lymphocytes and Reprograms the Tumor Microenvironment in Murine Syngeneic Tumor Models |
Christopher Nirschl, PhD; Heather R. Brodkin, PhD; Connor J. Dwyer, PhD; Daniel J. Hicklin, PhD; Nesreen Ismail; Celesztina Domonkos, PhD; Cynthia Seidel-Dugan, PhD; Philipp Steiner, PhD; Zoe Steuert; Jenna M. Sullivan, PhD; William M. Winston, PhD; Andres Salmeron, PhD |
Immune-stimulants and immune modulators |
Cytokine;Metabolism;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1097 |
Poster Presentation |
MDK1654: A Branched Synthetic Peptide that Activates Both the IL-7 Receptor and the βγc Form of the IL-2/15 Receptor |
Inkyung Angie Park, Ph.D.; Steven E. Cwirla; Alice V. Bakker; Ronald Barrett; Michael C. Needels; Praechompoo Pongtornpipat; Blake M. Williams; Prarthana Joshi; William J. Dower |
Immune-stimulants and immune modulators |
Cytokine;NK/NKT cell;T cell |
| 1098 |
Poster Presentation |
Targeting wildtype IL-2 to CD8 T cells induces potent anti-tumor immune responses and decreases IL-2 mediated toxicity |
Selvi Ramasamy, PhD; Joanathan Nardozzi; Shannon Boi; Joanna Swain; Anthony Coyle, PhD; Stefano Gulla |
Immune-stimulants and immune modulators |
Antibody;Cytokine;Immune toxicity;Regulatory T cell (Treg cell);T cell;Targeted therapy |
| 1099 |
Poster Presentation |
ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein showing increased efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity |
Christoph Huber, PhD; Kirsten Richter, PhD; Laetitia Petersen; Nicole Egli; Patrizia Murer, PhD |
Immune-stimulants and immune modulators |
Antibody;Checkpoint blockade;Cytokine;NK/NKT cell;T cell |
| 1100 |
Poster Presentation |
IL-15 enhances cytotoxicity of sipuleucel-T from metastatic castration-resistant prostate cancer patients by activating CD8+ T and NK effector cells |
Muhammad A. Saeed, PhD; Kevin Kim; Russell K. Pachynski, MD |
Immune-stimulants and immune modulators |
Adoptive immunotherapy;Cytokine;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment;Vaccine |
| 1101 |
Poster Presentation |
ASKG315 - An IL-15 Prodrug with Antibody-Like PK, Enhanced Safety and Expanded Therapeutic Window |
Chunxiao Yu, Ph.D.; Kurt Shanebeck; Jieye Sun, Ph.D.; Chao Wang; Shiguang Yu, Ph.D.; Jeannie Luiz; Ray Chuang, Ph.D.; Ming Li, Ph.D.; Yong Wen, Ph.D.; Jeff Lu, Ph.D.; Yuefeng Lu, Ph.D. |
Immune-stimulants and immune modulators |
Cytokine;NK/NKT cell;T cell;Tumor microenvironment |
| 1102 |
Poster Presentation |
A Single Spark Can Start a Prairie Fire - Re-think the Combination Strategy and Clinical Setting of IL-12 with Anti-PD-1 |
Pei-Yi Tsou; Wan-Ying Lin; Meng-Na Lee, Ph.D Candidate; San-chi Chen, MD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Cytokine;Tumor microenvironment |
| 1103 |
Poster Presentation |
Half-life extended, conditionally active IFNa prodrug induces tumor-selective activation and potent antitumor response |
Alice Yam, PhD; Kshama A. Doshi, PhD; Krishna Bajjuri; Millicent Embry; Frank Xiao; Grace Lee; Stephanie Armstrong; Daniel Calarese; Xiaofan Li; Gang Yin; Kristin Bedard, PhD; Trevor Hallam, PhD |
Immune-stimulants and immune modulators |
Cytokine;Immune toxicity;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1104 |
Poster Presentation |
A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy |
Fan Ye, Ph.D; Zoey Huang; Jianing Huang; Lili Cheng, Ph.D; Sandra Chen; Danny Huang; Michael Hua; Ella Li; Jenny Jiang; Hanna Lin; Xin Wang; Bella Yue; Shirley Shi; Henry He; Karen Yan; Binfeng Lu, PhD; Ziyang Zhong |
Immune-stimulants and immune modulators |
Antibody;Checkpoint blockade;Cytokine;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1105 |
Poster Presentation |
A novel triple action and pre-clinical safety profile of SLC-3010 predict its favorable translation in the phase I clinical study. |
Woong Hee Yoon, Ph.D.; Junhyeok Heo, M.S.; Daeun Kim, M.S.; Geona Kim, M.S.; Kyungmi Han, M.S.; Jun-Young Lee, Ph.D. |
Immune-stimulants and immune modulators |
Antibody;Cytokine;Immune adjuvant;T cell |
| 1106 |
Poster Presentation |
HZ-S506, a selective and orally bioavailable HPK1 degrader, is efficacious as a single agent or in combination with PD-1 antibody |
Yizhe Wu, PhD; Xinglu Zhou; Tingting Jin; Xinxin Jin |
Immune-stimulants and immune modulators |
Solid tumors;T cell |
| 1107 |
Poster Presentation |
Anti-HVEM mAB therapy improves antitumoral immunity both in vitro and in a novel mice model expressing human HVEM and BTLA molecules using HVEM expressing tumors |
Demerle Clemence, Pharm.D; Laurent Gorvel, PhD; Marielle Mello; Sonia Pastor; Clara Degos; Ana Zarubica; Frederic Fiore; Geoffrey Guittard, Ph.D.; Bernard Malissen, Ph.D.; Herve Luche, Ph.D.; Jacques Fieschi-Meric, PhD; Laurent Greillier, MD, PhD; Fabrice Barslesi, MD, Ph.D.; Daniel Olive, MD PhD |
Immune-stimulants and immune modulators |
Costimulation;Solid tumors;T cell |
| 1108 |
Poster Presentation |
Screening for immune response indicators after p53 gene transfer and cabazitaxel treatment in human prostate carcinoma in vitro |
Nadine Assis, B.S.; Bryan Strauss |
Immune-stimulants and immune modulators |
Chemotherapy;Gene expression;Solid tumors |
| 1109 |
Poster Presentation |
Progesterone impacts the growth and immune cell infiltration of murine mammary gland tumors |
Lauryn R. Werner, BBA; Eilidh I. Chowanec; Julio Tinoco; Harmony Saunders; Dominika E. Helm; Sean M. Holloran; Richard C. Hastings; Junping Wei; Gangjun Lei; Xiao-Yi Yang; Mary A. Markiewicz; Prabhakar Chalise; Justin M. Balko; Zachary C. Hartman; Christy R. Hagan |
Immune-stimulants and immune modulators |
Immune suppression;Regulatory T cell (Treg cell);Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1110 |
Poster Presentation |
Effect of sub-ablative hyperthermia on PD-1/PD-L1 axis modulation in the tumor microenvironment. |
Md Raihan Chowdhury, PhD; Mohamed Farghaly Ramadan; Vassiliki A. Boussiotis, MD, PhD; Muneeb Ahmed; Marwan Moussa, MD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Immune adjuvant;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 1111 |
Poster Presentation |
Immune modulation of melanoma brain metastases by IRAK-4 inhibition |
Bently Doonan, MD; Christina Von Roemeling, PhD; Erica Matich; Tyler Elliot; Vincent Archibald; Duane Mitchell, MD, PhD; Kelena Klippel; Vrunda Trivedi; Lan Hoang-Minh |
Immune-stimulants and immune modulators |
Checkpoint blockade;Immune adjuvant;Targeted therapy;Tumor microenvironment |
| 1112 |
Poster Presentation |
PARP inhibition increases in the suppressive capacity of tumor-associated Tregs in a BRCA1-deficient model of ovarian cancer. |
Daniel M. Falcon, PhD; Ichiko Kinjyo, MD PhD; Sarah F. Adams, MD |
Immune-stimulants and immune modulators |
Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1113 |
Poster Presentation |
Epigenetic modifications influence immune regulatory pathways in murine and human neuroblastoma and melanoma tumor models |
Arika S. Feils, BS; Lizzie Frankel; Ankita Shahi (De); Alina Hampton; Paul M. Sondel, MD, PhD; Amy K. Erbe, PhD |
Immune-stimulants and immune modulators |
Epigenetics;Gene expression;Immune monitoring;Immune tolerance;Pediatric tumors;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1114 |
Poster Presentation |
Immunotherapeutic activity of OX425 against PD-1 resistant HR+HER2- breast cancer |
Claudia Galassi; Wael Jdey; Lorenzo Galluzzi, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Chemotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1115 |
Poster Presentation |
T-DXd increases immune cell infiltration and enhances activity of immune checkpoint blockade in murine tumor models |
Liam Jenkins; Matt Wilson, BSc; Jerome Mettetal; Theresa Proia, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade |
| 1116 |
Poster Presentation |
OxPhos inhibition offsets the metabolic advantage of pancreatic cancer and promotes a pro-inflammatory tumor microenvironment. |
Madeline Steiner; Arthur J. Liu, BS; Sayan Alekseev; Charlotte Dahlem, PhD; Michael A. Curran, PhD |
Immune-stimulants and immune modulators |
Metabolism;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1117 |
Poster Presentation |
A Patient-Derived Tumor Organoid Platform to Investigate Radiation-Induced Neoantigen Exposure |
Samantha J. Van Nest, PhD, MS; Jared Capuano; Tuo Zhang, PhD; Bhavneet Bhinder; Xi Zhou; Adriana Irizarry; Laura Martin; Silvia C. Formenti, MD; Olivier Elemento, PhD; Nils-Petter Rudqvist, PhD; Sandra Demaria, MD |
Immune-stimulants and immune modulators |
Gene expression;Neoantigens;Radiotherapy;RNA;Tumor antigens |
| 1118 |
Poster Presentation |
Immunologically relevant effects of PT-112 on cancer cell mitochondria |
Takahiro Yamazaki, PhD; Lorenzo Galluzzi, PhD; Christina Y. Yim; Tyler D. Ames |
Immune-stimulants and immune modulators |
Chemotherapy;Cytokine;Inflammation;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 1119 |
Poster Presentation |
Glutamine antagonist prodrug JHU083 reprograms immunosuppressive tumor-associated macrophages to drives tumor immunity in urologic cancers |
Monali Praharaj, MS; Fan Shen; Thomas Nirschl; Alee J. Lee; Xiaoxu Wang; Liang Zhao; Alok K. Singh, PhD; Debebe Theodros; Laura Sena; Elizabeth D. Thompson, MD PhD; Ada Tam; Srinivasan Yegnasubramanian; Edward J. Pearce; Robert D. Leone; Jesse Alt; Rana Rais; Barbara S. Slusher; Andrew M. Pardoll, MD, PhD; Jonathan Powell, MD, PhD; Jelani Zarif |
Immune-stimulants and immune modulators |
Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors |
| 1120 |
Poster Presentation |
Neoadjuvant in situ intratumoral vaccination with empty cowpea mosaic virus nanoparticles is effective against canine mammary cancer. |
Daniel Alonso-Miguel, DVM; Guillermo Valdivia, DVM; Barbara Zimmermann, DVM; Lucia Lucia Barreno; Angela Alonso-Diez, DVM; Maria Dolores Perez-Alenza, DVM; Veronique Beiss; María Suárez-Redondo; Nicole Steinmetz, BS, PhD; Steven Fiering, BS, MS, PhD; Johannes Vom Berg; Laura Laura Peña, DVM; Hugo Arias-Pulido, PhD |
Immune-stimulants and immune modulators |
Chemokine;Cytokine;Immune adjuvant;Immune monitoring;Tumor microenvironment;Vaccine |
| 1121 |
Poster Presentation |
Tigilanol tiglate is a naturally occurring small molecule oncolytic that effectively ablates tumors via intratumoural injection and can enhance response to immune checkpoint blockade |
Jason K. Cullen, DPhil; Pei-Yi Yap; Blake Ferguson; Zara C. Bruce; Motoko Koyama; Herlina Handoko; Jacinta L. Simmons; Jenny Johns; Marjorie D’Souza; Natasa Broit; Praphaporn Stewart; Daniel Shelley; Tracey McMahon; Steven M. Ogbourne, Associate Professor; Yi Chieh Lim, PhD; Giovanni Appendino; Victoria A. Gordon, PhD; Paul W. Reddell, PhD; Glen M. Boyle, Professor; Peter G. Parsons, Professor |
Immune-stimulants and immune modulators |
Checkpoint blockade;Immune adjuvant;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 1122 |
Poster Presentation |
Radiotherapy-activated NBTXR3 nanoparticles induce Interferon Beta secretion by cancer cells |
Jordan Da Silva, PhD; Sebastien Paris |
Immune-stimulants and immune modulators |
Cytokine;Radiotherapy;Tumor microenvironment |
| 1123 |
Poster Presentation |
Preclinical Activity and Safety Profile or JANX008, a Novel EGFR-Targeting Tumor-Activated T Cell Engager for Treatment of Solid Tumors |
Shahram Salek-Ardakani; Thomas R. DiRaimondo; Natalija Budimir; Lina Ma; Simon Shenhav; Vanessa Cicchini; Hua Wu; Renee Jocic; Fabrece Roup; Calvin Cambell; Carolina Caffaro; Hans Aerni; Ugur Eskiocak; Wayne Godfrey; Charles Winter; Marc Nasoff; Neil Gibson; David Campbell |
Immune-stimulants and immune modulators |
Antibody;Bispecifics;Solid tumors;T cell |
| 1124 |
Poster Presentation |
Intratumoral administration of VAX014 cooperates with checkpoint blockade to reprogram tumor immune microenvironments and clear injected and noninjected tumors |
Matthew Giacalone, PhD, MBA; Katherine Reil; Shingo Tsuji; Kinsey Nelson; Elsa Molina; Kathleen McGuire |
Immune-stimulants and immune modulators |
Checkpoint blockade;Dendritic cell;Immune adjuvant;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 1125 |
Poster Presentation |
Intratumoral administration of SARS-CoV-2 reduces tumor progression and alters the tumor immune microenvironment similar to that of the seasonal influenza vaccine |
Eileena F. Giurini, MS; Kajal H. Gupta, PhD |
Immune-stimulants and immune modulators |
Cytokine;Immune adjuvant;Immune monitoring;Solid tumors;T cell;Tumor microenvironment;Vaccine |
| 1126 |
Poster Presentation |
Molecular mechanisms of DC activation by melanoma cells responding to LTX-315 |
Xiao-Qing Li; Takahiro Yamazaki, PhD; Tianzhen He; Md Masud Alam; Jia Liu; Anna L. Trivett; Baldur Sveinbjørnsson; Øystein Rekdal; Lorenzo Galluzzi, PhD; De Yang, PhD; Joost J. Oppenheim, M.D. |
Immune-stimulants and immune modulators |
Antigen presenting cells;Costimulation;Cytokine;Dendritic cell;Solid tumors;TLR;Tumor microenvironment |
| 1127 |
Poster Presentation |
Calcium phosphate biomaterials enhance immunotherapeutic mRNA delivery in melanoma |
Hannah L. Martin, BS; Joshua A. Choe, MS; Iris Baurceanu; William L. Murphy, PhD |
Immune-stimulants and immune modulators |
Cytokine;Gene expression;RNA;Solid tumors;T cell |
| 1128 |
Poster Presentation |
New viral-delivery of glycan-modifying sialidase induces anti-tumor immunity |
Natalia Rodrigues Mantuano, PhD; Michael Sandholzer, MSc.; Andreas Zingg, MSc.; Heinz Läubli, MD PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Immune suppression;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1129 |
Poster Presentation |
A Novel CpG motif Introduced into a Bispecifc AM003 Compound for the Treatment of Solid Tumors |
Neta Zilony- Hanin, PhD; Erez Lavi; Zohar Pode, PhD; Sapir Dahan; Vitaliy Buravenkov; Leeron Shefet Carasso, PhD; Ido Bachelet; Raanan Berger, MD; Irit Carmi Levy, PhD |
Immune-stimulants and immune modulators |
Antigen presenting cells;Bispecifics;Dendritic cell;Immune adjuvant;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 1130 |
Poster Presentation |
Investigating macrophage modulation in a murine model of soft tissue sarcoma |
Kurt N. Hildebrand, BScH; Karys M. Hildebrand, PhD Candidate; Franz J. Zemp; Carolina Salazar Arcila; Michael J. Monument |
Immune-stimulants and immune modulators |
Monocyte/Macrophage;Myeloid cells;Solid tumors |
| 1131 |
Poster Presentation |
GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses. |
Peter I. Joyce, PhD; Andrew Leishman; Asolina Braun; Mitul Patel; Michael Pinggera; Jessica Sette; Kate Anderton; Edd James; Valeriya Shunina; Anthony W. Purcell; Nicola Ternette; Jason Shiers, PhD; Martin Quibell; Wayne Paes; Tom McCarthy |
Immune-stimulants and immune modulators |
Antigen presenting cells;Neoantigens;Solid tumors;Surfaceome;T cell;Tumor antigens |
| 1132 |
Poster Presentation |
Impact of intralesional oncolytic viral therapy targeting in situ activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients |
Andreas Saltos, MD; Hong Zheng, PhD; Christy Arrowood; Georgia Beasley, MD, MHSc; James Ronald, MD, PhD; Ghassan El-Haddad, MD; Uzma Khan; Luiziane Guerra-Guevara; Steven Wolf; Lin Gu; Xiaofei F. Wang, PhD; Mark Cantwell, PhD; Scott J. Antonia, MD, PhD; Amer Beg, PhD; Neal Ready, MD, PhD |
Immune-stimulants and immune modulators |
Clinical study;Dendritic cell;Solid tumors;T cell;Tumor microenvironment |
| 1133 |
Oral Presentation |
Remodeling the immunosuppressive tumor microenvironment with oncolytic virus-mediated delivery of a potent TGF-b inhibitor |
Kristin DePeaux, BS; Dayana B. Rivadeneira, PhD; Kevin Quann, MD PhD; Konstantinos Lontos, MD, PhD; Andrew Hinck, PhD; Greg M. Delgoffe, PhD |
Immune-stimulants and immune modulators |
Immune suppression;Inflammation;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1134 |
Poster Presentation |
Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice |
David R. Withers; Anne R. Diers, PhD; Zhi Li; Suaad Idris; Claire Willis; Paul Peter Tak, MD, PhD, FMedSci; Francesca Barone, MD, PhD |
Immune-stimulants and immune modulators |
Biomarkers;Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1135 |
Poster Presentation |
Single Cell Resolution of Immune Responses to Oncolytic Herpes Simplex Virus C134 in Preclinical Medulloblastoma Models |
Jack Hedberg, B.S.; Adam Studebaker; Luke Smith; Chun-Yu Chen; Jesse J. Westfall; Maren Cam; Amy Gross; Ryan Roberts; Timothy P. Cripe; Elaine R. Mardis, PhD; Kevin A. Cassady; Jeffrey Leonard; Katherine E. Miller |
Immune-stimulants and immune modulators |
Antigen presenting cells;Gene expression;Pediatric tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1136 |
Poster Presentation |
Induction of tertiary lymphoid structures in non-small cell lung cancer improves B and T cell anti-tumor immunity |
Hye Mi Kim, BS; Dongyan Liu; Ayana Ruffin, PhD; Alexandra McDonough, BA; Caleb Lampenfeld; Sheryl R. Kunning; Ashwin Somasundaram, MD; Laura Stabile, PhD; Tullia Bruno, PhD |
Immune-stimulants and immune modulators |
B cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1137 |
Poster Presentation |
SuperNova1 (SNV1), a novel oncolytic-cell based platform for cancer therapy |
Duong H. Nguyen; Mohamed Hammad; Rachael Mooney; Forrest Neuharth; Ashley Alamillo; Ivelina Minev; Israel Romero; Stephanie Songco; Emma Kedl; Yunyi Kang; Hoi W. Ngai; Marisa McDonald; Linda Flores; Dae H. Kim; Jacqueline Lara; Thomas Herrmann; Barbara Härtl; Laura Edith; Daniela Kleinholz; Boris Minev; Karen Aboody; Antonio F. Santidrian |
Immune-stimulants and immune modulators |
Antigen presenting cells;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 1138 |
Poster Presentation |
Engineered oncolytic viruses expressing immunomodulatory genes enhanced anti-tumor immune responses in vitro |
Zhongbao Song; Limin Tian; Guangxu Ding; Ka Fung Noi; Jie Xu; Qingyang Gu |
Immune-stimulants and immune modulators |
Cytokine;Dendritic cell;NK/NKT cell;T cell;Tumor antigens |
| 1139 |
Poster Presentation |
Virotherapy with CodaLytic™, a codon-modified influenza virus, induces an anti-tumor immune microenvironment across preclinical models with different immune contextures |
Marcin Stawowczyk, PhD; Yiwen Zhao, PhD; Katie Pfeffer; Juliana Tafrova, PhD; Nusrat Jahan, PhD; James Rodriguez; Chen Yang, PhD; Sybil Tasker, MD; Steffen Mueller, PhD; J. Robert Coleman, PhD, MBA; Johanna K. Kaufmann, PhD |
Immune-stimulants and immune modulators |
Antigen presenting cells;Checkpoint blockade;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1140 |
Oral Presentation |
Cancer stem cells and PD-L1-expresing exosomes suppress anti-tumor effector B cells |
Ying Xin; You Qin; Max Wicha; Alfred E. Chang; Qiao Li, PhD |
Immune-stimulants and immune modulators |
Adoptive immunotherapy;Antibody;B cell;Checkpoint blockade;Immune monitoring;Immune suppression;Stem cell/cancer-initiating cell;T cell;Targeted therapy |
| 1141 |
Poster Presentation |
DKN-01 demonstrates immune modulatory activity and robust efficacy in colorectal cancer models |
Michael S. Haas, PhD; Michael Kagey; Walter Newman, PhD; James B. Rottman, DVM, PhD, DACVP; Milad Moloudizargari, PhD; Ajay Goel, PhD; Cynthia A. Sirard, MD; Jason Baum |
Immune-stimulants and immune modulators |
Antibody;Biomarkers;Checkpoint blockade;Chemotherapy;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1142 |
Poster Presentation |
Hypoxia reduction in combination with anti-angiogenic therapy remodels the PDAC microenvironment |
Arthur J. Liu, BS; Michael A. Curran, PhD |
Immune-stimulants and immune modulators |
Angiogenesis;Checkpoint blockade;Chemotherapy;Immune suppression;MDSC;Targeted therapy |
| 1143 |
Poster Presentation |
5T4-CD40 bispecific antibodies activate immune responses in a 5T4-dependent manner |
Fang Liu, PhD; Wenci Gong; Yuanyuan Yang, PhD; Zhijian Cai; Feifei Cui; Lei Fang; Wenqing Jiang |
Immune-stimulants and immune modulators |
Antibody;Antigen presenting cells;B cell;Bispecifics;Costimulation;Dendritic cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1144 |
Oral Presentation |
IL17-producing γδ T cells promote resistance to CDK4/6 inhibitors in HR+HER2- breast cancer |
Giulia Petroni, PhD; Kenneth H. Gouin, III; Claudia Galassi; Aitziber Buqué; Norma Bloy, PhD; Takahiro Yamazaki, PhD; Ai Sato, MSc; Carlos Jiménez-Cortegana; Alexander Kirchmair; Chiara Massa; Carlos Eduardo De Andrea; Belén Navarro; Irantzu Serrano; Esther Navarro Manzano; Francesca Finotello; Xi Zhou; Elena García-Martínez; María E. Rodríguez-Ruiz; Barbara Seliger; Víctor Sánchez-Margalet; Luis de la Cruz-Merino; Heather McArthur; Silvia Formenti; Simon Knott; Lorenzo Galluzzi, PhD |
Immune-stimulants and immune modulators |
Chemokine;Immune suppression;Radiotherapy;Solid tumors;T cell lineages;Tumor evasion;Tumor microenvironment |
| 1146 |
Poster Presentation |
NKG2D co-stimulation via anti-sMIC/MIC targeting antibody enhances CD8 T cell functional heterogeneity and memory development in mouse prostate tumors |
Tyler A. Smith, PhD; Sizhe Liu, BS; Lisha Zhu, PhD; Jennifer D. Wu, PhD |
Immune-stimulants and immune modulators |
Antibody;Costimulation;Epigenetics;Gene expression;Metabolism;RNA;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1147 |
Poster Presentation |
Differences in co-expression of T cell co-inhibitory and co-stimulatory molecules with PD1 across different human cancers |
Ahmad A. Tarhini, MD, PhD, MS; Dale J. Hedges, PhD; Aik Choon Tan, PhD; Paulo Rodriguez; Vineeth K. Sukrithan, MD; Aakrosh Ratan; Martin McCarter, MD; John D. Carpten, PhD; Howard Colman, MD; Alexandra Ikeguchi, MD; Igor Puzanov, MD, MSCI, FACP; Susanne M. Arnold, MD; Michelle L. Churchman, PhD; Patrick Hwu; Jose Conejo-Garcia, MD, PhD; William (Bill) S. Dalton, PhD, MD; George J. Weiner, MD |
Immune-stimulants and immune modulators |
Biomarkers;Checkpoint blockade;Costimulation;Gene expression;Immune monitoring;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1148 |
Poster Presentation |
Signal-regulatory protein alpha (SIRPα) confers tumor cell resistance to anti-tumor immunity |
Chien-Huan Weng, PhD; Linda Hamadene, MD; Shabnam Eghbali, BA; Divya Venkatesh, Ph.D.; Sébastien Monette; Levi M. Mangarin, BS; Fadi Samaan, BS; Cailian Liu, MD; Pamela M. Holland, PhD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD |
Immune-stimulants and immune modulators |
Immune suppression;Inflammation;Solid tumors;Tumor evasion;Tumor microenvironment |
| 1149 |
Poster Presentation |
Targeting regulatory T cells with CTM033, a novel anti-CCR8 antibody, inhibited tumor growth |
Yuanyuan Yang, PhD; Yuehua Chen; Feifei Cui; Wenqing Jiang; Lei Fang |
Immune-stimulants and immune modulators |
Antibody;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1150 |
Poster Presentation |
ATG-101, a tetravalent PD-L1x4-1BB BsAb, demonstrates potent in vivo anti-tumor efficacy in ICI-resistant or refectory mouse tumor models |
Hui Yuwen; Tengteng Li; Yijing Ren; Jay Mei; Bo Shan; Bing Hou, Ph.D |
Immune-stimulants and immune modulators |
Bispecifics;Immune tolerance;Regulatory T cell (Treg cell);Tumor microenvironment |
| 1151 |
Poster Presentation |
Revealing Novel Therapeutic Indications through Profiling of Immune Modulatory Properties by Uliledlimab |
Yanni Zhang, Ph.D; Zhen Sheng, PhD; Xinyun Zhu; Yanling Niu, PhD; Yuan Meng, MD; Zhengyi Wang, PhD; Andrew Zhu |
Immune-stimulants and immune modulators |
Angiogenesis;Antibody;Checkpoint blockade;Gene expression;Immune suppression;Myeloid cells;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1152 |
Poster Presentation |
In vitro anticancer and immunomodulatory activities of a novel molecular glue compound NBT-018 |
Sophia E. Zhang; Magdalena Dragan; Nicole Potter; Everett Henry; L. Harris Zhang, Ph.D.; Harris Zhang |
Immune-stimulants and immune modulators |
Cytokine;Inflammation;Leukemia/Lymphoma;T cell;Targeted therapy |
| 1153 |
Poster Presentation |
Preclinical activity of C-C chemokine receptor 2 (CCR2)-targeted immune stimulating antibody conjugate (ISAC), motivating clinical testing of TAK-500 |
Vicky Appleman; Atsushi Matsuda; Michelle L. Ganno; Angel E. Maldonado Lopez; Emily Rosentrater; Camilla L. Christensen; Samantha A. Merrigan; Hong Myung Lee; Min Young Lee; Linlin Dong; Jian Huang; Natasha Iartchouk; Dong Mei Zhang; Jianing Wang; He Xu; Tomoki Yoneyama; Konstantin I. Piatkov; Carole E. Harbison; Adnan O. Abu-Yousif |
Immune-stimulants and immune modulators |
Antibody;Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;T cell;Targeted therapy;Tumor evasion;Tumor microenvironment |
| 1154 |
Poster Presentation |
High-potency synthetic STING agonists rewire myeloid subsets in the tumour microenvironment to dismantle immunosuppressive stroma in refractory pancreatic ductal adenocarcinoma |
Akash R. Boda, MS; Casey R. Ager, PhD; Kimal Rajapakshe, PhD; Krithikaa Rajkumar Bhanu; Spencer T. Lea, BA; Michael A. Curran, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Immune suppression;MDSC;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1155 |
Poster Presentation |
ONM-501, a polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates |
Zirong Chen, PhD; Jason B. Miller, PhD; Wei Li; Katy Torres; Qingtai Su, Ph.D.; Gang Huang; Yasser Saud O Albaroodi; Rachel Morsch; Teresa McElvaney; Fiona Stavros; Don Kruppa; Tian Zhao, PhD; Jinming Gao, PhD; Ruolan Han |
Immune-stimulants and immune modulators |
Costimulation;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 1156 |
Poster Presentation |
STING Activation in Sarcoma: Assessing Translational Therapeutic Strategies |
Karys M. Hildebrand, PhD Candidate; Kurt N. Hildebrand; Kayla L. Marritt; Carolina Salazar Arcila; Michael J. Monument |
Immune-stimulants and immune modulators |
Checkpoint blockade;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1157 |
Poster Presentation |
Discovery of a novel, potent small molecule inhibitors of ENPP1 enhances anti-tumor efficacy in combination with immune check inhbitors. |
Juhyeon Kim, Ph.D; Pyoung Oh Yoon; A-Ram Lee; Eunji Son; Young Cheol Lee; Eunmi Jung; HyoungRae Kim; YeonHee Lee; SoEun Park; Dae-Yon Lee; Chul-Woong Chung |
Immune-stimulants and immune modulators |
Checkpoint blockade;Cytokine;NK/NKT cell;T cell;Tumor microenvironment |
| 1158 |
Poster Presentation |
High potency STING agonists induce adaptive-immunity dependent curative responses in checkpoint-refractory Glioblastoma models |
Spencer T. Lea, BA; Michael A. Curran, PhD; Chao-Hsien Chen, MD, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Immune adjuvant;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1159 |
Poster Presentation |
Use of small molecule STING agonist immunotherapy for canine soft tissue sarcoma: a cross-species analysis |
Ye-Jean Park, MD in progress; Joseph Kendal, MD, MSc, FRCSC; Carolina Salazar Arcila; Karys M. Hildebrand, PhD Candidate; Max Labrecque; Michael J. Monument |
Immune-stimulants and immune modulators |
Cytokine;Gene expression;Solid tumors |
| 1160 |
Poster Presentation |
STING signaling compensates for mutation burden-low tumors to stimulate the immune response. |
Jiayi Tan, MBBS; Colt Egelston, PhD; Weihua Guo, PhD; Peter P. Lee, MD |
Immune-stimulants and immune modulators |
Antigen presenting cells;Immune contexture;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1161 |
Poster Presentation |
Synthetic CD206 Targeted Constructs Carrying Pacletaxel or Novel Bisphosphonate Payloads Alter Macrophages Towards Pro-inflammatory Phenotypes; The Paclitaxel Construct Improves the Efficacy of anti-CTLA4 in CT26 Tumors |
David A. Ralph, PhD; Jeffrey Arnold, PhD; Michael Rosol, PhD |
Immune-stimulants and immune modulators |
Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Targeted therapy;Tumor microenvironment |
| 1162 |
Poster Presentation |
A Nectin-4 targeted TLR9 agonist antibody conjugate induces robust immune cell activation and anti-tumor responses |
Amy Chen, BS; Min Li; Maja Bonacorsi; Emma R. Sangalang; Danielle Fontaine; Ons Harrabi, BA; Mingrui An; Tiffany Chou; Laura Doyle; Janet Sim, PhD; Bora Han, PhD; Hong I. Wan, PhD; Tracy C. Kuo; Maria Jose Costa; Pavel Strop |
Immune-stimulants and immune modulators |
Antibody;Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;TLR;Tumor antigens;Tumor microenvironment |
| 1163 |
Poster Presentation |
A unique dendritic cell activation state utilizes inflammasomes to stimulate memory T cell responses in humans |
Jon Chow, PhD; Veronica Komoroski, BS; Emily Gosselin, PhD; Andrew Cornforth, PhD |
Immune-stimulants and immune modulators |
Antigen presenting cells;Cytokine;Immune adjuvant;T cell;T cell lineages;TLR |
| 1164 |
Poster Presentation |
Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysis. |
Bedrich Eckhardt; Kellie Mouchemore; Yang Liao; Wei Shi; Francesca Mercuri; Phil Kearney; Robin Anderson; Anna V. Galkin, PhD |
Immune-stimulants and immune modulators |
Gene expression;Granulocyte;Monocyte/Macrophage;TLR;Tumor microenvironment |
| 1165 |
Poster Presentation |
Impact of SD-101, a toll-like receptor 9 class C (TLR9C), agonist on myeloid derived suppressor cells |
Chandra C. Ghosh, PhD; Steven C. Katz, MD |
Immune-stimulants and immune modulators |
Immune suppression;MDSC;Monocyte/Macrophage;TLR;Tumor microenvironment |
| 1166 |
Poster Presentation |
Profiling the effects of targeted TLR9 stimulation within spontaneously arising breast tumors |
Caitlyn L. Miller, PhD; Idit Sagiv-Barfi, PhD; Patrick Neuhoefer, PhD; Debra K. Czerwinski, BS; Carolyn R. Bertozzi, PhD; Jennifer R. Cochran, PhD; Ronald Levy, MD |
Immune-stimulants and immune modulators |
Immune adjuvant;Inflammation;Solid tumors;T cell;Targeted therapy;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1167 |
Poster Presentation |
APR003, an oral liver- and GI-targeted TLR7 agonist, elicits a robust type I interferon response in advanced colorectal cancer patients |
Andrew T. Miller, PhD; Trinh Le; Jaymes Holland; Ron Weitzman; Tom YH. Wu |
Immune-stimulants and immune modulators |
Immune adjuvant;TLR |
| 1168 |
Poster Presentation |
A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models |
Shannon M. Miller, PhD; Caleb Beyer; Danielle Talbot; Konner Jackson; Margaret Whitacre; Janine Ward; Roman Schoener; Helene G. Bazin, PhD; David Burkhart, PhD |
Immune-stimulants and immune modulators |
Antigen presenting cells;B cell;Checkpoint blockade;Costimulation;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs) |
| 1169 |
Poster Presentation |
Systemic administration of TLR7/8 agonist micelles triggers a potent anti-tumor response mediated by neutrophils as primary effector cells followed by establishment of an immune memory response |
Simon S. Jensen, PhD; Esben Christensen, PhD; Morten Just Petersen; Anders Hansen, PhD; Martin Bak, PhD; Camilla Stavnsbjerg, PhD; Svetlana Panina, MD, PhD; Thomas Andersen, PhD |
Immune-stimulants and immune modulators |
Granulocyte;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1170 |
Poster Presentation |
EGFR-Ta:RNA: Multimodal mechanism of action potentiates immune checkpoint inhibitor activity |
Babette Schade, PhD; Derrick Broka; Caroline De Feyter; Shoshana Klein, PhD; Alexei Shir, PhD; Alexander Levitzki, Prof; Davor Bajic, PhD; Lucia D’Amico, PhD; David Colecchia, PhD; Eric Kitas, PhD; Anita Jarzebinska, PhD; Esteban Pombo-Villar, PhD; Maya Zigler, Dr |
Immune-stimulants and immune modulators |
RNA;Solid tumors;Targeted therapy;TLR;Tumor microenvironment |
| 1171 |
Poster Presentation |
CAN1012: a Selective and Potent TLR7 Agonist with Strong Antitumoral Properties Mediated by Localized Innate Immune Activation |
Henry Yu, PhD; Hong-Ming Hu, PhD; Rongliang Lou, PhD; Wanping Geng, PhD; Sanlong Wang; William L. Redmond, Ph.D.; Yoshinobu Koguchi, MD, PhD; Baotian Qin; John Mao, PhD; Shaoshan Wang, PhD |
Immune-stimulants and immune modulators |
Antigen presenting cells;Chemokine;Clinical trial;Cytokine;Dendritic cell;Immune adjuvant;MDSC;T cell;TLR;Tumor microenvironment |
| 1172 |
Poster Presentation |
A unique dendritic cell activation states utilizes inflammasomes to stimulate anti-tumor immunity in mice |
Dania Zhivaki; Kelsy Finn, PhD; Emily Gosselin, PhD; Holly Concepcion, BS; Andrew Cornforth, PhD; Caitlin Sullivan, BS |
Immune-stimulants and immune modulators |
Antigen presenting cells;Cytokine;Dendritic cell;Immune adjuvant;Inflammation;Neoantigens;Solid tumors;T cell lineages;TLR;Vaccine |
| 1173 |
Poster Presentation |
ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses |
Claudio Scuoppo; Gerald S. Falchook, MD, MS; Elisa Fontana; Anja Williams; Nehal J. Lakhani, MD; Jeff Evans; Fabio Iwamoto; Meredith McKean, MD; Stefan N. Symeonides, MD PhD; Alistair McLaren; Jason Henry, M.D.; Gina Capiaux, PhD; Robert E. Michel, PhD; Stephen Kaesshaefer; Alice Bexon; Jim Rotolo, PhD |
Immune-stimulants and immune modulators |
Clinical trial;MDSC;Monocyte/Macrophage;Tumor microenvironment |
| 1174 |
Poster Presentation |
Multi-epitope DNA vaccine targeting cancer neoantigens enhances efficacy of anti-PD1 therapy |
Pratik S. Bhojnagarwala, MS; Alfredo Perales-Puchalt, PhD; Ebony Gary; Niranjan Y. Sardesai, PhD; David B. Weiner, PhD |
Immune-stimulants and immune modulators |
Checkpoint blockade;Tumor antigens;Vaccine |
| 1175 |
Poster Presentation |
Memory T cells elicited by microorganisms cross-react with tumor-associated antigens. |
Luigi Buonaguro, MD; Maria Tagliamonte; Beatrice Cavalluzzo |
Immune-stimulants and immune modulators |
Adoptive immunotherapy;Microbiome;T cell;Tumor antigens;Vaccine |
| 1176 |
Poster Presentation |
Optimizing immunization schedules for therapeutic vaccination |
Yushe Dang, PhD; Denise Cecil, PhD; Lauren Corulli, MS; Erin Rodmaker, BS; Mary L. Disis, MD, FACP |
Immune-stimulants and immune modulators |
Adoptive immunotherapy;T cell;Tumor antigens;Vaccine |
| 1177 |
Poster Presentation |
Identification of and vaccination with antigen specific Th1 selective epitopes in bladder cancer: a step towards a multi-antigen vaccine for bladder cancer prevention |
Yushe Dang, PhD; Lauren Corulli, MS; Erin Rodmaker, BS; Denise Cecil, PhD; Yi Yang, MS; Carissa Walsh, BS; Will Gwin, MD; Jonathan L. Wright,, MD; Jennifer Childs, MPH; Shizuko Sei, MD; Mary L. Disis, MD, FACP |
Immune-stimulants and immune modulators |
Adoptive immunotherapy;T cell;Tumor antigens;Vaccine |
| 1178 |
Poster Presentation |
Delivery of DNA Origami Cancer Vaccine Using Alginate Microparticles |
Amani Djouadi; Niksa Roki, Ph.D.; Carlos Castro, Ph.D. |
Immune-stimulants and immune modulators |
Antigen presenting cells;Immune adjuvant;T cell;TLR;Tumor antigens;Vaccine |
| 1179 |
Poster Presentation |
EFFICACY STUDY OF STC-1010 ANTITUMOR VACCINE ASSOCIATED WITH STANDARD CHEMOTHERAPIES ON MC 38 SYNGENEIC COLON CANCER TUMOR MODEL |
Corinne Tortorelli, Pharm.D, Ph.D; Celine Gongora; Doriane Mathe; Benoit Pinteur; Lionel Chalus; Paul Bravetti; Nicolas Gadot; Sylvie Lantuejoul; Charles Dumontet; François Ghiringhelli |
Immune-stimulants and immune modulators |
Biomarkers;Dendritic cell;Immune monitoring;Monocyte/Macrophage;Neoantigens;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 1180 |
Poster Presentation |
Listeria-based immunotherapy sculpts CD8+ T cell response in the tumor microenvironment to control renal cell carcinoma |
Mariam Oladejo, B.Pharm; Laurence M. Wood, PhD |
Immune-Stimulants and Immune modulators |
T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1181 |
Poster Presentation |
Therapeutic vaccines consisting of cancer germline antigen-based synthetic long peptides are immunogenic in human hepatocellular carcinoma patients |
Yannick S. Rakké, MD, MSc; Marij J. Schoenmaekers-Welters, PhD; Lisanne Noordam, MD, MSc; Sanne Boekestijn; Luc Magre, BSc; Robbie J. Luijten, BSc; Rachelle S. van Gemerden, MSc; Monique T.A. de Beijer, MSc; Michael Doukas, MD, PhD; Jeroen A.A. Demmers, PhD; Anna-Sophia Wiekmeijer, PhD; Willem-Jan Krebber, MSc; Cornelis J. Melief, MD, PhD; Jan N. IJzermans, MD, PhD; Jaap Kwekkeboom; Sjoerd H. van der Burg, Prof.Dr.; Sonja Buschow; Dave Sprengers |
Immune-stimulants and immune modulators |
Antigen presenting cells;Proteomics;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 1182 |
Poster Presentation |
Modulating the tumor microenvironment by a targeting TGFB1 with vaccine-induced immune responses |
Brian T. Weinert, PhD; Tine Hannibal, PhD; Preeyam Patel; Evelina Martinenaite, PhD; Marion Chapellier, PhD; Marco Carretta; Alireza Alavi, PhD MBA; Ayako W. Pedersen, PhD; Muhammad Al-Hajj |
Immune-stimulants and immune modulators |
Gene expression;Immune suppression;T cell;Tumor microenvironment;Vaccine |
| 1183 |
Poster Presentation |
ASKG915 - An Anti-PD-1 Antibody-IL-15 Prodrug Fusion Molecule with Enhanced Therapeutic Potentials |
Kurt Shanebeck; Chunxiao Yu, Ph.D.; Shiguang Yu, Ph.D.; Jieye Sun, Ph.D.; Dongfang Wang; Jeanine Luiz; Ming Li, Ph.D.; Ray Chuang, Ph.D.; Jing Chen, Ph.D.; Samantha Luiz; Lynwel Cunanan; Stone Shi, Ph.D.; Matt Hsu, Ph.D.; Yong Wen, Ph.D.; Jeff Lu, Ph.D.; Yuefeng Lu, Ph.D. |
Immuno-conjugates and chimeric molecules |
Bispecifics;Checkpoint blockade;Costimulation;Cytokine;NK/NKT cell;T cell;Tumor microenvironment |
| 1184 |
Poster Presentation |
SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo |
Dori Thomas-Karyat, PhD; Robert Lutz; Douglas Burtrum |
Immuno-conjugates and chimeric molecules |
Antibody;Checkpoint blockade;Immune suppression;T cell;Targeted therapy;Tumor evasion |
| 1185 |
Poster Presentation |
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs) |
Graham Garnett, MSc; Katina Mak; Renee Duan; Truman Hirkala-Schaefer; Manuel Lasalle; Nichole Escalante; Joy Guedia; Kara Moyes; Sam Lawn; Raffaele Colombo; Jamie Rich; Stuart D. Barnscher |
Immuno-conjugates and chimeric molecules |
Antigen presenting cells;Cytokine;Immune adjuvant;Myeloid cells;TLR |
| 1186 |
Poster Presentation |
SGN-B6A induces immunogenic cell death as a secondary mechanism of action |
Robert P. Lyon; Vivian Trang, PhD; John Gosink; Michelle Ulrich; Allana Ubben; Sean Allred; Li-Ya Huang; Kelly Hensley; Piper M. Treuting; Kerry Klussman; Shaylin Higgins; Patrick Younan; Roma Yumul; Natalya Nazarenko |
Immuno-conjugates and chimeric molecules |
Antibody;Solid tumors;Targeted therapy;Tumor antigens |
| 1187 |
Poster Presentation |
Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors |
Devra Olson; Patrick Younan; Bernard A. Liu; Gabriele Blahnik-Fagan; John Gosink; Katie Snead; Elena Tenn; Kelly M. Hensley; Disha Sahetya; Albina Nesterova; Margo Zaval; Anthony Cao; Christine O'Day; Ryan A. Heiser, PhD; Timothy S. Lewis; Shyra J. Gardai; Taisuke Nakazawa; Masashi Shimazaki; Christopher Carosino; Sharsti Sandall, PhD |
Immuno-conjugates and chimeric molecules |
Checkpoint blockade;Cytokine;Gene expression;Solid tumors;Tumor antigens;Tumor microenvironment |
| 1188 |
Poster Presentation |
Antibody Substrate Oligonucleotide Conjugates (ASOCs): a new class of immunotherapeutic agents to inhibit metastasis of tumor cells and block checkpoint inhibition |
Beverly Packard, Ph.D.; Akira Komoriya |
Immuno-conjugates and chimeric molecules |
Antibody;Biomarkers;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1189 |
Poster Presentation |
A GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies |
Guillem Pascual-Pasto, PhD; Brendan McIntyre; Rawan Shraim; Samantha Buongervino; Amy K. Erbe, PhD; Dontcho Jelev; Anna M. Giudice; Daniel Martinez; Laura Garcia-Gerique; Dimiter S. Dimitrov, PhD; Paul M. Sondel, MD, PhD; Kristopher R. Bosse |
Immuno-conjugates and chimeric molecules |
Antibody;Monocyte/Macrophage;Pediatric tumors;Tumor microenvironment |
| 1190 |
Poster Presentation |
SGN-B7H4V induces immunomodulatory changes to the tumor microenvironment and pairs well with an anti-PD1 agent in a preclinical model |
Michelle Ulrich; Angela D. Epp; Kelly M. Hensley; Julie Hahn; Sean Allred; John Gosink; Piper M. Treuting; John Hernandez Villanueva; Sarah Anderson; Alyson J. Smith, PhD; Jason Schrum; Natalya Nazarenko; Shyra J. Gardai; Elizabeth Gray, PhD |
Immuno-conjugates and chimeric molecules |
Checkpoint blockade;Solid tumors;Targeted therapy;Tumor antigens |
| 1191 |
Poster Presentation |
STRO-003 is a novel ROR1-targeted ADC for breast and lung cancer |
Alice Yam, PhD; Jeff Hanson; Krishna Bajjuri; Sihong Zhou; Dayson Moreira, PhD; Jennifer Smith; Cristina Abrahams; Xiaofan Li, PhD; Grace Lee; Stephanie Armstrong; Amandeep Gakhal; Daniel Calarese; Young Park; Miao Wen; Gang Yin; Simon Chivers; Faye Hsieh; Guifen Xu; Werner Rubas; Andreas Maderna; Kristin Bedard; Trevor Hallam |
Immuno-conjugates and chimeric molecules |
Antibody;Solid tumors;Stem cell/cancer-initiating cell;Targeted therapy;Tumor antigens |
| 1192 |
Poster Presentation |
Identification of oncogene-induced surface protein IL1RAP as an immunotherapy target in multiple cancers |
Hai-Feng Zhang, PhD; Wei Li, PhD; Christopher S. Hughes, PhD; Rajesh Kumar, PhD; Alberto Delaidelli, PhD; Yue Zhou Huang; Michael Lizardo, PhD; Rimas J. Orentas, PhD; Dimiter S. Dimitrov, PhD; Poul H. Sorensen, PhD, MD |
Immuno-conjugates and chimeric molecules |
Adoptive immunotherapy;Antibody;CAR T cells;Pediatric tumors;Proteomics;Solid tumors;Surfaceome;Targeted therapy;Tumor antigens |
| 1193 |
Poster Presentation |
Inducing immunogenic cell death and antitumor activity in response to radioimmunotherapy |
Denis Beckford, PhD; Jason Li; Caroline Jennings; Megan McCloskey; Le-Cun Xu; Debbie Lewis; Patrik Brodin; Amanda Chin; Monideepa Roy; Mary Chen; Helen Kotanides |
Immuno-conjugates and chimeric molecules |
Targeted therapy;Tumor microenvironment |
| 1194 |
Poster Presentation |
Discovery and pre-clinical development of a novel and differentiated EphA2-targeted antibody in multiple bispecific formats |
Maryam M. Bhatti; Michael S. Weiss; Amanda R. Haltom; Jessica A. Finn; Annie Gai; Anne Ye; Danhui Zhang, MD PhD; Cathrin J. Czupalla; Andreea Stuparu; Yvonne Leung, Ph.D.; Erin Wechsler, PhD; Iraz T. Aydin; Daniel Emerling, PhD; Amy Manning-Bog, PhD; Nikhil Vad; Alexander Scholz, PhD; Philippe Marguet; Shaun M. Lippow, PhD |
Immuno-conjugates and chimeric molecules |
Antibody;B cell;Bispecifics;Costimulation |
| 1195 |
Poster Presentation |
Generation of a highly potent, cis-signaling PD1-IL2 immunocytokine using a novel chemical synthesis and conjugation platform |
Jean Ph. Carralot, PhD; Matilde Arévalo Ruiz, PhD; Rubén Alvarez Sanchez, PhD; Robert Tam, PhD; Lilian Gremlich, MSc; Andrew S. Chi, MD PhD; Vijaya R. Pattabiraman, PhD; Bertolt D. Kreft, PhD |
Immuno-conjugates and chimeric molecules |
Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 1196 |
Poster Presentation |
Streamlining T cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine |
Lindsay DeVorkin, PhD; Juntao (Matt) Mai, PhD; Kate Caldwell, MSc; Tim M. Jacobs, PhD; Raffi Tonikian, PhD; Karine Herve, MSc; Yuri Hwang, BSc; Cristina Faralla, PhD; Wei Wei, PhD; Emma Lathouwers, PhD; Rhys S. Chappell, BSc; Stefan Hannie, PhD; Katherine J. Lam, BSc; Harveer Dhupar, PhD; Tran N.T. Tran, MSc; Melissa Cid, PhD; Lena M. Bolten, PhD; Tova Pinsky, MSc; Ping Xiang, PhD; Courtenay Lai, PhD; Ahn Lee, PhD; Patrick Chan, PhD; Jasmine Chin, BSc; Aaron Yamniuk, PhD; Kush Dalal, PhD; Bryan C. Barnhart, PhD |
Immuno-conjugates and chimeric molecules |
Antibody;Bispecifics;Cytokine;Immune toxicity;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 1197 |
Poster Presentation |
Optimizing a T cell-engaging bispecific antibody targeting the highly recurrent p53 R175H neoantigen via affinity maturation |
Sarah R. DiNapoli; Katharine Wright; Emily HC. Hsiue, MD, PhD; Brian J. Mog; Sandra B. Gabelli, PhD; Kenneth W. Kinzler, PhD; Bert Vogelstein; Shibin Zhou, MD, PhD |
Immuno-conjugates and chimeric molecules |
Antibody;Bispecifics;T cell;Targeted therapy;Tumor antigens |
| 1198 |
Poster Presentation |
A dual targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and a manageable safety profile |
Melissa Dullaers, PhD; Geert Deschamps; Helene Bonnevaux; Stephane Guerif; Veronique De Brabandere; Celine Amara; Ann Brige; Eline Dejonckheere; Angela Virone-Oddos; Marielle Chiron; Annelies Roobrouck |
Immuno-conjugates and chimeric molecules |
Bispecifics;Leukemia/Lymphoma;T cell;Targeted therapy;Tumor antigens |
| 1199 |
Poster Presentation |
Comparison of four in vitro cytotoxicity assays for assessing the potency of CD3-bispecific antibodies redirecting T cells to kill tumor target cells |
Jun Guan; Charlie Kang; Alejandro Amador Arjona; Ricardo Macarron; Patrick Mayes, PhD; Yao-Bin Liu, MD |
Immuno-conjugates and chimeric molecules |
Bispecifics;Cytokine;T cell |
| 1200 |
Poster Presentation |
A Clinically Validated pH-Sensitive Nanomedicine Platform for Encapsulating Therapeutic Bispecific T cell engagers for Tumor Specific Delivery and Activation |
Stephen Gutowski; Qingtai Su, Ph.D.; Austin Burcham; Irina Kalashnikova, Ph.D.; Ashley Campbell; Zirong Chen, PhD; Bhargavi Allu; Jason B. Miller, PhD; Tian Zhao, PhD |
Immuno-conjugates and chimeric molecules |
Bispecifics;Immune toxicity;Solid tumors;T cell;Tumor microenvironment |
| 1201 |
Poster Presentation |
SGN-BB228 is a first-in-class CD228-targeted costimulatory Antibody Anticalin bispecific delivering potent and conditional 4-1BB costimulation to tumor-specific T cells |
Ryan A. Heiser, PhD |
Immuno-conjugates and chimeric molecules |
Bispecifics;Costimulation;Solid tumors;T cell;Targeted therapy |
| 1202 |
Poster Presentation |
Tri-specific killer engagers target natural killer cells towards mesothelioma |
Philippa (Pippa) R. Kennedy, PhD; Quinlan M. Kile; Blake A. Jacobson, PhD; Brianna Ettestad; Nicholas A. Zorko, MD, PhD; Caroline Hallstrom; Behiye Kodal; Deborah A. Todhunter; Daniel A. Vallera; Gregory I. Berk, MD; Jeffrey S. Miller, MD; Manish R. Patel, DO; Martin Felices |
Immuno-conjugates and chimeric molecules |
Bispecifics;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment |
| 1203 |
Poster Presentation |
Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity |
Derek Franklin, Ph.D.; Anne Lai, Ph.D.; Faraha Brewer, BSc; Arpita Patel, BSc; Kinsley Evans, BSc; Mahmud Hussain, Ph.D.; Louis Gonzalez, Ph.D.; Keith Wilson, Ph.D.; George J. Fromm, Jr., Ph.D.; Taylor H. Schreiber, MD, PhD; Suresh De Silva, Ph.D. |
Immuno-conjugates and chimeric molecules |
Bispecifics;Costimulation;Cytokine;Leukemia/Lymphoma;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 1204 |
Poster Presentation |
Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) |
Shee Kwan Phung, BS; Yvette Soignier, PhD; Nicholas A. Zorko, MD, PhD; Trygve Nelson; Joshua S. Walker; Philippa (Pippa) R. Kennedy, PhD; Jeffrey S. Miller, MD; Martin Felices |
Immuno-conjugates and chimeric molecules |
Bispecifics;Costimulation;Immune suppression;MDSC;Myeloid cells;NK/NKT cell;Targeted therapy;Tumor microenvironment |
| 1205 |
Poster Presentation |
Selective blockade of CD47-SIRP alpha 'don't eat me' signaling with a Her2-CD47 bispecific antibody-derivative |
Yuzhu Qi; Harm J. Lourens; Gerwin Huls; Edwin Bremer |
Immuno-conjugates and chimeric molecules |
Bispecifics;Monocyte/Macrophage;Targeted therapy |
| 1206 |
Poster Presentation |
Discovery and preclinical pharmacology of bispecific antibodies targeting an HLA-A2 restricted tumor-associated antigen |
Alejandro Ramirez, PhD; Nora Guidotti, PhD; John Leonard, PhD; Olivier Dalmas, PhD; Jake Kleiner; Joshua Goldsmith; Greg Tuffy; Jason Romero; Bindu Hegde, Ph.D.; Tina Giese; Lisa Kirkemo, PhD; Rafaela Truffer; Oralea Buchi; Nadine Uebersax; Philipp Wild, PhD; Rohan Eapen, PhD; Joanna Dreux; Alaina Cagalingan; Lena Flood, PhD; Kyle Pelot, PhD; Nathan Katz; Marvin H. Gee, PhD; Venita De Almeida, PhD; Johannes Schilling, PhD; Patrik Forrer, PhD; Leah V. Sibener, PhD |
Immuno-conjugates and chimeric molecules |
Bispecifics;Targeted therapy;Tumor antigens |
| 1207 |
Poster Presentation |
NKp46 engaging Bicycle NK-TICA™ drives targeted tumor cytotoxicity |
Alexandra Rezvaya, MS; Fay J. Dufort, PhD; Christopher J. Leitheiser, PhD; Hannah Gardner; Tucker Ezell; Liuhong Chen; Peter Brown; Philip E. Brandish, PhD; Michael Skynner; Kevin McDonnell, PhD; Nicholas Keen, PhD |
Immuno-conjugates and chimeric molecules |
Cytokine;NK/NKT cell;Tumor antigens |
| 1208 |
Poster Presentation |
DuoBody-PD-L1x4-1BB (GEN1046) reverses T-cell exhaustion in vitro |
Jordan M. Blum, PhD; Vanessa Spires; Gregg Masters; Christina Yu; Saskia Burm; Matt Hancock; Omar J. Jabado, PhD; Brandon Higgs; Alexander Muik; Kristina Nuermberger; Friederike Gieseke; Tahamtan Ahmadi; Kate Sasser; Ozlem Tureci; Maria Jure-Kunkel; Ugur Sahin; Mark Fereshteh; Nora Pencheva |
Immuno-conjugates and chimeric molecules |
Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Costimulation;Dendritic cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1209 |
Poster Presentation |
Antibody-lectin bispecifics for glyco-immune checkpoint blockade |
Jessica C. Stark, PhD; Melissa A. Gray; Simon P. Wisnovsky; Itziar Ibarlucea-Benitez; Nicholas M. Riley; Mikaela K. Ribi; Jeffrey V. Ravetch, MD, PhD; Carolyn R. Bertozzi, PhD |
Immuno-conjugates and chimeric molecules |
Antibody;Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells |
| 1210 |
Poster Presentation |
A human bispecific antibody targeting LAG-3 and PD-1 (INCA32459) potently activates exhausted T cells |
Shaun Stewart; Floris Fransen; Shane R. Harvey, B.S.; Franziska Mortensen; Anita Stam; Rahel Awdew; Arpita Mondal; Christina Stevens; Eric Rovers; Steef Engels; Melissa Rentrop-Boeijen; Linda JA. Hendriks; Brenda van Dieren; Rebecca Buonpane; Therese Visser; Pepijn Schellen; Ashwini Kulkarni; Jonathan Rios-Doria; Jing Zhou, MD, PhD; Paul Tacken; Lu Lu; Vanessa Zondag-van der Zande; Cheng-Yen Huang; Renate den Blanken-Smit; John de Kruif; Rinse Klooster; Simon Plyte; Horacio Nastri; Patrick Mayes, PhD |
Immuno-conjugates and chimeric molecules |
Antibody;Bispecifics;Checkpoint blockade;Immune tolerance;T cell;Targeted therapy |
| 1211 |
Poster Presentation |
Dual Targeting of Innate and Adaptive Immune Checkpoints with a PD-L1/SIRPα Bispecific Macrophage Engager to Promote Anti-tumor Activity |
Dawei Sun, PhD; Hongtao Lu, PhD; Haixia Jiang; Yanan Geng; Jiahui Hu; Ziqiao Ding, PhD; Jinfeng Zhao; Xiang Xu, PhD; Wenqiang Lu, PhD; Xiaofeng Niu, PhD; Rui Gao, PhD; Zhihao Wu, PhD; Quan Qiu, PhD; Zheng Song, PhD; Yangsheng Qiu, PhD |
Immuno-conjugates and chimeric molecules |
Bispecifics;Checkpoint blockade;Coinhibition;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment |
| 1212 |
Poster Presentation |
AFVT-2101, an innate immune-cell engager that selectively targets FOLR1 expressing tumor cells to safely harness potent anti-cancer responses |
Ahmad Trad; Michael Tomaszowski; Josef Caslavsky; Robert Freitag; Keith Haan; Markus Rohrwild; Daniel O'Shannessy; Jana Siegler; Sudhir Penugonda; Peter Sandy; Eric Gaukel; Daniela Penston; Zoe Johnson, PhD |
Immuno-conjugates and chimeric molecules |
Antibody;Biomarkers;Bispecifics;Monocyte/Macrophage;NK/NKT cell;Solid tumors;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 1213 |
Poster Presentation |
Hydrophobic interactions underlie recognition of a KRAS G12V neoantigen by a TCR-mimic antibody |
Katharine Wright, PhD; Sarah R. DiNapoli; Michele Miller; Katharine Wright; Sandra B. Gabelli, PhD; P. Aitana Azumendi; Jacqueline Douglass, MS; Kenneth W. Kinzler, PhD; Bert Vogelstein; Shibin Zhou, MD, PhD; Xiaowei Zhao; Zhiheng Yu |
Immuno-conjugates and chimeric molecules |
Antibody;Antigen presenting cells;Bispecifics;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 1214 |
Poster Presentation |
A Novel anti-MSLN x 4-1BB bispecific antibody with Fc effect function augments the antitumor efficacy |
Liansheng Cheng; Dayan Zhang; Lingling Wu; Weiming Zhou; Xiaoli Zeng; Xuejing Dai; Wenting Liu; Qun Zhao |
Immuno-conjugates and chimeric molecules |
Bispecifics;Costimulation;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 1215 |
Poster Presentation |
IGM-7354, an anti-PD-L1/IL-15 IgM immunocytokine, activates and expands NK cells and effector memory CD8+ T cells in vivo |
Mélanie Desbois, PhD; Thierry D. Giffon; Poonam Yakkundi; Sivani Pandey; Rodnie Rosete; Daniel Machado; Marigold Manlusoc; Susan Calhoun; Tasnim Kothambawala; Jey Ananta; Kristina Koyama; Yuan Cao; Dean Ng, Ph.D.; Tomas Miranda-Katz; Avneesh Saini; Abhinav R. Jain; Hongjun Yue; Yang Cai; Miho Oyasu; Liz Bogaert; Roel Funke; Genevive Hernandez, PhD; Denise Nagata; Maya K. Leabman; Eric Humke, MD; Stephen F. Carroll; Beatrice T. Wang, PhD; Bruce A. Keyt, PhD; Angus M. Sinclair, PhD; Maya F. Kotturi |
Immuno-conjugates and chimeric molecules |
Antibody;Biomarkers;Cytokine;NK/NKT cell;T cell |
| 1216 |
Poster Presentation |
The chimeric Ad5/Ad34 fiber of ICVB-1042 oncolytic virus requires the CD46 cell surface receptor for efficient tumor entry |
Michael Pokrass, PhD; Peter Rosenthal; Joshua Messinger; Nathaniel Rice; Heba Nowyhed |
Immuno-conjugates and chimeric molecules |
Biomarkers;Solid tumors;Surfaceome;Targeted therapy |
| 1217 |
Poster Presentation |
Efficacy and additional mechanism of action of Sacituzumab Govitecan, a TROP-2 directed antibody-drug conjugate, in preclinical models of non-muscle invasive bladder cancer |
Chih-Chien Chou; Dmytro Kornyeyev; Becky Yang; Jessica Orf; Hai-Ling Sun; Rutwij Dave; Yurong Lai; Giuseppe A. Papalia; Thomas M. Cardillo; Nathalie Scholler |
Immuno-conjugates and chimeric molecules |
Biomarkers;Solid tumors;Targeted therapy |
| 1218 |
Poster Presentation |
MSLN-targeted immunotoxin LMB-100 induces development of tertiary lymphoid structures and tumor regressions of orthotopic mesothelioma |
Wenlong Liu, PhD; Chin-Hsien Tai; Xiu-fen Liu; Ira H. Pastan |
Immuno-conjugates and chimeric molecules |
B cell;Chemokine;Cytokine;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 1219 |
Poster Presentation |
Nonclinical safety evaluation of sacituzumab govitecan, a TROP-2-directed antibody drug conjugate (ADC), for non-muscle invasive bladder cancer |
Carrie McMahon; Lauri Diehl; Laurie Tatalick; Jennifer Boggs; Sunish Mohanan; In Kyoung Mah; Jordan Kardos; Chih-Chien Chou; Congrong Niu; Rutwij Dave; Nathalie Scholler; Yurong Lai |
Immuno-conjugates and chimeric molecules |
Antibody;Biomarkers;Gene expression;Solid tumors;Targeted therapy |
| 1220 |
Poster Presentation |
Development of B cell Maturation Antigen (BCMA)-specific CD8+ Cytotoxic T Lymphocytes using induced Pluripotent Stem Cell Technology for Multiple Myeloma |
Jooeun Bae; Shuichi Kitayama; Zach Herbert; Laurence Daheron; Nikhil Munshi; Jerome Ritz; Shin Kaneko; Kenneth Anderson |
Immuno-Engineering |
Stem cell/cancer-initiating cell;T cell;Targeted therapy;Tumor antigens |
| 1221 |
Poster Presentation |
BP1202-NF2, a novel ADCC-enhancing CD39 antibody, induces destruction of regulatory T cells and enhances cytotoxic T lymphocytes induction. |
Toshifumi Obonai, Ph.D.; Haruka Ban, Ph.D.; Motoya Mie, PhD; Norihiro Nakamura, PhD |
Immuno-Engineering |
Antibody;Immune suppression;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor microenvironment |
| 1222 |
Poster Presentation |
In situCAR Therapy Using oRNA™ Lipid Nanoparticles Regresses Tumors in Mice |
Robert Mabry, PhD; Amy Becker; Alex Wesselhoeft; Allen Horhata; Akinola Emmanuel; Thomas Lee; David Soto; Akshi Thakkar; Ramya Elangovan; Magnolia Chinn; Sharmistha Kundu; Kevin Kauffman; Kristen Ott; Trent Stevens; Yessica Wiryawan; Ashley Wong; Ian Langer; Rahul Vungutur; Corey Ciullo; Zifiso Nyoni; Nelson Chau; Thomas Barnes |
Immuno-Engineering |
CAR T cells;T cell |
| 1223 |
Poster Presentation |
NG-796A: A T-SIGn vector designed to reprogram the tumor microenvironment and drive anti-tumor immunity |
Manuela Zonca; Katy West; Carla Cerqueira; Alice Muntzer; Rochelle Lear; Samuel Hardy; Darren Plumb; Maria Stella Sasso; Eva Vainiute; Tae Hyun Jang; Samantha Bucktrout; Brian R. Champion, PhD |
Immuno-Engineering |
CAR T cells;Chemokine;Cytokine;Gene expression;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1224 |
Oral Presentation |
Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer |
Nilesh U. Deshpande, PhD; Anna Bianchi, MS; Iago De Castro Silva, MD; Bapu Surnar, PhD; Ifeanyichukwu C. Ogobuiro, MD; Siddharth Mehra, PhD; Samara Singh; Vanessa Garrido, PhD; Nipun Merchant, MD; Shanta Dhar, PhD; Jashodeep Datta, MD |
Immuno-Engineering |
Granulocyte;Immune suppression;Inflammation;MDSC;Myeloid cells;Tumor microenvironment |
| 1225 |
Poster Presentation |
NCG-SGM3 humanized mice - an ideal model for human immune reconstitution of T and myeloid cell lineages |
Shiying Guo, PhD; Cunxiang Ju; Hongyan Sun; Mingkun Zhang; Liyou Dong; Mengting Wang; Shuai Li; Dong Li; Huiyi Wang; Santi Suryani Chen, PhD; Zhiying Li, PhD; Mark Moore, PhD; Jing Zhao; Xiang Gao |
Immuno-Engineering |
Adoptive immunotherapy;Bispecifics;Dendritic cell;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1226 |
Poster Presentation |
NCG-hIL15 humanized mice - an excellent model for human immune reconstitution of NK cells |
Xing Liu, PhD; Meirong Wu, PhD; Huiyi Wang; Weiwei Yu, PhD; Hongyan Sun; Cunxiang Ju; Hongyu Wang, PhD; Zhiying Li, PhD; Mark Moore, PhD; Jing Zhou, PhD; Xiang Gao; Santi Suryani Chen, PhD |
Immuno-Engineering |
Adoptive immunotherapy;Antibody;Bispecifics;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1227 |
Poster Presentation |
Eliminating the Immunotoxicity of Interleukin-12 through Protease-Sensitive Masking |
Jun Ishihara, PhD; Aslan Mansurov, PhD; Jeffrey Hubbell |
Immuno-Engineering |
Cytokine;Immune toxicity;Solid tumors;Targeted therapy |
| 1228 |
Poster Presentation |
Structural basis for LAG3 engagement of immunomodulatory ligands and antibodies |
Qianqian Ming, PhD; Daiana P. Celias; Chao Wu; Aidan R. Cole; Srishti Singh; Charlotte C. Mason; Shen Dong; Timothy H. Tran; Gaya K. Amarasinghe; Brian Ruffell; Vincent C. Luca, PhD |
Immuno-Engineering |
Antibody;Checkpoint blockade;Immune suppression;T cell |
| 1229 |
Poster Presentation |
Immunotherapy in three dimensions: the tumor microenvironment, immune cells, and tumor invasion |
W. Gregory WG. Sawyer, PhD; Duy T. Nguyen, MS; Ryan Smolchek, PhD; Jack Famiglietti, PhD; Stephanie Warrington, MS; W Gregory Sawyer |
Immuno-Engineering |
Checkpoint blockade;MDSC;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1230 |
Poster Presentation |
VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhance in vivo CAR T cell generation and antitumor activity |
Chris Nicolai, PhD; Jim Qin; Way Wu; Mollie McDonnell, PhD; Erica Shirazi; Greyson Hamilton; Max Chen, PhD; Don Parrilla; Susana Hernandez; Kathryn Michels, PhD; Shon Green, PhD; Andrew Scharenberg, MD; Laurie Beitz, MD; Ryan Larson, PhD; Byoung Ryu, PhD; Wai-Hang Leung, PhD |
Immuno-Engineering |
CAR T cells;Leukemia/Lymphoma;T cell;Targeted therapy |
| 1231 |
Poster Presentation |
Virus-free, targeted insertion of long transgenes within primary natural killer cells using CRISPR-Cas9 |
Keerthana Shankar, BS; Isabelle Zingler-Hoslet; Christian Capitini, MD; Krishanu Saha |
Immuno-Engineering |
Gene expression;NK/NKT cell |
| 1232 |
Poster Presentation |
Engineering a pseudotyped lentiviral platform to enable lineage-specific transduction of immune cells |
Blake Smith, BS; Stephanie Dougan, PhD; Michael Birnbaum, PhD |
Immuno-Engineering |
Adoptive immunotherapy;Neoantigens;T cell;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 1233 |
Poster Presentation |
Reprogramming primary melanoma cells to dendritic cell fate enhances tumor immunogenicity |
Marta Velasco Santiago, MSc; Olga Zimmermannova, MD PhD; Morten Hansen, PhD; Fabio F. Rosa, PhD; Cristiana F. Pires, PhD; Özcan Met, PhD; Carlos-Filipe Pereira, PhD; Inge Marie Svane, MD |
Immuno-Engineering |
Antigen presenting cells;Dendritic cell;Neoantigens;Solid tumors |
| 1234 |
Poster Presentation |
NCG-MHC dKO mice - an excellent model for PBMC reconstitution and pharmacodynamic evaluation in the absence of GvHD |
Huiyi Wang; Cunxiang Ju; Mark Moore, PhD; Jun Xing; Jialu Fan; Huanhuan Hou; Santi Suryani Chen, PhD; Zhiying Li, PhD; Jing Zhao; Xiang Gao |
Immuno-Engineering |
Adoptive immunotherapy;Antibody;Bispecifics;CAR T cells;Checkpoint blockade;Leukemia/Lymphoma;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1235 |
Poster Presentation |
Targeting the secretory pathway of T cells to boost the efficacy of cancer immunotherapy |
Anthea Wirges; Armin Rehm; Mario Bunse; Jara J. Joedicke; Eric Blanc; Venugopal Gudipati; Michael W. Moles; Dieter Beule; Johannes Huppa; Uta E. Hoepken |
Immuno-Engineering |
Adoptive immunotherapy;CAR T cells;T cell;T cell lineages |
| 1236 |
Poster Presentation |
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity |
Zhenhua Ren, PhD; Anli Zhang; Yang-Xin Fu |
Immuno-Engineering |
Adoptive immunotherapy;Checkpoint blockade;Cytokine;Immune toxicity;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs) |
| 1237 |
Poster Presentation |
In vivo programming of myeloid cells by mRNA mediated delivery of novel Fca fusion receptor activates anti-tumor immunity |
Yuxiao Wang, Ph.D.; Hongyun Zhao; Edward Cochran; Michael Gorgievski; Thomas Prod'Homme; Bruce McCreedy; Daniel Getts |
Immuno-Engineering |
Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor antigens;Tumor microenvironment |
| 1238 |
Poster Presentation |
Separating the wheat from the chaff: Engineering CARTs with superior metabolic attributes against solid tumors |
Yufan Zhou; Andre Kelly; Andrew Frisch; Decheng Song; Saba Ghassemi, PhD; Carl June; John Scholler; Roddy S. O'Connor, PhD |
Immuno-Engineering |
Adoptive immunotherapy;CAR T cells;Metabolism;Solid tumors;T cell |
| 1239 |
Poster Presentation |
Overexpression of the chemokine receptor CCR7 confers anti-CXCR5 CAR T cells with increased homing to lymph nodes and enhanced cytotoxicity toward B cell lymphoma |
Maria Zschummel; Jara J. Joedicke; Anca Margineanu; Susanne Blachut; Eric L.H. Lindberg; Norbert Hübner; Armin Rehm; Uta E. Höpken, UEH, PhD; Uta E. Höpken |
Immuno-Engineering |
Adoptive immunotherapy;CAR T cells;Chemokine;Leukemia/Lymphoma;Tumor microenvironment |
| 1241 |
Poster Presentation |
IL-1 blockade prevents cardiac toxicity and improves immunotherapy efficacy in mouse models of pancreatic cancer |
Rakesh K. Jain, PhD; Nilesh P. Talele, BSc (Hons), MSc, PhD; Heena Kumra, PhD; Igor L. Gomes Dos Santos; Sylvie Roberge; William W. Ho; Patrik Andersson; Sampurna Chatterjee; Marie Siwicki; Dan G. Duda; Mikael J. Pittet; Dai Fukumura |
Immunotherapy Toxicities |
Checkpoint blockade;Chemotherapy;Cytokine;Solid tumors |
| 1242 |
Poster Presentation |
Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define checkpoint inhibitor colitis |
Kamil Slowikowski, PhD; Molly Thomas, MD PhD; Kasidet Manakongtreecheep; Pritha Sen; Jessica Tantivit; Mazen Nasrallah, MD; Leyre Zubiri, MD; Neal P. Smith; Alice Tirard; Swetha Ramesh; Benjamin Y. Arnold; Linda T. Nieman; Jonathan H. Chen; Thomas Eisenhaure; Karin Pelka; Katherine H. Xu; Vjola Jorgji; Christopher J. Pinto; Tatyana Sharova; Rachel Glasser; PuiYee Chan; Ryan J. Sullivan, MD; Hamed Khalili; Dejan Juric, MD; Genevieve Boland, MD PhD; Michael Dougan; Nir Hacohen; Bo Li; Kerry L. Reynolds, MD; Alexandra-Chloé Villani |
Immunotherapy Toxicities |
Bioinformatics;Checkpoint blockade;Gene expression;Immune toxicity;Systems biology |
| 1243 |
Poster Presentation |
Immune checkpoint inhibitor-induced polyarthritis: a case series. |
Megan Smith-Uffen, MD; Konstantinos Tselios |
Immunotherapy Toxicities |
Autoimmunity;Checkpoint blockade;Inflammation |
| 1244 |
Poster Presentation |
Alliance A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events |
David Kozono, MD, PhD; Tyler Zemla, MS; Elie Dib, MD, MD, FACP; Mark Watson, MD, PhD; Yujia Wen, MD, PhD; Frank Keller, MD; John M. Kirkwood, MD; Gary Lyman, MD, PhD; Jarushka Naidoo, MD, MHS; Barb Mulhern; Laura Hoffman; Jennifer Le-Rademacher, PhD; Andrew Nixon, PhD; Elad Sharon, MD, MPH |
Immunotherapy Toxicities |
Biomarkers;Checkpoint blockade;Clinical study;Immune toxicity |
| 1245 |
Poster Presentation |
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with pre-existing organ dysfunction |
Meghana Kesireddy, MD; Apar K. Ganti, MD; Alissa Marr, MD; Makayla Schissel, MPH |
Immunotherapy Toxicities |
Checkpoint blockade;Immune toxicity;Solid tumors |
| 1246 |
Poster Presentation |
Troponin-T levels and long-term survival in immune checkpoint inhibitor associated myocarditis |
Nikhil Dubey, MS; Daniel A. Zlotoff, MD, PhD; Leyre Zubiri, MD; Kerry L. Reynolds, MD |
Immunotherapy Toxicities |
Antibody;Biomarkers;Checkpoint blockade;Clinical study;Epidemiology;Immune toxicity;Targeted therapy |
| 1247 |
Poster Presentation |
Distribution of immune-related adverse events (irAEs) in solid malignancies |
Dalia Kaakour, MD; Matthew Slaught; Armon Azizi; Gianna Kroening; Jennifer Valerin, MD, PhD; Nataliya Mar, MD |
Immunotherapy Toxicities |
Immune toxicity;Solid tumors |
| 1248 |
Poster Presentation |
Risk factors and a risk-scoring model for severe checkpoint inhibitor-related pneumonitis in lung cancer patients |
Haiyi Deng; Jiating Deng; Xinqing Lin; Chengzhi Zhou, MD; Yanbin Zhou |
Immunotherapy Toxicities |
Checkpoint blockade;Immune toxicity |
| 1249 |
Poster Presentation |
Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI) |
Evelyn Goodyear, BS; Songzhu Zhao, MS; Mingjia Li, MD; Yihzen Guo, PharmD, MS; Gabrielle Lopez, BS; Austin Secor; Parthib Das; Nitya Surya; Marium Husain, MD; Madison Grogan; Daniel Spakowicz, PhD; Lai Wei, PhD; Kai He, MD, PhD; Erin Bertino, MD; Asrar A. Alahmadi, MD; Regan Memmott, MD, PhD; Jacob Kaufman, MD, PhD; Carolyn Presley, MD; Peter Shields, MD; David P. Carbone, MD, PhD; Gregory Otterson, MD; Dwight H. Owen, MD, MSc |
Immunotherapy Toxicities |
Immune toxicity;Targeted therapy |
| 1250 |
Poster Presentation |
A novel in vivo PBMC humanized mouse platform for long-term analysis of efficacy and toxicity of T cell-based immunotherapy drugs |
Guoxiang Yang, PhD; Hongyuan Yang; Li-Chin Yao; Leonard D. Shultz; Danying Cai; James G. Keck; Mingshan Cheng |
Immunotherapy Toxicities |
Bispecifics;Immune toxicity;Solid tumors |
| 1251 |
Poster Presentation |
Immune checkpoint inhibitor-induced type 1 diabetes mellitus is associated with long-term response and survival in patients with melanoma |
John Marsiglio, MD; Magdalena Kovacsovics, MD; Xuechen Wang; Sheetal Hardikar, PhD, MBBS; Arabella Young, PhD; Jennifer Doherty; John Hyngstrom, MD; Jordan McPherson; Ben Haaland; Siwen Hu-Lieskovan, MD, PhD |
Immunotherapy Toxicities |
Biomarkers;Checkpoint blockade;Immune monitoring;Immune toxicity |
| 1252 |
Poster Presentation |
Immune-checkpoint inhibitor induced autoimmune diabetes is a heterogeneous disease with distinct clinical and immune phenotypes |
Karina N. Ruiz-Esteves, MD; Kaitlyn Shank, MD; Caitlin Colling, MD; Tianqi Ouyang; Leyre Zubiri, MD; Chloe Villani, PhD; Kerry L. Reynolds, MD; Meghan Sise, MD; Michelle Rengarajan, MD PhD |
Immunotherapy Toxicities |
Autoimmunity;Immune toxicity |
| 1253 |
Poster Presentation |
Retrospective analysis of Immunotherapy toxicities requiring hospitalization in Lung cancer patients |
Ayo S. Falade, MD, MBA; Leyre Zubiri, MD; Kerry L. Reynolds, MD; Meghan J. Mooradian, MD |
Immunotherapy Toxicities |
Checkpoint blockade;Immune tolerance;Immune toxicity;Solid tumors |
| 1254 |
Poster Presentation |
Distinguishing T-Cell Responses in Paired Heart and Tumor Samples from Patients with Immune Checkpoint-Related Myocarditis |
Steven Blum, MD; Neal P. Smith; Daniel A. Zlotoff, MD, PhD; Jaimie L. Barth; Swetha Ramesh; Isabela Kernin; Leyre Zubiri, MD; John McGuire; Alice Tirard; Dejan Juric, MD; Ryan J. Sullivan, MD; Genevieve M. Boland, MD, PhD; Mari Mino-Kenudson, MD; James R. Stone, MD, PhD; Molly Thomas, MD PhD; Kerry L. Reynolds, MD; Thomas G. Neilan, MD, MPH; Chloe Villani, PhD |
Immunotherapy Toxicities |
Biomarkers;Checkpoint blockade;Immune toxicity;Inflammation;Solid tumors;Systems biology |
| 1255 |
Poster Presentation |
Impact of Immune Checkpoint Inhibitors on Bone Turnover in Cancer Patients: Prospective Clinical Study and Preclinical Correlates. |
Tamara Gassner, MSc.; Sonia Vallet; Christina Chittilappilly; Theo Pirich; Judith Lind; Osman Aksoy; Vincent Sunder-Plassmann; Klaus Hackner; Elisabeth Zwickl-Traxler; Peter Errhalt; Martin Pecherstorfer; Klaus Podar |
Immunotherapy Toxicities |
Biomarkers;Clinical study;Coinhibition;Immune toxicity |
| 1256 |
Poster Presentation |
Relationships between irAEs and checkpoint inhibitor response in RADIOHEAD: a large prospective pan-tumor cohort of standard-of-care patients with clinical annotation, molecular and immune profiling |
Anastasia Lucas; Samantha I. Liang, PhD; Diane Da Silva; Arabella Young, PhD; Zoe Quandt; Silvia Boffo, PhD; Lisa M. Salvador; Lacey J. Padrón, PhD; Mark S. Anderson, MD, PhD; Marshall Thompson, PhD; Christine N. Spencer, PhD |
Immunotherapy Toxicities |
Checkpoint blockade;Epidemiology;Solid tumors |
| 1257 |
Poster Presentation |
Single Cell Immunologic Dissection of Checkpoint Inhibitor Hepatitis and Autoimmune Hepatitis Reveals Insights into Immune Tolerance in the Human Liver |
Molly Thomas, MD PhD; Tos Chan; Neal P. Smith; Marc Sherman; Swetha Ramesh; Alice Tirard; John McGuire; Mazen Nasrallah, MD; Kasidet Manakongtreecheep; Jessica Tantivit; Leyre Zubiri, MD; Dejan Juric, MD; Ryan J. Sullivan, MD; Genevieve Boland, MD PhD; Georg Lauer, MD PhD; Nir Hacohen, PhD; Kerry L. Reynolds, MD; Chloe Villani, PhD |
Immunotherapy Toxicities |
Antigen presenting cells;Autoimmunity;Checkpoint blockade;Immune tolerance;Immune toxicity;Inflammation;Monocyte/Macrophage;Systems biology;T cell;T cell lineages |
| 1258 |
Poster Presentation |
PBMC humanized mouse model with clinical relevance in assessing the safety profile of 4-1BB agonists utomilumab and urelumab |
Destanie Rose, PhD; Wenqian He, PhD; Bernard S. Buetow, PhD; Allison Vitsky, DVM; Maggie Lui, PhD; Jiwon Yang, PhD; Guoxiang Yang, PhD; James G. Keck; Bart Jessen, PhD |
Immunotherapy Toxicities |
Cytokine;Immune toxicity;Inflammation;T cell |
| 1259 |
Poster Presentation |
Real world experience of immunotherapy in an elderly trial-ineligible cohort of patients with advanced cutaneous squamous cell carcinoma |
Luke S. Mclean, MBBS (Hons); Annette M. Lim; Angela Pizzolla, PhD; Benjamin Solomon; Danny Rischin, MBBS, MD |
Immunotherapy Toxicities |
Checkpoint blockade;Immune toxicity;Solid tumors |
| 1260 |
Poster Presentation |
Comparative safety and effectiveness of IL6R Inhibitors, TNF inhibitors and Methotrexate for the treatment of Immune Checkpoint Inhibitor-associated arthritis |
Anne R. Bass, MD; Noha Abdel-Wahab, MD, PhD; Jeffrey Sparks; Pankti Reid, MD, MPH; Cassandra Calabrese; Deanna Jannat-Khah, DrPH, MSPH; Divya Rajesh; Nilasha Ghosh, MD; Komal Mushtak, MD; Farah Al Haj, MD; Lydia Gedmintas, MD, MPH; Adewunmi Falohun, DO; Lindsey Macfarlane, MD; Michael Postow, MD; Adi Diab; Ami Shah, MD; Clifton Bingham, III, MD; Karmela K. Chan, MD; Laura Cappelli, MD |
Immunotherapy Toxicities |
Antibody;Autoimmunity;Checkpoint blockade;Immune suppression;Immune toxicity;Inflammation |
| 1261 |
Poster Presentation |
Increased concentrations of S100B and neurofilament light chain in serum indicate checkpoint inhibitor-induced CNS inflammation |
Sara Bjursten, MD; Ankur Pandita, MD; Zhiyuan Zhao, MD, PhD; Joel Simrén, MD; Henrik Zetterberg, MD, PhD; Anna Rudin, MD, PhD; Lars Ny, MD, PhD; Max Levin, MD PhD |
Immunotherapy Toxicities |
Biomarkers;Checkpoint blockade;Immune toxicity |
| 1262 |
Poster Presentation |
Elevated serum TNF-α is a candidate prognostic biomarker for immune checkpoint inhibitor myocarditis |
Rebecca Caldwell; Gaspar Pina; Praise Oderinde; Abdelrahman Ali; Jensen Garrett; Bilal A. Siddiqui, MD; Sumit K. Subudhi, MD, PhD; Cezar Iliescu; Syed Wamique Yusuf; Efstratios Koutroumpakis; Ihab Hamzeh; Shaden Khalaf; Anita Deswal; Nicolas L. Palaskas, MD |
Immunotherapy Toxicities |
Cytokine;Immune toxicity;Inflammation |
| 1263 |
Poster Presentation |
Dermatologic immune related adverse event disease definitions: a multi-institutional Delphi consensus project presented on behalf of the oncodermatology working group |
Steven T. Chen, MD, MPH, MHPEd; Nicole LeBoeuf, MD; Kerry L. Reynolds, MD; Yevgeniy R. Semenov, MD |
Immunotherapy Toxicities |
Autoimmunity;Checkpoint blockade;Immune toxicity |
| 1264 |
Poster Presentation |
A set of easy and stringent criteria to identify Immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population |
Luca Mazzarella, MD, PhD; Federica Giugliano; Eleonora Nicolo'; Edoardo Crimini; Jacopo Uliano; Chiara Corti; Paolo d'Amico; Pamela Trillo Aliaga; Carmine Valenza; Matteo Repetto; Gabriele Antonarelli; Liliana Ascione; Grazia Vivanet; Pierpaolo Berton Giachetti; Ida Minchella; Carmen Belli, MD, PhD; Angela Esposito; Marzia Locatelli; Carmen Criscitiello; Giuseppe Curigliano, MD, PhD |
Immunotherapy Toxicities |
Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune toxicity;Solid tumors |
| 1265 |
Poster Presentation |
Vedolizumab plus anti-PD1 antibody in advanced melanoma patients with inflammatory enterocolitis |
Asad Javed, MBBS; Michele Freesmeier, MPAS, PA-C; Yousef Zakharia, MD; Mohammed M. Milhem, MBBS |
Immunotherapy Toxicities |
Checkpoint blockade;Immune toxicity |
| 1266 |
Poster Presentation |
Toxicity profiles of weight-based 2-weekly and flat-dose 4-weekly nivolumab regimen - a real-world Australian centre experience |
Sang Yoon Kim, MB ChB; Prajwol Shrestha; Andre van der Westhuizen |
Immunotherapy Toxicities |
Checkpoint blockade;Immune toxicity |
| 1267 |
Poster Presentation |
The Effect of Immunosuppression During Anti-PD-1 Treatment for Stage III Melanoma |
Andrew D. Knight, MD; John M. Kirkwood, MD; Lilit Karapetyan; Xi Yang, MD; Sneha Rajendran, MD; Na Bo; Hong Wang, PhD; Cindy Sander, BS |
Immunotherapy Toxicities |
Checkpoint blockade;Clinical study;Immune adjuvant;Immune suppression;Immune toxicity;Solid tumors |
| 1268 |
Poster Presentation |
Increased risk of cutaneous immune-related adverse events in patients treated with Talimogene Laherparepvec and immune checkpoint inhibitors: a multi-institutional cohort study |
Bonnie W. Leung, BS; Guihong Wan, PhD; Nga Nguyen, MD, MPH; Shijia Zhang, MBI; Wenxin Chen, BS; Sonia Cohen, MD, PhD; Genevieve Boland, MD PhD; Ryan J. Sullivan, MD; Riley Fadden, NP; Howard Kaufman, MD; Shawn Kwatra, MD; Nicole LeBoeuf, MD; Yevgeniy R. Semenov, MD |
Immunotherapy Toxicities |
Checkpoint blockade;Immune toxicity;Solid tumors |
| 1269 |
Poster Presentation |
Pretreatment prediction of anti-PD-1 immunotherapy response using machine learning in patients with metastatic melanomas using targeted transcriptomics in circulating CD8 cells. |
Fahad S. Ahmed, MD, ABAIM |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;RNA;T cell;T cell lineages |
| 1270 |
Poster Presentation |
Pretreatment prediction of non-responders to PD-1 axis inhibitors in advanced urothelial carcinomas using a hybrid multimodal deep learning algorithm. |
Fahad S. Ahmed, MD, ABAIM |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;RNA;Solid tumors |
| 1272 |
Poster Presentation |
Probabilistic mixture models improve calibration of panel-derived tumor mutational burden in the context of both tumor-normal and tumor-only sequencing |
Jordan Anaya; John-William Sidhom, M.D., PhD; Alexander Baras, M.D., Ph.D. |
Machine Learning, Artificial Intelligence and Computational Modeling |
Biomarkers |
| 1273 |
Poster Presentation |
Combining multiple Immunotherapy studies and real-world data improves prediction of IO treatment efficacy and highlights key driving features |
Gustavo A. Arango, PhD; Etai Jacob, PhD; Elly Kipkogei |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Clinical study;Systems biology;Tumor microenvironment |
| 1274 |
Poster Presentation |
Identification and characterization of immune checkpoint inhibitor induced immune-related adverse events from electronic health records using natural language processing techniques |
Hannah Barman; Sriram Venkateswaran; Antonio Del Santo; Krishna Rao; Bharathwaj Raghunatha; Unice Yoo; Lisa Kottschade; Matthew Block; G. Scott Chandler; Tyler Wagner; Rajat Mohindra |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Checkpoint blockade;Immune toxicity;Solid tumors |
| 1275 |
Poster Presentation |
Mapping the heterogeneous colorectal tumor microenvironment with multiplexed imaging and machine learning |
Blanca Cabrera Gil; Laura Gui Levy; Mario Kreutzfeldt; Joanna Kowal, PhD; Giusy Procopio; Deniz Eroglu, MSc.; Doron Merkler; Andrew Janowczyk; Diego G. Dupouy, PhD; Aitana Neves; Thomas McKee |
Machine Learning, Artificial Intelligence and Computational Modeling |
Proteomics;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1276 |
Poster Presentation |
From TCR-pMHC binding kinetic characteristics to TCR phosphorylation and initiation of signal transduction |
Jonathan Desponds; Mayra Cruz Tleugabulova; Jeanne Cheung; Shirley Ng Palace; Martine Darwish; Geraldine Strasser; Andrey Shaw; Ira Mellman, PhD; Andrei Chernyshev; Darya Orlova, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Adoptive immunotherapy;Bioinformatics;Neoantigens;Solid tumors;Systems biology;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) |
| 1277 |
Poster Presentation |
Identification of clinically relevant spatial tissue phenotypes in large-scale multiplex immunofluorescence data via unsupervised graph learning in non-small cell lung cancer |
Robert Egger; Andrew Fisher; Michael G. Drage; Jimena Trillo-Tinoco, PhD; John Abel; Andrew Browne; Deepta Rajan; Tai Wang; Jake Conway; Catherine King; Jacqueline Brosnan-Cashman, Ph.D.; Anne Lewin; Arnaud Amzallag; Thomas Lila; Tyler Simpson; Mike Montalto; Benjamin Chen, MD,PhD; Benjamin Glass, MS; Vipul Baxi, MS |
Machine Learning, Artificial Intelligence and Computational Modeling |
Biomarkers;Gene expression;Tumor microenvironment;Tumor stroma |
| 1278 |
Poster Presentation |
Crossdome: An interactive R package to predict T-cell cross-reactivity risk on immunopeptidomics databases |
Andre F. Fonseca, PhD; Dinler A. Antunes, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Adoptive immunotherapy;Bioinformatics;Gene expression;Tumor antigens |
| 1279 |
Poster Presentation |
A novel graphical deep neural network learning approach utilizing molecular data for optimizing patient selection for treatment with immune checkpoint inhibitors: An ORIEN pan-cancer study |
Issam M. El Naqa, Ph.D.; Payman Ghasemi, PhD; Aik Choon Tan, PhD; James Chen; Aakrosh Ratan; Martin McCarter, MD; John D. Carpten, PhD; Howard Colman, MD; Alexandra Ikeguchi, MD; Igor Puzanov, MD, MSCI, FACP; Susanne M. Arnold, MD; Michelle L. Churchman, PhD; Patrick Hwu; Jose Conejo-Garcia, MD, PhD; William (Bill) S. Dalton, PhD, MD; George J. Weiner, MD; Ahmad A. Tarhini, MD, PhD, MS |
Machine Learning, Artificial Intelligence and Computational Modeling |
Biomarkers;Checkpoint blockade;Gene expression;Immunoscore;Tumor microenvironment |
| 1280 |
Oral Presentation |
Radiomic and clinical prediction of overall and organ-specific response to ipilimumab-nivolumab in melanoma |
Zane N. Gray, MS; Alexandra Tompkins; Rebekah Dadey, PhD; Serafettin Zenkin; Afsaneh Amouzegar, MD; Priyadarshini Mamindla; Vishal Peddagangireddy; Murat Ak; Ryan C. Augustin, MD; Rivka Colen; Riyue Bao, PhD; Jason J. Luke, MD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Biomarkers;Checkpoint blockade;Solid tumors |
| 1281 |
Poster Presentation |
Recurrence prediction in cutaneous melanoma patients by exploiting deep learning on H&E slide images |
Michele Guida, MD; Maria Colomba Comes; Livia Fucci; Sabino Strippoli; Samantha Bove; Ivana De Risi; Annarita Fanizzi; Martina Milella; Fabio Mele; Alfredo Zito; Raffaella Massafra |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Immune adjuvant |
| 1282 |
Poster Presentation |
Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types |
Maria Guramare; Nishant Agrawal; George Lee, PhD; Adam Stanford-Moore, MS; Abhik Lahiri; Diksha Meghwal; Aryan Pedawi; Darren Fahy; Raymond Biju; Archit Khosla; Dimple Pandya, MD; Scott Ely, MD, MPH; Jimena Trillo-Tinoco, PhD; John B. Wojcik, MD, PhD; Falon D. Gray, DVM; Benjamin Chen, MD,PhD; Sergine Brutus; Benjamin Glass, MS; Cyrus Hedvat, MD, PhD; Ilan Wapinski; Michael Montalto; Andrew H. Beck; Charles Biddle-Snead; Vipul Baxi, MS |
Machine Learning, Artificial Intelligence and Computational Modeling |
Biomarkers;Immune contexture;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1283 |
Poster Presentation |
Applying machine vision to empower preclinical development of immunotherapies in patient-derived organoid models of solid tumors |
Chi-Sing Ho, PhD; Sonal Khare, PhD; Madhavi Kannan, MS; Michael Streit, MS; Timothy D. Lopez, MS; Luca Lonini, PhD; Brian Larsen, PhD; Brandon L. Mapes, MS; Jenna Shaxted, BS; Martin C. Stumpe, PhD; Ameen A. Salahudeen, PhD; Jagadish Venkataraman, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Adoptive immunotherapy;Bispecifics;CAR T cells;Tumor infiltrating lymphocytes (TILs) |
| 1284 |
Poster Presentation |
Biology-guided Deep Learning Predicts Prognosis and Cancer Immunotherapy Response |
Yuming Jiang, MD, PhD; Zhicheng Zhang, PhD; Wei Wang, MD; Weicai Huang; Chuanli Chen, MD; Sujuan Xi, MD, PhD; M. Usman Ahmad, MD; Yulan Ren, BS; Shengtian Sang, PhD; Jingjing Xie, PhD; Wenjun Xiong, MD, PhD; Tuanjue Li, MD, PhD; Zhen Han, MD, PhD; Qingyu Yuan, MD; Yikai Xu, MD; Lei Xing, PhD; George A. Poultsides, MD; Guoxin Lin, MD, PhD; Ruijiang Li |
Machine Learning, Artificial Intelligence and Computational Modeling |
Checkpoint blockade;Chemotherapy;Immune monitoring;Immunoscore;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma |
| 1285 |
Poster Presentation |
Spatial analysis of tumor-infiltrating lymphocytes (TILs) based on HER2 expression across multiple cancer types |
Sukjun Kim, PhD; Seulki Kim; Yoojoo Lim; Gahee Park; Sanghoon Song; Heon Song; Seonwook Park; Jeongun Ryu; Sergio Pereira; Donggeun Yoo; Kyunghyun Paeng; Chan-Young Ock, MD, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Biomarkers;Gene expression;Systems biology;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1286 |
Poster Presentation |
Structure-based prediction of neoantigens paired with T cell receptors on phenotype-selected CD8+ tumor-infiltrating lymphocytes |
Bo Ryeong Lee, PhD; Sungsik Kim, Ph.D.; Sung-Min Kim, PhD; Woong-Yang Park, MD, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
COVID and Immunotherapy;Gene expression;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 1287 |
Oral Presentation |
Radiomics and delta-radiomics signatures to predict response and survival in patient with non-small cell lung cancer treated with immune checkpoint inhibitors |
François Cousin; Thomas Louis; Mariaelena Occhipinti; Wim Vos; Julien Guiot; Roland Hustinx |
Machine Learning, Artificial Intelligence and Computational Modeling |
Antibody;Bioinformatics;Biomarkers;Solid tumors |
| 1288 |
Poster Presentation |
Spatial transcriptomics-enabled integrated morphology-transcriptome tumor cell phenotyping using machine learning |
Nga H. Luong; Wei Yan; Jeffrey C. Lim; Yuezhen Xue; Abu Bakr Azam, M.Engg; Joe Poh Sheng P. Yeong, MD, PhD; Mai Chan Lau; Yiyu Cai, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Gene expression;RNA;Solid tumors;Tumor stroma |
| 1289 |
Poster Presentation |
Predicting response to immune checkpoint inhibitors (ICI) in non-small-cell lung cancer (NSCLC) by combining spatial analysis of cells and RNA sequencing data from biopsies using deep learning (DL) |
Ettai Markovits, MD; David Soong, PhD; Becky Arbiv; Alon Groisman; Maya Lipinsky; Yoni Yedidia; Yoad Cohen; Yuval Gabay; Yuval Shachaf; Eyal Oren; Roman Gluskin; Ido Weiss; Hisham Hamadeh; Kate Sasser; Gali Golan; Brandon Higgs; Suzana Couto; Ori Zelichov, MD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Biomarkers;Checkpoint blockade;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1290 |
Poster Presentation |
A deep learning analysis pipeline for multiplex imaging identifies spatial features associated with clinical outcome in colorectal cancer |
Ettai Markovits, MD; Roman Gluskin; Tomer Dicker; Ido Weiss; Sun Dagan; Ron Elran; Amit Bart; Oleg Kuybeda; Becky Arbiv; Ori Zelichov, MD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Immune contexture;Solid tumors;T cell;Tumor microenvironment;Tumor stroma |
| 1291 |
Poster Presentation |
A multi-tumor machine learning model to identify tertiary lymphoid structures in histopathological H&E images as a potential clinical biomarker |
Vanessa Matos-Cruz, Ph.D.; Rachel L. Sargent, MD; Varsha Chinnaobireddy; Maryam Pouryahya; George Lee, PhD; Darren Fahy; Christian Kirkup; Kathleen Sucipto; Sai Gullapally; Jacqueline Brosnan-Cashman, Ph.D.; Archit Khosla; Nishant Agrawal; Benjamin Glass, MS; Sergine Brutus; Limin Yu; Benjamin Chen, MD,PhD; Vipul Baxi, MS; Scott Ely, MD, MPH |
Machine Learning, Artificial Intelligence and Computational Modeling |
B cell;Biomarkers;Inflammation;Solid tumors;T cell;Tumor microenvironment |
| 1292 |
Poster Presentation |
A reproducible pipeline for analysis of multiplex imaging (MIBI) data with application to uncovering novel features of the tumor-immune microenvironment |
Jessica Maxey, PhD; Marshall A. Thompson, PhD; Katie Campbell, PhD; Benjamin Kamphaus; Zaid Bustami, BS Candidate; Sandra Santulli-Marotto, PhD; Daniel Wells, BA, PhD; Silvia Boffo, PhD; Lisa M. Salvador; Philip O. Scumpia, MD; Christine N. Spencer, PhD; Adam Schoenfeld; Antoni Ribas, MD, PhD; Lacey J. Kitch, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Systems biology;Tumor microenvironment |
| 1293 |
Poster Presentation |
Establishing the preclinical PKPD relationship for NM32-2668 a ROR1 targeting T cell engager |
Hitesh Mistry, PhD; Fernando G. Ortega; Bithi Chatterjee, PhD; Nicole Bassler; Niels Kirk; Julia Tietz; Belinda Wickihalder; Simone Muntwiler; Simon Carnal; Daniel Snell, PhD; Christopher D. Chassagnole, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bispecifics;Costimulation;Cytokine;Immune toxicity;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1294 |
Poster Presentation |
An Automated Machine Learning Framework for Rapid Quantification and Analysis of Multiplexed Ion Beam Images (MIBI) |
Raghav Padmanabhan, PhD; Mate L. Nagy, PhD; Stanislaw Nowak, PhD; Peng Si, PhD; Sweta Bajaj, M.S.; Monirath Hav, MD, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers |
| 1295 |
Poster Presentation |
Systems biology analysis of anti-tumor immunity |
Mohammad Nikmaneshi, PhD; James W. Baish, PhD; Timothy P. Padera, PhD; Lance L. Munn, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Solid tumors;Systems biology;T cell;Tumor evasion |
| 1296 |
Poster Presentation |
Radiomics-based multi-modal prediction of treatment response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV non-small cell lung carcinoma (mNSCLC) |
Ravi B. Parikh, M.D., M.P.P.; Petr Jordan, Ph.D.; Rita J. Ciaravino, B.S.; Ryan A. Beasley, Ph.D.; Arpan A. Patel, M.D.; Dwight H. Owen, MD, MSc; Arya Amini, M.D.; Brendan D. Curti, MD; Ray Page, DO, Ph.D; Aurelie Swalduz, M.D.; Jean-Paul Beregi, M.D.; Jan Chrusciel, M.D.; Eric Snyder, B.S.; Pritam Mukherjee, Ph.D.; Heather M. Selby, Ph.D.; Soohee Lee, M.S.; Roshanthi Weerasinghe, M.P.H.; Shwetha Pindikuri, M.S.; Jakob Weiss, M.D.; Andrew L. Wentland, M.D., Ph.D.; Anish Kirpalani, M.D.; An Liu, Ph.D.; Olivier Gevaert, Ph.D.; George Simon, MD; Hugo J. Aerts, Ph.D. |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Checkpoint blockade;Solid tumors |
| 1297 |
Poster Presentation |
Uncovering the hidden structure of T cell compositions in peripheral blood after immune checkpoint inhibitor |
Xiyu Peng, PhD; Jasme Lee; Matthew Adamow, BS; Colleen Maher; Margaret K. Callahan, MD, PhD; Katherine S. Panageas, PhD; Ronglai Shen, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Checkpoint blockade;Immune monitoring;T cell |
| 1298 |
Poster Presentation |
A weakly supervised deep learning framework to predict KRAS-STK11 and KRAS-TP53 co-mutations in lung adenocarcinomas using H&E tissue sections |
Daniel Jiménez-Sánchez; Carlos E. De Andrea, MD; Álvaro López-Janeiro; Maria D. Lozano; Carlos Ortiz-de-Solórzano; Aida Romano-Martínez; Cristina Sainz; Luis M. Montuenga; Ignacio I.M. Melero, MD, PhD; Ruben Pio |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1299 |
Poster Presentation |
Predicting CD8+ cell density and tumor-immune phenotypes in non-small-cell lung cancer (NSCLC) from standard H&E slides using deep learning (DL) |
David Soong, PhD; Becky Arbiv; Ettai Markovits, MD; Alon Groisman; Yuval Shachaf; Tomer Dicker; Yoni Yedidia; Hisham Hamadeh; Kate Sasser; Gali Golan; Brandon Higgs; Suzana Couto; Ori Zelichov, MD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Biomarkers;Immune contexture;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1300 |
Poster Presentation |
CT scan normalization to improve radiomics generalizability and assess progression-free survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study |
Marion M.T. Tonneau, MD; Kim Phan; Cécile Low-Kam; Francis Dutil; Suzanne Kazandjian; Davy Vanderweyen; Justin Panasci; Julie Malo; François Coulombe; Arielle Elkrief; Wiam Belkaïd; Lisa Di Jorio; Michèle Orain; Nicole Bouchard; Thierry Muanza; Kam Kafi; Florent Chandelier; Philippe Joubert; Bertrand Routy |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Biomarkers |
| 1301 |
Poster Presentation |
Conditional bispecific T cell engager design and dosing optimization via mechanistic modeling |
Jess Q. Wu, PhD; Michael Vilkhovoy, PhD; Sara Shum, PhD; Johara Chouitar, PhD; Patrick LeRoy; Leticia Fridman; Eilene Kwok; Glendon Wu; Matyas Ecsedi, MD, PhD; Antara Banerjee, Ph.D.; Dean C. Bottino, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bispecifics;Solid tumors;Systems biology;T cell;Tumor microenvironment |
| 1302 |
Poster Presentation |
Spatial Analysis of the Tumor Microenvironment using Machine Learning-Enabled Integrated Morphology-Transcriptomic Cell Phenotypes |
Wei Yan; Nga H. Luong; Jeffrey C. Lim; Yuezhen Xue; Abu Bakr Azam, M.Engg; Joe Poh Sheng P. Yeong, MD, PhD; Mai Chan Lau; Yiyu Cai, PhD |
Machine Learning, Artificial Intelligence and Computational Modeling |
B cell;Bioinformatics;Gene expression;T cell;Tumor microenvironment |
| 1303 |
Poster Presentation |
Prediction of Best Response for NSCLC Patients Receiving Immunotherapy by Machine Learning Models |
Yili Zhang, Ph.D.; Samir Gupta, Ph.D.; Anas Belouali; Shaked Lev-Ari; Neil J. Shah, MBBS; Kanchi Krishnamurthy; Micheal Serzan; Adil Alaoui; Peter McGarvey; Michael B. Atkins, MD; Subha Madhavan, Ph.D. |
Machine Learning, Artificial Intelligence and Computational Modeling |
Bioinformatics;Clinical study;Immune monitoring;Immune tolerance |
| 1304 |
Poster Presentation |
Dietary patterns associated with increased abundance of Akkermansia muciniphila potentiates anti-PD-L1 immune checkpoint blockade response in triple-negative breast cancer |
Kenysha Y. Clear, BS; Elizabeth R. Stirling, MS, PhD; Adam S. Wilson; David R. Soto-Pantoja, PhD; Katherine L. Cook, PhD |
Microbiome and other environmental factors |
Biomarkers;Checkpoint blockade;Immune suppression;Microbiome;Monocyte/Macrophage;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1305 |
Oral Presentation |
Impact of Tet2-mutant clonal hematopoiesis on solid tumor immunology and response to checkpoint blockade |
Shelley Herbrich, PhD; Swetha Anandhan, M.Sc.; Padmanee Sharma, MD, PhD |
Microbiome and other environmental factors |
Checkpoint blockade;Immune suppression;Solid tumors;Tumor microenvironment |
| 1306 |
Poster Presentation |
Prevention of antibiotic-induced dysbiosis in human volunteers by DAV132 and preservation of responsiveness to anti-PD-1 therapy demonstrated by transplantation of human feces into tumor-bearing mice |
Meriem Messaoudene; Nathalie Saint-Lu; Frédérique Sablier-Gallis; Stéphanie Ferreira; Clément Le Bescop; Thomas Loppinet; Mayra Ponce; Céline Féger; Antoine Andremont; Jean De Gunzburg; Bertrand Routy |
Microbiome and other environmental factors |
Checkpoint blockade;Microbiome |
| 1307 |
Oral Presentation |
The microbiome-derived metabolite TMAO drives immune activation and boosts response to immune checkpoint blockade in pancreatic cancer |
Gauri Mirji, PhD; Alison Worth, MSc; Sajad A. Bhat; Mohamed El Sayed; Toshitha Kannan; Aaron Goldman; Hsin Yao Tang; Qin Liu; Noam Auslander; Chi V. Dang; Mohamed Abdel-Mohsen; Andrew Kossenkov; Ben Stanger, MD, PhD; Rahul Shinde, DVM PhD |
Microbiome and other environmental factors |
Checkpoint blockade;Gene expression;Immune suppression;Metabolism;Microbiome;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1308 |
Poster Presentation |
Bacteria specific IL-10 secreting T-cells derived from the gut are cross-reactive with tumor antigens and accelerate tumor growth in mouse models |
Denise Cecil, PhD; Jean Feng; Alex Paynter; Jessica Perry; Noah Simon; Nicholas Drovetto; Lauren Corulli, MS; Erin Rodmaker; Susan Strenk; David Fredricks, MD; Mary L. Disis, MD, FACP |
Microbiome and other environmental factors |
Immune suppression;Immune tolerance;Microbiome;Solid tumors;T cell;Tumor antigens |
| 1309 |
Poster Presentation |
Differential microbial enrichment is associated with oral cancer and perineural invasion. |
August Culbert; Adrian Chow, MD; Raad Gharaibah, PhD; Naseer Sangwan, PhD; Mohammed Dwidar, PhD; Rachel Newsome; Jin Dai, PhD; Siming Ma; Kristiann Fredenburg, MD, PhD; Emrullah Yilmaz, MD, PhD; Shlomo Koyfman, MD; Daniel McGrail, PhD; Jamie Ku; Christian Jobin, PhD; Natalie Silver, MD, MS, FACS |
Microbiome and other environmental factors |
Clinical study;Immune suppression;Microbiome;Solid tumors;Surgery;Tumor microenvironment |
| 1310 |
Oral Presentation |
Dietary tryptophan catabolite released by intratumoral Lactobacillus reuteri facilitates anti-PD-L1 therapy |
Alex McPherson, BS; Mackenzie J. Bender, BS; Catherine M. Phelps, MS; Mohit Rana, BS; Surya P. Pandey, PhD; Jake H. Shapira; Angela M. Gocher-Demske, PhD; Steven J. Mullett; Stacy G. Wendell, PhD; Diwakar Davar, MD; Reinhard Hinterleitner, PhD; Dario A. Vignali, PhD; Alok V. Joglekar, PhD; Hassane Zarour, MD; Marlies Meisel, PhD |
Microbiome and other environmental factors |
Microbiome;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1311 |
Poster Presentation |
The melanoma tumor microbiome as a predictor of outcomes in patients with metastatic disease treated with immune checkpoint inhibitors |
Caroline E. Wheeler, BA; Rebecca Hoyd, BS; Aik Choon Tan, PhD; Neli Ulrich, MS, PhD; Gabriel Tinoco, MD; Dwight H. Owen, MD, MSc; Jennifer Ose, PhD; Martin McCarter, MD; Vineeth K. Sukrithan, MD; Alexandra Ikeguchi, MD; Carlos H. Chan, MD, PhD; Yousef Zakharia, MD; Rebecca D. Dodd, PhD; Sheetal Hardikar, PhD, MBBS; George J. Weiner, MD; Youngchul Kim, PhD; Ning Jin, MD; YunZhou Liu, BS; Nicholas C. Denko, MD, PhD; Marium Husain, MD; John D. Carpten, PhD; Eric A. Singer, MD, MA, FACS; Lary A. Robinson, MD; William (Bill) S. Dalton, PhD, MD; Michelle L. Churchman, PhD; Daniel Spakowicz, PhD; Ahmad A. Tarhini, MD, PhD, MS |
Microbiome and other environmental factors |
Bioinformatics;Microbiome;RNA;Tumor microenvironment;Tumor stroma |
| 1312 |
Poster Presentation |
Gut dysbiosis suppresses anti-tumor ILC2s in pancreatic cancer |
Abderezak Zebboudj, PhD; Masataka Amisaki, MD, PhD; Pablo Guasp, PhD; Luis A. Rojas, PhD; Zachari M. Sethna, PhD; Waters Theresa; Adrienne K. Chandra; Rebecca Yu; Zagaa Odgerel, PhD; Kevin Soares, MD; Vinod P. Balachandran, MD |
Microbiome and other environmental factors |
Cytokine;Immune suppression;Microbiome;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1313 |
Poster Presentation |
Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor |
Girish Daginakatte, PhD; Chandrasekhar Abbineni; Saravanan Thiyagarajan; Mamon Dey; Aravind Basavaraj; Amit Dhudashiya; Sivapriya Marappan; Sandeep Sadashiv Patil; Naveen Kumar R; Raghavendra N. R.; Avinash Kumar; Uma Bharathi B. V.; Girish Renukappa; Venkata Siva Reddy; Amith A.; Suraj Gore; Lavanya C. S.; Subhendu Mukherjee; Samiulla D. S.; Thomas Antony; Rajesh Eswarappa; Kavitha Nellore; Shekar Chelur; Murali Ramachandra; Susanta Samajdar |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Epigenetics;Leukemia/Lymphoma;MDSC;Post-translational modifications;Regulatory T cell (Treg cell);Solid tumors;T cell;Targeted therapy;Tumor evasion |
| 1314 |
Poster Presentation |
Trilaciclib, an intravenous cyclin-dependent kinase 4/6 inhibitor, enhances antitumor responses by modulating T cells |
Sarah Ahn; John S. Yi, PhD; Subing Cao |
Novel Single-Agent Immunotherapies |
T cell;T cell lineages |
| 1315 |
Poster Presentation |
MVdeltaC, a new therapeutic vaccine demonstrates promising preclinical immuno-oncolytic activities |
Aleksandr Barinov, PhD; Chantal Combredet; Claude Ruffié; Valérie Najburg; Nicolas Boisgerault, PhD; Marc Gregoire, PhD; Véronique Riebbels, PhD; Jean-François Le Bigot, PhD; Frederic Tangy, PhD |
Novel Single-Agent Immunotherapies |
Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune adjuvant;Inflammation;RNA;Solid tumors;T cell;Tumor microenvironment;Vaccine |
| 1316 |
Poster Presentation |
A novel class of T cell-activating antibody that selectively targets the TCR b chain to promote antitumor activity through activation and expansion of a novel, polyclonal effector memory T cell subset |
Andy Bayliffe, PhD; Zhen Su, MD, MBA; John Wherry, PhD; Jonathan Hsu; Madan Katraggada, PhD; Jacques Moisan, PhD; Gurkan Guntas, PhD; Karunya Srinivasan; Jessica Lowry, PhD; Rajesh Chopra; Roya Servattalab; Wei Huang; Jian Tang; Andrew Bayliffe |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1317 |
Poster Presentation |
Citrullinated glucose-regulated protein 78 is a novel candidate target for cancer immunotherapy |
Victoria A. Brentville; Jia Chua; Peter Symonds; Anne Skinner; Ian Daniels; Katherine W. Cook, PhD; Lindy G. Durrant |
Novel Single-Agent Immunotherapies |
Neoantigens;Post-translational modifications;T cell;Tumor antigens;Vaccine |
| 1318 |
Poster Presentation |
A next generation DNA vaccine coding for the immunodominant sequence of alpha-Enolase with enhanced ability to induce effector T cell responses to cure pancreatic cancer |
Silvia Brugiapaglia, MS; Claudia Curcio, PhD; Daniele Giordano, MD; Rosella Spadi, MD; Ennia Dametto, MS; Monica Berrino, MS; Alessandro Scagliotti, MS; Antonio Amoroso, MD; Paola Cappello, PhD MS; Francesco Novelli, PhD |
Novel Single-Agent Immunotherapies |
Solid tumors;T cell;Tumor antigens;Tumor microenvironment;Vaccine |
| 1319 |
Poster Presentation |
Next-generation TCR Bispecifics (TCER) targeting peptide-HLA antigens for the treatment of patients with solid tumors |
Sebastian Bunk; Martin Hofmann; Gabriele Pszolla; Meike Hutt; Felix Unverdorben; Frank Schwoebel; Nadine Aschmoneit; Claudia Wagner; Maike Jaworski; Christoph Schraeder; Heiko Schuster; Sarah Missel; Toni Weinschenk; Dominik Maurer; Carsten Reinhardt |
Novel Single-Agent Immunotherapies |
Bispecifics;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 1320 |
Poster Presentation |
Non-clinical characterization of CYT-303 FLEX-NK™ engager antibody supports clinical evaluation. |
Liang Lin; Vishal Khairnar; Harish Potu; Hao-Ming Chang; Elisabetta Burchi; Armin Rath; Stanley Frankel; Jean Kadouche; Daniel Teper; Wei Li; Antonio Arulanandam |
Novel Single-Agent Immunotherapies |
Antibody;NK/NKT cell;Solid tumors |
| 1321 |
Poster Presentation |
A biparatopic anti-HER2 antibody enabled with conditional 4-1BB agonism induces potent anti-tumor efficacy |
Liandi Chen; Weifeng Huang; Xiaoniu Miao; Shaogang Peng; Chao Wang; Yao Yan; Chuan-Chu Chou, PhD; Andy Tsun; Yi Luo |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Costimulation;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1322 |
Poster Presentation |
Targeting immunosuppressive macrophages and Tregs by repurposing metabolic drugs |
Shipeng Chen; Ana Milena Vizcaino; Yuzhen Gao; Baukje Nynke Hoogenboom; Toos Daemen; Cesar Oyarce |
Novel Single-Agent Immunotherapies |
Immune suppression;Metabolism;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1323 |
Poster Presentation |
CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies |
Natasha Girgis, PhD; Yu Christie; Zohra Merazga, MSc; Steven Hatfield; Alex Histed; Fan Zhao, PhD; Raymond J. Moniz, PhD; Kristin Yeung; Fulvio Diaz; Wynona Bautista; John F. Ross; Saso Cemerski, PhD; Anish Suri, PhD; Matteo Levisetti; Steven N. Quayle |
Novel Single-Agent Immunotherapies |
Cytokine;T cell;Tumor antigens;Vaccine |
| 1324 |
Poster Presentation |
Inhibition of acid sensing by GPR65 normalises gene expression in macrophages, increases immune cell infiltration in tumors, and restrains subcutaneous MC38 growth in mice |
Alastair L. Corbin, DPhil; Stuart Hughes, PhD; Mussa Quareshy, PhD; Tobias Bopp, PhD; Barbara Cipriani, PhD; David J. Miller, PhD; Alan Naylor, PhD; Gavin Milne, PhD; Darryl Turner; Barbara Young, PhD; Anastasia Nika, MSc; Preeti Singh; Rupert Satchell, PhD; Sourav Sarkar, PhD; Gavin Knox, MSc; Toszka Bohn, PhD; Tom McCarthy, PhD |
Novel Single-Agent Immunotherapies |
Gene expression;Immune suppression;Monocyte/Macrophage;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) |
| 1325 |
Poster Presentation |
Preclinical Activity and Safety Profile of JANX007, a Novel PSMA-Targeting Tumor-Activated T Cell Engager for Treatment of Metastatic Castration-Resistant Prostate Cancer |
Shahram Salek-Ardakani; Thomas R. DiRaimondo; Natalija Budimir; Simon Shenhav; Hua Wu; Vanessa Cicchini; Renee Jocic; Lina Ma; Fabrece Roup; Calvin Campbell; Carolina Caffaro; Hans Aerni; Ugur Eskiocak; Wayne Godfrey; Charles Winter; Marc Nasoff; Neil Gibson; David Campbell |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Solid tumors;T cell |
| 1326 |
Poster Presentation |
A Bifunctional Tumor Activated Immunomodulator (TRACIr) Targeting PD-L1 And CD28 Is a Potent Enhancer of T Cell-Mediated Anti-Tumor Activity |
Shahram Salek-Ardakani; Thomas R. DiRaimondo; Natalija Budimir; Lina Ma; Simon Shenhav; Vanessa Cicchini; Robert Navert; Hua Wu; Renee Jocic; Cuiling Yu; Diane Aceveda; Hannah Best; Clara Prentiss; Kai Muskat; Jason Chang; Farhad Dastmalchi; Fabrece Roup; Carolina Caffaro; Hans Aerni; Wayne Godfrey; Charles Winter; Marc Nasoff; Neil Gibson; David Campbell; Shahram Salek-Ardakan |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Costimulation;Solid tumors;T cell;Tumor microenvironment |
| 1327 |
Poster Presentation |
Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells |
Jeremy Drees, PhD; Anissa S.H. Chan, PhD; Yunfang Li; Takashi O. Kangas; Weiyu Zhang, PhD; Maria Fumagalli; Iman Dewji; Kathryn Bieging-Rolett, PhD; Sho Fujisawa; Sharon Huang; Ben Harrison; Ashley LaCayo; Xiaohong Qiu; Nick Collette; Gemily Wang; Feven Tameire, PhD; Paulina Wojnarowicz, PhD; Crissy Dudgeon, PhD; Eric Lightcap, PhD; David Surguladze, PhD; Nandita Bose, PhD |
Novel Single-Agent Immunotherapies |
MDSC;Myeloid cells;Solid tumors;T cell;Tumor microenvironment |
| 1328 |
Poster Presentation |
A novel humanized T cell-engaging CD24xCD3 bispecific antibody for CD24-positive solid tumors |
Madelyn Espinosa-Cotton, PhD; Hong-Fen Guo; Nai-Kong V. Cheung, MD, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Pediatric tumors;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 1329 |
Oral Presentation |
Ultra-pH Sensitive Nanoparticles Increase Therapeutic Index of IL-2-Fc |
Qiang Feng, PHD; Gang Huang; Raymundo Pantoja; Zhichen Sun, Ph.D.; Wei Li, PhD; Katy Torres; Jonathan Wilhelm, Ph.D; Zirong Chen, PhD; Tian Zhao, PhD; Ruolan Han; Jinming Gao, PhD |
Novel Single-Agent Immunotherapies |
Cytokine;Immune toxicity;Solid tumors |
| 1330 |
Poster Presentation |
Characterising the immunotherapeutic capabilities of bacterial outer-membrane vesicles |
Jack Firth; Jingjing Sun; Jiandong Huang; Kenth Gustafsson; Mona Bajaj-Elliott |
Novel Single-Agent Immunotherapies |
Extracellular vesicles/exosomes;T cell;TLR |
| 1331 |
Poster Presentation |
Dual Blockade of the EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway |
Brian Francica, PhD; Justine Lopez; Anja Holtz; Dave Freund; Dara Burdette, PhD; Dingzhi Wang; Raymond Duboise; Sam H. Whiting, MD, PhD; Thomas W. Dubensky, Jr., PhD |
Novel Single-Agent Immunotherapies |
Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1332 |
Poster Presentation |
Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D |
Alexandria Fusco; Elizabeth Scanlon; Frano Irvine; Flavian D. Brown; Jeffrey D. Colbert; Andy Tu; Stephanie Gaerlan; Kelly Nichols; Teresse de Rham; Matthew Huggins; Kendall Dionne; Ming Tang; Heather Flick; Alison Tisdale; Seng-Lai Tan, PhD; Shruti Malu |
Novel Single-Agent Immunotherapies |
Antibody;Biomarkers;Checkpoint blockade;Coinhibition;NK/NKT cell;Solid tumors;T cell |
| 1333 |
Poster Presentation |
Development of IMGS-001, a novel anti-PD-L1/PD-L2 dual specific, multi-functional antibody, to treat immune excluded tumors |
Christine Gagliardi, PhD; Federica Pericle, PhD, MBA; Ahmad Salameh, PhD; Paul Blezinger; Michael A. Curran, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Checkpoint blockade;Targeted therapy;Tumor microenvironment |
| 1334 |
Poster Presentation |
AVA-ADR-001 Supresses Tumor Growth and Induces Anti-tumor Immunity by Selectively Inhibiting ADAR1 p150 |
Arun B Papaiah, MBA; Avijit Goswami; Sandeep Goyal; Kawaljit Singh; Princy Khurana; Aditya Kulkarni, PhD |
Novel Single-Agent Immunotherapies |
Solid tumors;Tumor microenvironment |
| 1335 |
Poster Presentation |
AVA-NP-695 Potently and Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model |
Aditya Kulkarni, PhD; Avijit Goswami; Sandeep Goyal; Princy Khurana; Arun Papaiah |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Chemotherapy;Radiotherapy;Solid tumors;Tumor microenvironment |
| 1336 |
Poster Presentation |
DPX-based Immune Education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens |
Brennan S. Dirk, PhD; Moamen Bydoun, PhD; Ava Vila-Leahey, PhD; Erin Kelly, MSc; Olga Hrytsenko, PhD; Jeremy R. Graff, PhD |
Novel Single-Agent Immunotherapies |
Antigen presenting cells;Dendritic cell;T cell;Targeted therapy;Vaccine |
| 1337 |
Poster Presentation |
Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors |
Zhen Su, MD, MBA; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Lillian L. Siu; Ryan J. Sullivan, MD; E. John Wherry, PhD; Ke Liu, MD, PhD; Renee N. Donahue, PhD; Madan Katraggada, PhD; Rajesh Chopra; Jacques Moisan, PhD; Jonathan Hsu, PhD; Yo-Ting Tsai, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1338 |
Poster Presentation |
SRF114, an afucosylated anti-CCR8 antibody, depletes intratumoral Treg cells and reduces tumor growth |
Robert R. Haines, Ph.D.; Marisella Panduro, Ph.D.; Andrew C. Lake, PhD; Vito J. Palombella, PhD; Jonathan A. Hill, PhD; James F. Mohan, Ph.D. |
Novel Single-Agent Immunotherapies |
Antibody;Immune suppression;Monocyte/Macrophage;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1339 |
Poster Presentation |
ALD2510: Next Generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers |
Jemila Houacine, PhD; Riad Abes, PhD; Anne Marie-Cardine, PhD; Aude LeRoy, PhD; Jerôme Giustiniani, PhD; Anne-Sophie Chrétien, PhD; Stéphane Fattori, PhD; Laurent Gorvel, PhD; Armand Bensussan, PhD; Daniel Olive, MD, PhD; Arnaud Foussat, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1340 |
Poster Presentation |
BT7455, a fully synthetic Bicycle tumor-targeted immune cell agonist, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy |
Kristen Hurov, PhD; Lia Luus; Johanna Lahdenranta, PhD; Punit Upadhyaya, PhD; Heather Cohen; Chinmayee Shah; Julia Kristensson; Peter Brown; Gemma Mudd; Carly Campbell; Elizabeth Repash; Eric Haines; Sailaja Battula; Mike Kelly; Phil Jeffrey; Paul Beswick; Liuhong Chen; Kevin McDonnell, PhD; Philip E. Brandish, PhD; Nicholas Keen, PhD |
Novel Single-Agent Immunotherapies |
Bispecifics;Costimulation;Gene expression;Solid tumors;T cell;Targeted therapy |
| 1341 |
Poster Presentation |
CD27 an emerging immuno-oncology target at the cross-roads of innate and adaptive anti-tumor immune responses |
Thierry Guillaudeux, PhD; Shawn Iadonato, PhD; Jessica Cross; Nathan Eyde; Emily Frazier; Neda Kabi; Chen Katz; Remington Lance; Yulia Ovechkina; Kurt H. Lustig; David Peckham; Shaarwari Sridhar; Carla Talbaux; Isabelle Tihista |
Novel Single-Agent Immunotherapies |
Antibody;Costimulation;NK/NKT cell;T cell;Tumor microenvironment |
| 1342 |
Poster Presentation |
Therapeutic targeting of MARCO with PY265 antibody promotes myeloid cell reprogramming and unleashes anti-tumor immunity |
Linnea Haeggblom, PhD; Subhadra Dash; Yelena Vayn; Josh Rudolph; Rachael Palmer; Xi Yang; Sergio Lacayo; Cesar Juarez; Erin Mayes; Rachel Greathouse; Kara Mojica; Carlos Santamaria; Johanna Ramoth; Ranna Mehta; Maryam Yousefi; Nadine Jahchan; Svetlana Gratch; Amy-Jo Casbon; Joshua L. Pollack; Marc Chamberlain; Leonard Reyno; Matthew Myers; Vladislava Juric; Linda Liang; Kristen Pierce; Kevin P. Baker |
Novel Single-Agent Immunotherapies |
Biomarkers;Checkpoint blockade;Chemokine;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment |
| 1343 |
Poster Presentation |
Antitumor effect of DA-4507, a novel GCN2 inhibitor as an immunotherapy in the tumor microenvironment |
Youngjee Jeong, Master's degree; Jun-Hwan Moon; Ik-Soo Jang; Kyu Hwan Kim; Na Yeon Park; Hyung Ki Lee; Cheonhyoung Park; Tae-Hun Kim; Do Young Choi; Ha Yoon Kim; Ki Moon Ryu; Min Jung Lee; Hyounmie Doh |
Novel Single-Agent Immunotherapies |
Immune suppression;Immune tolerance;Metabolism;Regulatory T cell (Treg cell);T cell;Tumor microenvironment |
| 1344 |
Poster Presentation |
Preclinical PK/PD profile, biomarker identification and rationale for indication selection of exoASO-STAT6™, a selective tumor-associated macrophage targeting candidate |
Sushrut Kamerkar, PhD; Charan Leng; Kelvin Zhang, PhD; Olga Burenkova; Su Chul Jang, PhD; Tong Zi; Sílvia Sisó; Kyriakos Economides; Karl Schmidt; Timothy J. Soos; Dalia Burzyn, PhD; Sriram Sathyanaryanan, PhD |
Novel Single-Agent Immunotherapies |
Biomarkers;Extracellular vesicles/exosomes;Gene expression;Monocyte/Macrophage;Myeloid cells;RNA;Solid tumors;Tumor microenvironment |
| 1345 |
Poster Presentation |
exoASO-C/EBPβ™: An engineered exosome therapeutic that selectively targets MDSCs and induces potent single-agent anti-tumor activity in checkpoint refractory tumor models |
Sushrut Kamerkar, PhD; Charan Leng; Olga Burenkova; Su Chul Jang, PhD; Kelvin Zhang, PhD; Samuel Kasera; Tong Zi; Sanah Langer; Silvia Siso, PhD; Timothy J. Soos, PhD; Dalia Burzyn, PhD; Sriram Sathyanaryanan, PhD |
Novel Single-Agent Immunotherapies |
Extracellular vesicles/exosomes;Gene expression;MDSC;Monocyte/Macrophage;Myeloid cells;Targeted therapy |
| 1346 |
Poster Presentation |
Antibodies against GlycoTargets as novel platform approach to address unmet needs in cancer therapy |
Patrik Kehler, Dr.; Theresa Neumann; Anika Jaekel; Manon Weis; Johanna Gellert; Antje Danielczyk; Evelyn Hartung; Timo Lischke; Stephanie Gurka; Naomi Kast; Manon Weiske |
Novel Single-Agent Immunotherapies |
Antibody;Glycoproteomics;Solid tumors;Targeted therapy;Tumor antigens |
| 1347 |
Poster Presentation |
Targeting of a cancer-associated LYPD3 glycoform for tumor therapy |
Patrik Kehler, Dr.; Theresa Neumann; Anika Jaekel; Johanna Gellert; Antje Danielczyk; Lisa Weiß; Luisa Willmann; Stephanie Gurka; Naomi Kast; Manon Weiske |
Novel Single-Agent Immunotherapies |
Antibody;Glycoproteomics;Solid tumors;Targeted therapy |
| 1348 |
Poster Presentation |
BDC-3042: A Dectin-2 agonistic antibody for tumor-associated macrophage-directed immunotherapy |
Justin A. Kenkel, PhD; Rishali K. Gadkari; Jess L. Nolin; Fang Xiao, PhD; Po Y. Ho; Cindy L. Kreder; Laughing Bear Torrez, PhD; David T. Omstead, PhD; Katelynn A. McEachin; Jason Ptacek, PhD; Lu Xu, PhD; Duy T. Nguyen; Karla A. Henning, PhD; Steven J. Chapin, PhD; David Dornan, PhD; Michael N. Alonso, PhD; Shelley E. Ackerman, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Antigen presenting cells;Chemokine;Cytokine;Immune adjuvant;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment |
| 1349 |
Poster Presentation |
TROCEPT mediated in-tumor delivery of immune checkpoint inhibitors reduces systemic toxicity risks and boosts immune activation |
David K. Cole, PhD; Rahul C. Khanolkar; James A. Davies; Alexander T. Baker; Thomas A. Webb; Alicia Teijeira Crespo; Hanni K. Uusi-Kerttula; Lucy M. Williams; Samantha L. Moore; Johanne M. Pentier; Bent K. Jakobsen; Alan L. Parker; Jez B. Gerry |
Novel Single-Agent Immunotherapies |
Antibody;Checkpoint blockade;Solid tumors;T cell;Targeted therapy |
| 1350 |
Poster Presentation |
AI/ML-driven discovery of Collagen Triple Helix Repeat-Containing 1, CTHRC1, a novel proteoglycan for disruption of stromal barriers and enhancement of immunotherapy responses in desmoplastic tumors |
Elizabeth Koch, Ph.D.; Amy Berkley, Ph.D.; Sean Phippen; Max London, Ph.D.; Kerry White; Amanda Hanson; Sam Cooper, Ph.D.; Christopher Harvey, Ph.D.; Michael J. Briskin, Ph.D. |
Novel Single-Agent Immunotherapies |
Antibody;Checkpoint blockade;Solid tumors;Tumor microenvironment;Tumor stroma |
| 1351 |
Poster Presentation |
Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody-CD3xB7H4 in solid cancer models |
Louise A. Koopman, PhD; Madelon Paauwe; Laura Smits-de Vries; Frosso Karaiskaki; Marcel Brandhorst; Patrick Franken; Theo S. Plantinga; Stefanie A. De Poot, PhD; Mischa A. Houtkamp, PhD; Kate Sasser; Esther C.W. Breij, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Biomarkers;Bispecifics;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 1352 |
Poster Presentation |
Selective Small Molecule Inhibitor of Integrin αVβ8 and αVβ1 Has Single Agent Activity and Potentiates Immune Checkpoint Blockade Therapy |
Vishal Kothari, Ph.D.; Colin Magowan, B.A.; Darren Finkelstein, Ph.D.; Gail G. Lee, B.S.; Chun Chen, Ph.D.; Tim F. Hom, M.A.; Manuel Muñoz, B.S.; Dennis Monteleone, M.S.; Subramanian Karur, M.A.; Marta Bogaczynska, M.S.; Erin H. Budi, Ph.D.; Prerna Kotak, M.A.; Shamra P. Martin, A.S.; Katherine Jenkins, B.S.; Simon G. Wong, Ph.D.; Timothy Machajewski, Ph.D.; Fernando Rock, Ph.D.; Scott M. Turner, Ph.D. |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Monocyte/Macrophage;Regulatory T cell (Treg cell);Solid tumors;Tumor stroma |
| 1353 |
Poster Presentation |
Targeting Complement Factor H mediated tumor immune and complement evasion as a next generation approach. |
Matthew R. Kraman, PhD; Carlo Zimarino; Danielle Minns; Jorge Dias; Chelsea Povall; Helen Graves; Bradley Holub; Ralph Minter; Jacob D. Galson; Jane Osbourn; Donna Finch |
Novel Single-Agent Immunotherapies |
Immune suppression;Immune tolerance;Monocyte/Macrophage;Tumor evasion |
| 1354 |
Poster Presentation |
CBL-B inhibition showed differentiated effects in a mixed lymphocyte reaction versus other immuno-oncology targeted approaches |
Yilin Qi, Ph.D; Jun Kuai, PhD; Yingzhi Bi; Huadong Sun; David Greco; Ken Carson; Timothy Reilly; Geraldine Harriman; Fang Wang |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Costimulation;T cell |
| 1355 |
Poster Presentation |
Novel Pharmacological Approach to Induce Direct Killing of Cancer and Activate Antitumor Immunity via Inhibition of Monocarboxylate Transporters |
Sambad Sharma, PhD; Nicole Bowman, MS; Sanath Wijerathna, MD PhD; Maolin Yu, PhD; Jennifer Duffy; Jaime Escobedo, PhD; Nelly Kuklin, PhD; Vincent Sandanayaka, PhD |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Metabolism;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment |
| 1356 |
Poster Presentation |
Transcriptional profiling of Bicycle tumor-targeted CD137 agonist-treated mouse tumors revealed an early and rapid activation of myeloid cells followed by infiltration of cytotoxic T cells into the tumor |
Johanna Lahdenranta, PhD; Kristen Hurov, PhD; Heather Cohen; Punit Upadhyaya, PhD; Kevin McDonnell, PhD; Philip E. Brandish, PhD; Nicholas Keen, PhD |
Novel Single-Agent Immunotherapies |
Bispecifics;Costimulation;Cytokine;Gene expression;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1357 |
Poster Presentation |
Reversible chemical modulation of antibody effector function maintains anti-tumor activity while mitigating peripheral immune activation |
Matthew R. Levengood, PhD; Chris I. Leiske; Noah A. Bindman; Xinqun Zhang; Nicole Duncan; Weiping Zeng; Serena W. Wo; Abbie Wong; Clark M. Henderson; Karalyne Crowder; Haley D. Neff-LaFord; Django Sussman; Shyra J. Gardai; Philip N. Moquist |
Novel Single-Agent Immunotherapies |
Antibody;Solid tumors;Targeted therapy;Tumor antigens |
| 1358 |
Poster Presentation |
Novel EGFR/PI3K dual-targeting nanoparticles induce immunogenic cell death in bladder cancer |
Zheng Zhu, MD, PhD; Xiangdong Xue; Gang Zhou; Zewen Song; Guoyin Li, PhD |
Novel Single-Agent Immunotherapies |
Solid tumors |
| 1359 |
Poster Presentation |
Half-life extended engineered IL18 variants that escape the negative regulation of IL18BP |
Xiaofan Li, PhD; Cristina Abrahams; Amandeep Gakhal; Junhao Yang; Kevin Brar; Daniel Calarese; Robert Henningsen; Grace Lee; Katie Neighbors; Jennifer Smith; Andrew McGeehan; Millicent Embry; Abigail Yu; Alan Nguyen; Krishna Bajjuri; Miao Wen; Young Park; Cuong Tran; Mary Rose Masikat; Gang Yin; Alice Yam, PhD; Kristin Bedard; Trevor Hallam |
Novel Single-Agent Immunotherapies |
Cytokine;Inflammation;Monocyte/Macrophage;NK/NKT cell;Proteomics;Solid tumors;T cell |
| 1360 |
Poster Presentation |
Pharmacodynamics of JNJ-70218902, a TMEFF2 × CD3 bispecific antibody, in cynomolgus monkey |
Cassandra Lowenstein; Subhasree Basu; Joshua Rusbuldt; Sathya Venkataramani; Robin Ernst; Steve Jarantow; Scott Brodeur; Daniel Rubio; Pharavee Jasiprasart; Margaret Yu; Brent Rupnow; Michael Russell |
Novel Single-Agent Immunotherapies |
Antibody;Biomarkers;Bispecifics;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1361 |
Poster Presentation |
HBM1022: an afucosylated anti-CCR8 antibody, depletes specifically tumor infiltrating Tregs and inhibits tumor growth with excellent safety profile in preclinical studies |
Shuang Lu, Master; Yiping Rong; Xin Gan; Joe Zhao |
Novel Single-Agent Immunotherapies |
Antibody;Checkpoint blockade;Immune monitoring;Regulatory T cell (Treg cell);Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1362 |
Poster Presentation |
Nonclinical characterization of ICVB-1042, a novel E2F-tumor selective oncolytic virus with the potential to treat solid tumors |
Michael Lyman, PhD; Jessica J. Field, PhD; Joshua Messinger; Nathaniel Rice; Matthew Lanahan; Alex Kato; Michael Pokrass, PhD; Heba Nowyhed |
Novel Single-Agent Immunotherapies |
Solid tumors;Targeted therapy |
| 1363 |
Poster Presentation |
Evaluation of the anti-tumor activity of ICVB-1042, a novel E2F-tumor selective oncolytic virus, selectively targeting tumor cells in an established human glioblastoma mouse model |
Michael Lyman, PhD; Jessica J. Field, PhD; Jinkil Jeong; Valentino Gantz; Nathaniel Rice; Heba Nowyhed |
Novel Single-Agent Immunotherapies |
Solid tumors;Targeted therapy |
| 1364 |
Poster Presentation |
Bispecific antibodies that block TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms. |
Noriko Matsumoto, M.S.; Yuji Mishima, PhD; Kanto Nakajima, PhD; Takahiko Aramaki, PhD; Mamoru Shiraishi; Haruka Matsumura; Noriko Watanabe; Norihiro Nakamura, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Checkpoint blockade;Immune suppression;T cell;Tumor microenvironment |
| 1365 |
Poster Presentation |
An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activity |
Kathleen A. McGuire, Ph.D.; Christina Baumgartner, PhD; Carey Backus; Rebecca Mathew, Ph.D.; Kelly Klinge; Joseph Klahn; Prasanthi Geda; Kyle Halliwill, Ph.D.; Jacqueline Aguado; Liang Mu; Ryan Duggan; Cara Hrusch, Ph.D.; Elliot Farney, Ph.D.; Zhaoming Xiong, Ph.D.; Marinka Bulic; Patricia Trusk; Loren Lasko; Hakimeh Ebrahimi-Nik; Kathleen Yates; Robert Manguso; Keith Hamel, Ph.D.; Marcia Paddock, Ph.D.; Jennifer Frost, Ph.D.; Philip Kym, Ph.D. |
Novel Single-Agent Immunotherapies |
Antigen presenting cells;Chemokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1366 |
Poster Presentation |
Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T cells expansion and long-lasting in vivo efficacy |
Aurore Morello, PhD; Margaux Seite; Justine Durand; Isabelle Girault, MD; Geraldine Teppaz; Virginie Thépénier; Vanessa Gauttier, PhD; Caroline Mary; Nicolas Poirier |
Novel Single-Agent Immunotherapies |
Bispecifics;Checkpoint blockade;Cytokine;T cell |
| 1367 |
Poster Presentation |
A highly-selective HPK1 inhibitor enhances T cell receptor signaling and T cell activation potential, increasing antigen recognition and efficacy of PD-1 therapy |
Andrew R. Nager, PhD; David A. Schaer; Rebecca A. Gallego; Eleanore Hendrickson; Sergei Timofeevski; Manqing Li; Allison Rohner; Ruth Seelige; Samuel Stoner; Christopher Dillon; Paulina D. Cuenca; Cinthia C. Jones; Sarah J. Firdaus; Robert Amezquita; Clifford Restaino; Derek Bartlett; Timothy S. Fisher |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;T cell;Tumor antigens |
| 1368 |
Poster Presentation |
A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity |
Pradip Nair, PhD; Arvind V. Goswamy, PhD; Jaya Bhatnagar, PhD; Srinivas R. Boreddy, Ph. D; Reshmi Nair, PhD; Shiv R. Krishn, PhD; Anshu Kuriakose; Prashanth K. Pandey; Hanumant Kulkarni; Kishore Punnath, PhD; Milind Sagar; Prashanthakumara V, PhD; Thulsi T.K.; Abhishek Sinha, PhD; Ravindra D.R.; Rachel Salazar, PhD |
Novel Single-Agent Immunotherapies |
Bispecifics;Costimulation;Cytokine;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor antigens |
| 1369 |
Poster Presentation |
CD64-directed scFv fusion protein exhibits cytotoxicity and is a tool for site-specific diagnosis of acute myeloid leukemia |
Siew Tai, PhD; Sikozile S. Ncembu, Mr; Stefan Barth, PhD, DMSc; Sue Harrison, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Biomarkers;Leukemia/Lymphoma;Myeloid cells;Targeted therapy;Tumor antigens |
| 1370 |
Poster Presentation |
Distinct anti-tumor response to Listeria-based vaccines between orthotopic and subcutaneous syngeneic mouse models of renal cell carcinoma |
Hong-My Nguyen, B.Pharm; Laurence M. Wood, PhD |
Novel Single-Agent Immunotherapies |
Immune suppression;MDSC;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 1371 |
Poster Presentation |
Identification of Vasoactive Intestinal Peptide (VIP)-specific Single-Chain Antibody Fragments (scFvs) via Yeast Surface Display |
Khue G. Nguyen, PhD; David A. Zaharoff, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Biomarkers;Immune suppression;Regulatory T cell (Treg cell);T cell;Targeted therapy |
| 1372 |
Poster Presentation |
XmAb143, an engineered IL18 heterodimeric Fc-fusion, features improved stability, reduced potency, and insensitivity to IL18BP |
Alex Nisthal, PhD; Sung-Hyung Lee, PhD; Christine Bonzon, PhD; Ruschelle Love, MS; Kendra N. Avery, PhD; Rumana Rashid, PhD; Panida Lertkiatmongkol, PhD; Nicole Rodriguez, PhD; Sher Karki, PhD; Norman J. Barlow, PhD, DVM, MBA; Seung Chu, PhD; Gregory L. Moore, PhD; John R. Desjarlais, PhD |
Novel Single-Agent Immunotherapies |
Cytokine;Inflammation;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs) |
| 1373 |
Poster Presentation |
STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergises with immune checkpoint blockade |
Yaara Ofir -Rosenfeld; Oliver Rausch, PhD; Jerry McMahon; Lina Vasiliauskaite; Claire Saunders; Alexandra Sapetschnig; Georgia Tsagkogeorga; Mark Albertella; Marie Carkill; Jezrom Self-Fordham; Josefin-Beate Holz |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Gene expression;RNA;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
| 1374 |
Poster Presentation |
Characterization and validation of a humanized lead antibody against OX003, a novel immuno-oncology target |
Chander S. Peddaboina, PhD; Arnima Bisht, PhD; Murray Cox, BS; Antonn Cheeseman, BS; Christian Rohlff; Abderrahim Fandi, MD, PhD |
Novel Single-Agent Immunotherapies |
Adoptive immunotherapy;Antibody;Biomarkers;Costimulation;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1375 |
Poster Presentation |
A hormone-based bispecific T cell engager (BiTE)-like molecule for the treatment of neuroendocrine tumors |
Eleonora Pelle, MD; Mauro Cives; Elliot Medina; Charlotte C. Mason; Sebastian Snedal; Xiomar E. Bustos Perez; Leticia Tordesillas, PhD; Miguel Gomez Fontela, PhD; Renata A.M. Rossetti; Gabriele Maiorano; Vincent C. Luca, PhD; Patrick Hwu; Daniel Abate-Daga, PhD; Jonathan R. Strosberg, MD |
Novel Single-Agent Immunotherapies |
Bispecifics;Solid tumors;T cell;Tumor microenvironment |
| 1376 |
Poster Presentation |
Novel, brain penetrant small molecule inhibitor of PD-L1 for targeting glioblastoma and brain metastasis |
Dhanalakshmi Sivanandhan, PhD; Sridharan Rajagopal, PhD; Chandru Gajendran, M.Sc; Naveen Sadhu M, M.Sc; Mohammed Zainuddin, PhD; Ramachandraiah Gosu, PhD; Luca Rastelli, PhD |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1377 |
Poster Presentation |
Preclinical Characterization of D3L-001, a novel bispecific antibody that enhance phagocytosis and eradication of HER2 positive solid tumor via HER2 and CD47 dual blockade. |
Haopeng Rui, Mr, PhD; Siwei Nie; Jiaxiang Shao; Xiaofeng Yang; Jiahao Chen; Jia Wang; Zhiqiang Zheng; Zhiqiang Chen; Jingtao Lu; Allison Wang; Jin Hong; Xiaosong Chen; Kunwei Shen; George Chen |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Monocyte/Macrophage;Solid tumors |
| 1378 |
Poster Presentation |
Preclinical characterization of IMGS-001, a dual antagonist anti-PD-L1, anti-PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade |
Ahmad Salameh, PhD; Federica Pericle, PhD, MBA; Christine Gagliardi, PhD; Paul Blezinger; Michael A. Curran, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Checkpoint blockade;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma |
| 1379 |
Poster Presentation |
Engineered toxin body targeting TIGIT depletes Tregs in the tumor microenvironment and reduces tumor burden in mice |
Elizabeth P. Saputra; Amit Chaudhary, Ph.D.; Desirae Martinez; Jennifer Mitchell; Rebecca Martin, Ph.D.; John Majercak, Ph.D.; Joseph D. Dekker, Ph.D.; Chris B. Moore, Ph.D.; Swati Khanna, Ph.D. |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Coinhibition;Immune suppression;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1380 |
Poster Presentation |
Synergistic anti-tumor effect of Allocetra-OTS, a cellular immune-therapy, in combination with immune checkpoint inhibitors/chemotherapy/CAR T, through in-vivo reprogramming of macrophages |
Dror Mevorach, MD; Barak Reicher; Oren Hershkovitz, PhD; Yehudit Shabat, MSC |
Novel Single-Agent Immunotherapies |
CAR T cells;Checkpoint blockade;Coinhibition;Monocyte/Macrophage;Solid tumors;Tumor microenvironment |
| 1381 |
Poster Presentation |
Lactate Modulation in Cancer and Immune Cells is Associated with Antitumor Efficacy of dual MCT1/MCT4 Inhibitor NGY-091 |
Nicole Bowman, MS; Sambad Sharma, PhD; Jennifer Duffy; Sanath Wijerathna, MD PhD; Nelly Kuklin, PhD; Jaime Escobedo, PhD; Vincent Sandanayaka, PhD |
Novel Single-Agent Immunotherapies |
MDSC;Metabolism;Myeloid cells;T cell |
| 1382 |
Poster Presentation |
DKK1 is a biomarker and immunotherapeutic target for bone metastases in malignant cancers |
Tao Shi, PhD; Kaijie Liang; Xiaoyu Zhou; Xueru Song; Hanbing Wang; Yipeng Zhang; Lixia Yu; Baorui Liu, PhD MD; Jia Wei, MD PhD |
Novel Single-Agent Immunotherapies |
Biomarkers;Dendritic cell;Monocyte/Macrophage;Tumor evasion;Tumor microenvironment |
| 1383 |
Poster Presentation |
Remodeling host immune response in head and neck cancer with personalized therapeutic mRNA nano-vaccines. |
Natalie Silver, MD, MS, FACS; Rekha R. Garg, PhD; Hector Mendez-Gomez, PhD; Paul Castillo, MD; Carlos Souza, DVM, MS; Lana Fagman; John A. Ligon, MD; Sadeem Qdaisat; Frances Weidert; Jonathan Chardon-Robles; Jin Dai, PhD; Siming Ma; Jessica L. Geiger, MD; Emrullah Yilmaz, MD, PhD; Shlomo Koyfman, MD; Jamie Ku; Daniel McGrail, PhD; Timothy A. Chan, MD, PhD; Duane Mitchell, MD, PhD; Elias J. Sayour, MD, PhD |
Novel Single-Agent Immunotherapies |
Myeloid cells;RNA;Solid tumors;Tumor microenvironment;Vaccine |
| 1384 |
Poster Presentation |
Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment |
Katrin Rupalla, PhD; Michel Janicot, PhD; Alexej Schmidt, PhD; Iris Helfrich, Professor; Bernhard B. Singer |
Novel Single-Agent Immunotherapies |
Antibody;B cell;Checkpoint blockade;Costimulation;Granulocyte;Monocyte/Macrophage;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Tumor microenvironment |
| 1385 |
Poster Presentation |
Divergent Therapeutic Outcomes of STING Agonist ADU-S100 in Intratumoral and Intravesical Treatment Regimens in Syngeneic Murine MB49 and in the N-methyl-N-nitrosourea (MNU) Rat Model of Urothelial Carcinoma |
Alok K. Singh, PhD; Kara Lombardo; Monali Praharaj, MS; Andres Matoso; William Bishai; Trinity Bivalacqua |
Novel Single-Agent Immunotherapies |
Immune adjuvant;Inflammation;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine |
| 1386 |
Poster Presentation |
Novel, gut-restricted small molecule inhibitor of PD-L1 for targeting GI cancers |
Dhanalakshmi Sivanandhan, PhD; Sridharan Rajagopal, PhD; Chandru Gajendran, M.Sc; Naveen Sadhu M, M.Sc; Mohammed Zainuddin, PhD; Ramachandraiah Gosu, PhD; Luca Rastelli, PhD |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Immune suppression;Immune toxicity;Inflammation;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1387 |
Poster Presentation |
Inhibition of the CD47-SIRPɑ axis for cancer therapy: a meta-analysis of emerging clinical data |
Ji Y. Son, MD, MS; Rodney Cheng-En Hsieh, MD, PhD; Heather Lin, PhD; Kate J. Krause; Ying Yuan; Amadeo B. Biter; James Welsh, MD; Michael A. Curran, PhD; David S. Hong, MD |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Granulocyte;Solid tumors;Targeted therapy |
| 1388 |
Poster Presentation |
Utility of humanized animal models for in vivo evaluation of NK-TICA™, novel Bicycle tumor-targeted immune cell agonists (Bicycle TICA™) designed to engage NK cells |
Lukas Stanczuk, PhD; Johanna Lahdenranta, PhD; Fay J. Dufort, PhD; Christopher J. Leitheiser, PhD; Punit Upadhyaya, PhD; Kevin McDonnell, PhD; Philip E. Brandish, PhD; Nicholas Keen, PhD |
Novel Single-Agent Immunotherapies |
NK/NKT cell;Targeted therapy |
| 1389 |
Poster Presentation |
GIGA-564, a third generation anti-CTLA-4 with minimal ability to block CTLA-4 binding to B7 ligands, has enhanced efficacy but reduced toxicity compared to ipilimumab in pre-clinical models |
Erica L. Stone, PhD; Kyle P. Carter; Ellen K. Wagner; Michael A. Asensio; Emily Benzie; Yao Y. Chiang; Garry L. Coles; Chelsea Edgar; Bishal K. Gautam; Ashley Gras; Jackson Leong; Renee Leong; Vishal A. Manickam; Rena A. Mizrahi; Ariel R. Niedecken; Jasmeen Saini; Savreet K. Sandhu; Jan Fredrick Simons; Kacy Stadtmiller; Brendan Tinsley; LaRee Tracy; Nicholas P. Wayham; Yoong Wearn Lim; David S. Johnson; Adam Adler, PhD |
Novel Single-Agent Immunotherapies |
Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1390 |
Poster Presentation |
RNA-nanoparticle vaccines overcome the immunosuppressive tumor microenvironment of metastatic osteosarcoma |
John A. Ligon, MD; Brian Stover; Hector Mendez-Gomez, PhD; Adam Grippin; Frances Weidert; Lana Fagman; Jonathan Chardon-Robles; Paul Castillo, MD; Natalie Silver, MD, MS, FACS; Joanne Lagmay; Rowan Milner; Duane Mitchell, MD, PhD; Elias J. Sayour, MD, PhD |
Novel Single-Agent Immunotherapies |
Monocyte/Macrophage;Pediatric tumors;RNA;Solid tumors;Tumor microenvironment;Vaccine |
| 1391 |
Poster Presentation |
ZM008, a first in class monoclonal anti LLT1 antibody demonstrated clinical potential in multiple solid cancers |
Maloy Ghosh, PhD; Anurag Tiwari, PhD; Ashvini K. Dubey; Sanghamitra Bhattacharjee; Yogendra Manjunath; Shalini Kashipathi; Subith Krishna |
Novel Single-Agent Immunotherapies |
Antibody;Checkpoint blockade;NK/NKT cell;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1392 |
Poster Presentation |
An atypical central-memory like phenotype can be induced in human T cells by Innate TCRαβ engagement |
Khiyam KH. Hussain, PhD; Pierre Vantourout, PhD; Maria C. Poole, MSc; Josephine Eum Eum, MSc; Thomas S. Hayday, PhD; Adam G. Laing, PhD; Seb Battaglia, PhD; Madan Katragadda, PhD; Jessica Lowry, PhD; Jonathan Hsu, PhD; Adrian C. Hayday, PhD |
Novel Single-Agent Immunotherapies |
Antibody;Cytokine;Gene expression;Immune adjuvant;Regulatory T cell (Treg cell);T cell;Targeted therapy |
| 1393 |
Poster Presentation |
Beyond CCR8: key epitopes targeting dynamic CCR8 conformational states and a diversity of monoclonal antibodies to modulate the tumor microenvironment for the treatment of cancers |
Claudine Vermot-Desroches, PhD; Xavier Leroy, PhD; Iseulys Richert, PhD; Malaury Schappler; Alice Gentil Dit Maurin; Mégane Jeannelle; Solène Rose; Luc Baron; Quentin Ruet; Camille Dietsch; Pauline Urquia; Safia Ayachi; Orphée Blanchard; Christel Franchet; Stephan Schann |
Novel Single-Agent Immunotherapies |
Antibody;Checkpoint blockade;Chemokine;Monocyte/Macrophage;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
| 1394 |
Poster Presentation |
Pre-clinical characterization of biodegradable injectable antigen presenting nanoparticles (AIM INJ) for in vivo treatment of solid tumors |
Haiyun Liu, Ph.D.; Aniket Wadajkar; Sophia Zhang; Christian Wirick; Duong Nguyen; Daniel Dembrow; Sojung Kim; Mathias Oelke |
Novel Single-Agent Immunotherapies |
Antigen presenting cells;Dendritic cell;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine |
| 1395 |
Poster Presentation |
CLN-619, a clinical-stage MICA/B-specific IgG1 antibody which restores the MICA/B-NKG2D axis requires Fc function for potent anti-tumor activity |
Kerry Whalen; Mehta K. Naveen, PhD; Kristan Meetze; Neil W. Gibson; Jennifer S. Michaelson; Patrick A. Baeuerle, PhD |
Novel Single-Agent Immunotherapies |
Antibody;NK/NKT cell;Targeted therapy |
| 1396 |
Poster Presentation |
Antibody blockade of the immunoinhibitory receptor Siglec-10 polarizes tumor-associated myeloid cells and promotes anti-tumor immunity |
Julia Schanin; Thuy Luu; Robert Sanchez; Milene Peterson; Lisa M. McEwan; Evan Henneberry; Katherine Chang; Wouter Korver; John Leung; Bradford A. Youngblood |
Novel Single-Agent Immunotherapies |
Antibody;Chemokine;Cytokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;T cell;Targeted therapy;TLR;Tumor microenvironment |
| 1397 |
Poster Presentation |
ATG-027, a first-in-class B7-H3/PD-L1 bispecific antibody, shows potent T cell activation capability and in vivo anti-tumor efficacy |
Hui Yuwen; Tengteng Li; Yijing Ren; Linjie Tian, PhD; Jay Mei; Bo Shan; Bing Hou, Ph.D |
Novel Single-Agent Immunotherapies |
Antibody;Bispecifics;Checkpoint blockade;Dendritic cell;T cell |
| 1398 |
Poster Presentation |
Personalized immunotherapeutic platfor |